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A common feature of several heterogeneous diseases that result in retinal degeneration (RD) is 
photoreceptor loss, leading to an irreversible decline in visual function [15-17]. There are no cell 
replacement treatments available for RD diseases such as age-related macular degeneration (AMD) and 
retinitis pigmentosa (RP). Although many RD cases are of a genetic origin, a promising strategy to treat 
diseased phenotypes is by replacing lost photoreceptor cells, for synaptic integration and restoration of 
visual function. To advance photoreceptor-replacement strategies as a practical therapy, in light of highly 
restricted integration rates reported across studies, this body of research focused on defining the 
molecular mechanisms facilitating migration of transplantable photoreceptor precursors in the retinal 
microenvironment. To accomplish this work we utilized bioinformatics, bioengineering and molecular 
biologic techniques for a systems level approach. 
 
Guided by classic neuronal migration models, we hypothesized that transplanted photoreceptor 
precursors navigate to specific retinal lamina in part due to cell surface receptor expression and in 
response to spatially gradated directional ligand cues provided by the host retinal microenvironment. 
Given the neural origin of the mammalian retinal system, we also predicted that these chemotactic 










canonical migration pathways exhibited by neuronal precursors. For a comprehensive account of these 
motility-deterministic biochemical interactions, we first performed in silico bioinformatics modeling of PPC 
transplantation into light-damaged retina by matching microarray datasets between PPC receptors and 
ligands in the light-damaged retinal microenvironment. We then refined the gene expression network data 
to focus on motility deterministic interactions at the interface of the PPC cell-surface receptors and 
extracellular ligands of the damaged retina. Our in silico network modeling generated a library of ligand-
receptor pairs associated with cellular movement specific for this retinal transplantation paradigm and the 
intracellular signaling pathways induced by candidate chemotactic ligands.  
 
Working from predicted interactions of in silico paired PPC receptors and retinal ligands, we then 
performed cell migration analysis to evaluate whether exposure to stromal derived factor-1α (SDF-1α) 
would guide the motility of PPCs and RPCs in vitro. We also assessed the chemotactic effects of 
epidermal growth factor (EGF) on RPCs. Cell surface expression of C-X-C chemokine receptor type 4 
(CXCR4) receptors on PPCs and RPCs, and EGF receptor expression on RPCs were verified via 
immunocytochemical staining and validated by Western blot analysis. Boyden chamber analysis was 
used as an initial high-throughput screen to verify the motogenic effects of the ligands on PPCs and 
RPCs. We determined that RPC motility was optimally stimulated in these chambers by EGF 
concentrations in the range of 20-400ng/ml, with decreased stimulation at higher concentrations, 
suggesting concentration-dependence of EGF-induced motility. Both RPCs and PPCs also demonstrated 
a concentration-dependent chemotactic response to an optimal SDF-1α concentration of 100ng/ml.  
 
Using bioinformatics downstream signaling pathway analysis of the EGF and SDF-1α ligands in a retina-
specific gene network, we predicted a chemotactic function for EGF involving the MAPK and JAK-STAT 
intracellular signaling pathways. Based on targeted inhibition studies, we show that ligand binding, 










necessary to drive RPC motility. The JAK-STAT pathway was also implicated in transducing similar 
motogenic effects on PPCs with SDF-1α induction.  
 
To test our hypothesis of the gradated nature of ECM ligand effects on both ontogenetic retinal cell types, 
we employed engineered microfluidic devices to generate quantifiable steady-state gradients of EGF and 
SDF-1α coupled with live-cell tracking, and analyzed the dynamics of individual RPC and PPC motility.  
Microfluidic analysis, including center of mass and maximum accumulated distance, revealed that EGF 
induced motility is chemokinetic in EGFR expressing RPCs with optimal activity observed in response to 
low concentration gradients. On the other hand, PPCs and RPCs exhibited significant chemotaxis 
towards the source of SDF-1α with longer accumulated Euclidean distances and Center of Mass (COM) 
compared to controls. We also ascertained that receptor mediated signaling was requisite for ligand-
induced motility by using the CXCR4 inhibitor, AMD 3100, to antagonize the SDF-1α receptor. CXCR4 
receptor inhibition resulted in decreases of PPC and RPC movement in uniform and steady state 
gradients for a number of migration indices measured.  
 
To advance translational application of the characterized chemotactic signaling potential of transplantable 
photoreceptor precursors, we performed computational drug analysis of our newly identified motility-
deterministic networks, to develop a library of FDA approved drugs and small molecules predicted to 
potentially influence the expression of target motility signaling mechanisms in photoreceptor progenitor 
cells. Using the Expression2Kinases software and LINCS drug computational algorithm, we were able to 
identify pharmacological drug targets that modulate the biochemical activity of transcriptional regulatory 
genes which govern the expression of candidate receptor protein targets, and provide preliminary results 
validating the up-regulatory effect of candidate drug aminophenazone on SDF-1α receptor CXCR4 
expression. Results from this study demonstrate the applicability of our systems level in silico modeling of 










signaling guiding migration. Verification of in silico predictions, using molecular and microfluidic analysis 
provide important data for defining cell response properties to specific ligands present during 
transplantation into the retinal microenvironment. The drug computational analysis provides a 
translational perspective to our in silico modeling paradigms extending its applicability.   
 
Future studies will validate the functionality of resolved ligand-receptor pairs from our in silico library and 
characterize down-stream signaling guiding motility and homing. This systems level paradigm can 
effectively be applied to defining the molecular basis of transplantable cell migration in vivo toward 
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CHAPTER 1 
Photoreceptor loss is a feature of the progression of macular degenerative diseases and retinopathies 
and a leading cause of blindness in the developed world [38, 39]. There are more than 1.6 million 
recorded cases of age related macular dystrophy (AMD) and 5.3 million patients with diabetic retinopathy 
in the U.S. alone [40]. In cases with significant photoreceptor degeneration there is permanent vision loss 
with no available restorative treatment. Disease progression is often irreversible and there are currently 
no effective strategies to replace lost photoreceptors. Significant efforts to identify effective treatments for 
individuals at high risk for developing such debilitating eye diseases are currently underway [39, 41]. 
Experimental approaches to treat photoreceptor degeneration and loss include vector-mediated gene 
therapy [42-44], stimulation of endogenous repair mechanisms by dedifferentiation of resident quiescent 
progenitor cells [45, 46] and cell replacement therapies facilitated by sub-retinal transplantation into host 
retina [47-52]. In this introductory chapter, we discuss some key molecular mechanisms involved in retinal 
degenerative diseases with special emphasis on disorders involving photoreceptor loss, outline current 
reparative strategies and their shortcomings. We then explore models of cell migration in neural tissues 
toward informing our hypothesis that chemotactic signaling mechanisms between transplantable 
photoreceptor precursors (PPCs) and host retina is involved in guiding PPC migration into host retina. We 
describe a systems-level approach defining migration of transplantable replacement cells for 
photoreceptor replacement and vision restoration. We also discuss how this paradigm may be applied to 
predicting cell replacement transplantation outcomes in other organ systems and disease phenotypes. 
 
1.1: PHOTORECEPTOR LOSS AND RETINAL DEGENERATIVE DISEASES 
1.1.1: Brief Anatomy and Physiology of the Mammalian Retina 
The retina involves a complex neural circuitry responsible for transducing light into patterns of electro-
chemical impulses providing information to the visual cortex. Figure 1.1A displays the structural 
organization of the retina bordered by the retinal pigment epithelium (RPE), choroid (C) and sclera (S) of 
the eye. Retinal architecture is conserved across mammalian and non-mammalian species with six 
classes of neurons, including two types of light sensitive or photoreceptor cells: cones (daytime color 
vision) and rods (low light sensors). Photoreceptor signaling is processed through horizontal and vertical 
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circuits involving horizontal cells, bipolar cells, amacrine cells, Muller glia and ganglion cells. In the outer 
plexiform layer (OPL), the synaptic terminals of rods and cones connect with horizontal and bipolar cells. 
These two cell types modify the incoming signals from photoreceptors and then relay them to the 
dendrites of the amacrine and ganglion cells via synapses in the inner plexiform layer (IPL). The amacrine 
cells further process the incoming signals (e.g. motion detection), whereas the ganglion cells relay the 
visual information to the brain via their axons forming the optic nerve (Figure 1.1B) [22, 31]. 
 
Rod and cone photoreceptors are elongated unipolar neurons consisting of morphologically and 
functionally distinct regions that function in the primary events of light detection. Figure 1.1C displays a 
schematic of typical rod photoreceptor cell highlighting the outer segment, which is designed to carry out 
photo-transduction by capturing light and generating a proportional electrical chemical signal. The outer 
segment disks contain photopigment molecules initiating the phototransduction cascade. Disks and 
phototransduction molecules undergo continual renewal processes in which newly synthesized 
membrane is added at the proximal region of the outer segment and distal outer segments are 
phagocytized by RPE cells. A thin, non-motile cilium links the outer segment to the inner segment, a 
cellular compartment that contains mitochondria, endoplasmic reticulum, golgi apparatus, and other 
subcellular organelles. Adjoining the inner segment is the cell body containing the nucleus. This region 
further extends into the synaptic region where the electrical-chemical signaling generated in the 
photoreceptor cell is transmitted to other neurons of the retina [2, 53]. 
 
For light to be detected by rods, it must first be absorbed by the visual pigment rhodopsin embedded in 
the disks of outer segments. Rhodopsin is a G protein-coupled receptor consisting of two parts. One part 
is a protein called opsin, and the other is 11-cis retinal. The G protein associated with the receptor is 
termed transducin. Photoexcitation is initiated when a photon converts the 11-cis retinal chromophore of 
rhodopsin to its all-trans isomer. This reaction leads to the formation of Meta II rhodopsin (R*) and 
activation of the visual cascade. R* catalyzes transducin activation via the exchange of GDP for GTP on 
its α-subunit (T-α). This in turn, leads to the activation of phosphodiesterase (PDE) and the hydrolysis of 
cyclic guanosine monophosphate (cGMP) to 5'-GMP. The decrease in intracellular cGMP causes the 
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Figure 1.1: Structural Organization of the 
Mammalian Retina – A) A cutaway view of 
the retina (left) shows the neural retina (R), 
the retinal pigment epithelium (RPE), the 
choroid (C) and the sclera (S). The location 
of the subretinal space is indicated (top right) 
between the neural retina and RPE that is 
bordered by the choriocapillaris and larger 
choroidal vessels. The magnified retinal 
cross section (bottom right) shows layering 
of the ganglion cell layer, the inner and outer 
plexiform layers and the inner and outer 
nuclear layers [22]. B) The outer plexiform 
layer constitute synaptic connections 
between rod and cone photoreceptors and 
bipolar and horizontal cells which along with 
amacrine cells also synapse with ganglion 
cells at the inner plexiform layer. Incident 
light travels through these layers of retinal 
neurons beginning at the ganglion cell layer 
to activate the light sensitive rod and cone 
photoreceptors [31]. C) Schematic anatomy 
of a typical rod photoreceptor cell 
highlighting an outer segment stacked with 
specialized discs involved in 
phototransduction. A thin, non-motile cilium 
links the outer segment to the inner 
segment, a cellular compartment that 
contains the mitochondria, endoplasmic 
reticulum, golgi apparatus, and other 
subcellular organelles. Adjoining the inner 
segment is the cell body containing the 
nucleus. This region further extends into the 
synaptic region where the electrical signal 
generated in the photoreceptor cell is 
transmitted to other neurons of the retina [2]. 
Figures A was adapted from ‘Diseases of the 
retina. D'Amico DJ. The New England 
journal of medicine (1994), 331:95-106.’ 
Figure B was adapted from ‘Tubby proteins: 
the plot thickens. Carroll K., Gomez C., 
Shapiro L. Nat Rev Mol Cell Biol. (2004), 
5:55-64.’ Figure C was adapted from 
‘Photoreceptor membrane proteins, 
phototransduction, and retinal degenerative 
diseases. The Friedenwald Lecture. Molday 






cGMP-gated channels in the adjoining plasma membrane to close and the rod cell to become 
hyperpolarized. Under this condition, glutamate release at the synaptic region of the rod cell is inhibited. 
The closure of cGMP-gated channels also causes Ca2+ levels in the outer segment to decrease since the 
Na+/Ca2+-K+ exchanger continues to pass Ca2+ from the outer segment. After photoexcitation, the 
photoreceptor cell returns to its dark state by the shutdown of the visual cascade system and re-synthesis 
of cGMP. Rhodopsin is inactivated by ATP-dependent phosphorylation at its C terminus and the 
subsequent binding of arrestin. Transducin and PDE are inactivated by the hydrolysis of GTP to GDP on 
T-α by its intrinsic GTPase activity [2, 27]. Figure 1.2 depicts this mechanism of phototransduction in 
mammals. The signal generated is transmitted through different retinal neurons, finally reaching ganglion 
cells that form the optic nerve and projects to the brain. 
 
 
Figure 1.2: Mechanism of phototransduction in the mammalian photoreceptor - Two specialized morphologically 
distinct rod and cone photoreceptor cells derived from neurons capture light using the same molecular mechanism. G-
protein coupled receptor Opsins in outer segment discs of these cells absorb photons and form a signaling state, which 
can bind to and activate their G proteins by catalyzing the exchange of GDP to GTP. The GTP-bound Gα dissociates 
from Gβγ exposing its active site. Activated Gα binds to its effector, PDE (cyclic nucleotide phosphodiesterase), and 
activates it. PDE breaks the phosphodiester bond of cyclic guaniosine monophosphate (cGMP) producing 5’GMP, and 
the decrease in the concentration of cGMP causes CNG (cyclic nucleotide gated) channels to close, creating a 
hyperpolarization response in the photoreceptor cells. The hyperpolarization of the membrane potential of the 
photoreceptor cell modulates the release of neurotransmitters to downstream cells. The light signal is transmitted through 
different cells, finally reaching ganglion cells which form the optic nerve and project to the brain [27]. Adapted from 
‘Evolution of opsins and phototransduction. Shichida Y., Matsuyama T. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2009), 
364:2881-2895. 
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1.1.2: An Overview of Retinal Degenerative Diseases  
Retinal degenerative diseases can broadly be categorized into outer and inner retinal pathologies [50]. 
Outer retinal diseases often result in the death of light-sensitive photoreceptors and are the focus of 
reparative strategies articulated in this study. Inner retinal pathologies can affect both bipolar and retinal 
ganglion cells (RGCs) disrupting flow of information through the visual pathway. The incidence of 
Glaucoma leading to the death of RGCs, is expected to rise to 79.6 million people affected worldwide by 
2020 [54, 55] and remains the most common inner retinal disorder. Disruption of the retinal pigment 
epithelia (RPE), although not a part of the retina, can cause secondary photoreceptor loss due to the key 
role of the tissue monolayer in maintaining photoreceptor homeostasis by phagocytosis of the outer 
segment, nutrient cycling and supplementation [30]. Leber’s congenital amaneurosis (LCA) is an inherited 
retinal degenerative disease caused by defects in the RPE enzyme RPE65 which prevents 11-cis-retinal 
recycling and impairing the visual cycle, leading to photoreceptor degeneration [44]. Despite various 
etiologies, a number of degenerative retinopathies culminate in the irreversible loss of photoreceptors and 
vision. Table 1.1 displays the current leading causes of irreversible visual impairment and the regions of 









Among outer retinal pathologies, age-related macular degeneration (AMD) is the leading cause of 
irreversible blindness in human populations over 55 years of age [30, 56]. It is predicted that, AMD arises 
as the result of chronic, low-grade inflammation in the central outer retina, which leads to degeneration of 
the retinal pigment epithelium (RPE), its basement membrane, and Bruch’s membrane. Illustration in 
Figure 1.4A and 1.4B compares the RPE of a 3-year-old to an 80-yearold person respectively to help 	  
Retinal Disease Incidence 
Cataract 8.4–29.7% of patients over 43 years  
Age-related Macular 
Degeneration (AMD) 6–22% of patients over 70 years  
Glaucoma 1–4% of patients over 45 years 
Diabetic Retinopathy (DR) 74.9–92.3% of diabetic patients over 30 years 
Retinitis Pigmentosa (RP) 1 in 4,000 people 
 




explain pathogenesis of the disease [56]. Under normal conditions, each RPE cell is responsible for the 
phagocytosis of millions of photoreceptor outer segment discs. Over a lifetime, the incomplete digestion 
of phagosomes results in accumulation of the lysosomal protein lipofuscin, which is toxic to RPE cells, 
and extra cellular deposits (drusen and basal laminar deposits) that contain complement complexes and 
other inflammatory markers [57]. In addition, Bruch’s membrane doubles in thickness reducing the import 
of nutrients and the export of waste from the RPE, and impairing the ability of the RPE to adhere to its  
 
Figure 1.3: Leading Causes of Irreversible Visual Impairment – 
Globally, some of the most prevalent retinal diseases are schematically 
represented at their sites of occurrence in either the anterior or posterior 
segments of the eye. The incidence rates of these disorders are also 
depicted in Table 1.1. Glaucoma is typically considered a disease of the 
anterior eye segment since treatments are directed at 
increasing/decreasing fluid flow at the ciliary body, however, the vision-
threatening pathology affects the ganglion cells and optic nerve of the 
posterior segment. In the posterior segment, degenerative retinal 
diseases include those affecting photoreceptors such as retinitis 
pigmentosa (RP) and retinal pigment epithelium such as atrophic macular 
degeneration (AMD). Retinal vascular diseases of the posterior segment 
would include diabetic retinopathy (DR) and neovascular macular 
degeneration (AMD). Figure is adapted from, ‘Stemming vision loss with 





basement membrane. In late-stage wet AMD, fluid accumulation occurs as the result of 
neovascularization from the choroid through Bruch’s membrane and the RPE into the subretinal space 
and occasionally through the retina as shown in Figure 1.4C. This neovascularization is stimulated by the 
presence of excess vascular endothelial growth factor (VEGF) on the apical side of the RPE, which 
promotes the growth of fenestrated, leaky capillaries that allow the build up of fluid. Occasional 
Figure 1.4: Age-determined comparative 
analogy of the Pathogenesis of Age-
Related Macular Degeneration (AMD) – 
Illustrations of Figures A and B compare the 
retinal pigment epithelium (RPE) of a 3-year 
old to an 80-year old respectively highlighting 
phenotypes of the retinal diseases. Over time, 
apical pseudopodial RPE processes (APRP) 
surround outer segments of the rods and 
cones phagocytizing shed disks which become 
encapsulated in the phagosomes and are 
digested in phagolysosomes in the cell 
cytoplasm of the RPE. The contents of the 
phagolysosomes are incompletely degraded 
within acid lysosomal compartments of 
phagosomes and form the residual bodies that 
are the substrates for lipofuscin formation. 
Following lipofuschin formation, one of its 
autofluorescent chromophores, retinoid A2E, 
can induce photonic toxicity by incident light 
damaging DNA and cell membranes and 
causing inflammation and apoptosis. The 
resulting porous and thickened Bruch’s 
membrane and the attenuation of the 
choriocapillaris are damaging phenotypes 
leading to induced apoptosis of 
photoreceptors. Drusen accumulation of 
inflammatory cytokines and extracellular 
material between the Bruch’s membrane and 
RPE causing geographic atrophy of the RPE is 
also depicted in Figure B. C) Optical 
coherence tomography (OCT) images are also 
shown, of a normal retina (top panel) and a 
retina with pigmented epithelium detachment 
due to choroidal neovascularization (CNV) 
(indicated by the white arrows) in wet age-
related macular degeneration (AMD) (bottom 
panel). D) Confluent soft Drusen accumulation 
(white arrows) always indicates onset of age-
related macular degeneration in the macula 
(bottom panel) when compared to normal 
retina (top panel). E) The visual field in a 
normal retina (top panel) is also compared to 
the visual field in late stage AMD. Adapted 
from ‘Stem cells in retinal regeneration: past, 
present and future.’ Ramsden C.M., Carr A.F., 
Smart M.J.K., Da Cruz L., Coffey P.J. 





hemorrhaging of these fragile vessels occlude the macula resulting in scarring. In the late-stage case of 
dry AMD, this gradual deterioration of RPE health leads to subsequent photoreceptor loss [22, 30, 56].  
 
AMD and other outer retinal diseases have a polygenic inheritance component associated with their 
pathologies. Figure 1.5 displays a typical photoreceptor outer segment disk with its adjoining plasma 
membrane and the various embedded proteins associated with phototransduction and photoreceptor 
homeostasis. Importantly, the diseases associated with mutations in these proteins are also specified and 
are tabulated in Table 1.2 along with their localized occurrence in the retina [2]. Notably, the autosomal 
recessive form of retinitis pigmentosa (ARRP) is depicted, although the disorder can be inherited as a 
dominant or X-linked type. ARRP mostly affects the rod visual system and patients report problems with 
night blindness and progressive peripheral visual field loss, leading to tunnel vision which is often 
followed by blindness. Of the 1 in 4000 people affected, the most common ARRP subtype occurs due to 
mutations in the gene encoding rhodopsin but many subtypes also begin with the primary failure of the 
retinal pigment epithelium (RPE) and Muller glia [2, 30] (Table 1.2). Stargardt’s disease is an autosomal 
recessive macular dystrophy with juvenile onset, clinically presenting as yellow flecks in the macular 
region, progressive loss of central vision and bilateral atrophy of the macular region of the retina and 
RPE. Stargardt’s is the most common cause of macular disease in children, with an incidence of 1:10,000 
live births [2, 30]. The yellow flecks correspond to the abnormal build up of lipofuscin in the 
photoreceptors and subsequently the RPE, after photoreceptor phagocytosis. The most common form of 
the disease STGD1 is reportedly caused by mutations in the ATP binding cassette transporter (ABCR) 
gene coding for a retinal rod-specific ABC protein usually localized to the rim region of rod outer segment 
disk membranes [58, 59]. Homozygous and compound heterozygous mutations in the ABCR gene have 
also been implicated in autosomal recessive retinitis pigmentosa (ARRP) and cone-rod dystrophy [58] 
(Table 1.2). The pleiotropic and polygenic nature of several retinal degenerative diseases and their 
definitive and chronic phenotypes of progressive photoreceptor and vision loss have inspired the current 













Figure 1.5: Distribution of disease-linked proteins in the rod outer segment 
(ROS) - Retinal diseases linked to mutations in these proteins are also displayed. A 
complete listing of these proteins, their associated diseases and retinal occurrences 
also provided in Table 1.2. ADRP (autosomal dominant retinitis pigmentosa), ARRP 
(autosomal recessive retinitis pigmentosa), CSNB (congenital stationary night 
blindness), CD (cone dystrophy), CRD (cone-rod dystrophy), MD (macular 
dystrophy), Stgdt MD (Stargardt's macular dystrophy), XLRS1 (X-linked retinoschists 
1), XLRP3 (X-linked retinitis pigmentosa 3) [2]. Adapted from, The Friedenwald 
Lecture; Photoreceptor Membrane Proteins, Phototransduction, and Retinal 
Degenerative Diseases; Molday R.S. IOVS (1998), 39:2491-2513.  
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Protein Localization Disease 
Rhodopsin Rod cells Autosomal dominant retinitis pigmentosa (ADRP) 
Autosomal recessive retinitis pigmentosa (ARRP) 
Congenital stationary night blindness (CSNB) 
Phosphodiesterase (α, β) Rod cells Autosomal recessive retinitis pigmentosa (ARRP) 
Congenital stationary night blindness (CSNB) 
cGMP-gated channel (α)  Autosomal recessive retinitis pigmentosa (ARRP) 
 
Guanylate cyclase (Ret GC1) Cone and rod cells Leber's congenital amaurosis (LCA) 
cone-rod dystrophy (CRD) 
Calcium-binding protein 
(GCAP1)  
Cone and rod cells Cone dystrophy (CRD) 
Arresttn Rod cells Congenital stationary night blindness (CSNB) (Oguchi 
disease) 
Rliodopsin kinase Rod cells Congenital stationary night blindness (Oguchi disease) 
Transducin (α) Rod cells Congenital stationary night blindness (Nougaret disease) 
Peripherin/rds Rod and cone cells Autosomal dominant retinitis pigmentosa (ADRP) 
Macular Dystrophy (MD), Pattern Dystrophy and Digenic 
ADRP  
Rom-1 Rod and cone cells Digenic ADRP 
ABCR/RIM Rod cells Stargardt's MD, Autosomal recessive retinitis pigmentosa 
(ARRP), Cone dystrophy (CRD) and Age-Related 
Macular Dystrophy (AMD) 
 
RPGR Rod cells X-linked retinitis pigmentosa (RP3) 
CRALBP RPE and Muller cells Autosomal recessive retinitis pigmentosa (ARRP) 
 
CRX (transcriptional factor) Rod and cone cells Leber's congenital amaurosis (LCA) 
cone-rod dystrophy (CRD) 
RPE65 RPE cells Leber's congenital amaurosis (LCA) 
Autosomal recessive retinitis pigmentosa (ARRP) 




Myosin VIIA Photoreceptors/RPE Usher syndrome (USHI) 
Bestrophin RPE Best's Macular Dystrophy (VMDd2) 
Table 1.2: Proteins Associated with Retinal Diseases - Many of these genes code for photoreceptor-specific proteins 
that play key roles in photo-transduction and outer segment morphogenesis. Adapted from, The Friedenwald Lecture; 
Photoreceptor Membrane Proteins, Phototransduction, and Retinal Degenerative Diseases; Molday R.S. IOVS 1998; 
39:2491-2513 [2]. 
 
1.2: CURRENT REPARATIVE STRATEGIES FOR RETINAL DEGENERATION 
1.2.1: Gene Therapy For Retinal Degenerative Diseases 
In its simplest form, gene therapy for retinal diseases involves the replacement or silencing of defective or 
absent genes in dysfunctional retinal cell populations to repair local or systemic components of visual 
function. Current progress in this field suggests that vision repair can be achieved using targeted viral 
transfection, manipulation of inducible gene switches, introduction of ribozyme technology or RNA 
inhibition (RNAi, siRNA) to remove or inactivate mutant proteins, and/or ex-vivo cellular manipulation with 
subsequent tissue transfer of transfected cells [5]. Retinal tissue contained within the posterior globe of 
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the eye is particularly suitable for gene therapy because the small quantities of viral vectors or donor cells 
required to deliver genes minimizes the risk of vector dissemination to other body organs. The 
transparent nature of the anterior eye also allows vector transport to be closely monitored, and retinal 
electrophysiological functions can easily be assessed to determine efficacy of gene therapies [44, 60, 61]. 
Additionally, the blood-retinal barrier further protects these vector antigens from local immune responses 
that may cause inflammations that limit transgene expression [44, 60, 62].  
 
The monolayer of the retinal pigment epithelium (RPE) can be virally-transduced more efficiently than the 
multi-layered neural retina whose complex synaptic arrangements complicate designs of disease-specific 
treatments [44]. Indeed, partial correction of RPE function has a substantial impact on photoreceptor 
function and survival. In a landmark study of retinal gene therapy for mutation in the RPE65 gene that 
converts all trans-retinoids to 11-cis retinoids, treatment by subretinal injection of the AAV2 or AAV4 
vectors containing a normal gene copy resulted in restoration of rod photoreceptor function and 
consequently improved visual mobility in dim light [63, 64]. For fast retinal dystrophies as found in rd1 
(retinal degeneration) strain of mice, inoculation of diseased organs with gene-corrected viral vectors may 
not effectively counter the rate of photoreceptor loss. As such, treatment of the rd1 mice, which has a 
mutation in the Pde6b gene that encodes βPDE, an essential protein in the phototransduction cascade, 
has proved elusive [65, 66]. Additionally, mutations in the genes coding for the main visual pigments of 
photoreceptors such as rhodopsin, result in dominant genetic diseases and are therefore unlikely to 
benefit from gene replacement therapy compared to recessive forms of mutant genes causing 
photoreceptor dysfunction [44]. Mutations in genes encoding proteins involved in the functioning of the 
connecting cilium in photoreceptors (Figure 1.1C), result in syndromic effects with widespread 
pathologies because cilium proteins are also found in many ciliated cells in the body. Usher syndrome 
type 1B for example also leads to hearing loss and balance problems due to mutations in the ubiquitous 
myosin (Ex. MYO7A) gene and development of therapy for this condition poses additional challenges 
although certain ciliopathies result only in photoreceptor defects [44, 67].  
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Recombinant adeno-associated viruses (rAAV) are currently the favored vectors for use in retinal gene 
therapies as they elicit minimal immune responses [62], and have shown considerable success in 
transducing cells at all layers of the retina either through intravitreal injections targeting ganglion cells, or 
subretinal entry routes targeting photoreceptors and the RPE [44, 60] (Figure 1.6). The success of the 
vector also depends on the AAV serotype, as different serotypes preferentially target specific retinal cells 
[60]. Lentiviral (LV) vectors are also being used for treatments in some animal studies, but have been 
observed to be less efficient, a feature suspected to be due to their larger size and their subsequent 
inability to bypass the outer limiting membrane and reach photoreceptors following subretinal injection 
[60]. The incorporation of promoters specific to the targeted cell type during viral vector design also 
increases their transfection potential [60, 68]. Besides the commonly used cytomegalovirus (CMV) 
enhancer-promoter and CAG promoter that combines the CMV enhancer with the chicken β-actin (CBA) 
promoter, RPE-specific expression has been enhanced using promoter fragments of RPE65 and VMD2, 
a gene encoding the bestrophin protein that causes macular dystrophic Best disease when mutated [5, 
60]. Photoreceptor targeting in the murine retina was successfully achieved using rhodopsin and 
rhodopsin kinase promoters, and the combination of serotype and cell-specific promoters typically lead to 
significantly higher tissue-restricted gene expression [69]. For safe and effective gene therapies, these 
cell-specific promoters may also serve as target regulatory sites to control the expression and behavior of 
the gene following insertion in host retinal tissue [5]. In one instance, the expression of an antagonists to 
a gene product was linked to an upstream modulator of the gene by attaching a complementary response 
sequence of the upstream modulator to a transfected gene thereby controlling the availability of the 
protein and effectively creating a local auto-regulatory pathway [70]. 
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The physiology and progression of a particular retinal degenerative disease also determines the 
effectiveness of gene therapeutic approaches employed. Early stage retinal degeneration may be more 
amenable to vector-mediated gene transfer protocols supplemented with anti-apoptotic factors that 
restrict further retinal cell loss, while end-stage disease states can benefit from strategies that attempt to 
transfer light-inducible pigments such as Channelrhodopsin-2 to residual non-damaged inner retinal cells 
to make them intrinsically photosensitive [60, 71]. However, as the retina degenerates, viral transduction 
of the remaining retinal layers may be less effective because of the structural changes associated with 
retinal damage. Nevertheless, there is no evidence as yet that currently available vectors are ideal for 
gene transfer in human retina [66]. Table 1.3 lists select clinical trials currently in progress using gene 
therapy and their hosting institutions, and even though some studies are yielding promising restorative 
results for degenerating retina, this therapeutic approach remains at an early stage of development [68].  
Figure 1.6: Vector delivery systems commonly 
employed in gene therapy for retinal degenerative 
diseases - A) Intravitreal injection of vector. B) 
Subretinal vector injection. Adapted from, ‘Gene 
Therapy for Age-Related Macular Degeneration.’ 





1.2.2: Cell-Based Therapy For Retinal Degenerative Diseases 
When compared to other regions of the central nervous system (CNS), the mammalian retina is a more 
amenable target for reparative cell-based therapies that may alleviate retinal degenerative diseases 
because its membranous expanse within the posterior segment of the eye eases access for sub-tenon,  
intravitreal, sub-retinal and systemic transplantation of donor replacement cells [5, 50]. Analogous to 
gene-replacement therapies, tools for assessing the effectiveness of retinal cell replacement therapies 
post-treatment and for measuring retinal structure and visual function are among the most effective 
compared to similar paradigms employed in other major body organs [50].  
 
Because the mammalian retina does not regenerate, terminal loss of retinal neurons due to disease or 
trauma suggests that a practical strategy to restore sight could involve cell replacement via 
transplantation [1, 48, 72]. Photoreceptor loss represents the final and irreversible end stage of several 
retinal diseases. Heterogeneous phenotypes characterizing some retinal pathologies have led to effective 
experimental strategies involving gene-specific or cell-type specific approaches. For instance, 









Choroidermia rAAV2.REP‑1 Encodes REP‑1 Imperial College of 





AAV2‑hRPE65 v2 Produces RPE65 
gene 





rAAV2‑VMD2‑hMERTK Produces MERTK King Khaled Eye Hospital I 
Stargardt’s StarGen Expresses ABC4 
gene 
Oxford Biosceinces/Sanofi I 
Usher’s syndrome 
(1B) 
UshStat Produces MY07A 
protein 
Oxford Biomedica I 
Table 1.3: Select on-going clinical trials of gene therapy for retinal diseases.  The phases of most of these 
clinical trials depict the infantile stage of this therapeutic strategy. Adapted from ‘Gene therapy for retinal diseases. 
Samiy N. J. Ophthalmic. Vis. Res. (2014), 9: 506-9’ [68]. AMD (age‑related macular degeneration); AR (autosomal 
recessive); REP‑1 (rab‑escort protein); VEGF, vascular endothelial growth factor); AAV2 (adeno‑associated virus 2); 
rAAV2 (recombinant adeno‑associated virus 2). 
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replacement of diseased retinal pigment epithelium (RPE) via traditional surgical transplantation of 
autologous RPE tissue in patients with age-related macular degeneration (AMD) has proven more  
effective than neural sub-retinal transplantation protocols, because the RPE is a monolayer, not requiring 
migration of transplanted cells or complex synaptic connectivity [72-74]. Photoreceptor replacement is 
challenging but probable due to their basic sensory physiology and signaling via a single synapse to 
downstream retinal neurons [72]. Bull et al (2011) [50] schematically localized experimental ports for 
current cell-based treatment models in the eye and is depicted in Figure 1.7.  
 
Cell-based therapies can broadly be categorized into regenerative or replacement and trophic or rescue 
treatment strategies [73-75]. Regenerative therapies utilize partially or fully differentiated cells such as 
RPE or photoreceptor precursors that have been isolated or expanded, and/or derived from pluripotent 
embryonic or adult retinal stem cells. These cells are intended to replace the damaged endogenous cells 
to restore retinal function [30]. In the trophic or rescue approach, grafted stem cells remain 
Figure 2.7: Schematic of ports in the eye for experimental stem cell-based therapies for retinal 
diseases currently under investigation. The possibility of using stem cells for replacement and/or 
rescue therapies is being explored for several common neurodegenerative retinopathies. Abbreviations: * 
= treatment currently in clinical trial; AMD, age-related macular degeneration; ES, embryonic stem cells; 
RGC, retinal ganglion cell; RP, retinitis pigmentosa; RPE, retinal pigment epithelium. Figure is adapted 
from ‘Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases. Bull N.D., 
Martin K.R. Stem Cells (2011), 29:1170-1175 [24].  
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undifferentiated and through a paracrine effect induce the resident tissue to self-restore and proliferate by 
secreting trophic cytokines or via cell-to-cell interactions [73, 74, 76]. Therapeutic replacement of neurons 
in the mature retina can be complicated as newly engrafted cells must not only differentiate into the 
appropriate neuronal cell type, but also regenerate appropriate synaptic connections within a highly 
ordered, hard-wired, spatially organized neural network. Given the complexity of this task, it is likely that 
trophic cell-based therapies will attain clinical development more quickly than regenerative therapies. 
However, trophic therapies can only hope to halt disease progression in the retina, whereas regenerative 
applications may be able to reverse functional vision loss and actually improve visual impairment [50, 75]. 
Tables 1.4A and 1.4B lists current pre-clinical and clinical studies that have shown potential for use in 
treating retinal degenerative diseases [75]. In some instances as with RPE cell transplantation for 
treatment of Best disease and some forms of retinitis pigmentosa, a combination of replacement and 
rescue therapies is adopted where human embryonic stem cells (hESCs) and induced pluripotent stem 
cells can be differentiated into RPE cells which integrate easily with host photoreceptors and also secrete 
trophic substance that support the photoreceptor cells [77-80]. 
 
 
Disease Cell type Delivery route Effect 
Rd1 and rd10 mouse BMHSC Intravitreal Rescue photoreceptors (primarily cones) 
Rhodopsin knockout 
mouse  BMMSC Subretinal Rescue photoreceptors 
Ischemic retinopathy Endothelial progenitor cells Intravitreal 
Vascular repair and reversal of 
ischemic injury 
Rd1, mnd and CRX-/- 
mouse Human ESCs Intravitreal, Subretinal Replace photoreceptors 
RPE65-/-mouse ESC-derived RPE Subretinal Rescue photoreceptors 
RCS rat BMMSC Intravenous Rescue photoreceptors and preserved retinal function 
RCS rat hES-RPE Subretinal Rescue photoreceptors and improved visual function 
RCS rat Human neural progenitor cells Subretinal 
Rescue photoreceptors and 
improved visual function 
RCS rat Human iPSC-derived RPE Subretinal 
Rescue photoreceptors and 
improved visual function 
RCS rat hUTSC Subretinal Rescue photoreceptors and improved visual function 
Elov14 mouse hES-RPE Subretinal Rescued photoreceptors 
Ush2a mouse Forebrain-derived progenitor cells Subretinal 
Reversed mislocalization of cone 
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(Kumar et al., 
2012) 
Table 1.4: Cell-based therapies for retinal diseases – Current cell based therapies can be categorized into 
rescue/trophic and regenerative/replacement treatment strategies depending on the purpose of the 
transplantation study. A) Pre-clinical trials using animal models that have shown potential in the treatment of 
retinal diseases [75]. B) Clinical trials currently underway and registered with the World Health Organization 
(WHO), the cell types transplanted and the sponsoring institution where these studies are being performed. 
Abbreviations: ESC (embryonic stem cells), iPSC (induced pluripotent stem cell), AMD (age-related macular 
degeneration), GA (geographic atrophy), RP (retinitis pigmentosa), hES-RPE (human embryonic stem cell-
derived retinal pigment epithelium), hUTSC (human umbilical tissue-derived stem cells), BMHSC (bone marrow-
derived haematopoeitic stem cell), BMMSC (bone marrow-derived mesenchymal stem cell), DR, diabetic 
retinopathy, RVO (retinal vein occlusion), STGD (Stargardt’s disease). Adapted from ‘The promise of stem cells 
for age-related macular degeneration and other retinal degenerative diseases. Zarbin M. Drug Discovery Today: 
Therapeutic Strategies (2013),10:e25-e33’ [75], and  ‘Stem cells in retinal regeneration: past, present and future. 




Stem cells, with their capacity for proliferative expansion and the potential to generate multiple cell types, 
are a practical source of cells for cell-based therapies because they can be produced en masse safely 
and induced to differentiate into ocular cell types with potential for replacement and rescue therapy [50, 
72, 75]. Two transcription factors Nanog and Oct4, are associated with helping to keep the cells in an 
undifferentiated state with the capacity for self-renewal [75]. Many studies in animal models suggest that 
stem cells have the capacity to regenerate lost photoreceptors and retinal neurons and improve vision  
[30, 46, 81, 82]. An overview of putative stem cell sources currently in use for clinical and pre-clinical trials 
in retinal degenerative models, and their differentiation capacities, is provided in Table 1.5 [83]. The 
major types of stem cells utilized include embryonic stem cell (ESCs), induced pluripotent stem cells 
(iPSCs), mesenchymal stem cells (MSCs), and retinal progenitor cells (RPCs). 
 
Type of cell Location Differentiation capacity 
Embryonic stem cells (ESCs) Blastocyst Totipotent (any cell type); photoreceptors in vitro 
Retinal stem cells Ciliary margin in rodent and 
human eyes 
Various cell types including photoreceptors, 
bipolar cells, Müller glia in vitro 
Neural stem cells Ciliary epithelium, optic nerve Neurons and glia; photoreceptors 
Retinal progenitor cells 
(RPCs) 
Fetal or neonatal retinas Neurons and specialized support cells in vitro 
Retinal Muller glia Inner nuclear layer of the retina Lamina-specific retinal neurons 
Retinal astrocytes Nerve fiber layer of the retina Limited neurogenic potential 
Retinal microglia All retinal layers Neurons and glia in vitro? 
Mesenchymal stem cells Bone marrow, adipose tissue, 
umbilical cord 
Various cell types including photoreceptors and 
retinal pigment epithelium in vitro 
Induced pluripotent 
stem cells (IPSCs) 
Generated from differentiated 
somatic cells 
Photoreceptors, RGCs 
Table 1.5: Putative cell sources for cell-based therapies in retinal degenerative disease models. Adapted from 
‘Cell-replacement therapy and neural repair in the retina. Schmeer C., Wohl S., Isenmann S. Cell and Tissue 
Research (2012), 349:363-374’ [83]. 
 
 
Figure 1.8 describes the generation of ESCs and IPSCs. Embryonic stem cells are isolated from the 8-
cell inner cell mass of blastocyst-stage embryos cultured on monolayer fibroblasts Figure 1.8A or from 
similar cloned blastocysts, generated through the process of somatic cell nuclear transfer Figure 1.8B. 
ESCs have self-renewal capabilities as well as the ability to differentiate into all adult cell types derived 
from the three embryonic germ layers [21, 84]. Studies have shown that ESCs can differentiate into 
photoreceptor progenitors, photoreceptors, or retinal pigment epithelium (RPE) in mice and humans [85-
88]. A recent study showed that transplantation of retinal cells derived from human ESCs into the 
subretinal space of adult Crx-/-mice promoted their differentiation into functional photoreceptors with 
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improved light responses [16]. Although ESCs are promising in retinal replacement therapies, they have 
also been associated with teratoma formation [89] and immune rejection issues [90], and there remains 
ethical concerns with fetal cell use even though ESCs can now be obtained without embryo destruction 
[91]. Another major limitation to the use of ESCs is the inability to control their differentiation as we are 
just beginning to understand the developmental cues that differentiate ESCs into the specific 
neuroprogenitors suitable for repair of damaged retinal tissues [72].  
 
The use of induced pluripotent stem cells (iPSCs) resolves most of the ethical issues associated with the 
use of ESCs as they are formed in vitro as pluripotent ESC-like cells reprogrammed from terminally 
differentiated somatic cells by retroviral transduction of transcription factors: Oct3/4, Sox2, Klf4 and c-
Myc, and are therefore not of embryonic origin Figure 1.8C [21, 92, 93]. iPSCs have similar 
developmental potential as ESCs, contribute to the development of all cell types in chimeric animals, 
including the germ line, and can mimic normal retinogenesis [93-95]. The use of defined transcriptional 
activators to generate cell-type specific iPSCs offers a treatment regimen that does not require the use of 
immunosuppressive drugs to prevent rejection due to the limited antigenicity, and proffers a targetable 
repair mechanism for genetic defects [90]. Figure 1.8D displays schematic of a potential treatment 
strategy for dystrophic retinopathies using autologous iPSCs where patient keratinocytes can be 
reprogrammed into iPSCs for sub-retinal re-implantation into donor retina by intraocular surgery [25]. 
iPSCs can provide an unlimited supply source of desired cell-type specificities. However, the cytogenetic 
protocol associated with IPSC generation is subject to transient genetic instabilities that increase the risk 
of viral integrations and oncogene expression [96]. iPSC cytogenesis can also leave an epigenetic 
memory of the tissue of origin that may influence cell differentiation efforts for applications in disease 




Figure 1.8: Generation of Embryonic Stem Cells (ESCs) and Induced Pluripotent Stem 
Cells (IPSCs) - A) After removal of the zona pellucida from supernumerary blastocysts ESCs can 
be isolated as epiblasts and cultured on mitotically inactivated mouse embryonic fibroblasts. B) 
ESCs can also be isolated from cloned blastocysts generated through somatic cell nuclear 
transfer. C) Delivery of a cocktail of transcription factors to somatic cells, such as dermal 
fibroblasts, reprograms them to a pluripotent state, providing a source of fully autologous induced 
pluripotent stem cells (iPSCs). Whatever their mode of derivation, all pluripotent stem cells have 
the capacity to differentiate into derivatives of each of the three embryonic germ layers: 
endoderm, ectoderm and mesoderm. D) An exemplary treatment strategy for 
degenerative/dystrophic retinopathies using autologous iPSC-derived keratinocytes for 
subsequent sub-retinal re-implantation into patient retina by intraocular surgery. This strategy 
limits immune rejection of retinal grafts but can harbor disease-causing genes endogenous to 
host. Figures adapted from ‘The challenge of immunogenicity in the quest for induced 
pluripotency. Fairchild P.J. Nat Rev Immunol. (2010),10:868-875’ [21] and Stemming vision loss 
with stem cells. Marchetti V., Krohne T.U., Friedlander D.F. J Clin Invest. (2010), 120:3012-3021 
[25].’  
 
d  Treatment strategy using autologous IPSCs 
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Mesenchymal Stem Cells (MSCs) are a bone marrow-derived cell population, independent of the 
hematopoietic system, which have the ability to self-renew as well as give rise to multiple tissue types [97, 
98]. Other sources of MSCs have been described including adipose tissue, placenta, cord blood and liver 
[99-101]. Adult Royal College of Surgeons (RCS) rat MSCs can be induced to express photoreceptor-
specific markers rhodopsin, opsin, and recoverin in vitro following induction using signaling factors such 
as activin A, taurine, and epidermal growth factors (EGF). After transplantation, these MSCs integrated 
into the host retina forming structures similar to the photoreceptor layer, and expressed photoreceptor-
specific markers [102, 103]. Besides integrating into host retina, MSCs injected into the subretinal space 
can also slow progression of retinal cell degeneration [103]. Because of its autologous characteristic, 
relative ease of isolation, decreased immunogenicity and less controversial nature, MSCs remain a 
popular choice of pluripotent stem cells for treatment of retinal diseases (see Table 1.4) [30, 73, 74, 104, 
105]. The broad developmental plasticity of MSCs was originally thought to contribute to their 
demonstrated efficacy in experimental animal models of retinal disease and in human clinical trials, 
however, new evidence suggest their rescue capabilities via secretion of soluble factors may contribute 
more significantly to retinal tissue repair than through their trans-differentiation potential [72, 75, 105]. 
 
Retinal progenitor cells (RPCs) are derived from fetal or neonatal retinas, and comprise an immature cell 
population that is responsible for generation of all retinal cells during embryonic development [90, 106]. 
Previous studies report that RPCs can proliferate, generate new retinal neurons and retinal support cells 
in vitro and in vivo, and can migrate into retinal layers following transplantation [17, 107]. However, with 
RPCs, as with ES or iPSC derived cells, migration and integration rates following transplantation are 
extremely low in healthy and diseased retina [108-111], a limitation attributed to an absence of research 
defining the molecular mechanisms underlying transplanted cell migration in host retina [112]. 
Notwithstanding the physiological limitations of these cells, comparative grafting studies reveal RPCs as 
an optimal choice of cells for transplantation studies [113, 114], and in our current study, we explore the 
potential of these cells as therapeutic donor cells. In the next section, we explore the two major cell-based 
treatment strategies currently being utilized in models of retinal degeneration – Cell rescue and cell 
replacement therapies. 
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1.2.2.1: Cell-Based Trophic Therapies For Retinal Degenerative Diseases 
Cell-based trophic/rescue therapies for retinal diseases can be summarily categorized into two 
applications – repair by endogenous cell regeneration and trans-differentiation, and paracrine biochemical 
rescue using transplanted stem cells. 
 
1.2.2.1.1: Retinal Repair By Endogenous Cell Regeneration And Trans-differentiation 
Amphibians such as newts have been shown to regenerate whole retina from the retinal pigment 
epithelium (RPE) [115] and in a few instances from innate retinal progenitor cells located at the periphery 
of the neural retina in the circumferential germinal zone (CGZ) [116]. Teleost fish are more limited in their 
regenerative capabilities compared to amphibians and employ a Muller glia-derived regenerative 
response to source replacement retinal progenitor cells in retinal and optic nerve damage [117, 118]. 
Neural retinal regeneration in these species occurs without the addition of exogenous factors and without 
preserving the vascular membrane of the eye. Adult birds cannot regenerate damaged retina but 
embryonic and post-hatch chick have demonstrated limited regenerative effects via an RPE-dependent 
event only through the first few days post-hatch [119-121]. In contrast to amphibians, teleost fish, and 
birds, the mammalian retina does not add retinal neurons after birth [117].  
 
Even though mammals cannot actively regenerate damaged retina post-birth, current research supports 
the possibility that analogous retinal cell types in other vertebrates can self-renew and thus mammals 
may retain an intrinsic regenerative potential that can be harnessed for retinal repair if the proper stimuli 
were provided [105]. Some resident adult stem cells that are multipotent fall into this category and can 
differentiate into multiple cell types of a single lineage. For instance, it was possible to activate Muller 
cells in vivo to differentiate along rod photoreceptor lineage in the outer nuclear layer via canonical Notch 
and Wnt signaling pathways using exogenous factors in juvenile rats [122]. Subsets of adult rodent retinal 
stem cells localized in the pigmented ciliary margin clonally proliferate in vitro to form sphere colonies of 
cells that can differentiate into retinal-specific cell types, including rod photoreceptors, bipolar neurons, 
and Muller glia [123-125]. Muller glia also express low levels of retinal progenitor markers [126] and can 
generate neurons and glia in culture [127], but for retinal ganglion cells (RGCs), they show very limited 
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capacity of regenerating optic nerve axons in the absence of exogenous stimulation [128, 129]. Human 
RPE also harbor multipotent cells that can be stimulated to trans-differentiate into neuronal sub-types and 
thus may serve as a potential source of progenitors for repair [130]. 
 
While strategies to direct these innate functional cells to differentiate into retinal neurons in mammals 
seem to be promising therapies for retinal diseases, there is a need to delineate the regenerative 
biochemical markers and molecular mechanisms that drive or limit robust regenerative responses. It is 
also important to understand how these regenerative mechanisms differ from gliotic or fibrotic responses 
following retinal damage in mammals, and how they can be modulated to avoid fibrosis, tumorigenesis 
and epiretinal membrane formation deleterious to any reparative endogenous cell regeneration strategies 
[117]. Potential retinal progenitor populations capable of regeneration in the mature and/or damaged 
retina may also be too limited in number to replace lost cells or reverse damaged photoreceptor 
phenotypes [131].  
 
Recent observations of spontaneous generation of ESC- [132, 133] and IPSc-derived [134] organ-like 
eye-cup and retinal tissues exhibiting markers of differentiated photoreceptors, demonstrate  a source for 
large populations of regenerative cells at an early ontogenetic stage for use in reparative strategies. 
Retinal tissue from these spontaneous generation experiments can provide different cell phenotypes, at 
different stages of development for cell replacement therapy [135, 136], the treatment method touted as 
the most feasible strategy for treating retinal disease due to photoreceptor loss [30].  
 
1.2.2.1.2:  Retinal Rescue By Paracrine Effects Of Transplanted Retinal Cells 
Paracrine signaling is a form of cell signaling in which the target cell is near (“para” = near) the signal-
releasing cell and both cells are of different lineages as opposed to autocrine signaling where both signal-
releasing and induced cells are of the same type. To be useful for cell-based paracrine rescue, 
transplanted cells must generate needed trophic factors and not proliferate in an uncontrolled manner. In 
a preclinical model of glaucoma, for example, intravitreal injected somatic neural stem cells and bone 
marrow-derived mesenchymal stem cells substantially reduce rates of retinal ganglion cell death [137, 
 24 
138]. Additionally, upon stimulation by pro-inflammatory agents such as tumor necrosis factor (TNF), 
bone marrow-derived mesenchymal stem cells release anti-inflammatory cytokines, modulating local 
inflammation, and improved vascular permeability for endogenous repair [105]. Both bone marrow-
derived hematopoietic and mesenchymal stem cells (MSCs) injected intravitreally exerted trophic rescue 
effects on photoreceptors in animal models of retinal light-damage, retinal ischemia, and diabetic 
retinopathy [139-141]. Human umbilical cord MSCs injected into the optic tract after a lesion have also 
rescued RGCs and promoted regrowth to the superior colliculus in rats [142]. Evolving interest in the 
paracrine signaling effect of candidate trophic factors has led to its being employed in many current 
clinical trials (Table 1.4B) [73, 74, 105], but the efficacy of this treatment strategy for degenerated retina 
with marked photoreceptor loss remains limited, but may be valuable in concert with cell transplantation 
[72, 143]. 
 
1.2.2.2:               Cell Replacement Therapy For Retinal Degenerative Diseases 
Cell replacement strategies for retinal tissue have been shown to be feasible in animal models using 
retinal progenitor cells, single RPE cells or RPE monolayers derived from embryonic stem cells (ESCs), 
neural progenitor cells (NPCs), induced pluripotent stem cells (iPSCs), or early postnatal retinal precursor 
cells [1, 16, 48, 49, 72, 83, 144]. In these studies, bolus injections of retina fragments, retinal cell 
suspensions, or fetal retinal sheets are transplanted into host retina via intravitreal or subretinal 
administration [48, 109, 110, 145, 146]. Subretinal transplantation is a delicate process involving surgical 
formation of a transient retinal detachment to provide a subretinal space between the photoreceptor layer 
and RPE. Intravitreal injection on the other hand, even though less invasive, requires transplanted cells to 
migrate through the viscous vitreous cavity, inner limiting membrane and inner retina (See Figure 1.6). 
Notwithstanding the route of administration employed, optimal efficacy of most retinal cell transplantation 
experiments is still hindered by extremely poor retinal graft integration [138, 147, 148].  
 
1.2.2.2.1: Replacement of Retinal Pigment Epithelium 
Subretinal transplantation of healthy RPE cells, either freshly isolated or generated from ESCs, into RCS 
rats demonstrated photoreceptor protection with preservation of neuronal connectivity and visual function 
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[149]. While it is surgically feasible to transplant whole monolayer RPE into the subretinal space of AMD 
patients, allogeneic transplants without immune-supression have led to fibrosis and tissue rejection, and 
this occurs in spite of the immune-privileged status of the sub-retinal space [150, 151]. Somatic cell 
nuclear transfer techniques can largely overcome this immunogenicity problem [146], however the 
restoration of vision will always be limited in the face of chronic photoreceptor apoptosis caused by 
recurrent and progressed disease environments [152]. Autologous RPE transplants also have the 
disadvantage of carrying the same genetic predisposition that caused the pathological condition [25, 83]. 
RPE tissue transplanted into the fovea of AMD patients after choroidal neovascular membrane removal 
maintained only transient central visual function with decline after 5 to 6 years [153, 154]. Additionally, 
induced pluripotent stem cells (iPSCs) are observed to spontaneously differentiate into RPE cells and 
form highly differentiated RPE monolayers upon culture [144]. RPE replacement therapy has been touted 
as one of the most promising paradigms for patients with early AMD (Table 1.4) as RPE cells do not 
require synaptic connectivity to integrate, and these cells supplement and preserve photoreceptor 
function [149]. An area of concern is the mild but chronic immune rejection elicited when RPE allografts 
are transplanted in rats and other mammals.  
 
1.2.2.2.2: Replacement of Retinal Ganglion Cells 
Compared to photoreceptor replacement, the replacement of RGCs is much more complex because it not 
only requires the migration and integration of donor cells into the ganglion cell layer and differentiation 
into RGC-like cells but also the extension of long axonal processes through the myelinated regions of the 
optic nerve to target synaptic sites in the brain [155]. ESCs [156], MSCs [157], RPCs [158] and Muller 
glia–derived stem cells [159] have been reported to migrate and integrate into the retina depleted of 
RGCs or populated by apoptotic RGCs. Foetal neurons also appear better able to survive transplantation 
surgery than adult neurons [160]. Nevertheless, evidence for synaptic integration and functional 
improvement remains elusive [138, 155]. iPS-derived retinal ganglion-like cells have also been generated 




1.2.2.2.3: Replacement Of Photoreceptors 
Transplantation studies have shown that a sub-fraction of freshly dissociated photoreceptor precursor 
cells (PPCs) from post-natal day 1-6 mouse retinas can integrate into adult host retina, exhibit 
photoreceptor morphology and improve light-responsiveness [1, 51]. These PPC populations have been 
characterized as post-mitotic, committed to a photoreceptor cell fate, and exhibit appropriate 
photoreceptor integration following transplantation in animal models [10, 148, 162]. Sub-populations 
already expressing rhodopsin are even more likely to integrate into the outer nuclear layer (ONL) and 
form morphologically mature photoreceptors [148]. Additionally, at an early post-natal developmental 
stage, the propensity for these cells to form tumors in situ is largely absent [72, 75]. It has been 
postulated that the observed preference of adult mammalian host retina for fate-committed photoreceptor 
precursor cells (PPCs) may be due to its inability to provide exogenous factors required for multi-stage 
differentiation of other transplantable multipotent retinal progenitors [72, 148]. Similar transplants using 
cultured or freshly dissociated cells older than the first postnatal week do not result in significant 
photoreceptor morphology following transplantation [148]. Developmentally, mouse post-natal day 0-6 
coincides with the time of birth of rod photoreceptors as shown in Figure 1.9A, active neuroblast migration 
from the neuroepithelium, and onset of opsin expression [148, 163]. It would be ideal to use human 
photoreceptor precursors in clinical studies but sourcing them from second-trimester human fetuses 
(Figure 1.9B), is a limiting factor and confounded by ethical constraints [83, 162]. 
 
In summary, subretinal transplantation studies have demonstrated extremely limited numbers of new 
photoreceptor morphologic and functional integration in host retina using either RPCs and PPCs [48, 162, 
164] or ESCs and iPSCs directed toward a photoreceptor fate in vitro prior to transplantation [49, 95]. 
Additionally, of the cells that successfully migrate into the host retina, only a small percentage (0.5-3%) 
have been shown to integrate in the appropriate retino-neural laminar loci and/or express ontogenetic 








Normal and diseased retinal tissue and RPE secrete diffusible molecules that influence migratory 
decision-making of transplanted cells [145, 167, 168], evidenced by increased donor cell integration after 
manipulation of the chemical environment of the retina [165, 169]. To advance retinal cell replacement 
strategies, it is essential that the biochemical cross-talk between transplantable cells and transplantation 
microenvironmental signals be better understood.  
 
1.3: DEVELOPING HYPOTHESES FOR SUCCESSFUL PHOTORECEPTOR CELL REPLACEMENT 
In this thesis investigation, we focus on improving photoreceptor cell replacement strategies because 
such efforts may contribute to the repair and/or reversal of degenerating photoreceptor phenotypes 
characteristic of several retinal disease types. According to Table 1.4, very few photoreceptor 
replacement therapies have been implemented for human treatment in part due to the limited integration 
rates reported in pre-clinical transplantation studies. This reparative strategy might thus seem unattractive 
for clinical development but it leaves unanswered questions for which testable hypotheses can be 
Figure 1.9: Photoreceptor genesis and maturation in mouse and human. The relative numbers of cone 
and rod precursor cells that are born over time are shown for mouse and human retinogenesis. A) In mice, 
cones are generated prenatally as early as embryonic day (E)11. Rods, which vastly outnumber cones, are 
generated from around E12 to postnatal day (P) 10, peaking at around time of birth with subsequent decline 
with maturation. This peak time of rod genesis also coincides with the onset of expression of S opsin and 
rhodopsin with M opsin expression beginning at ~P6. The inset panel shows double fluorescent detection of 
cone (red staining) and rod precursors (green staining)) in mouse retina at E18, superimposed on a phase 
contrast picture that reveals the outer neuroblastic layer (ONBL). Newly generated photoreceptors tend to 
reside near the edge of the retina. B) In humans, cones and rods are generated around foetal week (Fwk) 8 
and Fwk 10, respectively. Generation of cones is completed prenatally common with mice, whereas that of 
rods continues into the early postnatal period. Expression of photopigments begin well before birth, but 
functional maturation of photoreceptors continues postnatally. RPE (retinal pigment epithelium). Figure is 
adapted from ‘Transcriptional regulation of photoreceptor development and homeostasis in the mammalian 
retina. Swaroop A., Kim D., Forrest D.  Nat. Rev. Neurosci. (2010),11:563-576’ [10] 
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intelligently developed. Additionally, with growing interest in the paracrine rescue effects of grafted retinal 
stem cells on host damaged retinal tissue [73, 74, 104], an effective transplantation model will offer the 
dual benefit of both replacing and rescuing dystrophic retina. 
 
In general, for photoreceptor cell replacement to be feasible as a therapeutic treatment for vision loss, 
sub-retinally transplanted cells have to migrate through the interphotoreceptor matrix (IPM) and integrate 
in proportions large enough to affect/reverse the degenerated phenotype in a damaged host retina [146, 
148, 162]. The mature retina is implastic and inhibitory to cellular migration [83]. Progressed retinal 
degeneration leads to physical barriers to migration including meshes of heparan and chondroitin sulfate 
proteoglycans, inhibitory extracellular matrix (ECM) molecules, accumulated microglia [145, 170, 171], 
and limiting membranes of the outer and inner retina [172, 173]. Improved transplantation success has 
been observed in part due to photoreceptor progenitor matrix metalloproteinase release and experimental 
disruptions of ECM molecules and inhibitory limiting membranes in the retina [145, 167, 172]. In addition, 
newly engrafted cells must differentiate into functional photoreceptors and generate appropriate synaptic 
connections within a highly ordered, hard-wired, spatially organized neural network [50, 75]. This synaptic 
integration also has to restore damaged retinal architecture and visual function to experimentally 
acceptable levels [16, 170, 174]. An important finding in many studies is that cell replacement strategies 
worked best in young and newly damaged retinal microenvironments [175, 176]. Although these 
conclusions have since been challenged [148, 172], it was observed that following injury, strong activation 
of astrocytes and microglia occurs with concomitant release of cytokines to restore retinal homeostasis. 
Some other authors have suggested that only if a neutralization of these pro-inflammatory and glia-
activating stimuli in diseased retina is performed a priori will successful retinal transplantation be achieved 
[146, 177]. Recently, ectopic expression of target growth factors in recipient retinal tissue improved 
survival and integration of transplanted photoreceptor precursors further demonstrating support for the 
crucial reparative role played by the retina’s extrinsic trophic cues [43, 165].  
 
It is apparent that grafted photoreceptor precursor cells require optimal extracellular environments that 
facilitate the appropriate intrinsic signaling repertoire for successful homing and integration in damaged 
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retina. These biochemical environments are chiefly provided by the diffusible and bound chemicals in the 
host damaged retinal IPM, RPE and neural retinal lamina. A fundamental understanding of the effects of 
these local physical and chemical environments on the fate and long-term survival of transplanted retinal 
precursors in diseased retina is thus essential to the efficacy of photoreceptor replacement therapies, but 
has not been thoroughly investigated [112, 177]. We believe that only after such basic scientific, 
mechanism-driven studies are performed, will photoreceptor replacement strategies yield predictable 
outcomes with each cell type and retinal environment under investigation. To begin to delineate 
mechanism of migration in the retina we next describe potentially analogous migratory mechanisms 
active in the mammalian CNS during development and in normal and diseased physiological conditions.  
  
1.3.1: Models Of Neuronal Migration 
Appropriate migration and positioning of neurons during brain development is essential for the 
construction of functional synaptic circuitry. Although the generation, migration, and differentiation of 
neurons were once considered to end soon after birth in mammals, a significant number of neurons are 
born and migrate post-natally and well into adulthood [20, 178, 179]. Studies of neuronal migratory 
processes have revealed mechanisms underlying healthy nervous tissue organization as well as 
pathologies leading to diseased and disorganized tissue. In humans, defects in neuronal migration can 
cause developmental diseases including epilepsy [180], and advance adult-disease processes such as 
metastasis and invasion of neuroblastoma and glioma [181]. In birds and rats postnatal neural progenitor 
migration is required for learning and memory [182]. 
 
Two main types of migratory processes predominate during mammalian brain development (Figure 1.10). 
Radial migration is generally characterized by intimate, reciprocal interactions between migrating neurons 
and the processes of radial glial cells. Post-mitotic neurons migrate radially from the ventricular zone 
towards the pial surface, past previously generated neuronal layers to reach the top of the cortical plate, 
where their migration terminates and they assemble into layers with distinct patterns of connectivity [183, 
184]. Tangential migration is defined as a mode of non-radial neuronal translocation that does not require 
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specific interactions with radial glial cell processes [184, 185]. Neurons that eventually become pyramidal 
or glutamatergic cortical neurons tend to migrate radially, whereas GABA (γ-aminobutyric acid)-  
 
interneurons migrate tangentially [186]. Neurons can switch dynamically between tangential and radial 
modes of migration, as has been observed in cortical interneurons [187]. In post-natal rodents, three brain  
regions  - the cerebellum (CB), hippocampus (Hipp) and rostral migratory stream (RMS) maintain 
prominent neuronal migratory processes (Figure 1.11). In addition, a very small number of neurons are 
predicted to migrate into the hypothalamus near the time of birth [188]. A highly restricted pattern of 
neuronal migration is observed in the early postnatal human brain, including populations of elongated 
neurons around the periphery of the lateral ventricles and subgranular zone (SGZ) neuroblasts that 
migrate over short distances to the adjacent dentate gyrus (DG) (Figure 1.11) [20, 189, 190]. Given that 
the most extensive neuronal migration in adult mammals occurs in the RMS of rodents, it often serves as 
a model system to study the factors that control both radial and tangential neuronal dispersion [20]. 
 
Figure 1.10: Radial and 
tangential migration of 
neurons in the developing 
cortex - Radially migrating 
neurons either use somal 
translocation with a long leading 
process (a) or migrate in close 
apposition (b) to a radial glial 
process (blue). Tangentially 
migrating neurons (purple) travel 
along corticofugal fibres (green), 
or use marginal zone neurons 
(yellow) or the pial membrane 
(grey) as migratory guides. 
Figure adapted from ‘Neuronal 
migration in the adult brain: are 
we there yet? Ghashghaei HT, 
Lai C, Anton ES. Nat Rev 
Neurosci. 2007;8:141-151.’ [20] 
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 During brain development in mammals, neuroblasts born in the anterior subventricular zone (SVZ) 
migrate rostrally in a stream over long distances towards the olfactory bulb (OB) where they either settle 
into the deep granule cell layer, or in the superficial periglomerular layer of the bulb and differentiate into 
GABA-containing and dopaminergic local circuit interneurons (Figure 1.11) [178, 179, 182, 190, 191]. 
Through this route, new interneurons are continuously fed into the olfactory bulb — the first central relay  
 
station of olfactory sensory input — which has an ongoing demand for functional rewiring as a result of 
continuous death and replacement of receptor neurons in the olfactory epithelium [191]. Neuroblasts 
uniquely migrate as chains tangentially in the RMS in a highly directed manner with no dispersion into  
surrounding tissues, and then switch to radial migration upon reaching the olfactory bulb indicating the 
presence of orienting cues in or around the RMS. Cumulative evidence suggest that these cues are 
gradient combinations of diffusible and substrate-bound repulsive, motogenic and chemoattractive 
molecules secreted by neighboring SVZ cells [192],  and micro-architectural astroglial tubes that 
encapsulate chains of migrating neuroblasts, serving as locomotory guidance substrates [20]. These glial 
Figure 1.11: Sites of neuronal migration in the postnatal and adult mammalian brain – A) In rodent brains 
postnatal neuronal migration is evident in three main areas: the cerebellum (CB), the hippocampus (Hipp) and the 
rostral migratory stream (RMS). A small number of neurons also complete their migration into the hypothalamus 
(Hyp) at around the time of birth. Distinct germinal zones (green) give rise to neurons that migrate to adjacent target 
zones (red). Lighter shade indicates that migration in these regions occurs primarily during the very early postnatal 
period and does not persist into adulthood. B) Cells born in the anterior subventricular zone (SVZ, insert) initiate 
their migration from the SVZ (1) as chains (2) streaming towards the olfactory bulb (OB), where they end their 
migration (3). Abbreviations: EGL (external granule cell layer), IGL (internal granule cell layer), OE (olfactory 
epithelium), SGZ (subgranular zone). Figure adapted from ‘Neuronal migration in the adult brain: are we there yet? 




tubes can also initiate physiological switching of some neuroblast populations from a motile phase into a 
mitotic phase, through contact-mediated mechanisms [193].  
 
Gradients of semaphorins and Slit-1 and Slit-2 emanating from the septum and tissues surrounding the 
SVZ repel neuroblasts and initiate migration away from the SVZ [182, 194-196]. Astroglia-derived 
migration inducing activity (MIA) and heparan sulphate proteoglycans in the ECM further modulate this 
chemorepulsive function of Slit proteins [182, 197, 198]. Local chemoattractive cues Netrin-1 and its 
receptors neogenin and DCC (deleted in colorectal cancer), and prokineticin2 (PK2) and its receptors 
PRK1 and PRK2 also assist in initiating neuroblast migration by chemo-attraction towards the OB (Figure 
1.12A) [194].  Optimal levels of adhesion between neuroblasts maintain their movement in chains due to 
the expression of polysialated neuronal cell adhesion molecule (PSA-NCAM) which enhances hemophilic 
interactions between NCAMs on neuroblasts and enables them easily slide along each other within 
astroglial tubes (Figure 1.12B) [195]. These PSA-NCAM+ migrating neuroblasts also express the 
tyrosine kinase receptor ErbB4 and its ligands, neuregulins 1 and 2 (NRG1 and NRG2), and Eph tyrosine 
kinase receptors and their ephrin ligands in correlate to maintained orientation of the leading edge of 
polarized axio-tangential migrating neuroblasts [20, 199]. On arrival to the mature olfactory bulb, 
neuroblasts express the transcription factor ARX (aristaless-related homeobox gene) facilitating entry into 
the OB. Reelin and tenascin-R then act as detachment signals causing radial dispersion of neuroblasts 
from chains  (Figure 1.12C) [20, 200, 201]. 
 
1.3.1.1:  Positional Steering During the Migration of Neurons and Other Cell Systems 
The ability of migrating neurons to follow the same stereotypic pathways and be precisely guided by their 
outgrowing processes to target destinations, was part of an early proposal by renowned neuroscientist 
Ramón y Cajal termed the chemotropic theory of axon guidance [202, 203]. This theme was resounded in 
findings by Gundersen and Barrett where lumbosacral dorsal-root ganglions from chick embryos rapidly 
altered their direction of growth on exposure to an extracellular gradient of nerve growth factor (NGF) 
[204]. Since then, several guidance systems of diffusible molecules have been characterized that 
emanate from target neural destinations or are secreted locally by tissue microenvironments resulting in 
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concentration gradients of the molecules relative to their output sources [202, 205-207]. Understanding 
the mechanisms of directed neuronal migration to these and other conserved gradient systems will 
facilitate strategies towards guided migration of RPCS and PPCs in retinal neural tissue. Directional cell 
migration is facilitated in two ways: by intrinsic cell directionality and by external regulation [26, 208].  
 
1.3.1.1.1: Cell Migration Due to Intrinsic Cell Directionality 
While environmentally derived cues exert a potent influence on the migratory behavior of neuroblasts, 
migrating neural progenitors in the mature brain intrinsically polarize and extend a leading process in the 
direction of migration from a somatic region marked by clustered centrosome and golgi bodies (Figure 
1.13A) [20]. This cell polarizability with defined leading and trailing edges is essential for efficient cellular 
migration and can be observed when cells respond to a non-directional motogenic signals such as the 
uniform application of growth factors [209-211]. Cell polarity is well conserved and has been studied in 
many cells including epidermal and mesenchymal cells [212, 213], and in diverse conditions such as 
wound healing, immune surveillance and embryogenesis [26]. Forward movement of the centrosome 
facilitates nuclear translocation towards the leading process because microtubules extending from the 
centrosome are wrapped around the nucleus as observed in migrating cerebellar neurons [214]. 
Concurrently, centrosomal microtubular networks extend anteriorly to the edge of specialized tips of the 
polarized leading process known as growth cones (Figure 1.13B). Growth cones are tasked with sensing 
and rapidly responding to guidance signals, and with sustaining the intrinsic propagation of polarized 
cells. Growth cones are composed of lamellipodia containing cross-linked networks of actin filaments, and 









Figure 1.12: Canonical stages of Neuronal Migration in Mammals – A) Neuronal 
migration from the sub-ventricular zone (SVZ) is initiated following repulsion by septal 
chemo-repulsive factors (SLIT and ROBO), chemo-attraction by Netrin-1 and its receptor 
DCC motogenic mediation by glial tube-derived migration-inducing activity (MIA, orange). 
B) Neuroblasts migrate as chains sliding along each other. Maintenance of chain migration 
is dependent on the continued motogenic activity of MIA, neuregulin 1–ErbB4 interactions 
(both purple), adhesion mediated by the polysialated form of neuronal cell adhesion 
molecule (PSA-NCAM, yellow) and extracellular matrix (ECM)–integrin signaling (blue). 
Once the neurons reach the end of the rostral migratory stream, the entrance of migrating 
cells into the olfactory bulb depends on the transcriptional activity of aristaless-related 
homeobox gene (Arx). Termination of migration in the olfactory bulb is regulated by 
secreted reelin and its receptor, apolipoprotein-E receptor 2 (ApoER2), and by their 
downstream target, disabled 1 (DAB1). Tenascin-R also initiates the detachment of 
neuroblasts from their chains and their radial migration into the olfactory bulb. Arrows 
indicate the direction of migration from the sub-ventricular zone towards the olfactory bulb. 
Figure adapted from ‘Neuronal migration in the adult brain: are we there yet? Ghashghaei 








This peripheral actin network is located at the proximal portion of the growth cone and associates with the 
microtubules at the distal region of the axon shaft contributing to the assembly and translocation of 
microtubules into the growth cone. The regulation of actin polymerization at the leading edge of filopodia 
and lamellipodia, actin depolymerization in proximal regions of the growth cone, and of the rate of F-actin 
retrograde flow within both filopodia and lamellipodia together control growth cone advancement and 
retraction. The Rho family of small GTP-binding proteins plays a pivotal role in this regulatory process by 
catalyzing the hydrolysis and switching between bound GTP (active) and GDP (inactive) molecular states, 
profoundly affecting on actin cytoskeletal and microtubule dynamics [33, 208, 215-218]. This regulation of 
actin polymerization is phenotypically expressed as the multiple retracting and extending protrusions of 
Figure 1.13: Models of neuroblast migratory processes in the developing retina -  (A) Interkinetic nuclear 
migration (IKNM) showing the characteristic apical-to-basal nuclear oscillation in proliferative neuroepithelial cells 
as they progress through the cell cycle. IKNM is a conserved process which typically occurs pre-natally in most 
mammalian systems and through the initial post-natal weeks [13]. B-D) Modes of whole retinal cell migration – 
Following cell cycle exit, progenitor cells can use resident retinal precursors and glial cells as scaffolds to migrate to 
the appropriate lamina depth in the inner retina in guided migration (B) or they can extend cytoplasmic processes to 
anchor between the inner limiting (ILM) and outer limiting membranes (OLM) allowing for translocation of its cell 
body to the mature retinal loci with ultimate retraction of the processes in somal translocation (C). In unconstrained 
migration (D), retinal precursors send neurites to explore the environment and migrate to their functional positions 
with no apical or basal attachments [29]. These modes of migration are not mutually exclusive as some retinal cells 
employ multiple migration strategies. Figures 1.13A is adapted from ‘Nuclear migration during retinal development. 
Baye LM, Link BA. Brain Research. 2008;1192:29-36.’ Figure 1.13B is adapted from ‘Godinho L. LB. Cell Migration. 
In: Evelyne Sernagor SE, Bill Harris, Rachel Wong, ed. Retinal Development: Cambridge University Press; 







the leading edge of CNS neurons typically elicited by local chemical signals [219]. Additionally, the Par 
(partitioning defective) complex, consisting of PAR3, PAR6 and atypical protein kinase C (aPKC) is key to 
cell polarity and connects Rho GTPase signalling, centrosome reorientation, microtubule stabilization and 
membrane trafficking to the regulation of directional persistence during intrinsic cell migration [26]. A Rac-
1 mechanism, independent of canonical Rho-GTPase signaling, was also found to regulate switches 
between intrinsically persistent random and directional cell migration by controlling the number of 
peripheral lamellipodia and the total number of membrane protrusions that can mediate changes in the 
direction of cell migration [220]. External signals including external guidance molecules, ECM topography 
and adhesion receptors, in tandem with the intrinsic cell polarity converge on the Rho GTPases to 
regulate the number and orientation of lamellipodia (Figure 1.14), with the orientation of the most stable 
lamellipodial branch determining the direction of cell migration [26, 219]. Understanding how these factors 
are integrated to regulate directional migration is challenging and remains to be elucidated in retinal or 




1.3.1.1.2: Directional Cell Migration By External Regulation 
If a motogenic stimulus is presented as an external gradient or with another external guidance cue, a 
steering or compass mechanism coupled to the intrinsic cell polarizability described above responds to 
the asymmetric environmental factor [26]. The cell then undergoes directed migration [26, 208]. Directed 
migration is maintained by the stabilization of the filopodial and lamellipodial protrusions that sustain the 
orientation of the leading edge [221, 222], and by the intrinsic capacity with which such directed 
movements can persist, a property that is cell-type specific and quantifiable during chemokinesis [26]. 
Generally, attractive guidance cues have been reported to promote actin polymerization events and 
prevent retrograde actin flow, while in contrast repulsive guidance cues exert reciprocal effects on these 
processes [33, 208]. In addition, the nature of asymmetric environmental cues will often define the type of 
directed migration. Cells undergo chemotaxis in response to soluble cues [215], haptotaxis in response to 
graded adhesion to the underlying substrate [223], electrotaxis in response to electric fields [224], 
durotaxis in response to mechanical signals in the environment [225, 226], and even phototaxis to light 
Figure 1.14: Intrinsic Polarizability and Growth Cones in Neuronal Migration – A) It is theorized that in 
physiological conditions, diseased states or in the presence of uniform concentrations of chemokines, most cells 
display intrinsic polarity by producing a leading process (blue) to form in the direction of migration. Clustering of 
the centrosome (red) and the Golgi apparatus (green) seem to mark the area of a neuron from which the initial 
polarized process extension occurs. Forward movement of the centrosome allows the nucleus to translocate in the 
direction of migration as the cell’s trailing process (purple) detaches and repositions itself [20]. B) At the tip of the 
leading process are specialized growth cones made of lamellipodia of cross-linked actin filaments and filopodia of 
actin subunits. Growth cones sense attractive or repulsive guidance signals and extend or retract through 
regulation of the rates of actin polymerization and depolymerization at the plus (+) and minus (−) ends of actin 
filaments, respectively, and of F-actin retrograde flow [33]. Figure A is adapted from ‘Neuronal migration in the 
adult brain: are we there yet? Ghashghaei H.T., Lai C., Anton E.S. Nat Rev Neurosci. 2007;8:141-151.’ Figure B is 
adapted from ‘Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and 
guidance. Huber A.B., Kolodkin A.L., Ginty D.D. Annual review of neuroscience. 2002;26:509-563.’ 
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and geotaxis to gravitational fields in simpler organisms [225, 227]. Typically, a combination of these 
external stimuli and the corresponding cell response mechanism is at play during cell migration in most 
biological systems.  
 
Specific to our study of photoreceptor cell transplantation, it is expected that PPCs will exhibit durotactic 
responses to the variability in structural motifs between the sub retinal space transplantation site and the 
laminar substrata of the neural retina [228, 229]. PPCs are also expected to respond to haptotactic cues 
in the host retina as they interact with topographically attached chemical moieties of the IPM [112, 147, 
167, 230, 231]. Natural microenvironments in living tissues contain multiple embedded components within 
extracellular matrices composed of spatially oriented fibrils forming one-, two-, or three-dimensional 
structural montages with relative degrees of pliability [26]. Serving as physical cues, these topographical 
arrangements can geometrically constrain adhesion sites to guide migration. Fibroblasts have been 
observed to migrate towards more rigid surfaces during durotaxis which supposedly better stabilized 
lamellipodial protrusions [225]. Oligodendrocytes, hippocampal neurons and many other cell types 
polarize and migrate along grooved patterns in fabricated ECM lamina [232, 233]. Fibroblasts also 
migrate more rapidly with spindle-shaped or uni-axial morphology and pronounced uni-directionality in 
one- and three-dimensional matrices [234, 235] compared to two-dimensional laminar where they 
adopted a more flattened cell morphology with multiple lamellipodial extrusions that promote more 
random migration (Figure 1.15). Additionally, the centrosome and Golgi complex were oriented towards 
the posterior of the cell in one- and three-dimensional topographies but towards the anterior of the cell on 




1.3.1.2:  Chemical Gradients Influence Directional Migration of Cells 
Haptotaxis and durotaxis of cells occur in a fluid microenvironments with tissue specific biochemical 
compositions in vivo.  We aim to model in vivo signaling in this work to study chemotaxis of transplantable 
neurons. Additionally, dynamic metabolic activity, spatial-temporal loci of interacting tissue subsets and 
fluxes in levels of diffusible and bound molecules are expected to influence cell migration in retinal tissue 
[205, 222, 236]. Figure 1.16 compares two common types of cell responses to soluble chemical gradients 
– chemokinesis and chemotaxis. Chemokinesis occurs when a chemical applied to the cell either 
symmetrically or asymmetrically, stimulates cell migration without determining the direction of migration. 
Chemotaxis occurs when a soluble factor is applied asymmetrically and dictates the direction of cell 
migration [221, 237-239]. Cell behavior in these environments are quantifiable in terms of the positional 
displacement of the center of mass of single cells or distinct population of cells, directionality and turning 
angle (θ) as was performed in this study assessing RPC and PPC motility. Prior to chemical stimulation, 
or during chemokinesis, these parameters describe intrinsic cell directionality. During chemotaxis they 
characterize directed migration. Factors that increase directionality during chemokinesis can promote 
chemotaxis whereas factors that decrease directionality can inhibit chemotaxis [218, 240]. 
 
For a growth cone to be guided by a gradient, it must be able to sense a sufficiently large difference in 
ligand concentration over its length. Two non-neuronal mechanisms for gradient detection by growth  
 
 
Figure 1.15: Control of lamellipodial protrusions 
promotes directional migration. Directional migration 
is a result of regulated formation of lamellipodia during 
both intrinsic and directed cell motility. Various signals, 
including external guidance cues, the topography of the 
extracellular matrix, the intracellular polarity machinery 
and adhesion receptors, can converge on the Rho 
GTPases to direct the adhesion and cytoskeletal 
remodelling that is necessary for lamellipodium 
formation. A) Increased numbers of lateral lamellipodia 
can result in random intrinsic migration and a reduced 
capacity to respond to external cues during directed cell 
migration. B) Restricting lateral lamellipodium formation 
results in a single dominant leading edge, directionally 
persistent intrinsic cell migration and enhanced directed 
migration during chemotaxis. 
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cones have been proposed: 1) internal amplification of a small percentage change in external ligand 
concentration across the width of the growth cone and 2) a shifting internal baseline that reduces the 
effective concentration at one edge of the growth cone to zero [241]. The maximal distance over which a 
gradient can be detected regardless of the mechanism of detection has been resolved to be about 1cm 
and the shape of the gradient determines the mechanism of gradient detection [241, 242]. Gradient-
induced steering of cells has been widely observed in many cell systems. Cortical interneurons were 
observed to respond to chemoattractant signals by generating new leading process branches that were 
better aligned with the source of the chemical gradient both in vivo and in vitro and not by reorienting 
previously existing branches [219]. In some other instances, graded distribution of receptors to guidance 
Figure 1.16: Topographical control of directional migration – A) When plated 
on 2D surfaces, cells produce multiple lamellae (indicated by arrowheads), 
whereas cells in an oriented 3D matrix or on 1D lines produce a single lamella 
and have a uni-axial or spindle morphology. The centrosome and Golgi complex 
(asterisks) are oriented towards the posterior of the cell in 3D and 1D 
topographies but towards the anterior of the cell on 2D substrates. Cells either in 
a 3D matrix or on a 1D line have a single directional axis of travel (dashed lines), 
whereas the 2D surface promotes multiple axes and reduces directional 
migration. B) Migration on a 1D substrate is similar to that in a 3D matrix. The 
upper panel shows a confocal image of NIH 3T3 fibroblasts migrating through a 
3D cell-derived matrix (fibronectin is shown in blue). The cells have a uniaxial 
phenotype and a posterior-oriented Golgi complex (red). Microtubules are shown 
in green. A similar morphology is seen in fibroblasts migrating on 1D lines (lower 
panel). White arrows indicate the direction of migration. Figures adapted from 
‘Random versus directionally persistent cell migration. Petrie RJ, Doyle AD, 
Yamada KM.  Nat. Rev. Mol. Cell Bio. 2009;10:538-549 [26] . 
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molecules determined appropriate positioning and response of specific axons to Slit-Robo guidance 
mechanisms for midline axons [217]. Molecules distributed in gradients both in the peripheral olfactory 
system and basal forebrain influence movement of gonadotropic (GnRH) neurons to their hypothalamic 
destination [188]. In the establishment of the topography of thalamic axons in the cerebral cortex, netrin-1 
gradients form long-range chemoattractive cues that stimulate migration of rostro-medial thalamic axons 
in the ventral telencephalon [243]. Bone-marrow derived cells also mobilize to damaged regions of the 
brain and retina releasing stromal-derived factor (SDF-1α), hepatocyte growth factor (HGF) and leukemia 
inhibitory factor (LIF) [244]. Applying chemical gradients to mediums used for studying PPC replacement 
paradigms is an experimentally supported investigational strategy and in most cell systems, fluidic 
technology has enabled the micro-systemic generation of variety of gradients in manipulative ECM 
environments. For this thesis study, we fabricate a bridged µ-lane microfluidic device capable of 
generating and independently sustaining mathematically quantifiable ligand gradients over 72 hours. This 
microdevice fabrication and implementation for PPC studies was performed with supervision from my 
thesis committee member, Professor Maribel Vazquez.  
 
1.3.1.2: Bioinformatics analysis simplifies the characterization of signaling for neuronal migratory systems 
Along the migratory route, neuroblasts receive different stimuli from extracellular cues that collectively 
guide migration. As a result, a number of intracellular signaling molecules are activated. Subtypes of 
migrating neuroblasts have been found to share majority of intracellular signaling components that 
integrate external stimuli via overlapping canonical signaling pathways, and several molecular hubs have 
been identified that centralize these connections in the migration of most neuronal sub-types [195, 196, 
245]. Identified network hubs include cell division protein kinase 5 (Cdk5), disabled homolog 1 (Dab1), 
ras-related C3 botulinum toxin substrate 1 (Rac1) and focal adhesion kinase (FAK) [245].  Whilst these 
valuable studies reveal key molecules affecting neuronal migration, many of which were cytoskeleton 
proteins, during the last decade, interest has grown towards the identification of whole pathways and 
understanding their complex interactions [246]. Bioinformatics tools have been employed to mine 
databases that compile microarray gene expression data of many cell systems and species at target 
physiological states [6, 246]. This powerful approach allows statistically defined nodal construction of 
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experimentally defined molecular connectivity, the filling in of connection gaps, and can be used to predict 
whole signaling pathways, tasks that would be difficult to resolve using experimental data from one 
system only. Bioinformatics analysis has been successfully employed in predicting intracellular 
connectivity between genes involved in chemotactic pathways of migrating neuroblasts during 
neurogenesis and in adult neuronal progenitors in the sub-ventricular zone (SVZ) and cortex [245, 247-
252], and in angiogenetic processes of migrating retinal endothelial tip cells [253]. These bioinformatics 
findings are usually validated by experimental testing that provides functional proof of a molecule’s or 
network’s involvement in a specific function, cell or tissue system. Using this technique, the involvement 
of the cytoskeletal remodeling pathway combining calmodulin signaling and Akt1-DNA transcription 
networks in neuroblast migration were confirmed for murine neuroblasts using invivo and invitro 
techniques such as gene silencing and chemotactic assays [247]. In this thesis study, we employ the 
Ingenuity Pathway Analysis bioinformatics software technology to predict incident extracellular cues and 
relevant signaling pathways influencing migration of PPCs upon transplantation into a light-damaged 
retinal model, and delineate epidermal growth factor-induced intracellular signaling pathways in RPCs.  
 
1.3.2: Models Of Retinal Cell Migration 
Migratory processes during retinogenesis in mammals begins before birth and continues throughout early 
postnatal development. In humans, motility involved in retinogenesis has been studied during the pre-
natal gestational ages of 6.5-18 weeks [254, 255], with reported localized niches of migrating retinal 
progenitor cells during late development. In the formation of the mammalian retina, neuroblasts typically 
migrate from the neuroepithelium of the optic cup primarily in an apical-to-basal direction with subtle 
tangential displacements to form an even stratification of mature retinal cell types. Coordinated regulation 
of cell proliferation, cell cycle exit, cell type determination and morphogenesis, directed cellular migration 
and homeostatic synaptic partnering between heterogeneous retinal cells is required to establish the 
exquisite cyto-architecture of the mature retina [256, 257]. During the initial cell proliferative stage in 
retinal development, neuroepithelial progenitors exhibit interkinetic nuclear migration (IKNM), the process 
in which their nuclei migrate in an apical-to-basal manner through the length of the cell and in phase with 
their cell cycles (Figure 1.17A). M phase and cytokinesis in retinal progenitors were observed to occur 
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mostly when they were positioned at the apical surface near the RPE while G1, S and G2 phases 
occurred at more basal locations [13, 258]. Studies suggest that IKNM aids in the spatial asymmetrical 
positioning of cell bodies of retinal neuroblasts, which consequently determines cells that will continue to 
be mitotically active and thus their cell fates as they temporally form the outer and inner retina. Actin-
myosin cytoskeletal networks (actomyosin) are reported to be the main drivers of nuclear migration [259] 
while cytoplasmic microtubule-based motor systems of dynein-dynactin and kinesin play minor roles, in a 
process that is highly conserved among various species [13, 260] 
 
Following terminal mitosis at the apical surface of the neuroepithelium, newborn retinal cells migrate to 
their appropriate laminar position within the retina by employing multiple strategies. The modes of whole 
cell migration can be classified as guided cell migration, somal (nuclear) translocation or unconstrained 
(free) migration (Figure 1.17B-D), which are not necessarily mutually exclusive forms of motility because 
some retinal cell types have been observed to employ multiple migration strategies [29, 258]. In somal 
(nuclear) translocation, the neuroepithelial cells extend a leading (basally-directed) process through which 
the nucleus translocates until it reaches the appropriate strata in the lamina and then it retracts its apically 
and basally-directed processes [13, 20, 258] (Figure 1.17C). Somal translocation has been demonstrated 
for retinal ganglion cell and bipolar cell precursors [261, 262] and cone photoreceptor precursors also 
exhibit some degree of nuclear translocation despite their attachment and eventual somal positioning 
adjacent to the outer limiting membrane [263]. Rods also extend a basally directed process, particularly at 
later developmental stages, that does not reach the inner retinal surface [264]. Continued proliferation of 
the neuroepithelium also pushes early-born rods and cones deeper into the retina [263].  
 
Newborn amacrine cells have been shown to move using unconstrained migration in which dynamic and 
non-polarized neurites appear to sample the local environment en-route to the inner nuclear layer (Figure 
1.17D) [265]. Guided cell migration is similar to migration observed in the developing cerebral cortex 
where glial cells provide the substrates and cues for cell positioning. However, within the retina, adjacent 
neuroepithelial cells including terminal Muller glia cells all provide the scaffold for migrating post-mitotic 
retinal progenitors and this process is utilized to some extent in both somal translocation and free 
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migration (Figure 1.17A) [13, 263]. Horizontal cells exhibit a unique bi-directional migratory behavior 
where they overshoot the inner limiting membrane (ILM) and coalesce within the future amacrine cell 
layer before migrating back to their final destination [266]. In the mouse retina, this bi-directionality in 
horizontal cell movement requires the transcription factor gene Lim1 [256, 267], while in the chick retina, 
horizontal cells seemed to mirror this motogenic function but also re-enter the mitotic phase deep in the 
inner retina before migrating apically back to the horizontal cell layer [266, 268, 269].  
 
Important molecules and signaling pathways facilitating directed migration in the retina include those 
associated with apical cell junctions of neuroepithelia, which either regulates adhesion between cells or 
facilitates polarized secretion of guidance molecules [258]. Membrane-bound receptors such as 
dystroglycan and integrins as well as intracellular signaling molecules such as integrin-linked kinases and 
focal adhesion kinases also mediate directed cell migration [258]. Localized endogenous expression of 
epidermal growth factor (EGF) [270] and stromal-derived factor 1 (SDF1) [271-273] and their receptors in 
specific retinal lamina have also been linked to directional motogenic functions for retinal cell precursors. 
Slit1-Robo3 signaling downregulates N-cadherin based adhesion to allow for migration of retinal ganglion 
cell precursors in the developing optic chiasm of both zebrafish embryos and new born mice [215, 274, 
275], and Netrin-1 and Sema-3 expression in the optic chiasm guide glial precursor migration via the optic 
nerve towards infantile rat retina [276].  
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In contrast to organizing migratory processes observed during development, in late stage retinal disease, 
disorganizing migratory processes ensue.  For example, in proliferative vitreoretinopathy, RPE cells 
migrate into the retina and onto the vitreal surface through retinal tears and form cell assemblies in the 
vitreous known as epiretinal membranes [277]. However, in the tissue remodeling process that follows 
retinal detachment, Muller cells and radial glia of the retina hypertrophy and grow extensively into the 
sub-retinal space, where as photoreceptors retract their axons as their senesces begins and migrate 
deeper in the outer nuclear layer [278]. Horizontal and ganglion cells also extend neurites into the 
subretinal space and vitreous following retinal detachment [278]. Similar Muller cell reactivity and 
Figure 1.17: Chemokinesis Vs. Chemotaxis – Chemokinesis occurs when a 
factor, applied to the cell either symmetrically or asymmetrically, stimulates cell 
migration without determining the direction of migration. Chemotaxis occurs 
when a soluble factor is applied asymmetrically and dictates the direction of cell 
migration. The behavior of a motile cell exposed to these different treatments 
can be quantified. A) A cell at three time points as it migrates in a uniform 
concentration. B) A cell at three timepoints as it migrates in a gradient of 
increasing concentration of a motogen. At each time point, the migration can be 
defined by the centre of the cell mass, the distance travelled between positions 
(path length), the turning angle (θ) and the net displacement. This information 
can be used to describe the rate and directionality of migration. Directionality is 
defined as the displacement divided by the total path length of the cell. If a cell 
is migrating more randomly, directionality decreases and vice-versa. Figure 
adapted from ‘Figures adapted from ‘Random versus directionally persistent 
cell migration. Petrie RJ, Doyle AD, Yamada KM.  Nat. Rev. Mol. Cell Bio. 
2009;10:538-549 [26]   
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proliferation towards the site of injury has also been described in mammalian models of N-methyl-D-
aspartate neurotoxicity [46], and retinal laser photocoagulation [279].  
 
1.4: SUMMARY HYPOTHESES AND THESIS OBJECTIVES 
Our review of the pathophysiology of retinal diseases and their phenotypic manifestations reveals that an 
effective strategy to repair damaged retina will involve replacement of lost photoreceptors. Stem and 
progenitor cell-replacement therapy offers good restorative potential for damaged retinal tissue compared 
to most other treatment protocols. However, the efficacy of current cell-transplantation methods is limited 
due to poor migration, homing, and integration of transplanted cells in the host retina. Our developing 
understanding of the biochemical complexity involved in PPC navigation through the IPM site of 
transplantation to make synaptic connections in the neural retina layer will help define for the first time the 
chemotactic mechanisms guiding migration of transplanted retinal stem/progenitor cells within normal and 
damaged neural retina. This research may contribute to the advancement of photoreceptor cell 
replacement strategies to restore retinal architecture and light detection [49, 112, 145].  We suggest that 
in transplantation studies, RPCs and PPCs are navigating to specific retinal lamina as a result of cell 
surface receptor expression and in response to spatially gradated directional cues provided by the host 
retinal microenvironment. Given the molecular basis of neuronal and retinal cell migration during 
development and in adults, we also believe that the extracellular cues in host retinal microenvironments 
will modulate intrinsic motility signals in grafted RPCs and PPCs and trigger analogous overlapping 
canonical signaling pathways that govern cell migration as well as novel molecular interconnectivities. 
Our ultimate goal in this study is to provide experimental data toward development of strategies that will 
target grafted cells to their specific lamina and thus improve integration rates for vision restoration. To 
perform this task, we propose to 1) delineate extracellular chemotactic factors, their cognate cell-surface 
receptors and intracellular motility deterministic signaling pathways governing transplanted photoreceptor 
precursor cell (PPC) migration in the retina using a combination of bioinformatics, gene expression 
profiling and proteomics analysis, and 2) functionally evaluate RPC and PPC migratory and homing 
responses to identified chemotactic and haptotactic factors, and signaling cascades using high-
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throughput chemotactic assays, and in steady state gradients generated in retinal biomimetic microfluidic 
devices.  
 
In achieving our objectives, we have been able to compile a comprehensive library of chemotactic 
molecules whose interactions potentially guide transplanted RPC and PPC migration in a host damaged 
retina model with high statistical probability. Network designs of these molecular interactions shed more 
light on basic stem cell biology, retino-neural progenitor chemotaxis and retinal neurogenesis. These in-
silico tasks were performed using a novel cost-effective protocol designed to facilitate the analysis of 
microarray genomic data. Predictions of molecular signaling interactions were validated using microfluidic 
gradient generators with transferrable technology for use in stem cell migration research to repair other 
diseased organ systems with specific cell subtypes and extracellular matrix chemotactic parameters. 
Lastly, we have presented our findings at conferences and published in peer-reviewed journals in our 
commitment to advancing efforts that promote basic and translational stem cell research. Chapter 2 of 
this thesis study describes the bioinformatics methodology employed to resolve molecular mechanisms 
governing PPC migration, while chapter 3 describes the proteomic and chemotactic assays used to 
validate the bioinformatics findings. We then report results of assessments of the chemotactic potential of 
two key extracellular matrix ligands Epidermal Growth Factor (EGF) and Stromal-Derived Factor (SDF-
1α) in chapters 4 and 5 respectively, resolved from our analysis signaling network systems of motility of 
retinal precursor cells. We conclude in Chapter 6 by showcasing translational application of our 
bioinformatics paradigms to statistically predict drugs and small molecules that can induce migratory PPC 
phenotypes favorable to successful integration in the retina post-transplantation, and provide preliminary 
results of efficacy tests of our drug selection on RPC motility. 
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CHAPTER 2: BIOINFORMATICS ANALYSIS METHODS FOR RETINAL STEM CELL MIGRATION 
 
2.1 OVERVIEW OF BIOINFORMATICS ANALYSIS - FROM GENE TRANSCRIPT TO NETWORK 
PATHWAY FUNCTION  
Bioinformatics has traditionally involved the computational analysis of large molecular biology datasets 
drawn from protein structure experiments. Since the elucidation of whole genome sequences and the 
advent of high throughput sequencing techniques, gene expression at the transcriptome and proteomic 
levels has been measured simultaneously and repeatedly for different cells, tissues, organs, individuals 
and their physiological states. Such high-throughput expression profiling can be used to: 1) reveal 
signaling pathways and genes, whose expression states govern underlying biological conditions; 2) 
compare the level of gene transcription in clinical conditions to identify diagnostic or prognostic 
biomarkers, classify diseases that are indistinguishable by microscopic examination, monitor gene 
response to therapy, and understand the mechanisms involved in the genesis of disease processes [280, 
281]. Genome-wide expression information can principally be generated by cDNA Microarrays, 
GeneChips (High-Density Oligonucleotide arrays), serial analysis of gene expression (SAGE) and 
expressed sequence tags (ESTs) technologies [280]. GeneChips and SAGE measure absolute mRNA 
transcript levels per cell, while cDNA microarrays measure gene expression relative to a reference state 
to yield an expression ratio [280, 282]. A large amount of data is produced using these techniques and 
the first major bioinformatics task is to organize and store this information, in different repositories such as 
GEO (the NCBI Gene Expression Omnibus), the Stanford Microarray Database, Array Express and 
Express DB (Harvard) [283, 284].  
 
An early goal was to facilitate interpretation of cDNA microarray results verified by independent research 
groups. Toward this goal, the minimum information about a microarray experiment (MIAME) [285] was 
developed to standardize the annotation, organization and reporting of the microarray-based gene 
expression data. MIAME requires that the biological properties of the samples and phenotypes, the 
experimental conditions, transformation and normalization techniques accompany data obtained from the 
microarray-based assays. MIAME has since been further modified to provide minimum information about 
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high throughput sequencing experiments (MINSEQE) and similar variations that accommodate 
improvements next generation sequencing technologies [286].  
 
A basic outline of cDNA microarray analysis involves; total RNA extraction from experimental sample and 
reference sample, followed by reverse-transcription to cDNA then labeling with fluorescent probes and 
hybridization to complementary DNA sequences affixed in an orderly manner at specific locations (spots) 
on the microarray slide. The amount of cDNA bound to a spot will be directly proportional to the initial 
number of RNA molecules present for that gene [282]. Upon excitation at different wavelengths, the 
intensity of the emitted fluorescence of the different dyes corresponds to the amount of bound nucleic 
acid, which is used to calculate expression ratios for the sample relative to the reference set after 
negating background intensities. Raw intensity values are firstly numerically transformed to equivocate 
intensities to the direction of differential gene expression (up- or down-regulation), and normalized relative 
to the expression of one or more reference genes whose levels are assumed to be constant between 
samples. This allows for comparison of microarray data independent of the original hybridization 
intensities and eliminates variations inherent in sample preparations and during experimentation [287]. 
Gene expression data obtained can be absolute measurements of the expression level of a gene in 
abstract units, relative measurements where the expression level of a gene is normalized to its 
expression in a reference condition/sample, discrete values assigned based on a pre-defined threshold 
intensity or as vectors in a three-dimensional space where genes and biological conditions are used to 
form a matrix in the vector space [282]. Gene expression data for all genes under an experimental 
condition – sample expression profile – or for a gene across different experimental conditions – gene 








2.2: ANALYSIS OF GENE EXPRESSION DATA 
 
2.2.1: Rationale for Analyzing Gene Expression Data 
 
Analysis of gene expression data is primarily based on comparison of gene or sample expression profiles. 
Patterns derived from such analysis provide insights into the underlying biology of sets of genes or 
samples. In order to compare expression profiles, we need a measure to quantify how similar or dissimilar 
are the genes being considered. A variety of distance measures are commonly utilized to calculate 
similarity in expression profiles including Euclidean distance measurements between expression vectors 
per condition and Pearson or Ranked correlation coefficients that measure mean differences in 
magnitude, shape and/or ranking of expression profiles by condition [282]. Clustering methods are then 
further applied to resolved expression data sets to classify genes or samples hierarchically or non-
hierarchically into groups based on similarities in behavior and relationships between gene sets. 
Following the analysis of expression profiles, significant inferences into biological processes can be made 
based on assumptions that genes with similar expression profiles are regulated by the same set of 
transcription factors, have similar transcription factor binding sites, likely encode proteins that interact or 
have related functions, or highlight evolutionarily conserved functional modules [288-290]. Protein-protein 
interaction and transcription factor binding sites can then be predicted, transcriptional regulons 
delineated, and functional pathways designed [282, 291].  
 
2.2.2: Gene Ontology  
Data analysis protocols described above are important to begin to define the biological meaning of output 
obtained from preliminary analysis of microarray data. The genetic information represents independent 
events however, in biology, these events occur in a highly coordinated and interdependent manner and 
thus benefit from bioinformatics software packages, which can elucidate such interdependencies. Since 
the automation of gene ontological analysis was accelerated in 2002 with the launch of Onto-Express and 
DAVID programs [292], several analytic platforms have been designed to correlate expression profiles 
with cytogenetic location, biochemical and molecular  function,  biological  processes, cellular 
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components, and cellular roles of the translated proteins [19]. Some software platforms such as Ingenuity 
Pathway Analysis (IPA) maintain and regularly curate their own database (knowledgebase) in an 
algorithmically defined architecture for gene expression analysis [293]. Figure 2.1 graphically displays an 
evolutionary history of Gene Ontology (GO)-based functional analysis software [19]. In our current 
project, we selectively employed two bioinformatics software packages – Ingenuity Pathway Analysis 




2.2.3: Mechanisms of Knowledgebase Architectural Platforms 
The necessity for downstream in-silico bioinformatics analysis of gene expression data became most 
apparent when it was realized that direct inferences could not be made between statistically defined and 
clustered genetic data and biological function because most genes serve multiple context-dependent 
functions and not all changes in mRNA levels can be directly correlated to experiments being conducted 
[294].  Expertly curated databases assigning genes to various functional categories are firstly used to 
Figure 2.1: History and Evolution of automated gene Ontological software technologies – 
Since the launch of Onto-Express data analysis software platform in 2002 [19], several 
computational software platforms have been designed to analyze microarray based genetic 
surveys and match the explosion in quantity and variance of genomic data types acquired from 
novel high throughput genomic and proteomic technologies. The database for annotation, 
visualization and integrated discovery (DAVID) was used in our studies to verify results of Ingenuity 
Pathway Analysis (IPA)-based preliminary predictive analysis of chemotactic molecules influencing 
migration of retinal progenitor cells. Figure adapted from ‘Ontological analysis of gene expression 
data: current tools, limitations, and open problems. Khatri P, Draghici S. Bioinformatics 2005; 
21:3587-3595.’ 
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annotate candidate gene lists, a process known as Gene Ontology (GO). The candidate gene lists are 
obtained after pre-processing expression profiles of samples or genes from microarray analysis, or 
chosen through an enrichment of hypothesis-driven selection of molecules from vast literature review 
available. GO annotation tools are provided in separate modules as with KEGG, DGEM or DAVID, as part 
of commercial microarray gene-chip applications such as Affymetrix or incorporated into comprehensive 
pathway analysis tools as IPA or Partek [294]. Beyond GO classifications, promoter and regulatory 
network analysis as well as molecular pathway analysis can be performed.  
 
In delineating molecular pathways, the functional interactions between genes are emphasized by 
mapping a list of differentially expressed genes onto functional network pathways designed from vast-
accumulated, constantly curated published data describing molecular interactions. These molecular 
interactions are also statistically ranked to predict significant associations between an inputted 
experimental data set and the pathways defined within the database. Metabolic and kinase-based 
signaling pathways can be defined and inputting expression levels allows monitoring of transcriptionally 
regulated signaling pathways [294]. As most cellular processes involve more than one pathway, multiple 
pathway analysis can be performed to describe emergent networks and functional outcomes. Currently, 
optimal network analyses tools, like IPA, combine GO associations, pathway analysis, transcriptional and 
promoter sequence information with efficient data mining tools. 
 
2.3: DELINEATING MOTILITY-DETERMINISTIC SIGNALING PATHWAYS IN RPCs and PPCs 
  
2.3.1:  Approaches to identifying potential chemotactic factors and signaling pathways for RPC and PPC 
migration 
Being of the same embryonic origin, we performed bioinformatics analysis of migratory mechanisms in 
mammalian retinal tissue and cells, guided by analytic techniques employed to define signaling 
mechanisms of neuronal progenitor movement in the brain during development and for chemotaxis of 
adult neurons. As RPC migration has been associated with laminar positioning during retinal 
development, is known to be guided by intracellular and local environmental cues, and likely involves a 
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complex transcriptional regulatory cascade [256] [295]. We employed a bioinformatics approach to 
account for the myriad of biochemical interactions predicted to govern such chemotactic phenomena in 
retino-neural systems. Our ultimate goal was to define a library of candidate chemotactic molecules that 
modulate transplanted RPC and PPC migration and homing to their laminar position in host retina and to 
characterize the intracellular signaling mechanisms facilitating such cellular response. The functionality of 
the selected molecules and their signaling pathways can then be evaluated in vitro to test the hypothesis 
that in silico predictions of RPC and PPC motility can be applied to modulate motility-deterministic 
mechanisms. The characterization of these migratory, mechanisms capable of guiding successful 
migration of RPCs and PPCs is essential for increasing the efficacy of current photoreceptor replacement 
strategies. 
 
During central nervous system development and adult neurogenesis in the vertebrate brain, several 
extracellular matrix factors have been shown to interact through overlapping canonical intracellular 
signaling pathways to direct neuroblast migration and integration [195, 196, 245, 296, 297]. In the sub-
ventricular zone (SVZ) and cortex, the expression of Netrin and its receptors neogenin and DCC (deleted 
in colorectal cancer), prokineticin2 (PK2) and its receptors PRK1 and PRK2, and insulin-like growth factor 
(IGF-1) have all been implicated in attraction of neuroblasts [194, 296] ,while semaphorins and Slit-1 and 
Slit-2 expression in the SVZ and septum are thought to repel neuroblasts away from the SVZ during late 
stage adult neurogenesis [194-196]. The function of Slit proteins are further mediated by astrocyte-
derived migration inducing activity (MIA) factor secreted in the olfactory bulb (OB) [197]. Several 
intracellular molecular hubs such as protein kinase 5 (Cdk5), disabled homolog 1 (Dab1), ras-related C3 
botulinum toxin substrate 1 (Rac1) and focal adhesion kinase (FAK) [245] have been identified that 
centralize, control and translate extracellular signals for migration of most neuronal sub-types. Molecular 
pathways such as the cytoskeletal remodeling pathway involving calmodulin signaling and Akt1-DNA 
transcription networks have also been implicated in neuronal migration [247]. According to Ghashghaei et 
al [195], coordination of extracellular matrix, cell adhesion molecules, and cell-surface kinase or integrin 
signaling receptors such as tyrosine kinase receptor ErbB4 and its ligands neuregulins 1 and 2 (NRG1 
and NRG2), is required to maintain migration of neuroblasts. We predicted that RPCs in the retina would 
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respond to analogous canonical networks of guidance mechanisms directing migrating neural cells in the 
SVZ and cortex given their ontogenetic relationship [241, 298, 299].  
 
The elucidation of major neuronal signaling pathways and molecular networks arose from statistically 
significant predictions of molecular connectivity resolved with bioinformatics technologies [245, 247-252]. 
Similarly, expression profiles of post-natal retina [300], retinal pigment epithelia [301], retinal progenitor 
cells (RPCs) [302, 303], and migratory retinal endothelial cells [253] begin to describe signaling events in 
the retinal environment. In the research of this thesis, we begin to delineate migratory signaling of RPCs 
and PPCs by employing three successive bioinformatics methodologies: 1) Analysis of literature-derived 
candidate genes and pathways specific for retinal progenitor motility, 2) Mining genomic expression data 
of PPCs for potential chemotactic receptors, and 3) Analysis of chemotactic ligands from microarray data 
of normal and damaged retinal tissue. Computation of transcript gene expression was performed on an 
Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com, Redwood City, CA) software 
platform. Development of our final IPA based microarray data analysis was built upon techniques learned 
through our initial literature-derived migratory gene identification and enrichment. 
 
2.3.2: Enrichment analysis of literature-derived candidate genes and pathways specific for retinal cell 
motility 
 
Initial literature review of possible chemotactic molecules for RPCs and PPCs either during retinal 
development or in adult niches for reparative purposes, yielded a dearth of information specific for the 
tissue type, with most correlates documenting motility studies using cells of the nervous system and 
cancerous cells [195, 238, 245, 303]. However, using neuronal motility as a guide, we compiled a small 
library of seven (7) extracellular cues, prioritized by the efficiency of their receptor binding interactions in 
activating downstream signals that stimulate movement in the neural cell systems studied [196, 304]. 
These molecules are key players in a symphony orchestrated both during axon guidance and positioning 
in embryonic nervous system development and in early stage adult neurogenesis in the subventricular 
zone (SVZ) and subgranular regions of the brain where resident pools of slow-dividing, glia-like stem cells 
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generate progenitors that migrate along the rostral migratory stream (RMS) towards the olfactory bulb 
[33, 194-196]. The molecules represent members of major chemokine families including Netrin, ephrins 
and Slit proteins and are presented in Table 2.1 along with their characteristic motility functions in neural 
cell types. These cues served as seed genes input into the Ingenuity Pathway Analysis (IPA) software to  
generate interacting receptors, cytoplasmic and nuclear signaling pathways that intersect to yield a 
predictive model network biased towards activity in mouse neural tissue and retina (Figure 2.2). Genes 
that mapped to defined networks in IPA knowledgebase were labeled Network Eligible (NE) (N=32) and 
are presented in Table 2.2. The predictive network for motility in retino-neural systems was then verified 
with DAVID bioinformatics software [47, 48] by mapping the same 7-molecule library as gene identifiers 
onto a precompiled annotated gene knowledgebase architecture as has previously been performed [305]. 
NE genes were then correlated to canonical pathways in IPA to define sub-networks of interacting genes 
within our NE database by analyzing the number of NE genes that mapped to a canonical pathway using 
a Fisher’s exact test that generated p-values for the probability of associations between NE and 
canonical pathway. 
 
The top three canonical signaling pathways correlated with NE molecules were axonal guidance 
(p=8.12E-21), Ephrin receptor (p=1.54E-17) and FGF (p=2.39E-06) signaling. Two of the three canonical 
network pathways overlay the predictive network pathway map shown in Figure 2.2. Functions 
associated with these pathways include neuronal migration, cell morphology and nervous system 
development. A mammalian retinal tissue-specific enrichment analysis of NE molecules was then 
performed in IPA by predicting direct and indirect, upstream and downstream molecular connections to 
NE molecules that map to the top three canonical signaling pathways identified. By predicting second 










Biological Function Subcellular 
localization 
Receptor/Ligand 
Reelin RELN Regulates neuronal migration; Proteolytic activity on extracellular 
matrix adhesion molecules such as fibronectin, laminin and 
collagen; Neuronal positioning during embryogenesis; Required for 
the normal complement of rod bipolar cells to provide synaptic input 
to type AII amacrine cells; Chemorepellant [306-310],  
Extracellular matrix 
serine protease 
produced by neurons 
in the Ganglion Cell 
layer (GCL) of the 
retina 
ApoER2 (Apolipoprotein E receptor-
2) or Very Low Density Lipoprotein 
Receptor (VLDLR) 
Netrin 1 NTN1 Exhibits chemoattractant or repellant biological activity on 
neurons/cells depending on receptor; axon guidance, retinal neurite 
extension, guided migration of immature neurons; gradient-induced 
attractive and repulsive activity sorts ventral telenchephalic neurons 
to distinct cortical domains [243, 311-317] 
Produced by target 
axons in neural 
microenvironment 
Chemoattraction: 
Deleted in Colorectal Cancer (DCC) 
receptor Chemorepulsion: 
UNC5 – Uncoordinated locomotion 
5 receptor 
SLIT-1,  SLIT Regulating axon guidance and branching, and neural migration; 
expression in the sub-ventricular zone (SVZ) and septum repel 
neuroblasts towards the olfactory bulb; increasing dendritic growth 
and branching [33, 318, 319] 
 
Extracellular matrix ROBO (Roundabout) receptor 
Eph-Type A 
Receptor 7 
EPHA 7 Receptor tyrosine kinase that binds GPI-anchored ephrin-A family of 
ligands leading to contact-dependent bidirectional signaling, 
regulating brain development and activates components of the ERK 
signaling pathway. Involved in the guidance of corticothalamic axons 
and proper topographic mapping of retinal axons to the colliculus 
[320-322].  
Plasma Membrane Ephrin A5 cognate ligand  
 
Tenascin R TNR Reorientation from tangential to radial migration in mitral cells; 
neurite outgrowth, neural cell adhesion and modulation of sodium 
channel function. the extracellular matrix glycoprotein tenascin-R, 
expressed in the adult mouse olfactory bulb, initiates both the 
detachment of neuroblasts from chains and their radial migration 








IGF-1 Implicated in post-natal migration of neuroblasts in sub-ventricular 
zone (SVZ) into rostral migratory stream; Ectopic expression in 
retina promotes migration and integration of sub-retinally 
transplanted photoreceptor precursors [194, 324, 325]. 




EPHB2 Positively regulate progenitor proliferation while also disrupting 
neuroblast migration in the postnatal SVZ [319, 326]. 
Transmembrane 
protein 
Ephrin B ligand 
Table 2.1: Preliminary literature Review for Mammalian Retino-neural Chemotactic Genes - An extensive literature search for genes whose expression 
correlate to cellular movement, axonal positioning and homing functions during retinal and neural embryonic development, and neuroblast recruitment activities in 
adult tissues, were compiled and used as seed input genes in Ingenuity Pathway Analysis (IPA) bioinformatics software. This in-silico analysis attempts to grow the 
input gene connectivity, biased for retino-neural tissues, and identifying downstream signaling targets that may influence retinal progenitor (RPC) cell migration. As 































Figure 2.2: Predictive Network Pathway for Retinal Progenitor Cell 
Migration – An initial seven-molecule library compiled from literature review for 
chemotactic genes in retino-neural tissues was expounded using the Ingenuity 
Pathway Analysis knowledgebase, specified for their occurrence in mammalian 
retinal tissue and for cellular movement function, to yield a predictive model 
network of downstream signals influencing RPC migration. Both direct and 
indirect interactions between the Network Eligible (NE) genes (N=32) are 
highlighted in the network categorized by subcellular localization in the cell. An 
overlay of active canonical networks reveals axonal guidance (p=8.12E-21) and 
ephrin receptor signaling (p=1.54E-17) as possible underlying signaling 
pathways governing RPC motility.  
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Symbol Entrez Gene Name Family 
APOE apolipoprotein E transporter 
CXCL12 chemokine (C-X-C motif) ligand 12 cytokine 
DAB1 disabled homolog 1 (Drosophila) other 
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 translation regulator 
EFNB1 ephrin-B1 other 
EPHA7 EPH receptor A7 kinase 
EPHB2 EPH receptor B2 kinase 
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) kinase 
FABP7 fatty acid binding protein 7, brain transporter 
FGF1 fibroblast growth factor 1 (acidic) growth factor 
FGFR1 fibroblast growth factor receptor 1 kinase 
HIF1A hypoxia inducible factor 1 transcription regulator 
IGF1 insulin-like growth factor 1 (somatomedin C) growth factor 
LIF leukemia inhibitory factor (cholinergic differentiation factor) cytokine 
LRP8 apolipoprotein e receptor transmembrane receptor 
MAPK1 mitogen-activated protein kinase 1 kinase 
NEO1 neogenin 1 transcription regulator 
NOS1 nitric oxide synthase 1 (neuronal) enzyme 
NR1H3 nuclear receptor subfamily 1, group H, member 3 ligand-dependent nuclear 
receptor 
NRG1 neuregulin 1 growth factor 
NTN1 netrin 1 other 
OTX2 orthodenticle homeobox 2 transcription regulator 
PAX6 paired box 6 transcription regulator 
PRL prolactin cytokine 
PROK2 prokineticin 2 other 
RAX retina and anterior neural fold homeobox transcription regulator 
RELN reelin peptidase 
SEMA3C sema domain, (semaphorin) 3C other 
SLIT1 slit homolog 1 (Drosophila) other 
SLIT2 slit homolog 2 (Drosophila) other 
SOX2 SRY (sex determining region Y)-box 2 transcription regulator 
VEGFA vascular endothelial growth factor A growth factor 
Table 2.2: IPA Network Eligible Genes – Candidate retino-neural chemotactic seed gene connectivity were 
expounded using Ingenuity Pathway Analysis (IPA) bioinformatics to yield 32 Network Eligible (NE) genes 
predicted to influence retinal progenitor cell (RPC) migration. These genes were then used to design the 
function-specific networking pathway depicted in Figure 2.2. 
 
selective to the canonical signaling molecules, we further exclude interactions not relevant to cell motility, 
while expressing other cytoplasmic and nuclear gene connections possible in the network. This operation 
produced an enriched novel predictive network of interacting signaling pathways that expanded the data 
set for retino-neural motility genes to N=51. The expanded network, depicted in Figure 2.3, annotated 
molecular interactions pertaining to microtubule dynamics, cell proliferation and migration. Dominant 
interdependent biochemical signaling identifies the extracellular protein Reelin (RELN) regulation of 
Disabled-1 (DAB1) via the low density lipoprotein receptor-related protein 8 (LRP8) [49] and the mitogen-
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activated protein kinase (MAPK) pathway activated by insulin-like growth factor 1 (IGF1), fibroblast 
growth factor 1 (FGF1), and vascular endothelial growth factor A (VEGFA).  These signaling processes 
are critical for directing the migration of cortical neurons and microtubule function for neuronal lamination 
during brain development [50]. Additionally, the extensive overlapping connectivity between molecules 
depicted in Figure 2.3 as well as the numerous indirect relationships suggests that in a similar manner to 
the brain, signaling processes mediating progenitor migration in the retinal microenvironment is highly 
regulated via second messenger pathways.   
 
Following the enrichment network analysis, ligands that may serve as targets for retinal progenitor cell 
migration studies included the extracellular cytokine reelin (RELN) which is active in neuronal migration 
[51, 52], brain derived neurotrophic factor (BDNF) active in axonal guidance [53], fibroblast growth factor 
(FGF) and plasminogen activator (PLAT), both expressed during survival, proliferation and migration [24, 
54], and insulin-like growth factor (IGF-1).  Cell-surface receptors predicted to be involved in directional 
migration include ionotropic glutamate (NMDA-GRIN, NMDA-Ca2+), ephrin (Eph), FGF receptor and 
CXC-motif chemokine receptor type 4 (CXCR4) [55]. For clarity, candidate molecules identified in the 
enrichment model are presented as matching ligand-receptor pairs and non-matched ligands and 
receptors in Table 2.3. Priority is given to the matched pairs, as the likelihood of a biochemical interaction 
is more likely if the cognate ligand or receptor are present in the molecular milieu. Priority is also given to 
ligand and/or receptors present specifically in mammalian retinal tissue. The matched pair Neuregulin-
ErbB receptor signaling has previously been described in the nervous system to stimulate cerebellar 
granular cell migration along radial glial fibers during development [327] and isoforms of the ligand act as 
short and long range chemoattractants, providing directional guidance to GABAergic interneurons 
migrating from the subpallium to the developing cortex of mice [328]. In developing rat retina, the 
expression of Neuregulin and an ErbB isoform have also been postulated to regulate retinal ganglion cell 
dendrite growth that actuates their migration to the RGC layer from the ventricular surface, and the 
consequent formation of synaptic connections with amacrine cells [329]. Upregulation of chemokine type 
4 (CXCR4) and its ligand CXCL12 in the inner limiting membrane of the developing human fetal retina 
have been associated with the differentiation of angioblasts and their migration to sites of vessel 
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assembly [330]. Target chemotactic interactions resolved from this enrichment analysis were proposed to 






Figure 2.3: Enrichment Analysis of IPA-predicted retinal chemotactic molecules and signaling pathways - 
Predictive network pathway from Figure 2.2 was further enriched to include second-messenger signaling upstream 
and downstream the network eligible (NE) genes for a comprehensive account of all possible chemotactic retino-
neural interactions. Both direct and indirect genetic connectivity are depicted categorized by their subcellular 
localization in the cell. Some discernable signaling pathways for RPC motility in the network include Reelin 
signaling which targets DAB1; the MAPK pathway that is activated by IGF1, FGF1 and VEGFA; and ApoE binding 
to LRP8. 
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Ligand Description  Receptor Description 






CXCR4 chemokine receptor type 4 
FGF1 fibroblast growth factor 1 (acidic) FGFR1 fibroblast growth factor receptor 1 
FGF2 Fibroblast Growth factor 2 FGFR1 fibroblast growth factor receptor 1 
RELN reelin LRP8 apolipoprotein e receptor 
EFNB1 ephrin-B1 EPHB2 EPH receptor B2 
NRG1 neuregulin 1 ERBB4 Erythroblastic leukamia viral oncogene homolog 4 
     








EPHB2 EPH receptor B2 
SLIT1 slit homolog 1 (Drosophila) GRIN1 Glutamate Receptor, Ionotropic, N-methyl D-aspartate 1 
SLIT2 slit homolog 2 (Drosophila) GRIN2A Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2A 
VEGFA vascular endothelial growth factor A GRIN2B Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2B 
PLAT Plasminogen Activator, tissue GRIN2C Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2C 
EFNB1 Ephrin-B1   
CCL5 Chemokine (C-C motif) ligand 5   
NRG1 neuregulin 1   
APP Amyloid beta (A4) precursor protein   
IGF1 insulin-like growth factor 1   
BCAR1 Breast cancer anti-estrogen resistant   
NTN1 Netrin 1   
BDNF Brain-derived neurotrophic factor   
Table 2.3: Predicted Ligand-Receptor Interactions from Enrichment Network Analysis – Our predictive motility 
network-signaling model was enriched by adding up- and downstream second-messenger molecular connectivity. 
The new gene list was then used to create an enrichment model of RPC motility signaling networks (Figure 2.3) and 
key matched and non-matched ligands and receptors are presented in this table. Selection priority is given to the 
matched ligand-receptor pairs as they identify possible candidates for future invitro function validation tests for 
motility. Some original seed input genes including RELN, NTN1 and SLIT recur in this list, also emphasize their 
possible role in regulating RPC motility. 
 
2.3.3: Mining genomic annotations of photoreceptor precursors for potential chemotactic factors 
The enrichment analysis performed above synthesizes networks of molecular connectivity from gene 
annotations provided in the Ingenuity Pathway Analysis knowledgebase. Hierarchies of functional clusters 
and tissue-specific gene groupings used in the analysis are generally compiled from results of peer-
reviewed investigations into specific biological phenomena. As the accuracy and inclusive nature of the 
gene knowledgebase depends on the breadth and frequency of data curating process (usually quarterly), 
it is possible that important cell-specific physiological information might be absent when the software 
analytical tools are employed. For a comprehensive account of cell-specific signaling interactions 
governing migratory processes observed in RPCs and PPCs, we employed a back-end approach by 
mining relevant source genomic databases publicly available and using IPA bioinformatics. RPC and PPC 
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migration has previously been associated with laminar positioning during retinal development, is guided 
by intracellular and local environmental cues, and likely involves a complex transcriptional regulatory 
cascade [256, 295]. We thus explored the following microarray datasets of mouse rod and cone PPCs 
available in the Gene Omnibus (GEO) database [331], obtained around peak periods of rod genesis 
(post-natal day 4) [332] and cone genesis (embryonic day 17.5) [333] - 1) P4 mouse Rho-EGFP rod 
progenitors (GEO Accession GSE29318) [332]; 2) E17.5 mouse Bac‐Crx‐EGFP cone progenitors (GEO 
Accession GSE25607) [333]. These ontogenetic stages also coincide with active migration periods of 
PPCs to their laminar loci, prior to onset of terminal cell type differentiation processes [256, 263]. Tissue-
specific genetic data have previously been used in a similar way to formulate statistically significant 
predictions of molecular connectivity in chemotactic pathways of migrating adult neural progenitors in the 
sub-ventricular zone (SVZ) and cortex [245, 252] and in angiogenetic processes of migratory retinal 
endothelial tip cells [253]. 
 
After uploading each microarray data set into IPA, rod and cone genes were mapped to their 
corresponding identifier in IPA’s knowledgebase and resolved as cone (n=20,200) and rod (19,206) 
network eligible (NE) molecules. The NE data sets was then biased towards their occurrence in 
mammalian retinal and nervous tissue and overlaid onto the IPA global molecular interactions platform. 
Gene networks were algorithmically generated based on connectivity in the tissues specified. Analysis of 
the networks using the right-tailed Fisher’s exact test identified biological functions most significantly 
correlated to the molecules in the network and p-values determined the probability that each biological 
function assigned to that network was due to chance alone. The top associated network functions 
identified in both data sets included tissue morphology, cellular movement, cell-to-cell signaling, 
embryonic and nervous system development. Network molecules associated with the cellular movement 
function (3.79E-02<p>7.96E-03) were then used to design predictive pathways of rod and cone PPC 
migration (Figures 2.4 and 2.5 respectively). The pathway from the rods data set overlapped with axon 
guidance and G-protein coupled receptor (GPCR) signaling canonical pathways, while cytokine-based 
acute phase response signaling, Neuregulin, GPCR and IL-6 signaling were identified for cone genes. As 
neural cell responses to extracellular motogenic cues involve ligand-receptor interactions [245], 
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extracellular and plasma membrane-bound molecules common to both the rod (N=79) and cone (N=132) 
signaling pathways were merged and receptor-ligand relationships appropriately matched. A sample of 
the results set is presented in Table 2.4. The table depicts some members of the chemokine receptor 
family that bind C-C or CXC motif ligands, of which up-regulation of chemokine type 4 (CXCR4) in the 
inner limiting membrane of the developing human fetal retina has been associated with the differentiation 
of angioblasts and their migration to sites of vessel assembly [330]. The epidermal growth factor (EGF) 
family of ligands that include ampiregullin, EGF, TGF-alpha, heparin-binding EGF (HB-EGF), betacellulin 
and epiregulin is also well represented and their migratory role in nervous systems has been well studied 
[334]. The representation of the matrixin family members, collagenase MMP-8 and stromelysin MMP-3, 
and their suppressants, tissue inhibitors of MMPs (TIMP) suggests active regulation of progenitor 
development, ECM degradation and retinal tissue remodeling processes [335]. Elevated matrix 
metalloproteinase (MMP) expression has also been reported to induce an environment permissive for 
migration and integration of photoreceptor progenitors and decreased deposition of inhibitory ECM 
molecules [336, 337]. Following the data mining protocol employed, four signaling pathways were 
eminent – Neuregulin-ErBB receptor signaling, Chemokine (C-C or CXC) signaling, Epidermal Growth 
Factor Receptor (EGFR) signaling, and Matrixin (MMP) regulatory signaling. To further our investigations 
we performed in vitro validation of the chemotactic effect of a member of the EGFR signaling family – 

























Figure 2.4: Predicted molecular interactions governing the migration of Rod Photoreceptor 
Progenitors - Using IPA core analysis tool, rod gene microarray data was specified for their expression 
in mammalian retino-neural tissue and statistically mapped to the cellular movement functional cluster 
(p=7.96E-03). Results depict only direct molecular interactions with specified sub-cellular locations (ECM, 
Plasma membrane, Cytoplasm and Nucleus) of the genes, overlaid with cell chemotaxis and homing 
function identifiers Top resolved pathways include G-Protein coupled receptor signaling, Axon guidance 









Figure 2.5: Predicted molecular interactions governing the migration of Cone Photoreceptor 
Progenitors - Using IPA core analysis tool, cone gene microarray data was specified for their expression 
in mammalian retino-neural tissue and statistically mapped to the cellular movement functional cluster 
(p=3.79E-02). Results depict only direct molecular interactions with specified sub-cellular location (ECM, 
Plasma membrane, Cytoplasm and Nucleus) of the genes, overlaid with cell chemotaxis and homing 
function identifiers. Top resolved signaling pathways include Neuregulin and Epidermal growth factor 
signaling pathways, and cytokine-mediated acute phase response signaling. 
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Resolved Interacting Cognate Molecules 
Ligands  Receptor/Co-Factor 
Symbol Nomenclature  Symbol Nomenclature 
AREG/A
REGB amphiregulin  
EGFR epidermal growth factor receptor 
EGF epidermal growth factor  
BTC betacellulin  
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,  
TGFA transforming growth factor, alpha  
NRG1 neuregulin 1  
ERBB4 
v-erb-a erythroblastic 
leukemia viral oncogene 
homolog 4 (avian) 
EREG epiregulin  
HBEGF heparin-binding EGF-like growth factor  
NRG1 neuregulin 1  ERBB3 
v-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 3 (avian) 
CCL1 chemokine (C-C motif) ligand 1  CCR8 
chemokine (C-C motif) 
receptor 8 
CCL2 chemokine (C-C motif) ligand 2  
CCR4 chemokine (C-C motif) receptor 4 CCL17 chemokine (C-C motif) ligand 17  
CCL22 chemokine (C-C motif) ligand 22  
Ccl9 chemokine (C-C motif) ligand 9  CCR1 chemokine (C-C motif) receptor 1 CCL3L1/
CCL3L3 chemokine (C-C motif) ligand 3-like 1  
CCL20 chemokine (C-C motif) ligand 20  CCR6 
chemokine (C-C motif) 
receptor 6 
CCL24 chemokine (C-C motif) ligand 24  CCR3 chemokine (C-C motif) receptor 3 CCL3L1/
CCL3L3 chemokine (C-C motif) ligand 3-like 1  
CXCL1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha)  
CXCR2 chemokine (C-X-C motif) receptor 2 CXCL2 chemokine (C-X-C motif) ligand 2  
CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)  
CXCL16 chemokine (C-X-C motif) ligand 16  CXCR6 
chemokine (C-X-C motif) 
receptor 6 
IFNA16 interferon, alpha 16  IFNAR1 interferon (alpha, beta and omega) receptor 1 IFNA1/IF
NA13 interferon, alpha 1  
IL6 interleukin 6 (interferon, beta 2)  IL6R interleukin 6 receptor 
IL11 interleukin 11  IL6ST 
interleukin 6 signal 
transducer (gp130, 
oncostatin M receptor) OSM oncostatin M  
IL1A interleukin 1, alpha  
IL1R1 interleukin 1 receptor, type I 
IL1B interleukin 1, beta  
SIGIRR single immunoglobulin and toll-interleukin 1 receptor (TIR) domain  
LEP leptin  LEPR leptin receptor 
NPY neuropeptide Y  NPY5R 




protein C (inactivator of coagulation factors Va and 
VIIIa) 
 PROCR 






inhibitor, clade E (nexin, 
plasminogen activator 
inhibitor type 1), member 
1 
 THBD thrombomodulin 
RIPK1 









epidermal growth factor 
receptor 
TIMP1 
TIMP metallopeptidase inhibitor 1 
 MMP3 
matrix metallopeptidase 






TIMP3 TIMP metallopeptidase inhibitor 3  MMP3 
matrix metallopeptidase 
3 (stromelysin 1, 
progelatinase) 
Table 2.4: Matched Interacting Molecular Partners Common to both Rod and Cone Microarray 
Data – Following network pathway designs of rod and cone gene microarray data relevant to cellular 
movement function in mammalian retino-neural systems, extracellular and plasma membrane-bound 
molecules common to both the rod (N=79) and cone (N=132) pathway designs were merged and 
receptor-ligand relationships appropriately matched. A sample set of the results is presented in the 
table, revealing four major signaling families – Epidermal Growth Factor (EGFR) signaling, Matrix 
Metalloproteinase (MMP) regulation, Chemokine (C-C or CXC) signaling, and Neuregulin-ErBB 
receptor signaling. The results culminate data mining efforts of relevant ontogenetic retinal tissue data 
and formed the basis for selecting the initial chemotactic factors validated for their effect on retinal 
progenitor cell motility using chemotactic assays. 
 
 
2.3.4: Genomic analysis of microarray data typifying photoreceptor transplantation into damaged retinal 
tissue 
To characterize chemotactic cues released by damaged retina that may stimulate increased migration of 
sub-retinally transplanted RPCs and PPCs as has been observed in recent studies [43, 165, 167, 172, 
173], we initially proposed a comprehensive genomic and biochemical analysis strategy where a laser 
microdissection procedure would be used to isolate the major retinal laminar layers so that differential 
extracellular and intracellular molecular expression states of the various layers can be ascertained using 
high throughput technologies as HPLC-MS, Gene-Chip microarray and RT-qPCR methods. Comparison 
of molecules identified in the different lamina layers will be especially important in identifying the potential 
homing cues for PPCs.  
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However, we realized that our investigative goals could be achieved using efficient computational 
techniques that can model the transplantation paradigms being studied. Using organism and tissue-
specific ontogenetically defined microarray gene expression data available in the publicly accessed 
databases with appropriate MIAME annotation, we could perform in-silico modeling of PPC 
transplantation into damaged mammalian retinal tissue and obtain the desired genetic and biochemical 
data. In addition to annotating genes in software-knowledgebase platforms, we can refine the data mining 
protocol previously employed in section 2.3.3 by also taking into account the current relative expression 
state of the respective genes when predicting their influence on PPC migration. An increasing number of 
studies are utilizing bioinformatics platforms, their knowledgebase and analytical tools in a analogous 
manner to understand cell and tissue specific signaling interactions [6, 338, 339], and many research 
groups have similarly identified the efficacy of this non-invasive, cost-effective strategy, combining it with 
traditional wet lab methods for gene function discovery [6, 23].  We took advantage of the comprehensive, 
curated knowledgebase of literature findings from genomic and molecular research investigations, 
available in IPA, to reveal chemotactic signaling between damaged retina ECM molecules and cell 
surface PPCs receptors.  
 
2.3.4.1: Rationale for Selecting Retinal Microarray Data   
The feasibility of cell replacement as a therapeutic remedy for vision loss lies mostly in the ability of sub-
retinally transplanted cells to move from the interphotoreceptor matrix (IPM) to the adjacent outer nuclear 
layer and integrate in proportions large enough to affect/reverse the vision phenotype in an appropriate 
damaged host retina [146, 148, 162]. Post-mitotic PPCs have been found to be the ideal donor cells but 
sourcing them from second-trimester human fetuses, which are limited in supply, are faced with ethical 
constraints [83, 162]. Even when other replacement cell sources are used, ES/iPS cell-derived PPCs still 
migrate in low numbers in recipient retina [49, 95] similar to results found in studies using other 
mammalian photoreceptor progenitor cells [48, 146, 162]. Additionally, of the populations that 
successfully migrate into the host retina in these studies, only a small percentage (≤3%) have been 
shown to integrate in the appropriate retino-neural laminar loci or express ontogenetic photoreceptor 
morphology or markers [16, 17, 112, 148, 162, 165, 166]. Normal and diseased retinal extracellular 
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microenvironments and retinal pigment epithelia compound glycoprotein moieties and secrete diffusible 
chemicals that orchestrate intrinsic decision-making of transplanted cells [145, 167, 168], evidenced by 
increased donor cell integration after genetic manipulation of the chemical architecture of the retina [165, 
169]. To advance photoreceptor cell replacement strategies, it is essential that the biochemical cross talk 
between specified cell grafts and host retina is better understood.  
 
We reasoned that comparing existing time-defined molecular expression data of PPCs with gene 
expression data of recipient adult damaged retinal model would begin to describe the biochemical 
interactions and gene expression patterns in stasis at onset of transplantation. Our goal was to delineate 
libraries of motogenic extracellular cues that directly target receptors expressed on PPCs and cause 
downstream signaling and motility. For this purpose, we resolved only the plasma membrane receptor 
expression profiles of the previously employed publicly available rod and cone PPC gene microarray 
datasets in the Gene Omnibus (GEO) database [331] - P4 mouse Rho-EGFP rod PPCs (GEO Accession 
GSE29318) [332] and E17.5 mouse Bac‐Crx‐EGFP cone PPCs (GEO Accession GSE25607) [333] using 
the Ingenuity Pathway Analysis (IPA) software tool. We then matched the datasets with extracellular 
matrix ligands released from a 10-week old light-damaged mouse neurosensory retina and retinal 
pigment epithelia (GEO Accession GSM928109) [340].. The rod and cone PPC ontogenetic stages 
coincide with active migration periods and laminar positioning during embryonic and postnatal 
development [256, 263] The damaged retinal model is an established retinal degenerative model inducing 
retinal oxidative stress [340].  
 
2.3.4.2: Pre-processing of retinal microarray data 
MIAME report for independent microarray datasets of rod PPCs (A), cone PPCs (B) and light-damaged 
retinal tissue (C) indicated that cDNA from each cell or tissue type was hybridized on Affymetrix Mouse 
Genome 430 2.0 array for (A) and Mouse 1.0 ST arrays for (B) and (C) datasets respectively in triplicates 
per experimental condition for 16hrs at 45°C. Signal intensities of all replicates were quantile-normalized 
using the RMA normalization algorithm filtered via the respective established threshold intensities per 
experimental study. Replicate intensity values were then log2 transformed where appropriate, and a 
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significance test for change in average intensities of positive versus negative FAC/MAC-sorted triplicate 
gene transcripts was calculated using a two-tailed two-sample t-test with unequal variances sampled from 
the same population of genes in excel spreadsheets. Transcript data was then input into the IPA 
bioinformatics software program that annotates and automates the computation of fold change values. 
Genes identified as having at least a two-fold change between experimental and control conditions and 
whose significance test of change falls below the p-value threshold of 0.05 annotate gene products that 
may affect various cellular processes, with the level of expression informing statistical predictions of cell 
phenotypes.  
 
To specifically examine the expression profile of the rod and cone PPC gene transcripts, volcano plots of 
the negative logarithm of the p-value of each IPA-annotated gene transcript (Y-axis) versus a logarithmic 
function to the base 2 of their respective fold change (X-axis) was performed (Figure 2.6). Approximately 
26.82% of rod PPC gene transcripts exhibited statistically significant difference between negative and 
positive-sorted genes less than the value of 0.05 and only 0.8% of the genes expressed more than two-
fold up- or downregulated states. 10.3% of cone genes expressed significant p<0.05 with about 2.27% 
exhibited greater than two-fold change in expression states. Genes with high statistical significance and 
large magnitude fold change criterion depict dynamic expression states that play major roles in PPC 
function, and they are categorized by their subcellular localization in the extracellular matrix (ECM), 
plasma membrane, cytoplasm or nucleus. Figures 2.6A and 2.6B display the rod and cone PPC gene 
data sets respectively, with selected high profile criterion genes identified by numbered red circles in their 
dispersed spatial locations. In the rod PPC gene data (N=38626), elevated nuclear Pax7 expression 
(Circle 1; X=2.05, Y=4.7) could label the multipotent organogenesis stem cell state as with most other 
Pax proteins [341] and Pax7 has been identified as one of the first cohort of transcription factors to 
specify the neural plate border and initiate the expression of secondary factors as Sox9/10, FoxD3, and c- 
Myc that specify the neural crest [341-343]. Other early developmental rod PPC genes fitting the high 
expression profile criterion were identified and include the leucine-rich repeat containing 4C membrane 
protein (LRRC4C) binding partner specific for Netrin G1, identified as an axon guidance-signaling 
molecule that guides outgrowth of developing mouse thalamo-cortical axons to their striatum and cerebral 
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cortex destinations [344], and is up-regulated in mouse retinal neovascularization models and myopia age 
of onset [345, 346]. Membrane-Associated Ring Finger (C3HC4) 1, E3 Ubiquitin Protein (MARCH 1) 
MARCH proteins adds ubiquitin to target lysines in substrate proteins signaling their vesicular transport 
towards endosomal/lysosomal degradation and may explain photoreceptor degeneration process is 
associated with the remodeling of the inner retina, at the state the cDNA lysates were prepared [60]. The 
down-regulated state of another early neuronal progenitor marker lysophosphatidic acid (LPA) receptor 4 
type I (LPAR4) (Circle 3; X=-1.1, Y=5.4), the ubiquitously expressed rhodopsin-like G protein–coupled 
receptor (GPCRs), might identify active regulatory signaling for embryonic stem cell proliferation, 
differentiation and motility as previously described for neuroblasts, fibroblasts and cancer cells [347, 348]. 
Ultimate validation of the rod progenitor cell state specification of our data set is by upregulated 
Rhodopsin (Rho) expression (Circle 2; X= 1.62, Y=4.04) subsequent to the peak of rod genesis and 
required for photoreceptor cell viability after birth and image-forming vision at low light [60, 61]. In 
combination, these gene expression states describe shifts from multi-potency towards rod PPC fate and 












Figure 2.6: Volcano plots of rod and cone PPC gene expression profiles – Genes with high statistical 
significance (Y-axis) and large magnitude fold change values (X-axis) are of interest and their dynamic expression 
indicate the important role they play in photoreceptor precursor cell fate and function. A few of these genes have 
been identified (red circles) in our cDNA microarray datasets of P4 mouse Rho-EGFP rod progenitors (N=38626) 
(GSE29318) (A) and E17.5 mouse Bac-Crx-EGFP cone progenitors (N=20744) (GSE25607) (B). 1) Nuclear gene 
PAX7, plasma membrane proteins rhodopsin (Rho) (2) and rho-like G-protein coupled receptor LPAR4 (3) illuminate 
shift in genetic specification from multi-potency towards photoreceptor cell fate specification and peak of rod 
genesis. A similar maturation and differentiation profile in the cone gene array show relative high transcript levels of 
semaphorin co-receptor PLXNA2 (5) suggesting premature retinal lamination and axon guidance processes while 
the significantly up-regulated state of transcriptional activator NeuroD4 (6) validates the ontogenetic overlap 
between cone genesis and onset of amacrine cell fate specification (E17.5) in our cone microarray dataset. Gene 
array displays are categorized by subcellular location. Red dashed line indicates the p-value cut-off (0.05). 
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A similar differentiation profile exists in the cone PPC gene array (N=20744) (Figure 2.6B) annotated by 
IPA which exhibited high transcript levels of plexin co-receptor PLXNA2 (Circle 5; X=1.16, Y=3.77) which 
is involved in the proper lamination of the inner plexiform layer (IPL), remodeling of the cytoskeleton, and 
axon guidance by affecting binding affinity of semaphorins 3/6 to their receptors [61, 349]. Other global 
expression studies report insignificant expression levels for PLXNA2 during mouse embryogenesis [350]. 
The significantly up-regulated state of the transcriptional activator NeuroD4 (Circle 6; X=2.61, Y=3.20) 
required for the regulation of amacrine cell fate specification in the retina [351, 352] validates the time-
specified ontogenetic overlap between cone and amacrine cell genesis (E17.5) in our cone PPC dataset.  
 
2.3.4.3: Analysis of Microarray Data 
A flowchart of our step-wise bioinformatics analysis, beginning with microarray data, is provided in Figure 
2.7. Gene transcripts from rod PPCs (N=38626) and cone PPCs (N=20744) annotated in the IPA 
knowledgebase were defined as mapped IDs, also termed network eligible (NE) molecules. NE molecules 
were similarly resolved from transcript IDs of neurosensory retina (NSR) and retinal pigment epithelium 
(RPE) of light damaged adult retina (N=23176). Following the subcellular localization of NE molecules to 
their ECM, plasma membrane, cytoplasmic or nuclear loci, and a statistical cut-off for genes whose 
resolved mean intensity values are significantly greater than their negative FAC-sorted analogue by a t-
test p-value of 0.05, NE extracellular matrix (ECM) molecules resolved from the damaged retina NSR and 
RPE dataset were then matched with NE plasma membrane receptors from the rod and cone PPC 
dataset. Matched pairs included – 1) rod receptor genes matched with ECM genes from NSR (N=2013), 
2) rod receptor genes matched with ECM genes from RPE (N=1945), 3) cone receptor genes matched 
with ECM genes from NSR (N=735), and 4) cone receptor genes matched with ECM genes from RPE 
(N=667). These matched pairings predict biochemical interactions between receptors on transplantable 







Figure 2.7: Flow Chart of Bioinformatics Analysis Method for Selected Microarray Datasets. 
Figure description is on the next page.	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After IPA core analysis of the four matched data sets, molecules in each dataset mapping to cellular 
movement functional clusters were used to design signaling networks specifying direct ligand effects on 
their paired receptor while also considering expression levels to predict downstream activating or 
inhibitory effects, or an effect inconsistent with the gene interaction curated in the IPA knowledgebase 
based on the state of the downstream gene in the matching gene pairs. In performing the core analysis 
function on our matched datasets, the IPA network algorithm uses gene identifiers in our data to build 
small networks based on their interconnectivity with molecules they connect to in the IPA knowledgebase. 
A right-tailed Fisher exact test (p<0.05) is then used to calculate the probabilistic fit between the networks 
and lists of biologic functions and canonical signaling pathways curated in the IPA knowledgebase, 
assigning scores to networks based on the probability of associating network molecules to gene 
annotations in the IPA by random chance only [83]. Canonical growth factor and cytokine signaling 
pathways that significantly overlap with our matched datasets were selectively resolved given the 
notoriety of these signaling-type paradigms in cell motility processes [231, 236, 272, 297, 353]. A Z-score 
algorithm was then used to predict activation or inhibition of each resolved canonical signaling pathway 
given the expression state of our matched dataset genes. Pathway computation takes into account both 
the activation state of key molecules in our dataset when the signaling pathway is activated and the 
molecules’ causal relationships with each other based on literature findings, to predict an activity pattern 
for our dataset genes. These Z-score calculations are independent of p-values associated with the 
canonical pathways resolved for our data set, and conventionally, Z-scores greater or less than ±2.0 
indicate predictable canonical pathway activity with highest statistical confidence. As our objective was to 
Figure 2.7: Flow Chart of Bioinformatics Analysis Method for Selected Microarray Datasets - Schematic of work flow for 
selecting genes predicted to be significantly involved in the migration of sub-retinally transplanted photoreceptor precursors in a 
light-damaged model of adult retina. Normalized log transformed replicate intensity values of FAC-sorted genes were assessed 
for significant difference in their expression states (p<0.05), and ratios of positive/negative intensity values of the significantly 
expressed genes were then uploaded to ingenuity pathway analysis (IPA) software platform as fold change values. These 
selected genes were then paired to mimic typical sub-retinal transplantation paradigms – Cone/Rod receptor paired with 
released extracellular matrix molecules from light-damaged retinal tissues. A core analysis of each paired dataset mapped 
constituent genes to their functional annotation in the IPA knowledgebase based on chance alone using a Fisher Exact test, 
and genes involved in cellular movement were selectively used to design network pathways that account for the expression 
profiles of the interacting genes and their effects on cellular movement function. Ligands predicted to activate or inhibit their 
downstream cognate receptors, or whose downstream effect is inconsistent with literature findings in the IPA knowledgebase at 
the current expression state, were selected and the involvement of the ligand and receptor genes in the top ten cellular 
movement subcategories assessed. This analysis was used to determine candidate chemotactic ligand-receptor pairs for invitro 
functional assays validating their influence on cell motility. Signaling cascades downstream candidate receptors were also 
resolved using similar criteria to obtain a custom network model of statistically predicted interactions active following 
transplantation of freshly isolated photoreceptor precursors into light-damaged retina. 
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define motility-deterministic cues in the ECM of recipient retina and their target receptors on PPCs, 
molecules correlating to cellular movement in each data set were selected for two post-analysis 
processing steps. Firstly, a connect function was used to establish direct ECM ligand binding to plasma 
membrane receptors in custom motility-deterministic networks for PPC motility genes. Secondly, a 
Molecule Activity Prediction (MAP) function was used to overlay individual gene expression states to 
predict gene activation state-dependent motility-deterministic interactions existent upon PPCs receptors 
binding NSR and RPE ligands in light-damaged retina. The molecular activity predictor algorithm uses 
node genes in our dataset whose interactions are known to predict the activity of neighboring unknown 
genes given their expression states, and Z-scores the prediction as a measure of statistical confidence.   
 
To rank the degree to which each resolved directly interacting ligand-receptor pair influences cellular 
movement and thus prioritize candidate ligand-receptor pairs for motility validation assays, a subsequent 
MAP analysis was performed using a ‘Grow’ function tool in IPA to statistically define single gene 
expression state effects on the top 10 relevant sub-types of cell motility phenomena (varied across the 4 
custom networks), predicting an activation or inhibition in sub-type function. By specifying only 
downstream ligand effects on scored receptor genes, we relate gene expression states to cell movement 
function, determining the likelihood that a ligand/receptor interaction will activate or inhibit a chosen 
cellular function. In the determination of candidate chemotactic interactions, precedence was given to the 
ratio of the total number of cellular movement sub-types related to each gene in the motility network 
pathways and associated with cellular movement sub-types. The top 10 relevant cellular movement sub-
types were ranked by p-value calculating the probability of involvement of the cell movement sub-type 
relative to gene expression states within our custom networks. Using this method, ligand-receptor 
pairings in which either the ligand or receptor showed at least 80% involvement in the top 10 cellular 
movement sub-types were selected for further analysis. Subsequently, an IPA Downstream Effects 
analysis was performed via the ‘Grow’ function in IPA to determine nuclear and cytoplasmic molecules 
related to our resolved ECM ligand and plasma membrane receptor pairs for each of the 4 datasets. 
Downstream nuclear and cytoplasmic genes were selected based on a 2/4 ratio for their involvement in 
the top 4 cellular movement sub-types ranked by p-value, similar to the criteria used for selecting 
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candidate ligand-receptor pairs. Results of these bioinformatics analyses of microarray datasets are 
presented in Chapter 5. 
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CHAPTER 3: RECEPTOR EXPRESSION AND FUNCTIONAL ANALYSIS METHODS FOR RPC and 
PPC MIGRATION 
 
3.1: EXPERIMENTAL VALIDATION OF IN SILICO PREDICTED CANDIDATE MOTOGENIC 
INTERACTIONS IN RPCs and PPCs 
 
3.1.1: DESCRIPTION OF ANIMAL CARE METHODS EMPLOYED 
All animal procedures were performed in compliance with the Association for Research in Vision and 
Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research, and the City 
University of New York, Lehman College Animal Care and Use Committee (IACUC). PPCs used in 
experiments were obtained from B6.SJL-Tg (Crx-GFP-ALPP)1Clc/J (Stock No.007066) post-natal day 0-5 
transgenic mice (The Jackson Laboratory, Bar Harbor, Maine) which express GFP gene ubiquitously by 
the cone-rod homeobox (Crx) promoter and maintained on a C57BL/6J background (Stock No.000664). 
The day the vaginal plug was found was considered as embryonic day 0 (E0); and the day of birth, as 
postnatal day 0 (P0). 
Enucleation of Mouse Eyes 
(P0-P5) Crx/GFP+/+new born pups were sacrificed by immersion in ice. After decapitation, a longitudinal 
cut beginning at the nostrils is made superiorly along the axis of the nasal palate until the frontal lobe. 
Superficial cranial cuticle is laterally peeled to expose globes connected to the orbit/eye socket via the 
optic nerve. Forceps are then used to enucleate eyeballs by severing the optic nerves.  
 
3.1.2: RETINA AND PPC ISOLATION AND CULTURE METHODS 
3.1.2.1: Preparing Retinal Tissue Slices 
To obtain retinal slices for immunohistochemical studies, enucleated eyes are immediately fixed in 4% 
para-formaldehyde in phosphate buffered saline (PBS). Eyes are subsequently incubated in 400 mL of 
10% sucrose overnight and 30% sucrose overnight successively at 4°C. Eyes are then mounted in OCT 
embedding compound (TissueTek, Fisher Scientific, PA), and frozen at -20 to -80 °C. Cryosections (5-8 
µm thick) are then obtained on a cryostat Microm HM500 (MICROM International, Germany) and thaw-
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mounted onto positively charged 0.5% gelatin-coated colorfrost Plus histological slides (Thermoscientific, 
Rochester NY) that enhance adhesion of the tissue sections. Slides are then dried for 30mins at 37°C 
and stored at -80°C for use in histologic staining protocols. 
 
3.1.2.2: Retinal Tissue Extraction and Cell Dissociation  
To obtain retinal cell suspensions, enucleated eyes were briefly submersed in 70% ethanol and then 
suspended in cold Neurobasal medium (NB). An incision is made at the border between the cornea and 
sclera and the neural retina is separated from the sclera, retinal pigment epithelium after the lens, optic 
nerve, ciliary body, and iris are carefully removed with forceps. Detached retina tissue are warmed in a 
water bath at 37 °C for 8 min and digested in pre-warmed (37 °C) trypsin (0.05%) (Sigma-Aldrich, 
St.Louis, MO)  in Hanks Balanced Salt Solution (HBSS) (Life Technologies, Grand Island, New York) for 
20 min. Trypsinization was inhibited using FBS (20%) and DNase I (0.2%) in HBSS. Cells were 
dissociated by gentle trituration in 1% BSA, 10 mM HEPES and 2 mM EDTA HBSS solution, de-clumped 
by straining through a 40µm cell strainer and after a brief sedimentation period, the supernatant re-
suspended in Ca2+- and Mg2+-free HBSS and put on ice for the FACS-sorting protocol. This extraction and 
dissociation procedure for photoreceptor precursor cells (PPCs) has previously been described [332, 354, 
355].   
 
3.1.2.3: Fluorescent Activated Cell Sorting (FACS)  
To isolate the Crx-GFP expressing cells from dissociated retinal tissue, a FACS-sorting protocol was 
carried out on a FACSAria II and FACS Diva ver 6.1.3 software (BD Biosciences). Dead cells and cell 
debris are excluded from analysis by gating for a high level of GFP expression with forward scatter (FCS, 
cell size) and side scatter (SSC, cell complexity) as indicators. Cell sorting into Crx.gfp-positive and 
Crx.gfp-negative populations was done at a flow rate of 271 events/second and sheath pressure of 12 psi 
through a 130µm nozzle tip, to yield a final concentration of ~2 x 106 cells/ml of sorted Crx.gfp-positive 
cells. The FACS analysis protocol has previously been employed in a similar investigation [49]. The 
FACS-sorted cells are counted using a trypan blue cell viability assay and used immediately for 
experiments, representing our post-mitotic photoreceptor precursor cell (PPC) population. Figure 3.1A 
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depicts freshly isolated PPCs imaged at 20x magnification showing intact cell body attached to an 
elongated inner segment of immature rod photoreceptor by a thin outer process and lacks synaptic 
extensions and outer segments. 
 
 
3.1.2.4: Retinal Progenitor Cell Culture 
A second set of retinal progenitor cells (RPCs) isolated from P3-5 transgenic mice expressing green 
fluorescent protein (GFP) on the actin promoter (actin-GFP) were received as a gift from the laboratory of 
Dr. Michael Young at the Schepens Eye Research Institute (Massachusetts Eye and Ear, Boston, MA) 
and maintained in mitotic Neurobasal (NB) complete culture medium containing 2% B-27, 1% L-
glutamine, 1% penicillin–streptomycin, 1% N2 (50X), 2% Nystatin, and 93% NB only (Invitrogen-Gibco, 
Rockville, MD) and 20ng/ml epidermal growth factor (Promega, Madison, Wisconsin) as previously 
described [356].  These cells were passaged every three to five days incubated in 5% CO2 at 37C°, and 
the number of live and dead cells are counted using the trypan blue assay (Sigma-Aldrich) at the onset of 
every experimental procedure. These cells represented our retinal progenitor cell (RPC) population 
(Figure 3.1B), ontogenetically distant from photoreceptor cell fate specification compared to PPCs, and 






Figure 3.1: Experimental RPCs and PPCs – A) Freshly isolated post-mitotic P2 Crx-GFP+ PPCs imaged using wide 
field fluorescence at 20x magnification. PPC morphology is compared to a mature rod photoreceptor model [1] and 
reveals a thin outer segment connecting a cell body to a growing inner segment region. Development of synaptic 
terminals and optically active outer segments occur with maturity and further terminal differentiation. B) P0-P3 Actin-
GFP+ RPCs are maintained in mitotic Neurobasal complete media with a passage cycle of 3-5 days. RPC culture 
passage No. 12 was chemically fixed on a glass slide for imaging at 20x, showing characteristic neurite processes typical 
of multipotent RPCs. 
A B 
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3.1.3: Retinal Progenitor Cell Proliferation Assay 
MTT cell proliferation assays (Vybrant MTT, Invitrogen, Grand Island, NY) were perfromed to examine 
RPC growth in different chemotactic ligand concentrations for the same 24hr duration used in our cell 
motility experiments. This assay was carried out to ensure that ligand concentration effects measured in 
the course of our study were for motility only, distinguishable from cell proliferation. In n=6 wells per 
condition, approximately 5000 RPCs per well were incubated in NB with 5% CO2 at 37°C overnight in 
duplicate 96-well culture plates and in quadruplicate wells/plates. Media was then aspirated and replaced 
with 100µl of NB media supplemented with: 0, 20, 40 and 400ng/ml epidermal growth factor (EGF) 
concentrations. Wells were incubated for 24hrs, after which 10µl of 10% MTT reagent was added for 4hrs 
followed by 100µl of MTT solubilization buffer overnight. Absorbance was measured at 575nm and 
650nm using a Synergy Mx plate reader (BioTek Instruments Inc., Winooski, VT), and results plotted 
against EGF concentrations after background correction. A standard curve was then used to correlate 
absorbance units to cell number. The standard curve was created by plotting absorbance versus 
increasing numbers of RPCs ranging from 1000 to 20000 cells/well obtained by serial dilution of NB 
media containing a stock concentration of RPCs. A Dunnett statistical test was then used to assess 
significant difference in RPC proliferation between control conditions and stimulant ligand concentrations.  
 
3.2: PROTEIN DETECTION METHODS 
 
3.2.1: IMMUNOCYTOCHEMICAL (ICC) ANALYSES OF CHEMOTACTIC RECEPTORS ON RPCs and 
PPCs 
Approximately 5µl of freshly dissociated FACS-sorted PPC suspension was smeared onto gelatin-coated 
(0.5%, Sigma-Aldrich, St. Louis, MO) glass slides (n=6) and very briefly heat-fixed at 35 to 45°C. RPCs 
from growing cultures were seeded onto n=6 laminin-coated (10µg/mL) coverslips (15mm (19/32”), 
Thermoscientific, Rochester NY) at a density of 9,000 to 13,000 cells/cm2 in 6-well culture plates and 
incubated overnight at 37°C for slide adherence. Some seeded RPCs were then pre-incubated in 
100ng/ml stromal-derived factor (SDF-1α, Sigma-Aldrich, St. Louis, MO) or 20ng/ml epidermal growth 
factor (EGF, Sigma-Aldrich, St. Louis, MO) overnight at 37°C/5% CO2 prior to chemical fixation. Adherent 
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RPCs were chemically fixed for 10mins in 1% paraformaldehyde in PBS. Fixed PPCs and RPCs were 
then rinsed twice with wash buffer (0.1% bovine serum albumin (BSA) in phosphate-buffered saline 
(PBS)), and non-specific staining was blocked and cells permeabilized with 0.3% Triton® X-100 and 10% 
normal donkey/goat serum (Sigma-Aldrich, St. Louis, MO) for 45 minutes at room temperature.  
 
Cell staining procedures were modifications of previously described protocols [302, 357, 358]. Primary 
antibodies were diluted in incubation buffer (1% BSA plus 1% normal donkey/rabbit serum plus 0.3% 
Triton X-100 and 0.01% sodium azide in 1X PBS) and applied to fixed cells overnight at 4°C. Primary 
antibodies used for RPC immunoblotting experiments include: mouse anti-total epidermal growth factor 
receptor, (1:100, Sigma-Aldrich, St. Louis, MO) which binds both phosphorylated and non-phosphorylated 
EGFR, and anti-phosphorylated epidermal growth factor receptor (1:100, Abcam, Cambridge, MA) 
antibodies; Rat monoclonal anti-CXCR4 antibodies (1:50, R&D systems Mab21651, Minneapolis, MN) 
were used to detect CXCR4 expression; Goat polyclonal anti-DCC (1:200, R&D Systems, Minneapolis, 
MN), rabbit polyclonal anti-FGFR phosphospecific antibody (1:50, Invitrogen, Grand Island, NY), rat 
monoclonal anti-GFRα-1 (1:100, R&D Systems, Minneapolis, MN), and rat monoclonal anti-ROBO1 
(1:100, R&D Systems, Minneapolis, MN) antibodies were also used to detect innate expression of 
receptors for Netrin-1, fibroblast growth factor-acidic (FGF-a), Glial-derived neurotrophic factor (GDNF) 
and Slit homolog-1 ligands respectively. Rabbit polyclonal anti-CXCR4 antibody (1:500, Abcam Ab7199, 
Cambridge, MA) was used to detect endogenous stromal derived factor-1α (SDF-1α) receptor expression 
in PPCs. Rabbit anti-β-tubulin III (1:500, Sigma-Aldrich, St. Louis, MO) antibody was used as ICC positive 
control for retinal stem cells. Coverslips incubated with only secondary antibody were used as negative 
control. RPCs and PPCs were then washed three times (5 min each) with wash buffer and subsequently 
incubated with the following secondary antibodies for 1hr at room temperature: anti-mouse TritC-
conjugated antibody (1:10000; R&D systems, Minneapolis, MN) for phospho- and total-EGFR detection in 
RPCs; NL637 fluorochrome-conjugated goat-anti-rat (1:200; R&D systems, Minneapolis, MN) secondary 
antibody for CXCR4 detection in RPCs. Dylight 594 goat-anti-rabbit secondary antibody (1:500; Jackson 
ImmunoResearch, Westgrove, PA) was used for CXCR4 detection in PPCs and FGFR detection in RPCs, 
and Dylight 594 goat-anti-rat antibody (1:500; Jackson ImmunoResearch, Westgrove, PA) was used to 
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detect GFRα-1 and ROBO1 expression in RPCs. Dylight 594 rabbit anti-goat secondary antibodies 
(1:500; Jackson ImmunoResearch, Westgrove, PA) stained DCC receptors in RPCs. After rinsing once 
for 15 min and thrice for 5 min with wash buffer, cover slips were inverted onto glass slides coated with 
DAPI-containing anti-fade mounting medium or TO-PRO-3 iodide in DMSO (for confocal microscopy) (Life 
Technologies, Grand Island, NY). Stained nuclei, GFP+ cell body and TritC-conjugated receptor 
expression were then imaged on fluorescent and confocal microscopes. Fluorescence microscopy was 
performed on an inverted fluorescent microscope (Nikon Eclipse Ti, Melville, NY) using a CFI60 Plan 
Fluor 40× objective and 100× oil immersion lenses. EGFR immunostained slides were also viewed on a 
confocal microscope (Leica TCS SP5). GFP-positive cells were located using epifluorescence illumination 
before taking a series of XY optical sections, approximately 0.2 - 0.4 µm apart, throughout the depth of 
the section. Individual XY scans are built into a stack to give an XY projection image. GFP+ fluorescence 
and Dylight 594 secondary antibody were sequentially excited using the 488 nm line of an argon laser 
and the 594 nm line of a HeNe laser, respectively. For CXCR4 detection, confocal images (LSM 510, Carl 
Zeiss, Thornwood, NY) of stained SDF-treated and non-treated RPCs were also obtained in triplicates for 
use in calculating net integrated density values of selected cell image views with Trit-C filter on an image 
J platform after subtracting background mean gray values. In this procedure, pixel intensity and density 
over the selected image area served as a semi-quantitative assessment of cell surface receptor 
expression due to SDF-1α effects. A statistical comparison of mean integrated density values of the 
selected images and background was then performed using a student’s T-test. Similar image quantitation 
protocols have previously been described [359]. 
 
3.2.2:  WESTERN BLOT ANALYSES OF CHEMOTACTIC RECEPTORS 
Ice cold lysis buffer (0.5ml per 5 X 106 cells) containing: 150mM NaCl, 1% Triton X-100, 50 mM Tris, pH 
8.0, 1 mM phenylmethylsulfonyl fluoride (PMSF, Sigma-Aldrich, P7626), Halt Protease inhibitor Cocktail 
(Pierce IL, 78425), and phosphatase inhibitor (Sigma-Aldrich, P5726), was added to PBS-rinsed RPC 
cultures that had been pre-incubated overnight with varying concentrations of EGF (0, 20 and 40ng/ml) 
and SDF (0 and 100ng/ml) concentrations, and to pellets of freshly dissociated PPCs. The cell mixture 
was agitated for 30mins and then centrifuged at 12,000rpm for 20mins at 4°C. The resulting supernatant 
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was used to determine protein concentration by the Bradford assay and subsequently, 25-40 µg of protein 
was separated on 8% SDS-PAGE (Clear Page Gel, CBS Scientific, San Diego, CA) and then transferred 
onto nitrocellulose membranes. Preliminary visualization of protein transfer to membrane is carried out 
using Ponceau red staining (VWR, Bridgeport, NJ). Membranes containing RPC lysates then probed 
overnight at 4°C with the following primary antibodies: monoclonal mouse anti-EGFR (1:1000, Sigma-
Aldrich, St. Louis, MO) and anti-phospho-EGFR (1:200, Abcam, Cambridge, MA), rabbit polyclonal anti-
ERK1/2 and anti-phospho-ERK1/2 (1:200, Santa Cruz Biotech., Dallas, TX), anti-PI3K (1:1000), rabbit 
polyclonal anti-phospho-STAT3 (1:1000, Cell Signaling Technology, Danvers, MA), rabbit polyclonal anti-
STAT3 (1:1000, Calbiochem, Darmstadt, Germany) and rabbit polyclonal anti-CXCR4 (1:1000, 
SAB3500383 Sigma-Aldrich, St. Louis, MO) primary antibodies. PPC lysates were also probed overnight 
at 4°C with monoclonal rat anti-CXCR4 (1:500, R&D systems, Minneapolis, MN). Rabbit polyclonal anti-β-
tubulin and heat shock protein HSP90 (1:1000, Cell Signaling Technology) were used as positive control 
to correct for blotting efficiency and normalize results.  
 
The corresponding secondary antibodies conjugated to horse-radish peroxidase (HRP) (1:1000, anti-
rabbit IgG, anti-mouse IgG, Cell Signaling Technology, Danvers, MA) and polyclonal goat anti-rat 
(1:1000, R&D systems, Minneapolis, MN) were bound to the nitrocellulose membranes for 1hr at room 
temperature and X-ray detection was carried out after applying enhanced chemiluminescence substrate 
mixture (ECL Plus; Pierce IL) to the membrane. Standard molecular weight markers (Bio-Rad 
Laboratories, Hercules, CA) served to verify the molecular sizes for receptor detection. 
Similar blotting protocols for detecting receptor proteins and intracellular signaling activity have previously 
been described [360-362].  
 
3.3:  FUNCTIONAL ANALYSES OF RPC and PPC CHEMOTAXIS 
 
3.3.1:  MODIFIED BOYDEN CHAMBER TRANSWELL ASSAY 
To assess the influence of chemical gradients on cell motility phenomena, Stephen Boyden in 1962 
developed the Boyden chamber, which has since been modified to the transwell assay [363]. In the assay 
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method, a chemoattractant solution is placed in the lower compartment of a culture well, wherein a 
porous membrane bottom is seeded with cells and inserted in the lower compartment such that the 
chemoattractant diffuses across the membrane into the upper chamber containing cells (Figure 3.2). The 
resulting one-dimensional gradient induces cells seeded on the topside to migrate through the trans-
membrane holes to the lower compartment. Migrated cells are then fixed, stained and counted to quantify 
the degree of chemotaxis induced by the gradient. The advantages of the Boyden Chamber/Transwell 
Assay are that it is easy to perform, readily elicits chemotactic responses from cells, provides a 














allows multiple assays to be run in parallel with a choice of testing varied chemotactic factors at a time, 
thereby increasing the statistical strength of the observed findings [364].  
 
3.3.1.1: Transwell Motility Assay For RPCs and PPCs 
Initial screening for chemotactic response of RPCs and PPCs to uniform gradients of candidate 
chemotactic factors was assessed using modifications to the Boyden chamber assay as previously 
described [360, 363, 365-367] [368, 369]. Prior to transwell motility assays, diluted aliquots of all cell 
Figure 3.2: Transwell Assay – Approximately 5X104 RPC or PPCs (yellow) 
suspended in a 350μl NB media solution are seeded in the upper compartment 
separated from a lower compartment by an 8um pore size polyethylene 
terephthalate (PET) microporous membrane insert. The porous membrane allows 
upward diffusion of varying concentrations of chemotactic factors tested to the 
upper compartment. The experimental set-up allows measurement of one-
dimensional mass transport of retinal stem cells in response to chemotactic factors.  
Adapted from Corning  Transwell  Permeable Support and Use Guide. Available at: 
http://www.corning.com/media/worldwide/cls/documents/CLS-CC-
010%20REV8%20DL%20(5).pdf. Accessed June 7, 2015 [11]. 
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suspensions are subjected to a Trypan Blue (Sigma-Aldrich, St. Louis, MO) viability assay using a 
Brightline hematocytometer cell counter (Hausser Scientific, Horsham, PA). Serum starved RPC cultures 
and fresh PPC isolates were pelleted and re-suspended in neurobasal (NB) media (2% B-27, 1% L-
glutamine, 1% Pen Strep, 1% N2 (50X), 2% Nystatin, and 93% NB only) supplemented with 10% fetal 
bovine serum (FBS), at a seeding density of 5 X 104 viable cells/350µl volume, in the upper chamber of 
non-coated polyethylene terephthalate (PET) membrane filters (8µm pore size, BD Falcon, NJ). These 
filters insert into tissue culture wells (BD Falcon, NJ) containing 700µl volumes of NB media treated with 
varying concentrations of chemotactic factors. Following incubation, the total number of cells migrating 
through the micropores toward the lower well are quantified, compared to cell migration in control filters 
exposed to NB media without chemotactic factors, and used as a measure of chemotaxis to candidate 
chemotactic factors [363, 365, 366, 370]. 
 
The following growth factors were assessed for their chemotactic effects on RPCs. Tested concentrations 
are expressed in parenthesis: Stromal derived factor-1 alpha (SDF-1α; 50, 100ng/ml; Sigma-Aldrich, St. 
Louis, MO), CXCL3 (50, 100ng/ml; R&D systems, Minneapolis, MN), Tumor necrosis factor (TNF; 
50,100ng/ml; R&D systems, Minneapolis, MN), Glial-derived neurotrophic factor (GDNF; 50,100ng/ml; 
R&D systems, Minneapolis, MN), Epidermal growth factor (EGF; 20, 40, 400ng/ml), Glutamate (10, 50, 
500µM; Sigma-Aldrich, St. Louis, MO), Gamma amino-butyric acid (GABA; 5, 10, 30µM), Netrin-1 (10, 50, 
100, 200, 250ng/ml; R&D systems, Minneapolis, MN), Vascular endothelial growth factor (VEGF; 0.026, 
1.026, 2.56nM; R&D systems, Minneapolis, MN), Hepatocyte growth factor (HGF; 1, 10, 100nM; R&D 
systems, Minneapolis, MN), Fibroblast growth factor-acidic (FGF-acidic; 10, 40, 400, 1500ng/ml; 
Invitrogen-Gibco, Rockville, MD), Transforming growth factor-alpha (TGF-α; 10, 50, 200nM; Invitrogen-
Gibco, Rockville, MD), and Platelet-derived growth factor (PDGF-AA; 0.0001, 0.001, 0.01nM; Sigma-
Aldrich, St. Louis, MO). Chemotactic assays for PPCs were carried out in a similar manner using the 
following growth factors at the denoted concentrations: (SDF-1α; 50, 100ng/ml; Sigma-Aldrich, St. Louis, 
MO), CXCL3 (50, 100ng/ml; R&D systems, Minneapolis, MN), Tumor necrosis factor (TNF; 50,100ng/ml; 
R&D systems, Minneapolis, MN), Glial-derived neurotrophic factor (GDNF; 50,100ng/ml; R&D systems, 
Minneapolis, MN), and Transforming growth factor-alpha (TGF-α; 50, 100ng/ml; Invitrogen-Gibco, 
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Rockville, MD). Triplicate wells per treatment were incubated for 24hrs at 37°C/5% CO2. Filters were 
thereafter fixed with 4% paraformaldehyde in PBS for 5 min and stained with DAPI or Hoechst 33342 
nuclear stains for 10 min. Cells are scraped from the upper chamber, and the number of stained 
transmigrated cells at the bottom surface of the filter were counted at five fields per filter for triplicate and 
quadruplicate filters in two independent experiments using a CFI60 Plan Fluor 10× objective lens of an 
inverted fluorescent microscope (Nikon Eclipse Ti, Melville, NY). Dunnett tests, ANOVA and pairwise 
Tukey HSD statistics assessed significant mean differences (p<0.05) in the number of transmigrated cells 
normalized to chemotaxis in control filters. 
  
3.3.1.2: Optimizing in vitro RPC incubation for Motility Assays 
Chemotaxis of RPCs to the various chemotactic factors is assessed over a 24hr in transwell experiments. 
For RPCs that exhibit robust survivability in NB culture media conditions, it became imperative to 
determine incubation times that support optimal ligand stimulation of the cells, given differing incubation 
periods per ligand reported in retino-neural migration experiments [211, 365, 371-375]. These 
optimization studies were performed in triplicates on different days using Epidermal Growth Factor (EGF) 
at 40ng/ml concentration added to the lower chamber of transwell set-ups, stimulating RPCs incubated in 
the upper chamber for time periods ranging from 6-48hrs. After the respective incubation time periods at 
37°C/5% CO2, filters are fixed with 4% paraformaldehyde in PBS for 5 min and stained with DAPI or 
Hoechst 33342 nuclear stains for 10 min. Cells are scraped from the upper chamber, and the number of 
stained transmigrated cells at the bottom surface of the filter were counted at five fields per filter for 
triplicate filters in two independent experiments per time duration using an inverted fluorescent 
microscope. Dunnett tests are used to assess mean differences in RPC migration relative to control filters 
placed in NB media without motogenic factors (p<0.05), while pairwise Tukey HSD statistics compared 
migration rates across the different time periods for each chemotactic factor. in the number of 




3.3.1.3: Method Improvement: Comparing Resolution Techniques For RPC Transmigration Through 
Transwell Filters: Manual Microscopic Counts Vs. Fluorescence Analysis 
 
Cell counting subsequent to chemotaxis through 8.0 µm pore filters, fixing, staining and removal of non-
migrated cells from the interior of upper chambers of transwell filters, was performed using two 
comparative methods, Manual cell counting and fluorescence spectrophotometric analysis. Manual cell 
counts was done by determining the number of GFP+ RPCs in five view fields per filter for triplicate filters 
per condition using the 10x or 20x objective lenses in an inverted fluorescent microscope. Cell count 
values are then extrapolated to actual cell numbers in the effective growth area of the filter membrane as 
provided by the manufacturers. Resolved mean number of cells is then normalized to control filters across 
conditions and normalized values used for further statistical analysis. The drawback of this method lies 
mainly in human error during cell counting procedures. In a comparative method, we collaborated with the 
Manfred Phillipp laboratory in the Chemistry Department of Herbert H. Lehman College to measure 
fluorescence emission of GFP+ retinal cells as an index of transmigrated cells. In this protocol, a standard 
curve was plotted using increasing numbers of GFP+ RPCs correlated to relative fluorescence units 
(RFU) of detected emission spectra at 528nm after 485nm peak excitation using the high energy Xenon 
flash of Synergy Mx multi-mode microplate reader (Biotek, Winooski, VT) and subtraction of background 
fluorescence was firstly performed (Figure 3.3). In subsequent transwell assays, the number of migrated 
cells was then determined by extrapolating RFU obtained per well to the resolved standard curve 
equation (y = 0.0011x + 10.072; R² = 0.98256, (Figure 3.3). These cell numbers were then normalized 
and used for further statistical analysis. After incubation periods allotted for cell transmigration in this 
protocol, transwell filters are rinsed with 1X PBS and transferred to culture wells containing Hanks based-
enzyme free cell dissociation media (Invitrogen-Gibco, Rockville, MD) where slow rotation for 30mins is 
used to recoup transmigrated cells in the bottom surface of the filters, prior to fluorescence detection 
analysis. This posed a limitation to this method as RPCs may be displaced during the washing step or not 
accounted for during the dissociation step of the protocol. Manual counting protocols was thus adopted 
for analyzing cell chemotaxis using Boyden Chamber assays.  
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3.3.1.4: Transwell Motility Inhibition Studies 
As the Boyden Chamber assay measures one dimensional mass movement of cells to ligand stimulants, 
it is best suited to investigate RPC population responses to targeted antagonistic effects of inhibitors at 
the receptor level and for intracellular cascade molecules. These inhibition studies are typically performed 
to validate mitogen-induced signaling mechanisms under investigation, identify hub molecules in signaling 
cascades, and functionally validate ligand-specific motility-deterministic pathways resolved in our 
investigations [376-381]. RPCs are pre-incubated with an inhibitor for an amount of time and in 
concentrations recommended by the drug manufacturer and concurred with times employed in peer-
reviewed publications reporting inhibition of retino-neural cells [382, 383]. The cells are then subjected to 







In delineating motility-deterministic EGF signaling in RPCs, cells were pre-incubated with inhibitors to 
EGFR and target intracellular molecules at 37°C in 5% CO2 before loading in the upper chamber of a 
transwell filter as previously described [360, 367, 384]. Inhibitor concentrations and their incubation times 
are as follows: (1) monoclonal anti-EGFR (100nM, 2hrs, Sigma-Aldrich Co., St. Louis, MO), (2) STAT3 
inhibitor, AG 490 (5µM, 60mins, Calbiochem, Darmstadt, Germany), (3) the cell-permeable, irreversible 
and selective inhibitor of EGFR tyrosine kinase activity Tyrphostin AG1478 (200nM, 30mins), (4) ERK1/2 
inhibitor PD98059 (10µM, 60mins) and (5) PI3K inhibitor Wortmanin (250nM, 60mins), all from Cell 
Signaling Technology, Danvers, MA. RPCs were then allowed to transmigrate through filters inserted in 
chambers containing 20ng/ml and 40ng/ml EGF concentrations for 24hr at 37°C/5% CO2. Filters were 
then dipped in wells containing 4% paraformaldehyde in PBS for 5 min and stained with DAPI or Hoechst 
33342 nuclear stains for 10 min. Cells were removed from the upper chamber, and the number of stained 
migrated cells at the bottom surface of the filter were counted at five fields per filter for triplicate filters in 
two independent experiments (n=6 each) using an inverted fluorescent microscope. A Dunnett statistical 
Figure 3.3: GFP Fluorescence Standard Curve – Increasing populations of GFP+ retinal progenitor 
cells (RPCs) were excited by a Synergy Mx microplate high energy laser at 485nm and subsequent 
emission spectra was detected at 528nm wavelength and quantified in relative fluorescent units 
(RFU) following subtraction of background fluorescence. The standard curve was then routinely used 
to determine the number of migrated cells in transwell assays by measuring fluorescence emission of 
membrane inserts following chemotaxis assays. 
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test was used to determine the number of migrated RPCs normalized to cell migration in control filters. 
Successful inhibition of RPC migration was determined by RPC numbers in test wells that were 
significantly (p<0.05) less than cell numbers in control chambers containing no inhibitors. To similarly 
investigate receptor-mediated signaling by the stromal-derived factor 1 (SDF-1α) motogen, after pre-
incubation with 5µg/ml of the highly specific SDF-1α receptor CXCR4 antagonist AMD3100 (Sigma-
Aldrich, St. Louis, MO) for 30mins at 37°C/5% CO2, both PPC and RPC suspensions were loaded in the 
upper chamber of transwell filters incubating in 100ng/ml of the ligand for 24hrs as previously described 
[361, 385, 386].  
 
3.3.2: EVALUATING RPC and PPC CHEMOTAXIS USING MICROFLUDIC TECHNOLOGY 
 
Chemical gradients have been shown to play essential roles in a range of cellular processes including 
inflammation, motility, disease and development [236, 387]. The Boyden Chamber assay is a traditional 
method for establishing one-dimensional chemical gradients perpendicular to cell growth fields, and relies 
on the diffusive properties of tested biomolecules. In contrast, in vivo concentration profiles of chemical 
species are heterogeneously formed by not only the molecule’s diffusive properties, but also its binding 
kinetics to other biomolecules in a dynamic physicochemical microenvironment [388] and the architectural 
planes defining the living tissue. Defining the spatial distribution and concentration of these molecules is 
further complicated by control and feedback regulatory mechanisms in living tissues for normal 
physiological activities that continually change the biochemical composition of these tissue systems [389]. 
As such, deciphering the true characteristics of physiologically relevant gradients and how these highly 
dynamic gradients are integrated to produce specific cell responses requires a way to expose cells to one 
or more biomolecular gradients, each with defined spatial and temporal distributions [205]. By doing so, 
we can determine specific biomolecule concentrations and gradient profiles that elicit the most efficient 
motility responses, and determine how these gradient characteristics influence the cell’s sensitivity to 
other biomolecular gradients. 
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Such temporal control and quantitation of stable gradients are difficult to accomplish in Boyden chamber 
assays. This is due to the gradient instability created by fluid level imbalances between lower and upper 
compartments during pipette-loading of the transwell culture system, which is exacerbated by the 
requirement that the membrane insert, with its liquid-porous bottom, be dropped into the lower 
compartment containing chemical media [364]. Lowering the porous membrane insert into the lower 
compartment allows instant chemical flows to the upper chambers of the transwell filter, producing rapidly 
dissipating gradients with chemical homogeneity expected in both compartments within a few hours (data 
not shown). These geometric limitations of the experimental set-up (see Figure 3.2) thus restrict the 
nature of chemical gradients that can be generated in this assay to mono-axial opposing gradients. Multi-
factorial combinatory gradients reminiscent of in vivo conditions cannot be formed, and cell responses 
cannot be correlated to specific gradient characteristics. The optically translucent, but not transparent, 
membrane filters used in the assay also makes such a correlation even more cumbersome as 
visualization of transmigrated cells is difficult using conventional brightfield and fluorescent microscopes 
[364]. As such, the Boyden Chamber assay is best suited for studying ligand-induced population-based 
migration.  
 
Microfluidic technology has proven highly valuable in the creation of biomimetic micrometer-scale 
environments with predictable, reproducible, and easily-quantified biomolecule gradients in vitro [7] 
compared to traditional methods as the Boyden chamber [390-392], with recent advances merging both 
methodologies [393]. Microfluidic technology uses miniaturized devices to study, manipulate and 
approximate isolated cell and tissue physiological processes that would have hitherto, been too complex 
to characterize. These biomimetic devices are inexpensive, requiring low amounts of reagents, and allow 
intrinsic gradient profiles that decrease time for analyzing cellular physiologic phenomena [394]. The use 
of microfluidic technology is critical to our study for it enables us create and sustain spatial and temporal 
gradients that model behavior of released chemokines in damaged retina that may influence our RPC and  
PPC  responses. In typical microfluidic devices, gradients are generated within micro-scale conduits fed 
at both ends by differential concentrations of chemical species. Knowing the precise dimensions of the 
microfluidic devices coupled with the detailed understanding of laminar flow of fluids in such microscale 
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conduits enables accurate mathematical determination of the movement and distribution of chemical 
species in the microchannels over defined time scales and distances. Variations of the technology have 
shown the potential to create multiple biomolecular gradients, each with its own user-defined 
spatiotemporal distribution, as well as complex gradient generation parameters based on the chemical 
behavior of combinations of soluble and substrate-bound biomolecules [395, 396]. The ability to create 
such complex, user-defined gradient environments enables quantitative elucidation of multi-gradient 
signal integration and provides the specific recipes for engineering the growth, migration, and 
differentiation of a variety of cell types [390, 391, 397].   
 
3.3.2.1: The Bridged U-Lane Microfluidic Assay 
To comprehensively examine migratory responses of RPCs and PPCs to quantitatively defined gradients 
of candidate chemotactic molecules we used a retinal biomimetic microfluidic device, known as the 
bridged µLane [7]. The bridged µLane was fabricated using lithography techniques and elastomeric 
molding of Poly-dimethylsiloxane (PDMS), a flexible silicon polymer. This work was performed in 
collaboration with the Maribel Vazquez Microfluidics and Nanotechnology Laboratory at the Biomedical 
Engineering Department of City College of the City University of New York. When bonded to an inert 
substrate, the PDMS device is designed to assist molecular diffusion of chemotropic factors down the 
length of a microchannel located at the bottom of the device, due to minute convective velocities initiated 
by buoyancy-driven forces. This enables the attainment of steady state gradients of these chemical 
factors within short experimental times. The device has previously been shown to sustain gradient profiles 
of over five orders of magnitude of chemical concentrations, and over time scales sufficient to model 
dynamic chemotactic microenvironments generated in vivo [7, 398]. Quantification of ligand mass 
transport within the microsystem was solved using finite element methods (FEMLab Version 3.4, Comsol 
Inc., Burlington, MA). Sequential optical monitoring of individual cell movement within predictable 
chemical concentrations, and at finite loci along the microchannel, permitted measurement of mechanistic 
parameters governing retinal stem cell migration such as polarizability, directionality and chemo-
sensitivity to steady state chemical gradients [391]. This microfluidic device also has the added 
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advantage of not requiring automation to maintain steady state gradients for up to 72hrs [32, 398] and its 
ease of fabrication enables rapid assessment of cellular chemotactic phenomena.  
 
3.3.2.2: Design Of The Bridged U-Lane Device  
 
The framework of the bridged µ-Lane device consists of two layers of silicon polymer poly-
dimethylsiloxane (PDMS): the bottom layer consisting of a closed microchannel (0.1µL volume, 95µm-
hydraulic diameter: 90µm-depth, 100µm-width (using Dh=4A/P [399], where A is the cross-sectional area 
and P is the perimeter, 1.3cm-length), connecting a source reservoir (SRR) to a sink reservoir (SKR) each  
9µL-volume (2mm-height), and a top layer comprising a source chamber (SRC) and sink chamber (SKC) 
each 170µL-volume (6mm-height; 6mm-diameter) connected by an open, hemispherical bridge channel 
(2-mm-depth; 9-mm-length) (Figure 3.4). Both PDMS layers are fabricated using contact 
photolithography and soft lithography techniques followed by bonding together of the two PDMS layers 
and the composite PDMS layers to glass substrates. The SRC and SKC chambers are thus vertically and 
fluidically connected with the underlying SRR and SKR reservoirs respectively, and the bridge channel 
connects the SRC and SKC chambers in order to balance their solution volumes. The complete bridged 
µ-Lane system is thus composed of an upper user interface layer with an open bridge channel that 
connects the SRC and SKC chambers, as well as a bottom layer closed microchannel that connects the 
SRR and SKR reservoirs [7]. 
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3.3.2.3: Fabrication Of The Bridged U-Lane Device 
The fabrication of early microfluidic systems was inspired by technology derived from microelectronics 
including photolithography and etching in silica and glass [400, 401]. The opacity of silica made it 
unsuitable for optical detection of biological systems, while the amorphous nature of glass made etching 
problematic and its use requires cleanroom facilities. Additionally, micro-fabrication with silica or glass 
etching is an expensive and time-consuming venture [394]. Search for inexpensive manufacturing 
methods led to the adoption of malleable polymers such as poly-dimethylsiloxane (PDMS), and its replica 
molding on micro-patterned solid substrates to yield negative replicas of the substrate’s contoured 
surfaces. Such solid substrates are machined from metal, acrylic or aluminum or etched on inert silicon 
wafers using photolithography. Cured PDMS molds can then be peeled of the micro-patterned surfaces 
and sealed on glass, replicating the desired hollow dimensions of miniaturized biological conduit systems. 
 
The bridged u-Lane was fabricated in three major steps using conventional manufacturing processes: 
Step 1: Fabrication of microchannel-patterned mold using contact photolithography (Rapid Prototyping) or 
Computer Numerical Control (CNC) Router. Step 2: Replica Molding Of Double-Layer PDMS Using Soft 
Lithography Step 3: Adhesion of PDMS polymers to substrate. These steps enabled the rapid 
Figure 3.4: Design of the Bridged μ -lane Microfluidic Device – The schematic 
shows the first layer PDMS with 9μl volume source (SRR) and sink (SKR) reservoirs 
connected by a microchannel measuring 13mm (length), 90μm (depth), 100μm (width), 
and 95μm (hydraulic diameter). The second layer PDMS, the user interface layer, 
consists of a semi-circular open bridged channel that measures 9mm (length) and 2mm 
(depth) and fluidically connects to the first layer via 170μl volume source and sink 
chambers [7]. 
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manufacturing of the bridged u-lane microfluidic device and a schematic overview of the process is 
provided in Figure 3.5a.  
 
3.3.2.3.1:Step 1a - Fabrication Of Microchannel-Patterned Mold Using Contact Photolithography (Rapid 
Prototyping) 
 
In contact photolithography, microfluidic device design is performed on computer software programs 
compatible with commercial image setters that print the designs on photomask transparencies. The 
photomask designs are imprinted onto thin silicon wafers containing high contrast epoxy-based 
photoresist material that forms structural crosslinks on exposure to  
 
UV thermal radiation. Crosslinked photoresist is insoluble in common SU-8 developer solvents, and thus 
covered photomask regions un-exposed to UV will be easily rinsed off leaving a positive relief ‘Master’ of 
the design on the silicon wafer. Steps in standard photolithography protocols are outlined in Figure 3.5b 
[394]. Following replica molding of PDMS on the SU-8 Masters, a cured negative replica of the Master 
mold can be routinely fabricated for experimental uses. Rapid prototyping reduces time and cost for a 
cycle of micro-device fabrication and testing of new ideas. Where chrome masks are used instead of 
Figure 3.5a – Overview of fabrication 
steps for the bridged μ -lane 
microdevice – A computer aided 
design of the first layer PDMS 
dimensions of the bridged U-lane was 
produced on photomask 
transparencies which is then micro-
patterned on silicon wafers using 
contact photolithography to produce an 
SU-8 ‘Master’ mold (A). Rapid 
prototyping of the first layer of the 
bridged U-lane was then performed by 
curing PDMS over the SU-8 ‘Master’ (B 
& C). Adhesion of the PDMS polymer 
to a glass flat-surface substrate (C) 
completes the fabrication process for 
the 1st layer PDMS. The 2nd layer 
PDMS (user interface layer) is 
produced by simply curing PDMS over 
the 1st layer with defined source and 
sink chamber compartments [14].   
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transparencies, the resolution of the ‘Master’ relief obtained after photolithography is higher, but the 
masks are more expensive [394]. 
  
In our experiments, silicon wafers (SVM, Santa Clara, CA) were rinsed with acetone and isopropyl alcohol 
(Sigma-Aldrich Co., St. Louis, MO), followed by deionized water in succession. After drying, wafer 
substrates are coated with a 100-µm-thick layer of negative photoresist, SU-8 2075, (MicroChem Inc., 
Newton, MA) using a spin coating apparatus (Laurell Tech. Corp., North Wales, PA). Wafers were pre-
baked on a hot plate at 65°C for 5mins and 95°C for 15mins, covered with both the computer-aided 
design (CAD)-photomask containing desired patterns of the first layer of the bridged u-lane and a filter, 
and then exposed to UV irradiation for 18 seconds (Intensity after filtering: 215-240 mJ/cm2, Model 30-UV 
light source, OAI San Jose, CA) to create a positive relief of the design known as the ‘Master.’ Wafers 
were then re-baked for 2-5mins at 65°C and for 8-10mins at 95°C, allowed to cool at room temperature 
 
(25°C), and immersed in SU-8 developer (MicroChem Inc., Newton, MA) for approximately 10mins on a 
slow shaker, or until photoresist patterns were visible. The SU-8 Master is then successively rinsed with 
fresh developer, isopropyl alcohol and deionized water, and then completely dried for use. 
 
 
Figure 3.5b:  Contact 
Photolithography - A) 
Computer-aided measurements 
of the 1st PDMS layer are 
imprinted onto photomask 
transparencies and placed onto 
thin silicon photoresist wafers. 
B) Upon exposure to UV 
thermal radiation, regions not 
covered by the photomask 
dissolve, exposing the positive 
relief of the microdevice 1st 
layer design. C) Following 
replica molding of PDMS on the 
relief ‘Master’, cured negative 
replicas of the ‘Master’ mold 
can be replicated.  
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3.3.2.3.2: Step 1b - Fabrication Of Microchannel-Patterned Mold Using A CNC Router 
 
An alternative approach to fabricating a relief ‘Master’ patterned to dimensions of the bridged u-lane 
device is by mechanically carving out molds from durable materials as acrylic, metal and aluminum. 
Computer-aided designs (CADs) are programmed into milling machines as the CNC router (Rockler, 
Buffalo, NY) followed precision cutting through substrate molds to achieve the microlane diameters useful 
for mimicking biological systems.  
 
In our study, a prototype metal cast mold for the bridged u-lane microfluidic device was fabricated using a 
CNC Milling machine computer-controlled with SketchUp-fed (Trimble, Sunnydale, CA) design 
specifications (Figures 3.6a and 3.6b). Metallic materials for the cast master were purchased from 
McMaster-Carr Supply Company (Robbinsville, NJ) and the work was done in collaboration with the 
Mechanical Engineering Department at City College, CUNY, where Mark Stasiak assisted in the CAD and 
performed the metal milling procedure. Machining to produce imprints of precise dimensions of the 
bridged u-lane was simplified by fabricating three metal plates – bottom, middle and top plates that line up 
with two edge guide pins measuring 6mm in diameter (Figure 3.6a). The bottom plate contains four (4) 
2.4mm diameter press fit pins, 2mm height forming the source and sink reservoirs of 9ul volumes each. 
These pins are connected in pairs by two 90um (0.025inches) deep microchannels, and fits with the 
middle plate to form casing for the first layer of the device. Placing the top plate containing four (4) 6mm-
diameter/6mm-height pins over the unified plates marks out dimensions of the source and sink chambers  
(170uL volumes) with the connecting bridged channel. Figure 3.6b shows top design view of the device 
with relevant dimensions. Advantages to this design is that the double PDMS layers can be made during 
one elastomeric PDMS molding cycle and thus significantly decrease device fabrication times. 
Unfortunately, we realized that high temperatures attained within the metallic cast master during the 
silicon polymerization step distorted shapes of the PDMS molds; thus using less heat conducting 
materials would be encouraged. Most importantly, the CNC router available for use at the Mechanical 
Engineering department failed to accurately machine 100um u-lane width microchannels in the bottom 
plate producing channels five-fold in magnitude larger than requested.  
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A second aluminum cast-master replica mold (ASCO, Detroit, MI) with identical micro-patterned 
dimensions as design of the bridged u-Lane (Figure 3.7) was then adopted, and it yielded the desired 
PDMS first layer and microchannel dimensions upon bonding to glass substrates. Work cones of 6mm-
diameter pipette tips (VWR Bridgeport, NJ) placed above the first layer PDMS were used to estimate the 
volumes of the source and sink chambers, and after pouring PDMS over the first layer formed the 
chambers of the PDMS second layer. The bridged channel was then manually carved out to connect both 
chambers after baking the PDMS double layer molds.  
 
3.3.2.3.3: Step 2 – Replica Molding Of Double-Layer PDMS Using Soft Lithography 
 
Once a ‘Master’ Mold is fabricated, we employ replica molding, a soft lithography technique to replicate 
our desired design patterns in polymers such as PDMS. Soft Lithography represents a suite of techniques 
that begins with the non-photolithographic fabrication of a ‘Master’ following by replica molding as an 
alternative to accelerate the rapid prototyping of microfluidic devices [14, 402]. In its replica molding 
application, a suitable pre-polymer is cast against the master generating a negative replica of the master 
in the polymer; i.e. ridges on the Master appear as valleys in the replica and vice-versa. After curing the 
polymer, the replica peeled of from the ‘Master’ will contain the desired etched pattern. The schematic in 
Figure 3.5a outlines the basic steps in replica molding [394]. PDMS (Poly-dimethylsiloxane) is one of the 
most commonly used elastomeric polymer and is an excellent material for replica molding of microfluidic 
devices. It is a silicon polymer that is optically transparent down to 240nm allowing it to be used for varied 
detection schemes including UV/Vis absorbance and fluorescence. It cures at low temperatures and its 
non-toxic nature allows mammalian cells to be cultured directly on it. The elastomeric nature of PDMS  
polymer also permits it to conform to different planar surfaces, and its inert surface chemistry can be 
easily manipulated to facilitate sealing to surfaces and chemical modifications of cell binding interfaces 











Figure 3.6a: Side-View Design 
Specifications for CNC Fabrication of 
Micro-patterned Double-layered PDMS 
Molds – By inputting the Sketch-Up design 
into a Computer Numerical Controlled (CNC) 
router, three metal plates could be machined 
to design specifications and aligned to create 
a positive relief ‘Master’ for a double-layered 
PDMS Bridged U-lane microdevice. The 
bottom plate contains four (4) 2.4mm 
diameter pins as positive relief for the 9uL 
source and sink reservoir volumes. The 
13mm microchannel (Bridged channel in 
diagram) connects the reservoirs at two 
locations on the bottom plate. 6mm guide 
pins attach the bottom middle and top metal 
plates; middle plate placement on top of the 
bottom plate forms the 2nd PDMS layer. 
Placing the top plate containing four (4) 6mm 
diameter pins over the bottom and middle 
plate assemble demarcates the source and 
sink chamber 170 µL volumes. Two double-
layered bridged µ-lane microdevices can be 
fabricated in one PDMS elastomeric molding 
cycle using computer-aided design (CAD) 
above. Designs were made using the Sketch-
Up 3D modeling software and a 1:2 
horizontal scaling.  Figure is courtesy of Mark 
Stasiak, Mechanical Engineering Dept. City 




In the Maribel Vazquez lab, we used one of the most common PDMS elastomers, Sylgard 184 from Dow 
Corning (VWR, Bridgeport, NJ). Sylgard is a two part resin system containing vinyl groups (part A) and 
hydrosiloxane groups (part B) shown in (Figure 3.8). The two part A:B resin were thoroughly mixed 
together as polymer base and curing agent in a ratio of 10:1 respectively to facilitate the formation of 
cross-linked networks of dimethyl siloxane groups [12]. The PDMS pre-cured mixture is then completely 
degassed twice for 5mins each in a vacuum desiccator and poured into the relief ‘Master’ aluminum mold 
(see section 3.3.2.3.2) up to the tip of needles that provide the sink (SKR) and source (SRR) volume 
reservoirs that form the bottom layer PDMS (Figure 3.7).  After curing the PDMS polymer in an oven at 
70 °C for 15-20mins, the top layer PDMS is cured with two pipet tips mimicking 170uL volumes of the sink 
(SKC) and source (SRC) chambers. Alternatively, fluidic punch ports can be made using appropriately 
sized drill punches into the first or second layer PDMS polymers. Due to the flexibility of PDMS, the 
microfluidic device can easily be unmolded (peeled) from the cast master, leaving the master intact and 
ready to produce another device. Once the device is peeled from the mold, it is prepared for assembly on 
a glass substrate, by initially trimming off excess polymer around the bottom surface of the first layer 
PDMS to facilitate bonding to the flat glass substrate. 
 
Figure 3.6b: Top and Edge-Side-View 
Design Specifications for CNC 
Fabrication of Micro-patterned Double-
layered PDMS Molds – Dimensions used 
in the fabrication of each of the three 
individual metal plates are as specified in 
section 3.3.2.3.2. The side-view panel 
shows an image of the concatenation of 
the three metal plates – bottom, middle 
and top to reveal microchannel, reservoir 
and chamber volumes on one side of the 
microchannel device. Designs were made 
using the Sketch-Up 3D modeling 
software and a 1:2 horizontal scaling. 
Figure is courtesy of Mark Stasiak, 
Mechanical Engineering Dept. City 






for second layer 
PDMS Mold  
A 
B 
Positive relief for 
Source/Sink Reservoir  
Edge-line threading for 
Microchannel volume 
(0.1µl)  
Figure 3.7: Aluminum Cast-Master Mold for the Bridged μ-lane Device – An alternative 
pre-fabricated aluminum mold was employed as positive relief for doubled layered PDMS 
microchannel. A) Depicts cast mold for 1st layer PDMS identifying loci for source and sink 
reservoirs and the microchannel. B) Aluminum encasing for 2nd layer PDMS showing a 
completely assembled cast mold for the double-layered PDMS bridged μ-lane. Piths for the 
source and sink chambers are demarcated by placing two 6mm diameter pipette tips above 
cured 1st layer PDMS polymer.   
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3.3.2.3.4: Step 3 - Adhesion Of PDMS Polymers To Substrate. 
Of the many advantages of PDMS as an elastomeric polymer for micro-fabrication, the ability to modify its 
surface chemistry was utilized in our study to chemically bond the double-layered PDMS to glass. Being 
an inert substance, modifying PDMS surface properties can be quite difficult but has been achieved using 
oxygen plasma mixtures of ions, particles and electrons, corona discharges or ultraviolet (UV) light [14, 
403]. On exposure to an energy stream, methylsiloxane (Si-CH3) groups on PDMS surfaces are oxidized 
to silanol (Si-OH) groups which greatly facilitates the ability of the polymer to bond irreversibly to PDMS, 
glass, silicon, polystyrene and polyethylene substrates [14, 404]. Upon contact, a nucleophilic siloxy 
group on one substrate can attack electrophilic silicon in another forming a covalent bond across the 
interface between the two materials. For PDMS and glass bonding, the reaction yields Si-O-Si bonds after 
water loss (drying) [394, 404]. Utilizing higher voltages and frequency generators for an appropriate time 
as well as 100% oxygen content of air plasma flow strengthens the irreversible nature of the covalent 
bond [404]. Reversible sealing is also possible between PDMS and other silicon substrates via Vander 
waals forces but this seal cannot withstand pressures greater than 5 psi [394]. 
PART A PART B 
Figure 3.8: PDMS Crosslinking Reactions - Two- component silicone elastomer mixture (Part A - base 
monomer (pre-polymer) and Part B - curing agent) is poured over a cast ‘Master’ template in a mixed ratio of 
10:1 for A:B to produce double-layered PDMS bridged U-lane devices. In terms of chemical structure, the base 
pre-polymer (Part A) is composed of about 60 repeating units of-OSi(CH3)2- terminating with a vinyl-CH=CH2 
group (Sylgard 184, Dow Corning). The curing agent (Part B) is similar, but is much smaller with only about ten 
repeating units with periodic silicon hydride -OSiHCH3- units. During the curing step, a hydrosilation reaction 
crosslink the base and the curing agent forming -Si-CH2-CH2-Si- complexes. The resulting structure is 




In preparation for sealing PDMS onto glass, the glass slides are thoroughly washed with laboratory 
detergent, rinsed with water and placed in a beaker containing Nanostrip (Cyantek, Fremont, CA) for 
30mins to 2hrs for chemical cleaning. After thorough rinsing under a constant water stream for 5mins, 
glass slides are blow-dried using nitrogen (N2) gas and stored covered in a dry place until use to prevent 
dust accumulation. Prior to bonding, both double-layered PDMS and glass surfaces are exposed to an 
ozone plasma stream generated using a BD-10A High Frequency Generator 115V (ElectroTechnic, 
Chicago, IL) 3cm from exposed surfaces for 25 seconds each and then immediately adhered together 
with little pressure. The PDMS-on-glass is then cured in the oven for 5 hours to overnight at 70°C to 
secure irreversibility of the covalent bonds. A completely assembled bridged U-Lane device set-up is 
shown in Figure 3.9. 
 
3.3.2.4: Innovative Operation Of The Bridged U-Lane 
 
The bridged µ-Lane system works by using the large volume chambers and bridge channel of the upper 
user interface layer to generate concentration gradients within the smaller volume microchannel in the 
bottom layer. After incubating cells along the microchannel, the cell culture media is manually loaded until 
it has filled the SRR, microchannel, SKR, SKC, and bridge channel. The test chemical solution is then 
loaded drop-wise into the SRC until the sample makes contact with the solution within the bridge channel 
to initiate system operation. The volume ratio of the chambers to the reservoirs (140:1) facilitates manual 
micropipette/syringe loading which initiates gradual transport of chemicals into the bottom layer 
microchannel with minimal channel entrance effects. This volume difference also maintains constant 
reagent concentrations and gradient profiles during experiments without need for replenishment. The 
bridged channel connects the SRC and SKC to balance their solution volumes eliminating hydrostatic 
pressure differences between both chambers so that only density differences of the chamber reagents 
exist to initiate minuscule convective velocities that assist molecular diffusion of chemotropic factors 
through the 13mm-microchannel in the bottom layer.  
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This ultra-low bulk flow generates large differences in concentration gradients along the channel within a 
shorter time compared to one-layer PDMS experiments where larger bulk flows persist to form smaller 
concentration differences in the u-Lane, or where chemical transport by diffusion alone requires much 
longer time spans for steady-state gradients to be established [7, 32]. Given the optically favorable 
characteristics of PDMS, this microfluidic system thus allows sequential live optical monitoring of single 
cell motility responses within predictable microenvironments that create precise spatial and temporal 
profiles of chemical species.  
 
3.3.2.5: Mathematical Modeling Of The Bridged U-Lane Microfluidic System 
Two-dimensional ligand mass transport within the bridged µ-lane had previously been computed using 
the constitutive relations of (1) 2D continuity, (2) convective-diffusion, (3) momentum, and (4) hydrostatic 
equations as described below, on a Finite Element Method platform (FEMLab Version 3.4, Comsol Inc., 
Burlington, MA) with successful modeling and implementation of chemokine gradient profiles [7, 32, 405].  
 
1) Continuity equation:     
 
2) Convective-diffusion equation:   
 
Source Reservoir  










Sink Reservoir  
(9µL volume)  
 
Sink Chamber  
(170µL volume)  
 
Figure 3.9: The Bridged μ-Lane Microfluidic Device - Functional bridged 
u-lane microchannel fabricated by soft lithography of PDMS in dimensioned 
aluminum casts followed by polymer-polymer bonding of first and second 
PDMS layers and then bonding of PDMS to glass. Mass differences between 
drop-wise loaded motogens in source chambers and control media in sink 
chambers induces convective-diffusive chemical flow through the microfluidic 
system with minimal hydrostatic pressures due to fluid volume equilibration by 
the bridged channel. 
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3) Momentum equation:     
 
4) Hydrostatic equation:    h = 0 
 
Key: ρ (kg/m3) is reagent density, u (m/s) is fluid velocity, C (g/l) is solution concentration, D (m2/s) is the diffusion 
coefficient of the reagent molecule, p (Pa) is hydrodynamic pressure, h (m) is the height of the first and second layer 
PDMS with y and x (m) representing the vertical and horizontal directions respectively.  
 
The first equation describes the steady state fluid dynamics of mass chemical particles entering or leaving 
any part of the microsystem. The second equation computes diffusivity ( ) of the chemical species 
(C) over time (t) as a consequence of convective flow ( ). The third equation represents linear 
momentum of diffusing particles over time, while the fourth equation accounts for the negligible 
hydrostatic fluid flow at constant velocity. FEMLAB simulations of the transport of three molecular species 
– Dextran (10KDa), Epidermal Growth Factor (EGF, 6KDa), and Stromal-Derived Factor-1A (7.9KDa) - 
within the microchannel of the bridged U-lane system have previously been experimentally validated and 
described below. 
 
3.3.2.5.1: Measurement of Dextran Transport  
 
Bulk flows were optically measured at different positions along the microchannel using fluorescent beads 
and values were inputted into the convective-diffusion transport model for numerical simulation of Dextran 
transport. Mathematical modeling of molecular transport within the bridged U-lane system was initially 
performed by measuring transport of fluorescently labeled 10KDa molecular weight Dextran at different 
loci optically detected with bulk flow of 1.9um diameter fluorescent beads [7]. The fluorescent beads were 
diluted in PBS to a concentration of 104 beads/ml and loaded into the microchannel, while the PBS was 
added slowly to fill the SKC and bridged channel. Fluorescent dextran at 40ug/ml concentration was then 
added dropwise into the SRC to initiate operation of the bridged U-lane (Figure 3.10a). Dextran density 
differential at the source and sink reservoirs generated both minute diffusive flow (diffusivity = 0.82 X 10-6 
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cm2/s) [7, 406, 407], and ultra-low bulk flow velocities (0.17µm/s) in the microchannel with a system-wide 
average of 0.37 um/s, and no significantly detectable bulk flow in the bridged channel indicative of 
constant concentrations in the SRC and SKC during experiments [7]. These ultralow bulk flows occur due 
to hydrostatic balance between both source (SRR) and sink chamber (SKR) volumes ensured by the 
bridge channel, and enabled the attainment of a steady state gradient through the length of the 
microchannel after only 40hrs of system operation with gradient profiles ranging from shallow profiles of 
10-3ng/(ml.mm) near the SRR to 101ng/(ml.mm) near the SKC [7]. Numerical simulation of Dextran 
transport at loci 5mm away from the source reservoir (SRR) is presented in a 2-D plot of Dextran 
concentration over time, and steady state gradients of dextran was mathematically predicted to be 
attained after 11hrs and maintained steadily through the length of the microchannel for up to 72hrs 
(Figure 3.10b) 
 
3.3.2.5.2: Measurement of EGF Transport 
 
Experimental measurement of one-dimensional Epidermal Growth Factor (EGF, mol.wt. ~ 6.0kDa) 
transport within the microchannel over time generated a diffusivity value of 2.0 X 10-6 cm2/s [32]. Using 
this value, mathematical models of EGF concentration profiles within the U-Lane as a function of time and 
axial position were generated, and it was found that steady state EGF gradient through the entire length 
of the microchannel was established after 18hrs of initiating system operation independent of initial SRC 
EGF concentrations (Figure 3.10c) [32]. These numerical simulations were experimentally validated for 
uniform (system-wide) and gradient concentrations (microchannel only) of 40ng/ml, 80ng/ml and 
400ng/ml EGF. Investigations by the researchers revealed a convection-dominated transport system for 
EGF in the microchannel which forms proximal shallow gradients through half of the channel length and 
steeper gradients closer to the SKC when constant concentrations of EGF are established in these 
regions (>18hrs). Bridged U-lane EGF gradient systems were also shown to stimulate greater cell 




3.3.2.5.3: Determination of SDF-1α Transport in the Bridged U-lane System 
Understanding mechanistic flow in the microchannel of the bridged U-lane has enabled the predictive 3D 
COMSOL modeling of SDF-1α concentration change in water (mol/m3) along the Y-axis length of the 
microchannel from an infinite supply of 1M SDF in SRR (x,6500µm,y) to 0M SDF in SKR (x,-6500µm,y) 
as a function of time (Figure 3.10d). 2D representation (Figure 3.10e) of changing SDF-1α gradient 
profiles with increasing distance from SRR to SKR loci (8000>>-8000µm) predicted that steady SDF-1α 
gradients were maintained for the first few thousand microns (~2700um) from the SRR after which 
concentration fluxes became irregular. In the analysis, we assumed the chemical species diffused 
through water from an infinite 1M reservoir (SRR) to sink (SKR) at either side of the microchannel and 
that the entire system is governed by a standard transport of diluted species model within COMSOL. The 
sides of the microchannel were modeled as perfectly impermeable. This modeling protocol has similarly 
been applied to microfluidic systems in previous studies [408]. Simulation results obtained for SDF-1α are 
similar to the gradient profiles formed by differing EGF concentrations in the microchannel (see section 
above) and SDF-1α molecular transport in the microchannel would comparably be dominated by 
convective flow with minute diffusivity. Given the diffusion coefficient of SDF-1α ~ 1.11-1.7 X 10-6cm2/s 
[409-411] within range of EGF (2.0 X 10-6 cm2/s) and Dextran (0.82-2 X 10-6cm2/s) values, time 
dependent attainment of SDF-1α steady-state gradients in the entire microchannel was estimated to be 







Figure 3.10: Mathematical Modeling of Molecular Transport in the Bridged μ-lane Microfluidic System – FEMLAB 
simulations of molecular transport of three chemical species – Dextran (10kDa), Epidermal Growth Factor (EGF, 6kDa), 
and Stromal-Derived Factor-1α (SDF-1α, 7.9kDa) - was used to model the establishment of their steady state gradients 
in the 13mm microchannel of the bridged U-lane device over time: A) Dextran density differential at the source and sink 
reservoirs generated both minute diffusive flow (diffusivity = 0.82 X 10-6 cm2/s) and ultra-low bulk flow velocities (0.17μ
m/s) that enabled the attainment of a steady state gradient through the length of the microchannel after only 40hrs of 
system operation. These ultralow bulk flows occur due to hydrostatic balance between both source (SRR) and sink 
chambers (SKR) by the bridge channel. Bulk flows were optically measured at different positions along the microchannel 
using fluorescent beads and values were inputted into the convective-diffusion transport model for numerical simulation of 
Dextran transport. B) Simulation of Dextran transport at loci 5mm away from the source reservoir (SRR) is presented in a 
2-D plot of Dextran concentration over time, and steady state gradients of dextran was mathematically predicted to be 
attained after 11hrs and maintained steadily through the length of the microchannel for up to 72hrs [7]. C) Mathematical 
modeling of EGF concentration as a function of time (2, 5, 7, 10 and 18hr) and axial position in the microchannel displays 
gradual attainment of steady state gradients until 18hrs when the change in EGF concentration remains relatively constant 
along the 13mm length of the microchannel [32]. D) Understanding mechanistic flow in the microchannel of the bridged U-
lane has also enabled the predictive 3D-COMSOL modeling of SDF-1α concentration change in water (mol/m3) along the 
Y-axis length of the microchannel from an infinite supply of 1M SDF in SRR (x,6500μm,y) to 0M SDF in SKR (x,-6500μ
m,y) as a function of time. E) Preliminary modeling results are better visualized in a 2-D plot monitoring change in SDF-1α 
concentration gradient with increasing distance from SRR to SKR loci (8000>>-8000μm). Steady SDF-1α gradients were 
maintained for the first few thousand microns (~2700um) away from SRR after which concentration fluxes became 
irregular. In the absence of extensive experimental validation of SDF-1α transport phenomena in the microchannel and 
given proportionality between previously assessed Dextran and EGF gradient generation profiles and their molecular 
weights, we hypothesized attainment of sustained SDF-1α gradients to occur between 18-40hrs after introduction of the 
ligand into the microfluidic system. 
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3.3.2.6: Experimentation with the Bridged U-Lane 
 
To assess cell motility responses to chemical gradients in the bridged µ-lane microfluidic system we used 
methods previously established by the Vazquez laboratory [32]. Functional validation of chemotactic 
interactions for candidate ligand receptor pairs: EGF-EGFR and SDF-1α-CXCR4 was performed in the 
steady-state gradient system of the bridged µ-lane following bioinformatics predictions of motility 
deterministic signaling in PPCs and RPCs by these molecules (see section 2.3.4.3). To ensure viability, 
prior to microfluidic assays, cell suspensions were subjected to a Trypan Blue (Sigma-Aldrich, St. Louis, 
MO) viability assay using a Brightline hematocytometer cell counter (Hausser Scientific, Horsham, PA) 
(data not shown). 
 
The microchannel was coated with 10µg/mL laminin (Life Technologies, Grand Island, New York, 23017-
015, in PBS) for 1hr at 37°C prior to cell incubation. After rinsing and aspirating excess unbound laminin, 
0.1µl of PPC or RPC suspensions (1×106 viable cells/mL) in NB media supplemented with 10% FBS were 
injected into the microchannel for a 2hr incubation period. The SRC, SRR, SKC, SKR and bridged 
channel were also filled with NB media. Thereafter, growth medium is carefully aspirated from the entire 
system, and fresh NB media containing no motogens are added to the microchannel, reservoirs, SKC and 
bridged channel. NB media only (control) and NB media containing 100ng/ml SDF or 20, 40, or 400ng/ml 
EGF are then added drop-wise into the SRC till the solution makes contact with media in the bridge 
channel and initiate system operation. For inhibition studies performed using the bridged µ-lane, RPCs 
were pre-incubated CXCR4 inhibitor AMD3100 for 30mins at 37°C prior to cell loading into the 
microchannel. After filling, the system is placed in a micro-incubator at 37°C with 5% CO2/balanced air 
supply mounted on the motorized stage of an inverted microscope for live cell imaging, tracking and 






3.3.2.7: Live-Cell Imaging of Bridged U-lane Microchannels 
 
The bridged µ-Lane is mounted on the Proscan III motorized stage of a Nikon Eclipse Ti (Nikon 
Instruments Inc., Melville, NY) inverted microscope housed in a humidified incubator (Okolabs, NA, Italy). 
The temperature in the incubator is maintained at 37°C with 5% CO2/balanced air supply and >70% 
humidity. Live cell images were obtained with a CFI60 Plan Fluor 10× (0.3 NA) microscope objective lens 
at hourly intervals for 24-48hrs in three to five independent experiments per experimental condition to 
account for time required to attain steady state gradients of growth factors tested. Where appropriate, 
either brightfield or wide fluorescence images of RPCs or PPCs are taken in the microchannel of bridged 
µ-lane devices. Transmitted light and emitted fluorescence from GFP+-RPCs and PPCs are detected via 
a cooled CCD camera (Cool SNAP HQ2, Photometrics, Tucson, AZ) and collated with Nikon software 
(NIS Element 4.3AR with 6D module, Morrell Instrument Co. Inc., Melville, NY). The emitted GFP 
fluorescence is also indicative of cell viability during cell microscopic observations along with cell 
morphology and blebbing, clustering of fluorescent proteins, detachment from laminar matrix and cell 
motility behavior as previously reported [412].  
 
The dimensions of Brightfield images were 1392 X 1040pixels with a calibration of 0.65µm/pixel, and 
obtained via Cool Snap exposure times ranging from 1.2ms - 3.4ms at readout speeds of 20MHz, while 
wide fluorescence images measured 696 X 520 pixels with a calibration of 1.29µm/pixel. GFP was 
excited with ~25% of 100W TI-DH Diascopic iIlumination Pillar filtered through a custom 440/491/561/638 
dichroic mirror and a 520/35-nm band-pass 25mm ND4/ND8 epifluorescence filter cube controlled by a 
Lambda A Shutter wheel. Optimization strategies to limit phototoxic effects and improve signal-to-noise 
ratio during fluorescence live cell imaging involved increasing camera frame rate by manipulating binning 
and thus minimizing energy impact of the 200ms to 1.5s exposure time range used on cell viability during 
experiments. Figures 3.11a and 3.11b display sample brightfield and fluorescent images of RPCs and 
PPCs respectively incubated in the bridged µ-lane microchannel during attainment of SDF-1α steady 
state gradients.  Approximately 70 individual cells per 13mm-microchannel length of the bridged µ-lane 
were imaged to assess their motility response to each chemotactic factor concentration tested. Cell 
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suspensions were loaded into the microchannel from a 0.1uL volume of 1×106 viable cells/mL 
concentration of PPCs or RPCs as previously described (see section 2.5.2.6). Axial positioning of cells in 
the microchannel was determined by their X,Y (width (um), length (um)) coordinates in sequential field 
views 1mm equidistant from the SRR to the SKR, and over time, tracked cell trajectories per axial 
coordinate per track (cell) per slice (hour) in um/min. Differences in optical resolution of tracked cell 
images due to PDMS and laminar thickness of individually fabricated bridged U-lane microdevices was 
accounted for by the autofocus feature of the NIS Element software (v.4.3AR with 6D module, Morrell 
Instrument Co. Inc., Melville, NY) which calibrated the Z-axis of tracks (cells) based on user-defined 
ranges that accommodate X,Y,Z coordinates with the best image resolution. Cell tracking was perform 
both manually and using the automated tracking system in the NIS Elements Advanced Research (AR) 




A	   B	  
Figure 3.11: Sample bright-field image of multi-passage 
Actin-GFP+ retinal progenitor cells (RPCs) (A) and 
fluorescent image of freshly isolated Crx-GFP+ 
photoreceptor precursor cells (PPCs) (B) incubated in 
microchannels of the bridged U-lane during attainment 
of steady state SDF1-α gradients. 
 113 
3.3.2.8: Method Improvement Study: Tips for Bridged µ-lane Microfluidic Device fabrication and Live Cell  
 
Microscopy of Retinal Stem Cells 
During the micro-fabrication of the bridged µ-lane device, consequent incubation and live imaging of 
cellular motility response to chemotactic factors, we encountered several experimental problems that 
impeded accurate resolution of RPC and PPC migratory parameters. Incomplete reversible bonding of 
PDMS to the glass substrate after application of ozone plasma streams to both bonding surfaces resulted 
in leaky microchannels that subsequently increased the incubation volume and time required to attain 
steady state gradients of chemotactic factors tested, as well as the nature of the gradient profiles 
established along the 13mm length of the U-lane over time. Ozone plasma streams oxidize the 
hydrophobic surface of PDMS to hydrophilic silanol containing groups which on conformal contact with 
glass, yields Si-O-Si bonds forming the basis of a tight irreversible seal between the layers [394, 413]. 
Bond strength is affected by several factors including chamber pressure during ozone treatment and bond 
forming processes, surface exposure times to plasma streams, and the power of ozone generators. Bond 
strength has been reported to peak after 20 seconds of plasma exposure times due to optimal surface 
wettability and texture characteristics of PDMS, while a decrease in bond strength was observed below 
chamber pressures of 100mTorr [413, 414]. In our experiments, we observed that optimized glass slide 
cleaning protocols with successive Alconox laboratory detergent, Nanostrip and water volumes, as well 
as inert N2 gas cleaning of the PDMS surface increased glass-PDMS bonding efficiency by ~75% yielding 
a greater percentage of fabricated microdevices that can withstand typical fluid pressure in microflows of 
5-6 psi [415]. Contributing to the increased bonding efficiency was the extended overnight post-baking of 
glass-bonded replica molds of the bridged U-lane in a 75°C oven that ensured a high pressure 
environment for covalent bonding approaching optimal conditions [413]. 
 
An early issue encountered during live imaging and analysis of migration in bridged µ-lane devices was 
the low cell survivability rates of PPCs and RPCs incubated in humidified microscope incubators. Within 
short time-lapse durations of 6-8 hours, morphological and physiological changes in incubated cells, 
including blebbing, necrosis, cell detachment, GFP signal attenuation and reduced cellular kinetics 
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indicated an increased cell death rate once cells were removed from the confines of traditional laboratory 
incubator. These changes have previously been shown as signs of cell environmental stressors [412, 
416, 417] We thus postulated that stressful factors may have included phototoxicity from FITC-GFP 
illumination using the 100W mercury lamp, variations in osmolarity of the µ-lane media due to low 
humidity levels of the external chamber and the microincubator housing the microdevices on the 
microscope stage, and waste accumulation leading to PH variability may account for observed cellular 
apoptotic and necrotic behavior. A 10 millisecond exposure of cells to a 100W lamp similar to the one 
used our studies had been found to reduce GFP signals to 80% levels [412], and primary mammalian 
cells are fastidious in their environmental requirements, and thus physiologically reactive to even the 
slightest changes in their surroundings [417]. After an extensive troubleshooting protocol was completed, 
cell survivability increased by ~80%. Additional humidifiers were introduced into the cell incubation 
chamber that maintained minimal humidity levels of 65% close to saturated vapor pressure of water at 
37°C, increased flow rate of Air/5%CO2 mixture to >0.2nl/min supplied at ≥ 20mmHg pressure, image 
acquisition using wide-field fluorescent filters was largely replaced by bright-field transmission microscopy 
and only used for interval monitoring of cell health, employing microscopic settings that minimized cell 
exposure to light at lower magnifications and very limited exposure times, and an NB culture media 
formulation supplemented with 10mM HEPES to buffer PH changes in the cell culture media over the 
duration of time-lapse recording experiments [412]. 
 
3.3.2.9: Data Analysis of Microfluidics Assay 
 
Using cell tracking data exported into excel files, the cell motility parameters of center of mass (COM), 
COM vector resolution in the Y-axis direction, maximum accumulated and maximum Euclidean distances 
for each cell tracked over 24-48hrs, were resolved via sequential use of Nd-to-Image6d (National 
Institutes of Health, Bethesda, USA), Manual Tracking (Fabrice Cordelières, Institut Curie, Orsay, 
France), and Chemotaxis and Migration Tool 2.0 (ibidi, Verona MI) plug-ins (ImageJ) [418]. COM is a 
strong parameter for evaluating chemotaxis, and measures the spatial average displacement of all cell 
endpoints with positive or negative coordinates, depending on the direction of movement of a single cell 
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or a population of cells. COM displacement in the Y-axis further specifies directionality of cell movement 
towards the SRR from a normalized point of origin (0,0). Figure 3.12 illustrates the definitions of these 
cell motility parameters for a single cell. Cell tracking data selected for analysis included only video 
recordings of RPC and PPC movement after 18hrs post-incubation of cells in the microchannel to allow 
for complete periods of sustained steady-state gradients of EGF and SDF-1α in bridged µ-lane system. 
Mean COM, COM-Y-axis, Euclidean and accumulated distances of RPCs and PPCs in control channels 
were then compared to values in channels inducted with steady-state gradients of the candidate 
chemotactic factors using the Student’s t-test assuming unequal variances or the Dunnett statistical test 
for single or multiple chemotactic factor concentrations respectively. These analyses were performed 
using JMP (v 8.0; SAS technologies, NC) statistical software. A Tukey pairwise comparison test was also 
used to resolve statistically significant differences between pairs of chemical concentrations tested with 
significance level set to p <0.05. 
 
3.3.2.10: Method Improvement Study: Comparing Manual Vs. Automated Cell Tracking Systems 
 
The large amount of image frames acquired from datasets of time-lapse microscopy of large numbers of 
cells in the bridged µ-lane microchannel poses an obvious problem for manual tracking and image 
management purposes. Besides the obvious human error associated with manually tracking paths of 
single cells or cell clusters every hour for every position and the excessive estimation of cell positions 
associated with the task, we sought to use automated tracking software packages to enable the 
measurement of cellular motility with ease of quantitation and analysis. These software programs offer 
simultaneous cell centroid extraction capabilities on individual images, tracking of individual cell centroids, 
and track monitoring with minimal post-tracking computation required [419].  The new possibilities offered 
by recent advancements in software to aid imaging of cellular processes in space, time, and at multiple 
wavelengths has made it evident that to ensure efficiency, consistency and completeness in handling the 
wealth of data obtainable from even a single experiment, automation of computational image 


























We adopted the automated tracking add-in tool on the Nikon NIS Element 4.3AR software platform 
(Morrell Instrument Co. Inc., Melville, NY), to explore high throughput image processing of time-lapse 
recordings of RPC migration in brightfield illumination and PPC migration viewed through a FITC 
fluorescent filter. Typically, this automated tracking tool is implemented post-experimentation and uses 
pre-processing algorithms to improve object separation from background. Steps involved in automatic 
Figure 3.12: Parameters for Tracking Migrating Retinal Stem Cells – Manual tracking of 
migrating retinal progenitor cells (RPCs) and photoreceptor precursor cells (PPCs) was 
performed via sequential use of Nd-to-image6d, Manual Tracking and Chemotaxis and 
Migration Tool 2.0 software platforms. The diagram displays the definitions of the various 
parameters used to monitor cell’s trajectory during experiments. Path of travel (_) from point 
of origin (X) to point of destination ( ) is defined as the Accumulated distance while a straight 
line connecting both points is the Euclidean distance. Maximal values of both distances were 
computed for cells in our studies and travel distance, as a function of time is also an 
obtainable data reference. A strong indicator of chemotaxis is the center of mass (COM) 
parameter that accounts for directional mass movement of populations of cells. Selecting 
COM (yi,end) assisted the determination of directional chemotactic movement of retinal stem 
cells towards ligand source reservoir (SRR). 
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tracking include removal of image background signals, detection and specification of maximal projection 
for all image frames as well as image sharpening and contrast improvement. The Region of Interest (ROI) 
tracking algorithm option with a built-in detection phase for segmented objects was then selected to 
automatically define tracking objects per frame in both the transmission and fluorescence microscopy 
experiments. A motion model that agrees the most with the captured motion is initially user-selected to 
govern the computation of cell displacement over time or a best-fit algorithm can be adopted to ease 
mode selection from options which include random motion, constant speed, circular motion or a 
combination. Other principal motion parameters that can be pre-set include maximum cut-off speed for all 
objects, standard deviation multiplication factor that uses your tracking history to represent a probability 
that motion would be unexpected at certain track points, and maximum gap size to specifies limits to the 
number of allowable image frames with no trackable cell movement.  
 
Data output parameters can also be specified so that measurement of user-defined aspects of cellular 
displacement behavior can be performed. Measurable cell movement parameters include; segment 
length and speed which measures distance and time between two consecutive points in an object’s 
trajectory, path length and speed which sum segment lengths from origin to object’s current position, rate 
at which a destination is reached, acceleration, heading angle between the direction of the velocity vector 
and X-axis or XY-axis (Elevation), and line length and speed which measures Euclidean distances of 
tracked objects. A sample of automated tracking used to analyze time-lapse recording of the movement 
of six PPCs over 24hrs is shown in figure 3.13 including graphed cell path lengths (Figure 3.13a), speeds 
(Figure 3.13b) over time, comparable to accumulated distance and velocity measurements obtained in 
the manual tracking protocol respectively, as well as line lengths (Figure 3.13c) and speeds (Figure 
3.13d) over time which are commensurate to Euclidean distances. The range of output highlights the 







Figure 3.13A-D: Measuring RPC 
and PPC Motility Using 
Automated Tracking Systems – 
The need for efficient 
management of image data 
obtainable from time-lapse 
microscopy of retinal stem cell 
migration in microfluidic devices 
necessitated a test adoption of 
NIS Elements 4.3AR Automated 
Tracking add-in to automate and 
compute cell motility parameters. 
A 20hr sample video recording of 
the chemotaxis of six (6) freshly 
isolated photoreceptor precursor 
cells in SDF-1α  steady state 
gradient in the bridged U-lane 
microchannel was used to test 
the adopted tracking tool by 
automatically tracking movement 
of the six cells. Measurable 
migratory indices and display 
options available include: A) 
Pathlength as a function of time – 
analogous to accumulated 
distance of cell trajectory over 
experimental time course. B) 
Pathspeed as a function of time - 
computing acceleration for the 
cells. C) Line length as a function 
of time - analogous to Euclidean 
distance over time. D) Line speed 
as a function of time - computing 
velocity rates of cells. 
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Additionally, a Kymograph utility option which displays 360° motion tracking view is also a possible output 
style (Figure 3.13e) that further adds a strong directionality estimate to distance measurements, 
compensating for the Center of Mass (COM) function used in the manual tracking protocol. 
 
 
While automated tracking protocols have limitations including discernment of actual object tracks from 
artifacts and distinguishing single cells from cell clusters [420], the larger variety of output data and 
measurements resolvable, as well as the massive time saved when compared to manual tracking makes 
automated tracking a more efficient approach. A comparison of tracking results obtained using manual 
versus automated analysis of PPC motility in the presence of 100ng/ml SDF at 6 different positions along 
the microchannel over 20hrs is presented in Table 3.1. The results reveal large differences in maximum 
Euclidean and Accumulated distance and cell speed, although mean values of these measuring indices 
are similar as well as the patterns of peak cell distance and speed measurements around the 3rd and 4th 
loci away from the source reservoir (SRR) was observed. Additionally, more cells were manually 
Figure 3.13E: Kymograph of Migrating PPCs – This 
display option available using the NIS Elements 4.3AR 
Tracking tool shows 360° motion tracking of the six 
PPCs, and thus adds a strong directionality estimate to 
distance measurements, compensating for the Center of 
Mass (COM) function used in the manual tracking 
protocol. 
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trackable at different positions compared to automated tracking that at times, could not discern single 
cells from clusters. It thus seems ideal to adopt one preferred tacking system for all analysis to ensure 













1 7 164.9 0.3432 51.72 
2 4 77.4 0.117 69.15 
3 7 111.9 0.1602 67.89 
4 9 330.6 0.5502 298.4 
7 4 45.58 0.03996 23.74 
10 2 20.334 0.03474 10.904 














1 13 57.65 0.96 57.65 
2 10 122.79 2.05 122.79 
3 14 213.63 0.22 197.86 
4 11 186.63 0.31 108.03 
7 5 24.27 0.02 9.31 
10 5 41.14 0.23 22.75 
Average  107.69 0.60 86.40 
Table 3.1: Comparing Manual Versus Automated Tracking Results – Both 
types of tracking systems were used to analyze a 20hr sample time-lapse 
fluorescence microscopy recording of migrating GFP+ populations of photoreceptor 
precursor cells in bridged microfluidic system initiated by differential concentrations 
of SDF-1α in the source (SRC) and sink (SKC) chambers. Cells were tracked at 6 
different loci at increasing distance away from source reservoir (SRR) source of 
chemotactic factor tested. Such data comparisons will illuminate inconsistencies in 
data measurements and make more informed interpretations of cell chemotactic 
behavior. Results indicate large variations in values obtained for Maximum Path 
length/Maximum Accumulated Distance, Maximum Line length/Maximum 
Euclidean Distance and Maximum Path Speed pairwise comparisons, but averages 
of these measuring indices similar with a common pattern of peak travel distances 
and speed around positions 3 and 4 away from the SRR can be observed. 
Additionally, more cells were trackable using the manual tracking methodology 
although sampling subsets of cells to analyze cell motility characteristics is 
routinely employed in the field. 
 121 
CHAPTER 4:  RESULTS: MICROFLUIDIC GENERATED EGF-GRADIENTS INDUCE CHEMOKINESIS 
OF TRANSPLANTABLE RPCs VIA THE JAK/STAT AND PI3KINASE SIGNALING PATHWAYS. 
 
4.1:  INTRODUCTION – EGF-EGFR INTERACTIONS AS MODULATORS OF TRANSPLANTABLE RPC 
MOTILITY 
Retinal transplantation studies that report successful integration rates of grafted cells into host retina, 
employ a sub-retinal transplantation paradigm using PPCs isolated at early developmental stages [1, 112, 
148, 230, 421]. It follows that an understanding of the molecular signaling associated with these PPCs at 
the time of transplantation will inform strategies to improve migration and integration into appropriate 
lamina. Recent findings show that over a two-week period, only ≤ 3% of grafted PPCs successfully 
integrated in a damaged adult mouse retina model [112]; however, with large populations of rod and cone 
replacement cells needed to restore vision function in damaged retina, a more efficient transplantation 
strategy is needed [50, 112, 422]. Knowledge of the gene expression state and migratory response 
properties of donor PPCs can allow us to select for or engineer genomic profiles advantageous to 
movement and integration in host retina. Analogously, ectopic expression of selected chemokines in the 
adult recipient mouse retina has been shown to significantly increase migration rates of PPCs [230], 
highlighting the importance of biochemical signaling in host retinal microenvironments [422]. We thus 
analyzed microarray gene datasets of transplantable mouse rod PPCs (GEO Accession GSE29318) [423] 
and cone PPCs (GEO Accession GSE25607) [424] obtained at developmental times - post-natal day 4 
(P4) for rods [163, 425, 426], and embryonic day 17.5 for cones [163, 425, 426] in close proximity to their 
ontogenetic peaks. These temporal stages selected have been observed to be active migratory periods of 
photoreceptor precursors to their laminar loci prior to terminal cell-type differentiation processes [163, 
256, 263] allowing us postulate that the biochemical profile inherent in the genomic datasets will facilitate 
the identification of signaling molecules and pathways favoring PPC motility. Additionally, these 
photoreceptor cell type sources of the microarray data typify post-mitotic PPC sources widely used in 
current transplantation studies [112, 230, 421]. 
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Following a rigorous bioinformatics-based data mining protocol as described in section 2.3.3, ligand-
receptor cognate molecular pairs predicted to govern cellular movement in both rod and cone PPCs were 
resolved to define four major families of signaling molecules – Matrix Metalloproteinase (MMP) regulatory 
molecules, Neuregulin-ErbB signaling, Chemokine (CXC, C-C motifs) signaling, and Epidermal Growth 
Factor receptor (EGFR) signaling interactions (Table 2.4). The migratory role of epidermal growth factor 
family in nervous systems has been well studied for some of the members depicted in Table 2.4 including 
amphiregullin, EGF, TGF-alpha, heparin-binding EGF (HB-EGF), betacellulin and epiregulin [367, 427, 
428]. Muller cell proliferation and chemotaxis associated with retinal diseased states such as proliferative 
vitreoretinopathy (PVR) has also been linked to high expression levels of both HB-EGF and EGF 
receptors in mammals [429, 430]. We thus hypothesized that selective members of this ligand family 
would influence retinal progenitor cell chemotaxis in vitro. 
 
In the adult human and mouse retina, constitutive expression of the epidermal growth factor receptor 
(EGFR) has been observed in ganglion, amacrine and horizontal cells, and synaptic regions of 
photoreceptors [270, 431, 432]. Increased EGFR expression has also been described in the human retina 
during proliferative diabetic retinopathy [433], and the activation of EGFR has similarly been correlated to 
proliferation in RPCs [431] and both proliferation and motility of a range of neural progenitors [367, 384, 
427] and retinal pigment epithelial cells [434]. PPCs transplanted into adult retina have been observed to 
migrate through the outer limiting membrane (OLM) into the outer nuclear layer (ONL) and integrate by 
extending apical neurite processes to synapse with second-order neurons at the outer plexiform layer 
(OPL) forming outer segments [112, 435-437]. Other grafted populations localize to regions of the 
interphotoreceptor matrix (IPM), photoreceptor outer segments and Muller glia end-feet. Leading 
investigators believe that the glial processes, the retinal pigment epithelia and host neurosensory retinal 
lamina layers all contribute chemical signals influencing PPC migration and integration [436-438]. As 
adult human and mouse retinal ganglion cells have been shown to transcribe EGF mRNA [270, 432], and 
after retinal damage, Muller glia up-regulate synthesis of EGF to levels driving histogenesis during retinal 
development [431], it is plausible that a chemotactic gradient of EGF, among other target molecules, is 
generated from the inner retina to diffuse to the outer nuclear layer to influence migration of EGFR-
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expressing RPCs in the inner interphotoreceptor matrix regions. Growth factor gradients have previously 
been shown to stimulate proliferation and motility of neural progenitors [439], connective tissue-derived 
cells [32], and cancer cells [398, 440] and are utilized in many related biological applications [441]. We 
thus selectively investigated the motility effects of the EGF-EGFR pairwise signaling interaction using a 
retinal progenitor cell model. To recapitulate gradient events reminiscent of retinal micro-environmental 
conditions, steady-state nano-molar level gradients of EGF were generated in this study using a 
bioengineered microfluidic system [7]. 
 
For cell motility to be elicited, EGF typically binds to its receptor on the plasma membrane, induces 
dimerization of EGFR which activates its tyrosine kinase, followed by auto-phosphorylation and/or 
internalization of receptor-ligand complexes [442]. Mediators such as phospholipase C-γ1 (PLC-γ1), focal 
adhesion kinase (FAK) and Rho GTPases signal canonical downstream pathways including the 
PI3Kinase [367] and MAPK signaling pathways [443] responsible for disruption of focal adhesions and 
stimulation of cytoskeletal reorganization to facilitate cell motility [137, 444, 445]. We postulated that 
similar signaling cascades overlap to govern EGF-induced migration of RPCs.  
 
4.2: INTERACTIONS OF MAPK AND JAK/STAT SIGNALING PATHWAYS ARE PREDICTED TO 
GOVERN EGF-INDUCED RPC MOTILITY 
Prior to investigating ligand-induced RPC migratory phenomena, we sought the most conclusive ways of 
selecting cellular markers for monitoring motility-deterministic genomic changes that may be influenced 
by EGF induction. We decided on an in-silico bioinformatics approach to best elucidate the complex 
biochemical interactions expected to accompany EGFR activation, and ensure ligand-, tissue-, and 
function-type specification for the analysis of ligand-induced RPC movement. This analysis method also 
possesses high predictive powers as information supporting resolved biochemical pathways are current, 
peer-reviewed and extensive, with versatile tools provided to explore the bioinformatics data. A signaling 
interactions network specific for the EGF ligand was thus generated using the Ingenuity Pathway Analysis 
(IPA) (Ingenuity® Systems, www.ingenuity.com, Redwood City, CA) network pathway designer tool to 
illustrate the molecular network orchestrating cellular decision-making processes stimulated by the ligand. 
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Similar ligand-specific pathway designs have been resolved from microarray genomic data, and have 
enabled the description of subsets of canonical pathways influencing neuroblast migration along the 
rostral migratory stream to the olfactory bulb [297], delineation of transcriptional networks controlled by 
the Crx homeobox gene [446], and deciphering EGF-induced signaling dynamics in human carcinoma 
cells [447]. We simplified the in-silico technique by relying on a collation of experimental observations 
curated in the IPA knowledgebase to predict EGF-induced signaling interactions in the retino-neural 
system. 
 
EGF was input into IPA as a seed gene, and direct and indirect molecular interactions associated with the 
ligand were generated by annotation to IPA knowledgebase. The genes were then further specified for 
their occurrence in the mammalian retino-neural system, and a functional analysis was performed to 
identify the biological functions most significant to the resulting molecules in the network. A right-tailed 
Fisher’s exact test calculated a p-value determining the probability that each biological function and/or 
disease assigned to the EGF custom network was due to chance alone as has been previously 
performed [339, 448]. Figure 4.1 displays the predictive network model showing only direct molecular 
interactions induced by EGF in mammalian neural retina. Direct molecular connections denote 
consecutive nodal binding interactions with high statistical predictability, and help prioritize candidates 
when choosing signaling cascades induced by the EGF ligand. Molecules in the network pathway 
relevant to the chemotaxis function were identified by a right-tailed Fischer test for statistical significance 
(p=8.67E-10) and are outlined or shaded in red in Figure 4.1. Additional cellular functions resolved in this 
analysis include cell proliferation, cell-to-cell signaling, gene regulation and cell cycle progression. The 
network model also predicts two signaling pathways previously shown to be involved in EGF-induced 
motility. Activation of phospholipase C-γ1 (PLCG1) and subsequent hydrolysis of phospho-inositide 
bisphosphate (PIP) to yield products that activate protein kinase C (PRKCA) have been shown to 
increase cytoplasmic calcium levels which in turn stimulates cytoskeleton reorganization for cell motility 
[18, 443, 449]. PRKCA phosphorylates Raf1 (MAP kinase kinase kinase (MAP3K)) activating MAPK1/3 
signaling [450]. Figure 4.1 also shows the coupling of EGFR activation to docking proteins GRB2 
(Growth factor receptor bound)/SOS (Son of sevenless) via their SHC (Src homology) domain, an 
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interaction that can activate HRas and its effector, the protein kinase of Raf1. Raf can initiate 
phosphorylation events that activate the ERK1/2 signaling pathway leading to disruption of focal 
adhesions in mouse fibroblasts, and enhanced membrane ruffling, both essential processes for cell 
motility [18, 443, 451]. The same mechanism can phosphorylate insulin receptor substrate (IRS) and p85, 
which result in the activation of phosphoinositide 3-kinase (PI3K) [360], identified to be indirectly involved 
in the model network (Figure 4.1). Additionally, RAF1 directly associates with Janus Kinase (JAK) to 
activate Signal Transducer and Activator of transcription (STAT) proteins which can bind specific nuclear 
regulatory sequences to activate or repress transcription of target genes that are involved in cell motility 
[450].  
 
Our bioinformatics custom network model also predicts a potential cross-interaction between the 
JAK/STAT and the EGFR tyrosine kinase (RTK)/Ras/MAPK pathways (Figure 4.1). Activated EGFR has 
previously been shown to promote JAK-independent tyrosine phosphorylation of STATs, a process 
possibly involving Src kinase [450]. MAPK has also been shown to specifically phosphorylate a serine 
residue near the C-terminus of most STATs as our model predicts.  Although this phosphorylation event 
dramatically enhances transcriptional activity of STAT, it is not absolutely required for STAT activity [450]. 
Our bioinformatics model suggests that RPC motility signaling is a tightly regulated event involving a 
chemotactic role for EGF and the MAPK and JAK-STAT signaling pathways, with indirect involvement of 
the PI3K pathway. A custom network model displaying an overlay of both the direct and indirect molecular 
connections induced by EGF-EGFR activation in mammalian retinal neurons is presented in 
Supplemental Figure 4.1. 
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4.3: EGF RECEPTOR IS EXPRESSED AND LOCALIZES TO PUNCTATE STRUCTURES ALONG 
CELLULAR PROCESSES IN RPCS EXPOSED TO EGF  
 
To determine the expression and localization of EGFR in RPCs exposed to EGF, we performed 
immunofluorescence microscopic analysis of RPCs exposed to 20ng/ml EGF in comparison to controls 
with no EGF. Antibodies recognizing both total EGFR and a phospho-specific form of EGFR were used to 
detect ligand binding and activation states for the receptor respectively [431, 452, 453]. Our results show 
that both non-phosphorylated and phosphorylated forms of EGFR are present in RPCs and that the 
receptors localize to the cell body and cellular processes (Figures 4.2B and 4.2F, respectively). EGFR 
expression on RPCs appeared similar between 20, 40 and 400ng/ml EGF concentrations and remained 
relatively constant even at a saturating ligand concentration of 10000ng/ml (Supplemental Figure 4.2). 
Figure 4.1: EGF Signaling Pathways driving migration of RPCs - 
Predicted network of direct molecular interactions influencing RPC migration 
in the mammalian retina following induction by the EGF ligand. The network 
was generated using Ingenuity Pathway Analysis (IPA) bioinformatics tool. 
Molecular components of the EGF signaling pathway are localized to 
extracellular space, plasma membrane, cytoplasm and nucleus. Arrows 
indicate direct interactions between upstream and downstream pathway 
molecules. Molecule shapes outlined or filled in red denote significant 
association with chemotaxis as determined by a right-tailed Fischer test. 
Molecules displayed on the left represent key chemical groups predicted to 
participate indirectly in the network.  
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No observable differences were detected between experimental conditions for RPCs adherent to 
coverslips labeled with anti-total-EGFR and anti-phospho-EGFR. Immunostaining results were supported 
by positive protein blots of EGFR expression obtained from lysates of RPCs exposed to only 20ng/ml, 
40ng/ml and 10µg/ml EGF compared to control conditions (Figure 4.2I) and support our predictions that 
ligand binding is necessary for EGFR activation. Optical XY sections (0.2-0.4µm apart) made of RPCs 
labeled for total and phosho-EGFR were stacked to yield XY projection images (LSM 510, Carl Zeiss, 
Thornwood, NY). These EGF-stimulated GFP-positive cells were illuminated using a 488nm argon laser, 
and Dylight 594 secondary antibody was excited using a HeNe 594 laser (Figure 4.3). The labeling of 
EGFR observed in this work correlates with other studies showing similar results across a range of high 
and low EGF concentrations and in both RPCs and adult retinal cell types [431, 454, 455]. For this study, 
activated EGFRs represent the requisite cell surface mechanism to activate downstream JAK-STAT and 





















Figure 4.2. Immunocytochemical localization of RPC total and phosphorylated EGFR expression. Analysis of 
EGFR localization on RPCs was performed using cells isolated from P3-5 transgenic mice expressing green fluorescent 
protein (GFP) on the actin promoter (actin-GFP). A) Actin-GFP RPCs express GFP ubiquitously revealing cytoplasm 
shape of two RPCs in 20ng/ml EGF, B) Rhodamine bound anti-total EGFR antibody staining reveals robust receptor 
localization to cell membrane of soma and processes. C) DAPI labeling of nuclei, D) Overlay of A-C. Panels E-H show 
identical imaging parameters as A-D, with the exception that F) utilizes anti-phosphorylated (activated) EGFR labeling. 
Western blotting for EGFR expression in RPCs exposed to 0ng/ml, 20ng/ml, 40ng/ml and 10µg/ml EGF (I) show that 
ligand binding is necessary for EGFR activation in the retinal progenitor cell types used in our investigations. Results of 
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4.3.1: Exploring Endogenous Receptor Expression in Mitotic Retinal Progenitor Cells  
The enrichment bioinformatics analysis approach initially employed in this study (section 2.3.2) entailed 
firstly, selecting a set of ancestral motility-deterministic seed genes based on their frequency of 
occurrence in association with the motility of retinal neurons in scientific peer-reviewed literature, followed 
by a computational analysis for the statistical probability that the selected genes are involved in a nodal 
connection, annotated in a functional or canonical signaling pathway, or are part of a network of 
intersecting pathways. This analytical method was based on the hypothesis that, as retinal cells were 
embryonically related to neuronal cell types, similarities in their genomic and subsequent proteomic 
makeup are abound predicting a similar signaling profiles between both cell types. Resolved statistical 
probabilities were then used to create predictive network models visualizing probable molecular targets 
and probe-worthy biochemical interactions specific to the motility of retinal stem cells. Certain guidance 
factors recurred through the step-wise in-silico gene-enrichment process including Chemokine (C-X-C) 
motif ligand 12 (CXCL12), Netrin-1 (NTN1), Slit-1/2, Fibroblast growth factor (FGF-1) and its receptor 
FGFR, Reelin (RELN) and its receptor Apolipoprotein E receptor 2 (ApoER2), Ephrin B ligand and its 
receptor EphB2, and Insulin-like growth factor-1 (IGF-1). These genes were part of our original seed gene 
list (Table 2.1), part of the resultant expounded network eligible genes (Table 2.2), and/or part of the 
enrichment network of second messenger molecules (Table 2.3). The recurrences of these genes 
Figure 4.3: Confocal Image of EGF-stimulated RPCs - 
Confocal images of Actin-GFP+ RPCs stained with anti-
phospho EGFR to detect phosphorylated EGF receptor.  A) 
Dylight 594-conjugated anti-phospho EGFR was illuminated 
using HeNe 594 laser. B) GFP was excited using an Argon 488 
laser. C) displays an overlay of panels A and B. Optical XY 
sections were imaged 0.2-0.4μm apart and stacked together 
to yield the XY projection image. Scale: 55.6μm 
	  
 130 
suggested that they were likely involved in the migration of RPCs or PPC, and merit analysis for their 
effect on the migration.  
 
To determine if RPCs endogenously express receptors needed to respond to these guidance factors, we 
performed immunofluorescence analysis of four candidate receptors using techniques described above 
(section 4.3). The receptors analyzed for included CXC receptor 4 (CXCR4) for CXCL12 ligand, Deleted 
in Colorectal Cancer receptor for Netrin-1, Fibroblast Growth Factor Receptor (FGFR), and Roundabout-1 
(Robo1) receptor for Slit-1 protein. Figure 4.4B displays Trit-C conjugative labeling of DCC receptor 
localization on RPC soma and positive staining for Robo-1 receptors in Figure 4.4E. RPC cytoplasmic 
GFP fluorescence appears in Figures 4.4A and 4.4D with DCC and Robo-1 receptor labeling in Figures 
4.4B) and 4.4E. Figures 4.4C and 4.4F show overlay of GFP and Trit-C images for both DCC and Robo-
1 receptors respectively. Staining for the third FGFR using identical protocols gave negative 
immunoreactivity results. Detection of CXCR4 expression in RPCs is reported in chapter 5. This selective 
expression of receptors for these canonical guidance cues may be ascribed to dynamic genomic profiles 
associated with the competence of RPCs and likely guide the chemotactic response of RPCs in vitro and 
in vivo. Previous studies suggest that receptor expression of both FGF and EGF contribute to progenitor 
motility [456, 457]. FGFR1 expression levels have been observed to decrease significantly with 
maturation of freshly isolated rat RPCs while EGFR expression tends to increase[456, 457]. This 
observation also raises the possibility that the differential receptor expression observed in our RPC 
population is in a state of dynamic flux resulting from states of activation or inactivation of co-receptors 
and/or adaptor genes as modeled in our enrichment network (Figure 2.4) and exemplified by the 
modulatory role co-expression of ErbB receptors play of EGF binding affinity to its receptor [458] . 
However, along with a host of other chemotactic molecules, we were able to correlate findings for these 
protein expression studies to in vitro motility function tests. We next analyzed the effects of ligands 
specific for our identified receptors on RPCs using Boyden Chamber assays and microfluidic steady state 




4.4: MOTILITY TESTS SUPPORT PREDICTED ROLE OF JAK-STAT AND PI3KINASE SIGNALING 
IN EGF-INDUCED RPC MIGRATION  
 
We used functional validation tests to support or refute the hypotheses that bioinformatics-derived 
candidate molecules influence chemotaxis of RPCs and PPCs used in this study. One of the assessment 
methods utilizes diffusive perpendicular gradients of test ligands generated in the lower chamber of a 
modified Boyden Chamber assay (see section 3.3.1.1), to differentially test attractive or repulsive effects 
of the ligands on cells in the upper chamber [364]. Prior to the motility assays, a time-optimization study 
described in section 3.3.1.2 was performed using RPCs to identify the duration over which the most 
effective motility response is obtained from RPCs on exposure to the EGF ligand. The study was 
necessary given varied time intervals employed in many peer-reviewed Boyden Chamber motility studies 
conducted with retino-neural and neuroglial cells for different ligands [365, 459] and even when the same 
cell type and ligand are used [460, 461]. Given the canonical mitogenic role EGF plays in most cells, an 
.Figure 4.4: Endogenous Receptor Expression Patterns in RPCs – Following step-wise bioinformatics analysis 
for chemotactic molecules influencing RPC migration, the endogenous expression of receptors for four recurring 
candidates was assessed in RPCs A) GFP+ RPCs  with B) Trit-C conjugated anti- DCC shows receptors on RPC 
cell bodies. C) Overlay of images A and B.. D) GFP+ RPCs with E) Positive staining for Robo-1 receptors reveals 
punctate receptors on RPC cell bodies.F) Overlay image of D and E. Staining for the third receptor FGFR using 
identical protocols gave negative immunoreactivity results. Detection of CXCR4 expression in RPCs is reported in 
Figure 5. Scale: 10μm 
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MTT cell proliferation assay (section 3.1.3) was also performed before the cell motility tests to examine 
growth rate of RPCs in varying concentrations of the EGF ligand over the same time period, so that total 
RPC counts obtained upon completion of Boyden Chamber experiments result from ligand-induced 
motility effects distinguishable from the proliferative effects EGF may have on RPCs. After determining 
effective EGF concentrations driving RPC motility, we explored downstream signaling pathways that 
translate EGF ligand-binding effects into executable cell movement phenotypes. Computational modeling 
of motility-deterministic EGF signaling in RPCs predicted the roles of canonical MAPK and JAK-STAT 
chemotactic pathways in driving RPC motility (Figure 4.1) and we tested our predictions using functional 
migration analysis. A common approach that we employed is to chemically inhibit cytoplasmic and 
nuclear protein cascades influencing cell motility or the expression of cognate signaling molecules up- or 
downstream of pathways under investigation. Therefore, simultaneous identification of key cascade 






Figure 4.5: Optimizing Incubation Times for Retinal 
Progenitor Cell Motility Assay - RPCs were exposed to 40ng/ml 
EGF chemotactic concentration for various time durations ranging 
from 6-48hrs. Least square means plot modeling interaction 
between EGF concentration and duration of incubation on 
normalized migration of RPCs (N=218; R2 =0.501).  
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4.4.1: RPCs Exhibit Effective Migratory Phenomena after 24-hour duration in Boyden Chamber Assays. 
RPC suspensions at a concentration of 5 X 104 cells/350uL media volume was added to transwell filters 
submerged into 40ng/ml EGF chemotactic concentration in the lower compartment of a Boyden Chamber 
assay for the following time durations: 6-hr, 12-hr, 18-hr, 24-hr and 48-hrs. After incubation at 
37°C/5%CO2, Figure 4.5 shows that maximal stimulation of RPC motility was obtained after a 24-hr 
incubation period (p=0.0026; Normalized Mean ± SD = 1.97 ± 0.30), and the 12-hr (p=0.0001) and 48-hr 
(p<0.0001) incubation conditions (Table 4.1) also allowed for significantly higher RPC migratory rates 
compared to control conditions by pairwise Tukey’s HSD statistics. To ensure optimal cell viability and 
ligand stimulation the 24hr time-point was selected as the experimental run-times for all Boyden Chamber 












4.4.2: Retinal Progenitor Cell Growth rates are Independent of EGF Ligand Concentrations  
Approximately 5,000 RPCs in 100µl media volumes per well were prepared in quadruplicates for EGF 
concentrations of either 0, 20, 40 or 400ng/ml to which the cells are exposed for 24hrs in a 96-well plate. 
An MTT viability assay was then used to assess the ligand concentration-dependent growth rates of the 
cells on two different days. MTT is reduced by metabolically active cells in part by the action of their 
ubiquitous endogenous cellular dehydrogenase enzymes, that generate reducing equivalents such as 






Mean ± SEM p-value 
6 24 0.193 ± 0.05 0.6749 
12 24 1.88 ± 0.18 0.0001* 
18 15 1.29 ± 0.18 0.1067 
24 15 1.97 ± 0.30 0.0026* 
48 20 1.87 ± 0.21 <0.0001* 
Table 4.1: Optimizing Incubation Times for Retinal Progenitor 
Cell Motility Assay - Results indicate significant migratory effect 
stimulated after 12-hr (p=0.0001), 24-hr (p=0.0026) and 48-hr 
(p<0.0001) incubation periods with maximal normalized cell migration 
obtained after 24hrs (Mean ± SD = 1.97± 0.30).  
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activity level is relatively constant in cells such that an increase in cell number will thus be directly 
reflected by an increase in metabolic rates. A standard curve correlating absorbance of reduced 
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) at 575nm to serially diluted 
RPC suspensions containing 1000, 2500, 5000, 7500, 10000, 15000, and 20000 cells was used to 
compute RPC numbers obtained following the 24-hr growth time. Figure 4.6A shows the MTT 
absorbance curve for RPCs created by a bivariate fit method (Absorbance = 0.0299449 + 3.5802e-6*Cell 
Number; F(1,63) = 610.89; p<0.0001). Using this equation to compute RPC numbers from spectrometric 
absorbance values, Figure 4.6B revealed no change in RPC proliferation rates with increasing EGF 
concentrations. Using a Dunnett statistical test with the descriptive statistics for the MTT assay in Table 
4.2 there was a doubling in cell number to almost 10,000 RPCs across all conditions over the 24hr time  
period (0ng = 9431.1cells ± 1163.68 (p=1.0000); 20ng = 9219.5cells ± 713.36 (p=0.9611); 40ng = 
9388.2cells ± 669.46 (p=0.9966) and 400ng= 8779.8cells ± 1544.60 (p=0.4956). This test not only 
informs the typical growth rate of our RPCs in the presence of EGF, but also ensures that assessments of 
chemotaxis to test ligands can be accurately determined by simply counting the number of transmigrated 













Figure 4.6: RPC Proliferation is 
Independent of EGF Ligand 
Concentrations – To ensure that 
characteristic motility effects 
observed with RPCs when exposed 
to varying EGF concentrations is 
not a factor of their overall mitotic 
activity, sets of 5,000 RPCs per 
well were each exposed to either 0, 
20, 40 or 400ng/ml EGF for 24hrs 
and then subjected to an MTT 
viability assay. A) Standard curve 
correlating absorbance of reduced 
MTT at 575nm to increasing RPC 
number by bivariate fit method 
(Absorbance = 0.0299449 + 
3.5802e-6*Cell Number; F(1,63) = 
610.89; p<0.0001). B) The 
standard curve was then used to 
compute RPC number following 
incubation in the different EGF 
concentrations over the same time 
duration revealing no change in cell 
proliferation as the ligand 












































4.4.3: Retinal Progenitor Cells Migrate Preferentially to Optimal Physiologic Concentrations of EGF 
 
The Boyden Chamber assay has proven to be one of the most versatile high throughput methods for 
assessing the chemotactic influence of test ligands on cells [364, 463, 464], and the range of EGF 
concentrations used to validate RPC chemotactic responses in this study have previously been shown to 
drive motility in neuronal cell types in similar assays, and are relevant to the retinal microenvironment [32, 
367, 465, 466]. Following a chemotactic assay for RPC motility in response to EGF concentrations 
ranging from 20ng to 400ng/ml, Figure 4.7 shows a significant increase in RPC motility in response to the 
20ng/ml and 40ng/ml experimental conditions compared to control (n=6 Boyden Chambers each) by the 
Dunnett statistical test method. There was no significant comparative change in motility of RPCs exposed 
to 400ng/ml. Descriptive statistics of RPC movement at each EGF concentration analyzed is reported in 
Table 4.3 as normalized mean number of migrated RPCs, SEM and p-value:  0ng/ml = 1.0000 ± 0.09 
(p=1.0000), 20ng/ml =3.0981 ± 0.40 (p=<0.0001*), 40ng/ml = 2.0340 ± 0.18 (p=0.0001*) and 










# RPCs migrated 
(Mean ± SD) 
Dunnett Test 
p-Value 
0 8 9431.1 ± 1163.68 1.0000 
20 8 9219.5 ± 713.36 0.9611 
40 8 9388.2 ± 669.46 0.9966 
400 8 8779.8 ± 1544.60 0.4956 
Table 4.2: RPC Proliferation is Independent of EGF 
Ligand Concentrations - Displays descriptive statistics for 
the MTT assay with computed RPC numbers realized per 
EGF concentration after a 24hr exposure period. For the MTT 
proliferation assay, quadruplicate wells per EGF 
concentration were used in two (2) different experiments and 






4.4.3.1:  Exploratory High-throughput Analysis for Motility-Deterministic Motogens - Additional Transwell 
Validation Experiments 
Through the course of step-wise bioinformatics analysis to predict motility-inducing chemicals for RPCs, 
the Boyden Chamber assay served to validate hypothesis-driven selections made of chemotactic 
molecules. Certain other molecules tested were canonical motogens in other cell culture systems 
recurring in our analysis and/or suggested by cell migration expert collaborators. Wide range chemotaxis 
assays were thus performed using RPCs incubated for 24hrs with selective chemokines in triplicates on 
two different days using protocols described in section 3.3.1.1. Results of the chemotactic assays are 
presented in Figure 4.8 as mean normalized cell migration numbers by concentration compared to 
control conditions using Dunnett tests with pairwise comparison by Tukey’s HSD analysis.  
 
Gama-aminobutyric acid (GABA), a prominent inhibitory neurotransmitter in the mature mammalian CNS, 
has been postulated as a chemoattractant to migratory cortical plate neurons during mammalian 
embryonic development [239, 467] and for activating glial-dependent induction of neuronal migration 
rates in the anterior sub-ventricular zone (SVZ) and rostral migratory stream (RMS) of immature and adult 
[EGF] 
ng/ml 
# of cell 
counting fields Mean ± SEM p-Value 
0 30 1.00000 ± 0.09152 1.0000 
20 25 3.09807 ± 0.40443 <.0001* 
40 25 2.03397 ± 0.17810 0.0001* 
































Figure 4.7: Boyden Chamber analysis 
of RPCs to establish optimal 
physiologic range of EGF 
concentrations. The Boyden chamber 
provided a high throughput screen to 
analyze EGF concentrations and 
exposure times. Results demonstrate an 
optimal physiologic level of EGF, which 
facilitated significant RPC migration over 
24hrs. Each unit of normalization equals 
122 cells and each error bar is 
constructed using 1 standard error from 
the mean. Analysis of Boyden chambers 
containing either 20ng/ml or 40ng/ml 
EGF revealed significant migration 
compared to control, 3.0981 ± 0.40 
(p=<0.0001*), 2.0340 ± 0.18 (p=0.0001*) 
respectively (Table 4.3). * Depicts 
significant difference in number of 
migrated cells. While 400ng/ml EGF 
increased migration, this did not result in 
significant migration above control 
1.1885 ± 0.12 (p=0.7816). Pooled data 
from n=5-6 chambers are presented as 
normalized mean ± SEM.  
Table 4.3 
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mice [468, 469]. Synergistic activity between GABA and glutamate has been shown to affect proliferation 
and migration rates of cortical neuron populations along the rostral migratory stream and in the 
telencephalon [470-472], and the expression of glutamate receptors has been associated with the 
modulation of integrin-mediated migration of oligodendrocyte precursors [473]. The concentration-
dependent motility effects of both neurotransmitters are mediated by intracellular cytoplasmic calcium 
fluxes that stimulate cytoskeletal rearrangements for cell movement [470-473]. In testing relevant 
neuronal concentration of both chemicals on our RPCs, selective increase in GABA concentrations from 
5µM to 10µM significantly increased the number of migrating cells (p=0.05*), an indication of an effective 
concentration range for our cell type [468]. However, in comparison to control conditions, there was no 
significant change in migration rates using  
the tested concentrations of both GABA (N=6 wells, F3,47=2.67; p=0.06) and glutamate (N=6 wells, 
F3,47=1.33; p=0.28). Growth factors including Vascular endothelial growth factor (VEGF, N=6 wells, 
F3,10=3.78; p=0.07) and Platelet-derived growth factor-AA (PDGF-AA, N=6 wells, F3,10=0.48; p=0.71), as 
well as Tumor necrosis factor (TNF, N=8 wells, F2,49=2.46; p=0.10) and Glial-derived neurotrophic factor 
(GDNF, N=8 wells, F2,49=0.38; p=0.68) similarly did not stimulate RPC migratory responses that were 
significantly different from controls.  
 
Importantly, at optimal concentrations, certain chemokines did change the migratory behavior of RPCs. 
Transforming growth factor (TGF-α) concentration differential from 0.01µM to 0.02µM dramatically 
increased RPC migration rates (p=0.0241) Also 1.5µg/ml (p=0.0135) was determined to be an optimal 
chemo-repellant concentration for Fibroblast growth factor acidic (FGF-a, N=6 wells, F3,59=3.60; p=0.02) 
for our cell type. Hepatocyte growth factor (HGF) at a concentration of 0.01µM facilitated peak RPC 
migration (p=0.0473) as well as 100ng/ml Netrin-1 concentration (p=0.05). The CXC motif ligand 3 
(CXCL3, N=8 wells, F3,49=9.80; p=0.0003) stimulated more RPC transmigration as its concentration 
increased from 50ng/ml to 100ng/ml (p=0.0002) adding to the list of potential chemotactic factors worthy 
of future investigations. The chemokines tested have previously demonstrated chemotactic potential for 
neuronal progenitors and adult neural cells [210, 474-476], juvenile and adult retinal cell types [375, 477, 
478], and diseased state cells [433, 479, 480] all with correlated expression in neuro-retinal cell types 
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[477, 481-483],. Some ligands tested were canonical motogens for a broad range of cell types [238, 460, 
484-487], or candidate signaling pathway molecules in the bioinformatics network predicted to govern 





Figure 4.8:  High Throughput Analysis for Chemotactic Molecules Inducing RPC Chemotaxis – Through the course of step-wise 
bioinformatics analysis to predict motility-inducing chemicals for retinal stem cells, the Boyden Chamber assay served to validate hypothesis-driven 
selections made of chemotactic molecules. All assays were performed using P12-P17 retinal progenitor cells (RPCs) incubated for 24hrs with 
selective chemokines in triplicates on two different days using the protocol described in section 3.3.1.1. A, D, F) There was a significant increase in 
the number of migrated RPCs with increase in concentrations of Gamma- aminobutyric acid (GABA, 5-10μM; p=0.05), Transforming Growth 
Factor (TGF-α, 0.01-0.02μM; p=0.0241), and Hepatocyte Growth Factor (HGF, 0.001-0.01μM; p=0.0473). G, J) For Netrin-1 (p=0.05) and CXC 
motif ligand 3 (CXCL3, p=0.0002), increased RPC migration observed was determinant upon exposure to specific concentrations of 100ng/ml of 
each of the chemicals respectively. Fibroblast Growth Factor-acidic (FGF-a), a candidate pathway molecule was significantly chemo-repellant to 
RPCs at maximal concentrations of 1500ng/ml.  Asterisks denote significant change in number of migrated RPCs. Similar exploratory validation for 
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4.4.4:     Protein Inhibition Assays Validate Key signaling molecules in predicted EGF-induced motility 
signaling pathway 
 
To identify which molecules in the EGF signaling pathway contribute to RPC motility, inhibition studies 
were performed based on signaling pathways identified in initial bioinformatics analysis at 20ng and 
40ng/ml concentrations shown to be significant in Boyden Chamber studies. RPCs were treated with 
inhibitors prior to the 24hr motility assay. We compared RPC migration from two independent 
experiments for 20ng/ml and 40ng/ml EGF and controls (n=6 chambers each) with each pharmacologic 
inhibitor. Statistical significance was determined using the Dunnett test. For each condition, results are 
reported as normalized mean of migrated RPCs, SEM and p-value: In 20ng/ml condition, no Inhibition = 
1.0000 ± 0.08 (p=1.0000), PD 98059 = 0.7722 ± 0.05 (p=0.1341), AG 490 = 0.5913 ± 0.02 (p=0.0012*), 
Wortmanin = 0.4699 ± 0.04 (p=<.0001*), Anti-EGFR = 0.4499 ± 0.10 (p=<.0001*) and AG 1478 = 0.3427 
± 0.06 (<.0001*) (Table 4.4). At 20ng/ml, the majority of inhibitors effectively reduced migration. RPCs in 
the 40ng/ml condition appeared to exhibit a decreased response to selected inhibitors: in 40ng/ml, no 
Inhibition = 1.0000 ± 0.09 (p=1.0000), PD 98059 = 1.5810 ± 0.12 (p=0.0001*), AG 490 = 0.8619 ± 0.04 
(p=0.7727) Wortmanin = 0.7779 ± 0.04 (p=0.3368) Anti-EGFR = 0.4370 ± 0.12 (p=0.0002*) and AG 1478 
= 0.9433 ± 0.14 (p=0.9933) (Table 4.4). To determine if ligand binding to EGFR and receptor activity 
influenced observed increases in RPC motility, we incubated cells with either a monoclonal antibody to 
EGFR (anti-EGFR) or a specific EGFR tyrosine kinase inhibitor (Tyrphostin AG1478) to inhibit 
phosphorylation of the receptor cytoplasmic domain (Figure 4.9A). Our results show that inhibition of 
ligand binding to EGFR or receptor tyrosine kinase selectively inhibited motility of RPCs exposed to 
20ng/ml EGF but not to 40ng/ml EGF (Figure 4.9A).  To determine which downstream signaling 
pathways were involved in the EGF-induced motility, we also treated cells with inhibitors either to STAT3 
(AG490), ERK1/2 (PD98059), or PI3K (Wortmanin). Results in Figure 4A show that inhibition of the JAK-
STAT and PI3K pathways led to a significant reduction in RPC motility in response to 20ng/ml EGF.  A 
significant change was not observed in cells treated with 40ng/ml of EGF. Inhibition of ERK1/2 of the 




EGF induces a range of biological responses including proliferation, differentiation and motility by binding 
to its receptors and eliciting receptor dimerization and auto-phosphorylation, leading to downstream 
signaling cascades [431, 488]. Using western blot analysis, the activation states of ERK1/2, STAT3, and 
PI3Kinase intracellular proteins in RPCs incubated in either 20 or 40ng/ml of EGF for 24hr were 
determined. Our results show that all three proteins were phosphorylated in RPCs incubated with 20ng/ml 
but not 40ng/ml of EGF (Figure 4.9B).  Immunofluorescence results in Figure 2 confirm the presence of 
phosphorylated EGFR in RPCs exposed to 20ng/ml. These findings suggest that 20ng/ml EGF optimally 
stimulates EGFR tyrosine kinase activity and cell motility in our RPC population. The intracellular 
signaling cascades involving JAK-STAT and PI3K signaling appear necessary for EGF-induced RPC 
motility. The central role of ERK1/2-associated signaling predicted by our model network (Figure 1) may 









Figure 4.9: Pharmacologic inhibition of Signaling Pathways Predicted to influence RPC migration 
- RPCs were treated with selected inhibitors of signaling pathways identified in IPA bioinformatics 
analysis and evaluated for migration over 24hrs using n=6 Boyden Chamber assays per inhibitor. A) 
Analysis of RPC migration following pre-treatment with selected inhibitors reveal that significant inhibition 
of migration was observed in low 20ng EGF condition using anti-EGFR (0.4499 ± 0.10 SEM (p=<.0001*) 
to antagonize EGFR cell-surface binding, AG1478 0.3427 ± 0.06 SEM (<.0001*) to inhibit 
phosphorylation of the EGFR cytoplasmic domain, AG490 (0.5913 ± 0.02 SEM (p=0.0012*) to inhibit 
STAT3 activity and Wortmanin (0.4699 ± 0.04 SEM (p=<.0001*) to inhibit PI3K activity (Table 4.4). The 
use of PD98059 to inhibit ERK1/2 activity did not result in significant inhibition of migration. In the 
presence of a higher 40ng/ml concentration of EGF, significant inhibition of migration was observed with 
anti-EGFR (0.4370 ± 0.12 SEM (p=0.0002*), while PD98059 1.5810 ± 0.12 SEM (p=0.0001*) increased 
migration (Table 4.4). Statistical significance was determined using Dunnett analysis and data are 
presented as normalized mean. Each unit of normalization equals 227 cells and each error bar is 
constructed using 1 standard error from the mean. Drug inhibition was also numerically computed by 
expressing the ratio of cells migrating towards EGF in the presence and absence as % inhibition values 
(Table 4.4). Consistent high % inhibition values for anti-EGFR inhibitor indicate that ligand-receptor 
binding kinetics appears most relevant in determining RPC chemotactic response to EGF. Negative 
values denote unsuccessful inhibition results. B) Robust activation of identified signaling pathways was 
observed in 20ng/ml EGF concentrations. Western Blot analysis demonstrated the presence of both 
non-phosphorylated (inactivated) and phosphorylated (activated) STAT3, ERK1/2 and P13K proteins 
RPCs. Inhibition with significant p-values are denoted with an asterisk. 
Table 4.4 
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4.5:   EPIDERMAL GROWTH FACTOR (EGF) GRADIENTS STIMULATE CHEMOKINETIC MIGRATION 
OF INDIVIDUAL RPCS IN BRIDGED µ-LANE MICROFLUIDIC SYSTEM ANALYSIS. 
Temporal control and quantitation of stable chemical gradients are difficult to accomplish in Boyden 
chamber assays [364] but are needed physical parameters to recapitulate endogenous retinal 
microenvironmental gradients. In this study, we accomplish this task by employing the bridged µ-lane 
system, and we show that the concentration of EGF varies in a mathematically defined manner, is 
spatially and temporally quantifiable, and becomes constant for a defined period, once steady-state 
gradients are achieved (Figure 3.10C and [211, 489]). A number of studies have shown that EGF is 
capable of stimulating motility in the form of chemotaxis (directional migration) and chemokinesis (random  
migration) [427, 490, 491]. The employment of the bridged µ-lane system has enabled time-lapse imaging  
of individual RPC responses to different gradients and concentrations of EGF along the microchannel, 
providing data to distinguish between chemotactic and chemokinetic migratory dynamics (Figure 4.10). 
After exposing RPCs to gradients of 20, 40 and 400ng/ml EGF in the microchannel system, we analyzed 
accumulated maximum distance of migration and single cell center of mass (COM) directionality. COM 
defines the average point of all cell endpoints and quantifies migration direction. Analysis of three 
independent microfluidic experiments per condition revealed that RPCs exposed to gradients generated 
from 20ng/ml EGF exhibited significantly higher motility including accumulated maximum distances 
(328.3±109.04 SD) compared to control channels without EGF (238.4±68.16 SD) (Dunnett test, 
p=0.0129) (Figure 4.11). Accumulated distance migrated by RPCs in 40ng/ml EGF (237.71 ± 49.50 SD) 
and 400ng/ml EGF (293.53 ± 78.98 SD) microchannel conditions compared to control did not yield 
significant differences, p= 1.0000 and p= 0.1445 respectively.  Analysis of center of mass (COM) of RPCs 
yielded non-significant differences in both medians (Brown-Forsythe, p=0.1622) and means among test 
groups indicating no significant chemotactic or directed migration between EGF concentrations compared 
to control: 20ng/ml (0.27 ± 54.06; p=0.7965, 40ng/ml (0.21 ± 31.71 p=0.7774) and 400ng/ml (4.00 ± 37.45 






 In Figure 4.10, chemokinetic motility is visualized in trajectory plots of RPC movement tracked for 24hrs 
across EGF gradients. In Figure 4.10, red trajectories depict negative COM or cell movement away from 
the EGF source reservoir while black trajectories depict positive COM or cell movement towards the 
source reservoir. Greater multi-directional displacement of RPCs in the 20ng/ml EGF condition can be 
observed in this figure compared to other EGF gradient conditions. The degree of chemokinetic 
movement is also seen to decrease with increasing distance from the EGF source reservoir. A sample 
time-lapse video recording corresponding to the trajectory plot of RPC movement in EGF-gradients 




Figure 4.10. Trajectory analysis 
paradigm for RPC migration in 
microfluidic gradients at 
increasing distances from the EGF 
source. Positional tracking of RPCs 
migrating in steady state gradients of 
EGF generated in a 13mm bridged 
μ -lane device over a 24hr period 
was visualized using Ibidi Migration 
software to generate wind-rose plots 
(A-D).  A) Cell tracking results are 
depicted at increasing distances from 
the source reservoir (SRR): 0-500μ
m (I), 2000-3500μm (II), 5000-7000
μm (III). B-D) Depiction of RPC 
trajectory plot mapping in steady-
state gradients of 20, 40, and 
400ng/ml EGF analyzed from source 
reservoirs (SRR) to sink reservoirs 
(SKR). A trend of reduced 
chemokinetic migratory migratory 
dynamics can be observed with 
increasing EGF concentrations up to 
400ng/ml. Red and black traces 
indicate RPCs with negative and 
positive COM, respectively. Statistics 
resulting from trajectory data 
depicted here and analyzed for 
maximum distance and center of 
mass are reported in Table 4.5. The 
x- and y-axis denote RPC 
displacement in horizontal and 
vertical directions, respectively. 
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4.6:    SUMMARY OF FINDINGS 
 
4.6.1: Bioinformatics Modeling of Signaling Networks 
To refine targets from the wide range of biochemical signaling molecules involved in neural progenitor 
migration, we performed bioinformatics analysis using IPA software. Our bioinformatics-derived network 
molecules identified two signaling pathways previously shown to be involved in EGF-induced motility 
(Figure 1). Gene network databases have been used to predict connectivity of genes involved in 
chemotactic pathways of migrating adult neural progenitors to specific lamina [245, 251].  Bioinformatics 
approaches have also been used to validate molecular network interactions directing adult neuronal 
progenitor chemotaxis during neurogenesis in the sub-ventricular zone and cortex [247-250]. In this 
study, the bioinformatics predicted EGF signaling network resulted in valid molecular targets that were 
shown to influence RPC motility at the receptor and second-messenger level in Boyden chamber and 
microfluidic devices. 
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[EGF] Number of Tracks/cells (N) 
Maximum Displacement 
(um) Mean ± SD 
Dunnett Test        
p-Value 
Center of Mass (µm) 
Mean ± SD 
Dunnett Test 
p-Value 
0 42 238.41 ± 68.16 1.0000 -12.03 ± 39.38 1.0000 
20 34 328.26 ± 109.04 0.0129* 0.27 ± 54.06 0.7965 
40 36 237.71 ± 49.50 1.0000 0.21 ± 31.71 0.7774 
400 47 293.53 ± 78.98 0.1445 4.00 ± 37.45 0.5776 
	  
Figure 4.11: Analysis of RPC maximum accumulated distance and center of mass dynamics in microfluidic 
bridged μ-lane EGF gradients - A) RPC maximum displacement was analyzed in the absence or presence of varying 
EGF gradients measured post-steady-state within a 24hr period, and results are expressed as mean ± standard deviation 
for three independent studies per EGF concentration. Only RPCs cultured in 20ng/ml EGF exhibited significantly higher 
maximum displacement compared to cells in the control microchannel (328.26 ± 109.04, p=0.0166), Dunnett Test. B) 
Similar measurements for center of mass (COM) of RPCs yielded non-significant differences in both means and medians 
among test groups (Brown-Forsythe, p=0.1622) indicating no significant chemotactic or directed migration between EGF 
concentrations. This reveals that the increased Maximum accumulated distance response can be defined as chemokinetic. 
Table 4.5) displays averaged maximum distance accumulated and COM of RPCs in defined EGF concentration gradients 
with their respective standard deviation and p-values results from the Dunnett statistical test. Significant p-values are 

















































We successfully used bioinformatics to map intracellular EGF signaling pathways in RPCs, inhibit 
pathway molecules, and evaluate the influence on motility.  Bioinformatics modeled gene networks have 
previously been shown to successfully predict and target molecular interactions in vitro and in vivo [247, 
492]. Here, RPC migratory dynamics were analyzed in response to nanomole EGF concentrations alone 
and in the presence pharmacologic modulation of signaling pathways [454]. Stimulation and inhibition 
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parameters were initially screened using high-throughput Boyden assays. In the presence of optimized 
exposure time and concentration parameters, individual RPC migratory dynamics were analyzed in 
bioengineered microfluidic devices with defined quantifiable EGF gradients. Our results show that low 
nanomole EGF concentration ranges stimulate activity of JAK-STAT and PI3K pathways resulting in 
increased chemokinesis of RPCs. The results shown in this study further our understanding of molecular 
and biochemical interactions necessary for RPC motility and may help guide the development of 
optimized cell-replacement transplantation paradigms. 
 
4.6.2: Boyden and Microfluidic Approach 
Our Boyden analysis demonstrated that EGF stimulates migration of RPCs at selective uniform 
concentrations (Figure 4.7). In Boyden chamber assays, steep gradients of EGF generated at the start of 
experiments dissipate and rapidly become uniform. We utilized Boyden analysis as a high-throughput 
screen of multiple concentrations and incubation times. In contrast, microfluidic analysis provides steady-
state gradients maintained along the length of the microchannel as a function of time. The bridged µ-lane 
system can sustain steady state concentrations and concentration gradients of ligands over time spans of 
48-96 hours. The double-layered PDMS design exploits the ultralow bulk velocities generated by density 
differences of test ligand concentrations that ensure continuous one-dimensional transport within the 
microchannel by convective diffusion. Numerical simulation of mass transport within the bridged µlane 
system combines quantification of 2D continuity, convective-diffusion, momentum, and hydrostatic 
pressure that are computed using the Finite Element Method [7]. Previously, the microfluidic device has 
been used to generate gradient profiles that span over five orders of magnitude and over time scales that 
approach the microenvironments generated in vivo. Microfluidic technology has proven highly valuable in 
the creation of biomimetic microenvironments [7] and has been used to assess proliferative, survival and 
differentiation responses of neural progenitor cells to concentration gradients of extracellular signaling 
molecules [439, 493]. In this study, live-cell time-lapse microchannel data was analyzed for maximal 
accumulated distance and COM. The data revealed that steady-state EGF gradients were capable of 
influencing RPC motility and that chemokinesis was enhanced at low concentrations (Figures 4.10 & 
4.11). 
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4.6.3: RPC Motility is influenced by low EGF ligand concentrations 
Earlier investigations using retinal Muller glia and neurons revealed that binding of EGF to its receptor is 
highly specific, concentration dependent, and saturates at approximately 80-100ng/ml EGF [432, 494, 
495]. Specificity of EGF binding has been associated with higher numbers [494] and/or varying states of 
EGFRs [454, 495]. High and low affinity receptor states differ in their associations with the EGF ligand, 
and their activation differentially influences cellular function [454, 494, 495]. The number of high-affinity 
receptors has been suggested to be 5-10% of the total EGFR number [454, 455, 495]. Similarly, the type 
and proportion of EGFRs recruited and activated may differ with varying concentrations of EGF. Low 
levels of EGF have been reported to bind primarily high affinity receptors which trigger intracellular 
signaling proteins including Erk, Akt, Shc1, CrkL and Gab1, while higher concentrations of EGF bind low-
affinity receptors activating PLCγ1 and the Stat proteins [454]. Low- and high-affinity EGF receptors are 
derived from the same mRNA transcript and low affinity receptors can be converted to high affinity 
receptors to modify cell response dynamics [454]. Low-affinity receptor activation has been shown to 
modify integrin receptor levels and decrease cell adhesion. EGF concentrations capable of activating both 
high and low-affinity EGF receptors have been shown to facilitate cell motility in vitro and in vivo [384, 
427, 454]. Our results showing stimulation of RPC migration at low EGF concentrations of 20ng/ml and 
40ng/ml suggest that the increased motility is mediated in part by high-affinity receptor signaling. Further 
analysis could reveal specific ratios of high and low affinity EGFR dynamics involved in RPC motility. 
 
4.6.4: RPC Motility is Directed by the EGFR JAK-STAT Pathway 
Our results showing reduced motility of RPCs in response to steric inhibition of EGFR and chemical 
inhibition of receptor activity strongly suggest the involvement of EGFR and downstream activity in EGF-
induced RPC motility. EGF signal transduction pathways are shaped by interactions of many components 
of signaling networks. A subtle difference in input signals and/or interaction kinetics may result in 
differential response patterns. The kinetics (i.e. the transient and steady-state behavior) of the cellular 
response to EGF depends on many factors, including the number of receptors displayed on the cell 
surface; the concentration of the growth factor, docking, and target proteins; and their initial activity states 
[496]. Moreover, other signaling pathways that share or interact with one or more components of the 
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EGFR pathway can influence the kinetic pattern of EGFR signaling [497]. EGF receptors form either 
homo- or hetero-dimers following ligand binding, each dimer showing different affinity for ligands and 
different signaling properties. Often, components of different pathways interact, resulting in complex 
signaling networks, components some of which are described in Figures 1 and 4. These networks exhibit 
emergent properties such as integration of signals across multiple time scales, generation of distinct 
outputs depending on input strength and duration, and self-sustaining feedback loops. Furthermore, there 
are slower processes involving receptor internalization and its subsequent degradation in lysosomes, 
which have an important role in EGF-induced signaling [496, 498]. In this study, RPCs stimulated with 
20ng/ml of EGF expressed activated forms of EGFR, ERK1/2, STAT3 and PI3K. Analysis of Inhibition of 
individual downstream signaling pathways suggests that EGF-stimulated motility involves the JAK-STAT 
and PI3K pathways and not the ERK1/2 pathway.  These findings suggest differential activation and 
inhibition of canonical EGF signaling pathways.  Additional studies could explore additional factors 
involved in EGF signaling including multiple interacting ligands; receptor density/degradation and 
overlapping signaling network dynamics.   
 
4.6.5: RPCs Show Chemokinetic Migratory Response in low nanomole EGF Microfluidic Gradients 
Defined steady-state gradients generated using microfluidics provide mathematically modeled, 
quantitative information about ligand concentrations in a controlled environment. By carefully choosing 
the concentration of the input, a wide variety of gradient steps and concentration ranges can be created in 
microfluidic devices [364]. Applying a 20ng/ml EGF media concentration in the bridged µ-lane device 
stimulated the greatest chemokinetic responses at regions closest to the source reservoir (SRR), where 
the chemical gradient is steepest (Figure 5). The ligand concentration at 18hrs in the region of the 
channel closest to the SRR is approximately 63% of the starting EGF concentration [32] suggesting that 
RPCs respond to steep gradients of low EGF concentrations. The results are supported by several 
studies describing saturating effects of EGF in signal transduction and motility [32, 454, 494].  Our study 
is the first demonstration of the effect of controlled gradients on RPC motility in vitro.  
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Findings from this study defining EGF receptor ligand interactions and emergent motility dynamics may 
be useful towards developing in vitro models of endogenous signaling guiding transplanted RPC motility 
in vivo.  Sub-retinally transplanted RPCs migrate through interphotoreceptor matrix to reach appropriate 
retinal lamina for repair. To accurately model RPC migration, future microfluidics studies may replicate the 
topological and biochemical properties of the interphotoreceptor matrix by employing three-dimensional 
biomimetic extracellular matrix gel composed of laminin, fibronectin and collagen proteins as well as 
chondroitin sulfate proteoglycans and glycosaminoglycans [499, 500]. An ECM substrate available for 
initial testing is MaxGel, and engineered hydrogels can be covalently modified with chondroitin and 
heparin-sulfate proteoglycans and peptides [501, 502]. Transparent synthetic ECM matrices form porous 
soft gels along the length of the microchannel, allowing formation of a chemical gradients and visual 
tracking for quantitative assessment of morphology and motility. A number of recent studies have shown 
that stem and progenitor cells cultured in 3D gels attach to and remodel their extracellular matrix 
environments allowing for proliferative and migratory dynamics comparable to those observed in vivo 
[503-505]. The use of 3D gels to mimic the retinal microenvironment could enhance future in vitro models 
analyzing RPC motility. 
 
In summary, we present experimental work showing a mode of migration of RPCs in microfluidic 
environments, which was previously not described. We demonstrate that EGFR activation of downstream 
JAK-STAT signaling pathways in our population of RPCs is optimal at low EGF concentrations. The 
inhibition of these pathways results in inhibition of migration. In addition live-cell imaging of RPCs in 
defined gradients demonstrates that EGF induces chemokinetic migratory dynamics. This work 
represents an important step in the analysis of transplantable RPC populations in physiologic 
concentrations comparable to those found in developing and disease retina [431]. The data presented 
here provides a model of stem and progenitor cell migratory analysis to inform future transplantation 
strategies.  
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CHAPTER 5: RESULTS: MODULATORY EFFECT OF STROMAL DERIVED FACTOR-1Α ON 
TRANSPLANTABLE RPC and PPC CHEMOTAXIS VALIDATES COMPUTATIONAL MODELING TO 
PREDICTING MOTILITY-DETERMINISTIC SIGNALING.  
 
5.1: Introduction 
In this chapter, biomimetic in-silico modeling of signaling present during retinal transplantation was 
performed by resolving ligand-receptor interactions and their downstream signaling pathways influencing 
migration of PPCs in the extracellular matrix of light-damaged retina. Figure 2.7 displays a flowchart of 
the bioinformatics analysis protocol used to analyze combinations of microarray gene expression 
datasets that represent the interacting tissues. Among the chemotactic interactions identified from the 
bioinformatics analysis, stromal derived factor (SDF-1α) and its C-X-C motif receptor 4 (CXCR4) were 
found to key mediators of PPC chemotaxis, exerting their effect on PPCs in a gradient-dependent manner 
via the canonical JAK-STAT signaling pathway. The in silico prediction model was then validated in vitro 
using cell migration assays to generate uniform and steady state gradients in environments typifying the 
laminar matrix of the host retina. 
 
5.2: Preliminary Functional Annotation and Selective Canonical Pathway Analysis of Matched Dataset 
Pairs 
To effectively examine the molecular basis for PPC motility after transplantation into damaged retina, we 
modeled typical donor and recipient tissue interaction by pairing microarray data of 10-week old light-
damaged retinal pigment epithelium (RPE) and neurosensory retina (NSR) (Geo Accession GSM928109) 
[340] with genomic data obtained from either donor E17.5 Bac-Crx-EGFP cone (Geo Accession 
GSE25607) [424] or P4 mouse Rho-EGFP rod (Geo Accession GSE29318) [423] precursor cells. At 
these ontogenetic stages, the post-mitotic PPCs have been observed to exhibit optimal migration and 
integration into host retina upon sub-retinal transplantationAlso the developmental time range of isolation 
coincides with periods of PPC migration to appropriate  laminar loci [112, 230, 506]. We compiled four-
matched dataset pairs - NSR/Rod, NSR/Cones, RPE/Rod and RPE/Cones, and vetted our compilation by 
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selecting only genes with statistically significant expression over their negative FAC-sorted counterparts 
using a right-tailed Fisher Exact test T-test threshold of p≤0.05. 
 
We next employed an Ingenuity Pathway Analysis (IPA) network algorithm (Ingenuity Systems, Qiagen, 
Redwood City, CA) to map seed gene identifiers in the p-value sorted matched datasets to small 
networks in the IPA knowledgebase based on their connectivity to the curated network molecules. A right-
tailed Fisher exact test (p<0.05) then calculated the probabilistic fit between the networks, lists of 
biological functions and canonical pathways sourced from results of published experimentally data 
curated in the IPA knowledgebase. Scores were assigned to networks based on their probability of 
containing molecules in our data sets by random chance [507]. IPA analysis parameters specified 140 
molecules per network for the top 10 functional networks associated with each matched dataset. Figure 
5.1 presents an overview of the top ten (10) functional clusters in the IPA knowledgebase associated with 
the NSR/Rods (Figure 5.1A) and RPE/Cones (Figure 5.1C) datasets. These functional categories are 
plotted against the negative logarithm of the Fisher exact test p-value and higher bars denote functions 
with greater likelihood of occurrence given the expression states of genes in our datasets. Cellular 
movement function ranked highest for genes in both NSR/Rods (4.11E-83≥p≤8.73E-14; N=507 
molecules) and RPE/Cone (2.55E-24≥p≤3.36E-06; N=194 molecules) datasets. Other top predicted 
molecular and cellular functions common to both NSR/Rod and RPE/cone dataset pairs include cell-to-
cell signaling and interactions, and tissue and cellular development. Of utmost importance to this study 
are the expression profiles of genes mapped to the cellular movement function. An IPA molecular activity 
prediction tool was used to further analyze these gene expression profiles for their interaction effects on 
PPC motility. 
 
Canonical cytokine and growth factor signaling pathways in the IPA knowledgebase that contain 
significantly expressed genes from each of our matched datasets were also ranked based on their 
probability of containing the molecules in our datasets by chance alone in a right-tailed Fisher’s exact 
test. Figures 5.1B and 5.1D displays graphical results of the canonical pathway analyses for the 
NSR/Rods and RPE/Cone datasets respectively showing a p-value threshold of 0.05, and ratios 
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comparing the number of our matched dataset genes in each canonical pathway to the total number of 
genes originally designated to the respective pathway in the IPA knowledgebase. Resolved canonical 
pathways common to both NSR/Rod and RPE/Cone matched datasets include interleukins IL-1 and IL-8 
signaling, C-X-C motif receptor 4 (CXCR4) signaling, Transforming Growth Factor (TGF-β) signaling and 
transcriptional regulator high mobility group box 1 (HMGB1) signaling. Z-scores predicting the likelihood 
that a signaling pathway will be activated (orange bars) or inhibited (blue bars) given the expression state 
of genes in our datasets was used to color-code the bar chart, with color gradations corresponding to 
degrees of activation or inhibition. These Z-scores infer likely canonical pathway activity based on a 
model that represents experimentally observed causal relationships between the genes when the 
canonical pathway is activated or inhibited. Even though over 80% of the predicted canonical pathways 
are common to both NSR/Rods and RPE/Cone datasets as shown in Figures 5.1B and 5.1D, 
comparative Z-score valuations of individual canonical pathways in both matched datasets reflect the 
unique gene expression profiles of each cell/tissue type and may inform future selections of donor 
photoreceptor precursor cells for reparative transplantation experiments. For instance, inhibition of 
CXCR4 signaling activity is predicted in the NSR/Rods dataset (Z= -1.706; p= 9.37E-07; 29/152 
molecules (Ratio= 0.191)), however the reverse is predicted in the RPE/Cones dataset although with 
lower statistical confidence (Z= 1.00; p= 4.59E-02; 9/152 molecules (Ratio=0.059)). In some other 
instances, consistent canonical pathway activity is predicted as with IL-8 signaling in the NSR/Rods (Z= -
1.732; p= 5.53E-06; 31/183 molecules (Ratio=0.169)) and RPE/Cone (Z= -0.832; p=4.5E-03; 13/183 
molecules (Ratio=0.071)) datasets, and the acute phase response signaling indicative of tissue trauma in 
both NSR/Rods (Z=1.964; p =8.48E-06; 29/169 (0.172)) and RPE/Cones (Z=1.387; p=4.99E-06; 18/169 
molecules (Ratio =0.169). Although some of the canonical pathway Z-scores fall below the conventional 
threshold (-2.0≥ Z ≤2.0), they illuminate dynamic underlying physiological signaling cascades that may be 
triggered at onset of rod or cone PPC grafting into damaged adult retina. Results of summary analysis of 
RPE/Rods and NSR/Cones matched datasets are presented as supplemental figures 5.1A/C and 




                                                                                                                                                                 
Figure 5.1: Summary Results of Bioinformatics Core Analysis of Matched PPC Receptor / ECM ligands from Damaged Retina – Using the Ingenuity 
Pathway Analysis (IPA) software platform, extracellular matrix genes of damaged retinal models matched to plasma membrane receptors of either rod or cone 
photoreceptor precursors were analyzed to resolve canonical pathways and molecular and physiological functions annotated to each respective matched dataset. 
Analysis parameters specified 140 molecules per network for the top 10 functional networks associated with each matched dataset by random chance using a 
right-tailed Fisher Exact test (p<0.05). A) Top ten functional clusters in the IPA knowledgebase associated with ECM molecules of neurosensory retina (NSR) and 
rod receptors  (NSR/Rods, N=2013 genes) reveals cellular movement function as the top functional category (outlined in red). C) Similar results were obtained 
using matched dataset of retinal pigment epithelial ECM molecules and cone receptor genes (RPE/Cones, N=667 genes). B and D) Cytokine and Growth factor 
canonical signaling pathways that significantly overlapped with each matched dataset were selectively ranked based on their probability of annotating curated 
seed genes in our molecular datasets by chance alone using a right-tailed Fisher exact test with a p-value threshold of 0.05 (shown in graphs). Ratios comparing 
the number of our matched dataset genes in each canonical pathway to the total number of genes originally designated to the pathway are also depicted on the 
Y-axis with individual pathway values connected by a line graph. This ranking is also color-coded by assigned Z-scores that predict activation (positive Z-score, 
orange bars) or inhibition (negative Z-score, blue bars) of the canonical signaling pathways based on the expression state of genes in our matched datasets. 
Resolved canonical pathways common to both NSR/Rod (B) and RPE/Cone (D) matched datasets include interleukins IL-1 and IL-8 signaling, C-X-C motif 
receptor 4 (CXCR4) signaling, Transforming Growth Factor (TGF-β) signaling and transcriptional regulator high mobility group box 1 (HMGB1) signaling. 








Following functional annotation and canonical pathway analyses of our matched datasets, molecules 
specified to IPA’s cellular movement function cluster were used to design custom signaling networks 
predicting direct ligand-to-receptor interactions governing PPC motility in the light-damaged retina. The 
predictions were based on our dataset gene expression profiles, and the consequent effect of the 
expression profiles on tissue interactions, and on cellular movement function. In examining the gene 
expression states of these cell movement genes culled from our ligand-receptor matched data sets, 
Figure 5.2 displays sample volcano plots correlating fold change ratios of the genes (X-axis) to the 
overall significance of the change in their expression (Y-axis) from two of our four matched donor-
recipient dataset pairs (NSR/Rods, N=507 cell motility genes) and (RPE/Cone, N=194 cell motility genes). 
In the figure genes are represented as dots colored to depict their subcellular localization revealing that 
less than 10% of the cell motility genes exhibited more than 2-fold change in expression levels in both the 
NSR/Rods (Figure 5.2A) and RPE/Cones (Figure 5.2B) datasets. It is possible that low levels of receptor 
expression in both rod and cone PPcs may explain limited motility by these cells in transplantation 
studies.  Low PPC integration rates have been reported even when donor cells were grafted into 
damaged retinal microenvironments where on would predict an optimal level of released extracellular 
cues are present [112, 148, 230]. If the impedance in PPC motility is attributable to low receptor 
expression levels, it may be a result of PPC receptor desensitization following isolation from their native 
retinal environment and deprivation of exogenous ligand stimulation, stress responses or structural 
aberrations [278, 508, 509]. Modified volcano plots of cell motility genes resolved from the NSR/Cones 
and RPE/Rods matched datasets are also provided as Supplemental Figures 5.2A and 5.2B 
respectively. A listing of these genes that correlate cell movement functional cluster in IPA are presented 
according to their subcellular locations as plasma membrane receptors expressed on rods 
(Supplemental table 5.1A) and cones (Supplemental table 5.1B) and ligands released from 
neurosensory retina (NSR) (Supplemental table 5.1C) and retinal pigment epithelia (Supplemental 
table 5.1D), ranked by their fold change values.  
 
We postulated that chemotactic interactions resolved in our custom network designs would be supported 
by experimental testing, serving as proof-of-principle of the biological applicability of in-silico  
 157 
                                                                                                                                                             
Figure 5.2: Modified volcano plots of cellular movement genes with statistically 
significant expression states resolved from transplantable photoreceptors and damaged 
recipient adult retina matched microarray dataset pairs – To mimic typical transplantation 
paradigms, normalized gene transcripts of donor mouse P4 Rho-EGFP rod and mouse E17.5 
Bac-Crx-EGFP cone photoreceptors and light-damaged adult mouse recipient retina were 
sorted by their tissue and subcellular localization, filtered for their statistical difference (p=0.05, 
T-test) from negative-FAC-sorted replicates, and ligand-receptor pairs matched. Following 
bioinformatics analysis, genes annotated to the cellular movement function in the Ingenuity 
Pathways Analysis (IPA) knowledgebase were graphed. A) Cell motility genes from matched 
pairs of rod receptors and extracellular membrane (ECM) ligand of damaged neurosensory 
retina (NSR) (N=507 genes). The negative logarithm of their p-values was plotted against fold 
change. These genes were used to design signaling interaction networks predicting activating 
or inhibitory interactions between ligand and receptor pairs based on their expression states. B) 
A similar analysis was performed using resolved cellular movement molecules from matched 
ECM genes released from the light-damaged retinal pigment epithelia (RPE) and receptors 
expressed on transplantable cone precursor cells (N=194 genes). Volcano plots of NSR/Cone 
Receptor and RPE/Rod cell motility genes are also presented as supplemental figures 5.2A and 
5.2B respectively. Tables listing these selected gene pairs are presented in supplemental tables 




simulation of PPC transplantation paradigms. In silico modeling has potential to be a cost-effective 
method to investigate biochemical interactions in multitudes of tissue types and disease conditions. 
Systems-level analyses of microarray data from retino-neural tissue lysates have similarly been used to 
successfully predict gene ontology and biological function under healthy and diseased conditions [245, 
297, 340, 510-513]. We explore this mode of analysis by correlating changes in individual gene 
expression states to predicted interaction effects and cellular functions specific to motility. The probability 
that an interaction between two such gene products would activate or inhibit a function is determined by 
the statistical fit of the expression states of genes in our data set, to the gene expression states for 
functional activation or inhibition in the IPA database. Using cellular movement as the selected function, 
the resultant networks hold predictive powers, as individual components of resolved chemotactic 
signaling cascades that can be manipulatied to improve transplantable PPC migration..  
 
5.3: Motility-deterministic network pathways characterize biochemical interactions governing migration 
of transplantable PPCs in light-damaged adult mouse retina. 
  
In designing motility-deterministic network pathways, significantly expressed genes from each of our 
matched dataset libraries that map to the cell movement functional cluster – (NSR/Rods = 507 molecules; 
NSR/Cones = 223 molecules; RPE/Rods = 479 molecules; RPE/Cones = 194 molecules), were specified 
to extracellular matrix and plasma membrane locations, and their direct connections determined by 
experimentally reported connections in the IPA knowledgebase. Overlaying the expression profile of 
these genes using the IPA molecular activity prediction (MAP) tool enabled the prediction of each gene’s 
effect on its cognate downstream molecule. From each matched dataset pairing, we selected for only 
released ligands predicted to activate or inhibit their downstream cognate receptor at their current 
expression states. This approach identifies active motogenic stimulation initiated in the light-damaged 
retina. Figures 5.3A and 5.3B displays custom signaling network designs for the NSR/Rods and 
RPE/Cones matched datasets while network designs for NSR/Cones and RPE/Rods gene sets are 
displayed as supplemental figures 5.3A and 5.3B respectively. In these figures, the connecting edge 
lines between genes identify their native interactions and the line coloring represent overlaid MAP 
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predictions of the outcome of the interactions between the genes at their up-regulated (red gene color) or 
down-regulated (green gene color) expression states. The MAP algorithm predicts downstream activation 
(orange line color) or inhibition (blue line color) of non-IPA annotated molecules by their biochemical 
interactions with a seed gene set of “known” neighboring molecules in our dataset. A Z-score is then used 
to quantify the confidence of the prediction, which decreases with nodal distances away from the “known” 
seed gene. Literature findings of a variety of biochemical interactions are taken into consideration in 
making the predictions including transcription, phosphorylation, translocation and proteolytic activity. In 
predictions where the expression state of the downstream molecule in our dataset does not coincide with 
IPA-curated experimental findings with respect to the expression state of the upstream gene, a “Findings 
inconsistent” yellow line color is used to differentiate such relationships.  
 
In Figure 5.3A, upregulated matrix metalloproteinase (MMP14) expression is predicted to inhibit 
endocytic and ECM clearance activities of LRP-1 gene product LDL receptor-related protein (LRP-1) [9], 
and regulation of cell-ECM binding by discoidin domain receptor (DDR1) [28]  and transmembrane 
proteoglycan syndecan (SDC1) [35], important requisites for PPC migration and invasion. Leukemia 
inhibitory factor (LIF) release could be a result of the Muller glial-derived neuro-protective mechanism 
typical in injured retina [36], and is predicted to activate its receptor, which may trigger replication of 
downstream transcriptional and protein modification processes [37]. Canonical chemotactic factors C-X-C 
motif chemokine 12 (CXCL12), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor 
(BDNF) and transforming growth factor beta 3 (TGFB3) are all expressed in the light-damaged retina and 
predicted to interact with their cognate receptors raising the possibility that effective migratory phenotypes 
can be induced. In Figure 5.3B, activation of the chemokine C-X-C receptor 4 (CXCR4) by 




(KDR) by vascular endothelial growth factor (VEGF) natively occur but are predicted to be negatively 
regulated at their respective expression states. The plasminogen activating system by urokinase (PLAU) 
promotes cytoskeletal organization and cell adhesion that regulate neuronal cell motility during 
development and is predicted to activate G-protein-regulated inducer of neurite outgrowth (GRIN1) 
Figure 5.3A: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-Deterministic 
Interactions in the Matched NSR/Rods Dataset – Downstream signaling interactions between motogenic ECM 
ligands released from light-damaged neurosensory retina (NSR) and their cognate receptors expressed on rod PPCs 
were correlated to the expected causal interaction between each molecular pair at their given expression state (up-
regulation (red genes) or down-regulation (blue genes)) using the molecular activity prediction tool of the Ingenuity 
Pathway Analysis (IPA) protocol suite. Predictions of activating (orange connections) or inhibitory (blue connections) 
effects on downstream genes were then computed based on similarities or differences between a causal effect model 
of known gene expression states and the expression profile of our resolved matched dataset genes. Yellow 
connecting lines denote interactions between genes whose expression states differ from the curated information in the 
IPA knowledgebase supporting such an interaction. Molecular interactions whose downstream effects are not 
predicted, as well as all upstream signaling relationships have been excluded from the network for clarity. Upregulated 
matrix metalloproteinase (MMP14) expression is predicted to inhibit endocytic and ECM clearance activities of LRP-1 
gene product LDL receptor-related protein (LRP-1) [9], and regulation of cell-ECM binding by Discoidin Domain 
Receptor 1 (DDR1) [28]  and transmembrane proteoglycan Syndecan (SDC1) [35], important requisites for PPC 
migration and invasion. Leukemia inhibitory factor (LIF) release could be a result of the Muller glial-derived neuro-
protective mechanism typical in injured retina [36], and is predicted to activate its receptor, which may trigger 
replication of downstream transcriptional and protein modification processes common during retinogenesis [37]. 
Canonical chemotactic factors CXCL12, GDNF, BDNF and TGFB3 are also predicted to interact with their cognate 
receptors. Asterisks denote genes whose expression profiles were computed after resolving duplicate gene identifiers 
in our matched dataset. Replicate network pathway designs for motility genes resolved from NSR/Cones and 
RPE/Rods dataset pairings are presented as supplemental figures 5.3A and 5.3B respectively. Further analysis of 
the causal effect of these network interactions on cellular movement function was performed and results are 




expressed in cone receptors [4]. Supplemental Tables 5.2A-D pairs these resolved motility-deterministic 
network ligands and their downstream cognate receptor from the NSR/Rods, RPE/Cones, NSR/Cones 
and RPE cell motility gene datasets respectively, describing the native biochemical interaction canonically 
existent between the paired genes, and the predicted interaction based on their expression states. 
Resolving downstream signaling perpetuated by these ligand-receptor interactions is key to complete 
understanding of motility-specific networks. 
 
To specify the causal effects of our network gene interactions on the cellular movement function, ligand-
receptor pairs predicted to activate or inhibit at least eight (8) out of ten (10) subcategories of cellular 
movement function were selected using IPA’s ‘Grow’ function tool. These cell movement sub-types are 
curated in the IPA knowledgebase and ranked by p-value computing the causal effect of each network 
gene and its expression state on the activation or inhibition of the activity of each cell movement 
subcategory using a right-tailed fisher exact test. Tables 5.1-D displays the top ten (10) cellular 
movement subcategories and their rankings resolved for the A) NSR/Rod, B) RPE/Rod, C) NSR/Cone, D) 
RPE/Cone ligand-receptor networks respectively including the number of network genes associated with 
each cellular movement sub-type. Criterion selection resolved twenty-three (23) and seventeen (17) 
ligand-receptor pairs from the NSR/Rod and RPE/Rod signaling networks respectively. Three (3) ligand-
receptor pairs each were resolved from the RPE/Cone and NSR/Cone motility-deterministic networks 
respectively. In all resolved molecular pairs, at least one gene in the pair exhibited an activating or 
inhibiting effect in at least 80% of the top ten (10) p-value sorted cell movement subcategories. Selected 
ligand-receptor pairs are presented in Tables 5.2A-D for the NSR/Rod, RPE/Rod, NSR/Cone, RPE/Cone 
custom ligand-receptor signaling networks respectively outlining the fraction of cellular movement 
subcategories activated or inhibited per gene. Genes are also color-coded by their up-regulated (red) or 
down-regulated (green) expression states, which consequently determined the predicted effect on the 







Figure 5.3B: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-Deterministic 
Interactions in the Matched RPE/Cones Dataset – Similar to the downstream signaling NSR/Rods network pathway, 
motogenic ligands released from light-damaged retinal pigment epithelium (RPE) predicted to directly affect their cognate 
cone receptors were resolved. At their expression states, activation of the chemokine C-X-C receptor 4 (CXCR4) by 
chemoattractant cytokine macrophage migration inhibitory factor (MIF), and kinase insert domain receptor (KDR) by 
vascular endothelial growth factor (VEGF) are negatively regulated. The plasminogen activating system by urokinase 
(PLAU) promotes cytoskeletal organization and cell adhesion that regulate neuronal cell motility during development and is 
predicted to activate G-protein-regulated inducer of neurite outgrowth (GRIN1) expressed on cone receptors [4]. Asterisks 
denote genes whose expression profiles were computed after resolving duplicate gene identifiers in our matched dataset. 
Further analysis of the causal effect of these network interactions on cellular movement function was performed and 











The predicted “ACTIVATION” or “INHIBITION” effect of a ligand on its downstream cognate receptor is 
described, and where the predicted ligand’s effect on the receptor is inconsistent with curated interactions 
in the IPA knowledgebase given the observed expression states of the genes, the native biochemical 
effect of ligand binding to the receptor is indicated in small letters as “activation” or “inhibition.” A 
comprehensive listing of both native and predicted activation states for each downstream receptor and  
Table 5.1: Functional Categorization of Motility Deterministic Network Pathway Molecules. Motility-
deterministic networks of ligand-receptor interactions resolved from our matched datasets were assessed 
for their causal effects on the top ten cell movement functional sub-types curated in the IPA 
knowledgebase, based on their expression state using a right-tailed Fisher Exact test. A) Displays analysis 
results for the NSR/Rod network with the number of network genes involved in each cell movement 
category placed in parenthesis. P-values score the probability that network genes at their expression states 
activate or inhibit each respective cell movement subcategory, and are used in ranking the functional sub-
types. B) RPE/Rods network genes were also categorized for cell motility function along with C) NSR/Cone 
and D) RPE/Cone networks. Genes with significant activating or inhibiting effects in at least 8 out of these 
top 10 cell movement subcategories are presented in Table 5.2 and represent our repertoire of candidate 




Table 5.2. Top predicted retinal ligand-PPC receptor pairs involved in migration. To refine 
motility-deterministic ligand-receptor interactions, we correlated ligand-receptor expression state 
to the effect of each gene on the functioning of at least 80% of the top ten p-value-sorted cellular 
movement subcategories (Table 5.1A & B, Supplemental Tables 5.3A & B). Ratios of cell 
movement subtypes activated or inhibited by the genes are displayed. Gene levels are color-
coded, up-regulated (red) or down-regulated (green) and assigned “ACTIVATION” or 
“INHIBITION” when expression states are consistent with IPAs database.  Where the expression 
state is inconsistent with curated information in the IPA database, the native predicted effect of 
ligand- receptor signaling is indicated as “activation” or “inhibition.” Ligand-receptor pairs 
associated with a high percentage of cellular movement categories and exhibiting high ratios of 
activation or inhibition, identifies target motility-deterministic signaling pairs whose predicted 
downstream effect influences cell motility. A) Notable interacting pairs in the NSR/Rods gene set 
include chemoattractant CXCL12 and its CXCR4 receptor, and fibronectin (FN1) and RAC1 
interactions, B) the RPE/Rods gene set include inflammatory cytokine SPP1-ITGAV (α-integrin), 
VEGFA-KDR and macrophage migration inhibitory factor (MIF) and CXCR4, C) NSR/Cones 
ligand-receptor network predicts CXCR4 receptor binding to both CXCL12 and MIF, both strongly 
predicted to affect cellular movement function determined by the gene expression states, D) 
RPE/Cones ligand-receptor network reveals interaction between macrophage migration inhibitory 
factor (MIF) and CXCR4, strongly predicted to inhibit cellular movement function.   
 
 165 
their effector ligands observed in all four motility-deterministic custom network designs are provided in 
Supplemental Table 5.2A-D. 
 
The number of cellular movement subcategories in which a gene is involved, as well as the predicted 
ratios of cellular movement subtypes differentially activated or inhibited by motility-deterministic ligand-
receptor pairs prioritized the selection criteria for chemotactic interactions active in our custom network 
designs. Additionally, the computed downstream effect of the ligand on its receptor expression state 
determines the direction of function (increased or decreased activity) of the different categories of cellular 
movement. In exemplifying the selection criteria, an analysis of the NSR/Rods custom network presented 
in Table 5.2A indicates significant statistical predictions of functional effects on PPC movement by  
fibronectin (FN1) interacting with alpha-integrin (ITGAV) and Rac1 membrane bound GTPase. These 
reactions are known to signal diverse cell functions including cell migration of human corneal epithelial 
cells [514] and hepatocellular carcinoma cells [515]. Evidently, the collective down-regulated states of the 
receptors conflicts with IPA-annotated predictions of their downstream phenotypes leading to 
indeterminable conclusions as to the consequences of the pairwise ligand-receptor gene interactions. 
However, these molecular pairs remain likely candidate chemotactic genes for consideration due to the 
high number of cellular movement subcategories they are each involved in, the high fraction of these cell 
movement subtypes they each activate or inhibit, and the native activation of the downstream receptors 
canonically associated with the molecular interaction and identified in the table with “activation.” As earlier 
noted, analyses results depicted in Table 5.2 containing a preponderance of receptor down-regulation 
may explain the low migration and integration rates observed in transplantation studies using freshly 
isolated FACS-sorted PPCs [83, 148, 168, 516]. Other candidate chemotactic interactions affected by the 
downstream receptor expression states include activation of α-integrin (ITGAV) activity by inflammatory 
secreted phosphoprotein (SPP1), and macrophage migration inhibitory factor (MIF) and the C-X-C motif 
receptor 4 (CXCR4) interactions. In the mammalian retina, vascular endothelial growth factor (VEGFA) 
binds kinase insert domain receptor (KDR) expressed on retinal microvascular endothelial cells for 
downstream signaling to facilitate growth and migration of these cells during hypoxia-induced 
neovascularization [517]. However, an inhibitory effect is predicted at the given gene expression states.  
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On the other hand, CCL5, the T-cell specific RANTES protein is predicted to activate its downstream 
CCR3 receptor. However, the low number of cellular movement subtypes activated by the CCR3 receptor 
(5/10) suggests a lower ranked chemotactic interaction even though both genes are predicted to activate 
all cell movement subtypes in which they are involved. In understanding the biological implications of the 
selection criteria, we performed a literature review of CCL5-CCR3 biochemical interactions and realized 
that although CCL5 is a known leukocyte chemoattractant and tumor cell motility factor [518-520] its 
specific motility functions in neuronal cell types have rarely been established. In a similar manner, low cell 
movement subtype counts for GDNF family receptor alpha (GFRA1) excludes it and its upstream GDNF 
ligand from consideration even though the GDNF ligand has been reported to attract GFRA1-expressing 
mouse GABAergic cortical cells [521], rat glioma cells [460, 522] and mouse corneal epithelial cells [304]. 
The fact that the GDNF ligand also serves various neurotrophic and retino-protective functions in normal 
and diseased mammalian retinal models [43, 483, 523], and requires heteromeric multicomponent 
receptor signaling suites for its downstream signaling activity [524, 525] may altogether affect the degree 
to which it is specified to affect cell motility, validating the ranking paradigm used in our selection criteria. 
 
5.3.1: CXCL12-CXCR4 interaction is predicted to influence the migration of transplantable PPCs in light-
damaged retinal tissue 
 
Of the selected ligand-receptor pairs displayed in Table 5.2, the interaction effects of stromal-derived 
factor-1 alpha SDF1α (CXCL12) binding to G-protein-coupled CXC-motif receptor 4 (CXCR4) is of 
particular interest to our study for many cogent reasons. Both molecules remain the only resolved motility-
deterministic ligand-receptor pair among all selected pairs that activate or inhibit almost 100% of the top 
ten cellular movement subtypes across all matched datasets. Being a canonical chemoattractant, 
CXCL12 has been shown to regulate axon guidance and path-finding cell activities that precede neuronal 
and endothelial progenitor cell migration, trafficking and homing during organogenesis, tissue 
regeneration, inflammatory responses and tumor metastasis and vascularization [330, 526-528]. 
However, similar to most analyzed molecular pairwise interactions in our datasets, the down-regulated 
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state of CXCR4 in the NSR/Rods and NSR/Cones dataset (table 5.2A&C) is inconsistent with IPA-
annotated experimental findings of the receptor’s expression state when interacting with its CXCL12 
ligand. Nonetheless, such broad-spectrum involvement in physiological cell motility subtypes is a key 
characteristic of potential motogens, and unlike the binding interaction described for the GDNF-GFRA1 
pair, CXCL12 expression has been shown to promote activation of its receptor, a phenomenon 
suggesting that exposure of PPCs to optimal amounts of the ligand may induce functional expression of 
higher levels of CXCR4 and activate downstream signals required for cell movement to occur. Indeed, 
several findings report time- and concentration-dependent increases in expression of CXCR4 in rat 
microglial cells [361], rabbit lung  tissue [529], human hematopoietic stem cells [530], and human breast 
cancer cell lines [531] on exposure to optimal concentrations of the CXCL12 ligand. These ligand effects 
on the CXCR4 genes can also be cell type-dependent, as CXCL12-stimulated phosphorylation, 
internalization and rapid desensitization of its cognate receptor in CXCR4-expressing cancer cell lines 
have also been reported [531-533]. Surprisingly, hepatocyte growth factor (HGF) increased expression 
following mouse liver damage was observed to promote CXCR4 upregulation with consequent CXCL12–
mediated directional migration of human CD34+ progenitor cells [530]. For CXCL12-induced migration of 
most cells, the specific requirement for co-expression of both the ligand and receptor observed during 
development and invitro, differentiates CXCL12-CXCR4 signaling from many other canonical chemokine 
signaling pathways where knockout effects of one component of the signaling axis can largely be 
compensated for by overlapping motogens [34, 534, 535]. Additionally, increased CXCL12 mRNA levels 
following mouse RPE NaIO3 chemical damage [371], or mouse hepatic injury by irradiation [530] is 
supported by the up-regulated state of the ligand displayed in the NSR/Rods (Figure 5.3A) and 
NSR/Cones (supplemental figure 5.3A) motility-deterministic networks, and correlates to increased 
migration of the respective stem cells involved. A review of the IPA literature knowledgebase used to 
statistically annotate functional interactions between SDF-1 and CXCR4, and map their ontologies to 
respective cellular movement subcategories, strongly support a chemotactic influence of these molecules 
on neuronal precursors [303, 536-538]. 
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Reported expression of SDF-1α in the outer segments of human photoreceptors and retinal pigment 
epithelium (RPE), and the spatiotemporal localization of its CXCR4 receptor in the inner segment of 
photoreceptors in normal and diseased neurosensory retina and on Muller glial cells [273, 362], is 
suggestive of a role for this ligand-receptor pair in targeting sub-retinally transplanted PPCs to their 
laminar destination. Neonatal CXCR4+ RPCs migrate towards emergent tissues exhibiting higher SDF1 
concentrations during human fetal retinogenesis and neovascularization [330], suggesting a gradient-
induced cellular response to the ligand. Following these findings, we hypothesized that constitutive SDF1-
CXCR4 signaling will significantly modulate motility characteristics of transplantable RPCs and PPCs in a 
concentration-gradient dependent manner.  To investigate this paradigm, Boyden chambers and bridged 
µ-lane microfluidic devices capable of generating uniform and steady state chemical gradients 
respectively were used to test the migratory response of freshly isolated post-natal day 1-4 photoreceptor 
precursor cells (PPCs) and multi-passage RPCs to SDF1α. This work helps pioneer efficient systems-
based approaches to understanding the effects of small molecule signaling on RPC and PPC motility. 
 
5.3.2: IPA Downstream Effect Analysis Identifies Cytoplasmic and Nuclear Signaling in Motility-
Deterministic Network Pathways  
 
We extended our evaluation of molecular interactions downstream of the custom ligand-receptor pair 
networks to specify nuclear and cytoplasmic genes that transduce the biochemical signals resulting from 
ligand-induced receptor activation once PPCs are transplanted into light-damaged retina. After combining 
these motility-deterministic ligand-receptor pairs with significantly expressed, directly interacting nuclear 
and cytoplasmic genes from source rod, cone, NSR and RPE datasets, an IPA molecular activity 
prediction algorithm was used to generate downstream network pathways predicted to regulate cell 
motility in the light-damaged retinal microenvironment. These downstream relationships were further 
streamlined using the ‘Grow’ function tool to retain only nuclear and cytoplasmic genes significantly 
affecting activity of at least two (2) out of the following four (4) cell motility subtypes - 1) cell movement 
(5.14E-46≥p≤1.97E-06), 2) migration of cells (5.45E-42≥p≤4.87E-06), 3) cell movement of tumor cell lines 
(4.14E-29≥p≤3.08E-05), 4) migration of tumor cell lines (5.68E-28≥p≤9.27E-05). These four physiological 
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categories were top ranked and commonly recurred among all cell motility subtypes annotating the 
nuclear and cytoplasmic genes in the IPA knowledgebase. The p-value rankings computed the causal 
effect of our nuclear and cytoplasmic gene set on the activity of each cell movement subcategory. For 
each subcategory, the ranges of p-values resolved across the four (4) custom datasets are provided in 
parentheses. Figures 5.4A-D display network pathway designs of these custom datasets with the 
complete array of A) NSR/Rods, B) RPE/Rods, C) NSR/Cones and D) RPE/Cones chemotactic genes 
respectively categorized by their subcellular localization. Relationships where effects on the downstream 
genes are not predicted were removed for clarity.  
 
In Figure 5.5A, downstream signaling for CXCL12-CXCR4 ligand-receptor pair in the NSR/Rods custom 
network pathway is highlighted and predicted to involve phosphorylation by Janus Kinase (JAK) providing 
docking sites for signal transducer and activator of transcription (STAT), which is eventually recruited to 
the nucleus to bind specific DNA promoters and increase transcription rates affecting a number of 
important biological processes including cell migration [8]. However, this downstream JAK-STAT 
signaling is not predicted to occur in the network pathway given the down-regulated state of the CXCR4 
gene in freshly isolated FAC-sorted P4 Rho-EGFP rod PPCs. The hypoxic conditioning of these freshly 
isolated cells may account for activated hypoxia-inducible factor (HIF1A) known to up-regulate CXCR4 
mRNA in mouse mesenchymal stem cells [378]. To explore possible downstream signaling paradigms 
when the CXCR4 receptor is up-regulated, we used a gene specification tool in IPA to exclusively up-
regulate CXCR4 expression in this custom network pathway (Figure 5.5B) and resolved signaling 
interactions 2-nodal steps away from the CXCR4 receptor (blue outline). Results predict activation of 
JAK-STAT as the major motility-deterministic signaling pathway for the CXCL12-CXCR4 ligand-receptor 
interaction. Further simulation of downstream signaling events reveals the cooperation of hypoxia-
inducible factor-1 alpha (HIF-1a) and nuclear factor-kb (NFKB1A) in regulating transcription rates of the 
CXCL12-CXCR4 pair, as occurs during regenerative processes in damaged tissue [34]. In vitro functional 
activation and inhibition of individual components of the postulated network molecular cascade will 
validate the delineated SDF-CXCR4 signaling specific for PPC motility.  
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5.4: Preliminary chemotaxis screens confirm SDF-1α as a broad-spectrum chemoattractant for both 
RPCs and PPCs.  
 
To assess the potential for SDF-1α to induce chemotaxis of our RPCs and PPCs, two canonical migratory 
systems were employed. An initial chemotactic screen was performed using a modified Boyden chamber 
assay, which quantified transmembrane migration of respective RPC and PPC populations to dissipating 
SDF-1α gradients along a single axis. Steady state gradients of the chemokine were also generated in a 
bridged µ-Lane microfluidic system where single cell responses were correlated to specific gradient 
characteristics in a two-dimensional laminar matrix. Figure 5.6A displays analysis of variance (ANOVA) 
results comparing mean number of migrated RPCs in 50ng/ml and 100ng/ml SDF1α concentrations 
compared to control conditions (F(2,49)= 5.44, p=0.0075*) in a Boyden chamber transwell assay. A post-
hoc Tukey’s HSD test revealed concentration-specific migration of RPCs towards media supplemented 
with 100ng/ml SDF1α compared to control conditions (p=0.0083*). PPCs exhibited a robust migratory 
response to all SDF1α concentrations tested (F(2,44)= 5.64; p=0.0068*) (Figure 5.6B). The ligand 
concentration ranges used in these motility assays optimally stimulate chemotaxis of retinal and neuronal 
precursors [368, 539, 540]. Overall, approximately 0.3-0.6% of seeded viable RPCs and PPCs had 




Figure 5.4: Motility-deterministic Downstream Signaling Networks in PPCs - Following the selection of 
candidate ligand-receptor pairs predicted to govern PPC motility in the light-damaged retinal microenvironment 
(Table 5.2), an IPA molecular activity prediction (MAP) algorithm connected significantly expressed nuclear and 
cytoplasmic genes transducing biochemical signaling of activated or inhibited PPC receptors. The nuclear and 
cytoplasmic genes were selected for involvement in at least 2 out of 4 cellular movement subcategories, which were 
sorted by p-values that compute the causal effect of our nuclear and cytoplasmic gene set on each cell movement 
subcategory. A) Shows a custom network pathway for NSR/Rod-PPCs, B) RPE/Rod-PPCs, C) NSR/Cone-PPCs and 
D) RPE/Cone-PPCs. In these pathways ECM genes are displayed with a blue outline. Each line connecting edge 
(arrow or bar) between genes describes native interactions and line colors represent IPA-MAP algorithm predictions 
of outcomes derived from up-regulated genes (red color) or down-regulated gene (green color) expression states. 
The MAP algorithm also describes downstream activation (orange line), inhibition (blue line) of non-IPA annotated 
molecules by their biochemical interactions with a seed gene set of “known” neighboring molecules in our dataset. In 
predictions where the expression level of the downstream molecule in our dataset is not the same as in cell types in 
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the IPA-database, with respect to the expression state of the upstream gene, an inconsistent (yellow line) is used. A 
Z-score is then used to quantify the confidence of the prediction, which decreases with nodal distances away from the 
“known” seed gene. Literature findings of a variety of biochemical interactions are taken into consideration in making 
the predictions including transcription, phosphorylation, translocation and proteolytic activity. In figures A and B, 
network interactions were limited to only downstream signaling 2-nodal steps away from key plasma membrane 













Figure 5.5: PPC SDF-CXCR4 downstream signaling pathway with receptor activation - A) 
Using the NSR/Rod-PPC network pathway to highlight target interactions, downstream signaling 
cascades initiated via binding of candidate chemotactic factor CXCL12 to its CXCR4 receptor is 
shown to involve the canonical JAK-STAT pathway, which increases rates of transcription of 
migration signaling molecules [8].  Isolated rod-PPC CXCR4 expression is down-regulated (green 
with bold outline) relative to other cells in the light-damaged retina and migration activation is 
supported as a native function. B) With downstream signaling following CXCR4 up-regulation (red) 
via ligand exposure, we observe migration activation as a native function and with expression levels 
comparable to other cell types in IPAs database.  Enhanced activation is observed between CXCR4 
and JAK-STAT (orange arrow) as well as with MIF activation of CXCR4. Further downstream 
signaling events reveal the involvement of hypoxia-inducible factor-1 alpha (HIF-1α) and nuclear 
factor-kb (NFKB1A) in regulating transcription of the CXCL12-CXCR4 pair which increase chemo-





































Figure 5.6: Assessment of RPC and PPC chemotaxis to uniform gradients of SDF-1α using 
modified Boyden Chamber Assays. - In-silico bioinformatics analysis resolved SDF-1α as a 
potential chemotactic cue in the extracellular matrix (ECM) of light-damaged adult retina whose 
predicted effect on PPC motility would need experimental verification due to the expression state of 
its CXCR4 receptor (Figure 3C). Being a canonical chemoattractant to neuronal precursors, we 
screened SDF migratory effect on freshly isolated photoreceptor precursor cells (PPCs) in 
comparison to multi-passage retinal progenitor cells (RPCs) using a transwell assay protocol. A) 
SDF-1α (F(2,49) = 5.44; p= 0.0075*) chemokine induction of RPC migration is concentration-
dependent and optimal at 100ng/ml. 1 unit of normalization represents 65.5 cells. B) PPCs displayed 
very robust concentration-independent migration to SDF (0.0068≥p<0.0001*). 1 unit of normalization 
represents 87.3 cells. All assays were carried out in triplicates for 2-3 independent experiments. C) 
Segment of a transwell filter showing transmigration of PPCs indicated by red arrows. Overall, 
approximately 0.3-0.6% of seeded cells migrated through the 8µm transwell filters over 24hrs due to 
ligand induction. Statistical analysis of all data was carried out using ANOVA and post-hoc Tukey 
HSD. Each error bar is constructed using 1 standard error from the mean. Asterisks denote 






































































5.5: PPCs innately express CXCR4 while RPCs require induction by the SDF-1α ligand. 
Constitutive expression of chemokine (C-X-C motif) receptor 4 (CXCR4) in non-mammalian zebrafish and 
embryonic chick retinal tissue, has previously been associated with survival, proliferation, axonal 
guidance and chemotaxis of retinal cells [272, 541], and photoreceptor regeneration after light damage in 
zebrafish [509]. In the mammalian retina, CXCR4 immunoreactivity predominates in the retinal ganglion 
cell layer, inner nuclear layer, photoreceptor inner segments and the retinal pigment epithelia [273, 362, 
539, 542], while the expression of its cognate SDF-1α ligand in the neighboring outer plexiform layer and 
margins of inner retina increases in retinal degeneration models [362, 385, 542]. These loci facilitate 
ligand-receptor binding that has been shown to modulate rates of ocular neovascularization [543] 
photoreceptor apoptosis and inflammatory responses during retinal damage in vivo [362, 542]. Human 
RPE and retinal endothelial cells expressing CXCR4 migrate to motogenic concentrations of SDF-1α 
[330, 368, 385, 539], however, the present study pioneers characterization of motility-deterministic 
signaling for SDF-1α-CXCR4 interaction in PPCs. 
 
We performed immunofluorescence detection of CXCR4 on RPCs and PPCs. Rabbit polyclonal anti-
CXCR4 antibodies detected innate expression of the receptor on freshly isolated PPCs (Figure 5.7B).  
Punctate receptors localized over oblong-shaped Crx-GFP+ photoreceptor inner segments (Figure 5.7A) 
containing spherule bi-nucleoids (Figure 5.7C) consistent with immature rod morphology [136, 162]. 
RPCs displayed more diffuse CXCR4 staining (Figure 5.7H) in the periphery of soma (Figure 5.7G.I), 
and along axons following incubation overnight with 100ng/ml SDF-1α but not in non-stimulated RPCs 
(compare control Figures 5.7D-F). Semi-quantitative analysis of RPC confocal Trit-C images taken from 
control and SDF-treatment slides resolved mean density values for each image. USing Image J as a 
measure of cell surface receptor density, subtracting background intensity and comparing results using a 
student’s T-test, RPCs incubated in 100ng/ml exhibited significantly higher intensity values compared to 
control slides (Figure 5.7J, p<0.0001). This heterogeneity in receptor expression between PPCs and 
RPCs is mostly likely the result of both the ontogenetic state of the cells and conditions of the 
extracellular environment.  Physiologically relevant SDF-1α levels are detectable in the mouse retina 
[542] and will induce cell surface receptor expression in PPCs via homologous and heterologous 
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phosphorylation and priming mechanisms [531, 533], unlike multi-passage RPCs long deprived of ligand 
stimulation over successive proliferative cycles. Upon stimulation with the ligand, western blot analysis of 
RPC lysates reveals distinct 47kDa bands of glycosylated CXCR4 absent in control blots (Figure 5.7K). 
Blotting of PPC lysates also show faint bands of the glycosylated form of the receptor indicating that  
agonist-induced internalization and basal receptor turnover processes are active in freshly isolated 
photoreceptor precursors [544, 545].     
 
5.6: SDF-1α gradients stimulate chemotaxis of RCPs and PPCs in a bridged µ-lane microfluidic 
system 
The bridged µ-Lane microfluidic system, a type of flow-resistive gradient generator [364], maintains 
distinct regions of constant ligand concentrations that form time-invariant gradients along the 
microchannel. Chemokines travel down the channel by diffusive transport caused by mass differences 
between ligand source and sink reservoirs, while minimizing fluid convection [7]. Modeling mathematical 
derivations of similarly weighted epidermal growth factor (EGF, 6.8kDa) and 10kDa dextran transport 
within the bridged µ-Lane [7, 32] verified that duration of SDF-1α steady state gradients would range from 
18hrs to 40hrs after ligand addition into the source reservoir. Figures 5.8A and 5.8B show that although 
PPCs exposed to steady state SDF-1α gradients traveled significantly shorter distances compared to 
control conditions (Max. Euclidean: t(60.26) = -5.37, p<0.0001*; Max. Accumulated.: t(66.92) = -5.63, 
p<0.0001*), their spatial averaged end-points (center of mass (COM)) after the time course of 
experimentation, was significantly displaced towards the positive Y-axis containing higher ligand 















































Figure 5.7: Heterogeneity in CXCR4 expression by ontogenetically variant transplantable RPCs and 
PPCs – Wide-field fluorescence images of Crx-GFP+ cytoplasm (A) and Rhodamine bound antibody staining 
(B) of punctate SDF1α receptors (CXCR4) constitutively expressed in freshly isolated photoreceptor 
precursor cells (PPCs). An overlay image of both fluorochromes is shown in (C) and includes DAPI nuclear 
staining results (blue), Scale: 10µm. In comparison, multi-passage retinal progenitor cells (RPCs) do not 
innately express CXCR4 as observed in control cell cultures with no added chemokines (E) but display robust 
CXCR4 localization in the periphery of their soma and along axonal processes only after overnight pre-
incubation in 100ng/ml SDF-1α, and staining with NL637 fluorochrome conjugated to monoclonal anti-CXCR4 
antibodies (H). Images of RPC Crx-GFP+ cytoplasm (D,G), and an image overlay (F,I) is described, scale: 
20µm. J) Normalized pixel intensity values obtained for RPC confocal images of SDF treatment slides on an 
image J platform, was significantly different (student’s T, p<0.0001*) from control slide images, for triplicate 
measurements/slide in two independent assays (Error bars: ±SEM) and confirmed results obtained from 
fluorescence microscopy. Immunocytochemistry results were also validated by the successful detection of 
CXCR4 protein in neonatal PPCs and in SDF-induced multi-potent RPCs but not from control RPC lysates 
(K). Heat-shock-protein 90 (HSP90) was used to assess blotting efficiency, informative of the stressed states 
of the cells. 
	  
 177 
The COM is a major index for evaluating directed chemotaxis with either positive or negative coordinates 
indicating the direction in which the population of cells have drifted, and a magnitude that measures the 
difference between cell population COM at the beginning and at the end of the experiment [418]. RPCs 
also migrated towards increasing concentrations of SDF1α, exhibiting significantly higher maximal 
Euclidean distance (Figure 5.8A, t(83.1) = 2.29; p= 0.0247*), and mean COM Y-axis (Figure 5.8C, t(82.25) = 
2.52; p=0.0138*) compared to cells in control microchannels. Table 5.3 displays descriptive statistics for 
the microfluidic assay including the number of cells tracked and values of motility parameters measured. 
Time-lapse video recordings of RPC and PPC chemotaxis in different cell culture conditions are provided 
as supplemental movie files IV and V respectively. Representative trajectory plots of RPC and PPC 
chemotaxis at increasing distances (1-6.5mm) from the SDF-1α source reservoir are presented as 
Figures 5.9A-B and 5.9C-D respectively.   
 
5.7: SDF-1α induces PPC and RPC chemotaxis via binding to their cognate CXCR4 receptor  
 
Given results of Boyden chamber and microfluidic assays, we sought to verify whether SDF ligand 
binding to its CXCR4 receptor influenced the observed increases in ligand-induced RPC and PPC 
migration. CXCR4 expression is a requisite for the intracellular transduction of SDF-1α signaling during 
migration and organogenesis of many stem cell and tissue types [34, 534]. However, by inhibiting ligand-
receptor binding in RPCs and PPCs using the CXCR4 antagonist AMD3100, we pioneer the assessment 
of receptor-mediated SDF-1α signaling in these specific retinal stem cell types that are essential for cell 
replacement therapies. Figure 5.10A displays results of the AMD3100 inhibition of CXCR4 on RPC and 
PPC populations using a Boyden chamber assay. An analysis of variance test revealed significant 
difference in mean number of migrated RPCs between experimental and control conditions (F(2,31)= 4.5; 
p=0.0198*). Post-hoc Tukey HSD verified that significantly more RPCs migrated through transwell filters 
in the presence of 100ng/ml SDF-1α compared to control (p= 0.0467*), the migration rates were 
significantly reduced to rates comparable to control conditions (p=0.0364*), after pre-incubation with the 
receptor antagonist for 30mins at 37°C/5% CO2. A replicate inhibition assay performed using PPCs in 
transwells, did not show statistically significant differences in mean number of migrated cells (F(2,8)= 2.3; 
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p=0.1818) between culture conditions but AMD3100 reduced PPC migration rates (Figure 5.10A). 
Inhibition effects of AMD3100 on RPCs incubated in bridged microchannels maintaining SDF steady state  
gradient conditions was not evident as travel distances did not differ significantly from control conditions 
(Figure 5.10B-D). However, AMD3100 did reduce directed RPC chemotaxis towards the SDF- 
1α source reservoir, although not significantly. Summary results indicate that SDF-1α binding to its 
cognate CXCR4 receptor is a pre-requisite for ligand-induced motility effects on both RPCs and PPCs.   
 
5.8: CONCLUSION 
We were able to demonstrate that within statistically predictable limits, bioinformatics protocols can be 
used to simulate molecular signaling governing cellular physiological states using microarray expression 
data. The uniqueness of our approach lies in the fact that the prevalent gene expression states of 
classified molecules were used to make determinations as to their connectivity and to the consequent 
effect of their interactions on a biological function, advancing current methods that utilize gene 
annotations and expression states as independent entities in making predictions of gene function. Using a 
combination of molecular activity prediction and deductive-inferential analytical tools available in the 
Ingenuity Pathway software suite, and gene datasets resolved from ontogenetically appropriate tissues 
sorted based on their significant expression over non-target cell types, statistically meaningful 
relationships were established between gene fold change values, gene-gene interactions, and gene 
interaction and function. As a test of the efficacy of our predictions, we verified the role of SDF-1α as a 
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Figure 5.8: Microfluidics 
analysis of Retinal Stem 
Cell chemotaxis in steady 
state gradients of SDF-1α 
generated in bridged u-
Lane microhannels. A-B) 
PPCs in control 
microchannels traveled 
longer accumulated and 
euclidean distances 
compared to cells in SDF 
gradients while distances 
covered by RPCs were 
longer in the presence of 
the ligand. C-D) 
Interestingly, the spatial 
averaged endpoints for 
both retinal cell types after 
24hrs in SDF steady state 
gradients was analyzed by 
Student’s T-test and 
showed significant 
propagation towards the Y-
axis source reservoir of the 
ligand compared to cells in 
control microhannels. This 
result infers ligand-induced 
directed chemotaxis and 
the longer distances 
exhibited by cells in control 
channels would imply 
random migration 
phenomena. All assays 
were carried out in 
triplicates. Each blue/black 
error bar is constructed 
using 1 standard error from 
the mean. Asterisks denote 
significant mean difference 
in pairwise comparisons. 
Table 5.3 displays results 
of descriptive statistics 
including number of tracked 
cells, mean, standard error 
of mean (SEM) and p-
values of independent 
samples t-tests used for 
analysis of 2-3 runs per 
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Table 5.3: Descriptive statistics of Cell Motility Parameters obtained following Migration of Retinal Precursor Cells in 




We demonstrate that ligand activation of the CXCR4 receptor can be inhibited and activates downstream 
signaling leading to statistically significant RPC and PPC migration in uniform and steady state ligand 
gradient sources. Further bioinformatics analysis of SDF-1α-induced intracellular signaling pathways 
mediating PPC motility identified the JAK-STAT canonical pathway as the culprit signaling cascade. 
Additionally, other chemotactic interactions resolved using our selection criterion (see section 5.4) serve 
as target motogens for future functional validation studies using fresh PPC isolates. An interesting 
proposition will be to automate the decision-making paradigm employed in our deductive inferential 
analysis using mathematical algorithms possessing the flexibility for use as plug-in applications for varied 
tissue-type gene analyses. Finally, investigations using our cellular movement gene datasets revealed 
that most transplantable PPC receptor genes were downregulated compared to expression states of ECM 
ligands. It is possible that when PPCs are transplanted into damaged host retina, they do not express 
receptor levels sufficient to be induced by cytokine levels in damaged NSR or RPE, accounting for the 



























Figure 5.9: Wind-Rose plots tracking RPC and PPC chemotaxis in steady-state gradients of SDF-1
α . PPC and RPC motility parameters were assessed over a 24hr period in a 13mm bridged μ-lane 
device generating steady state SDF gradients, and visualized using Ibidi Chemotaxis and Migrating tool 
2.0 as wind-rose plots. Cell tracking results are depicted at increasing distances from the source reservoir 
(SRR): 1000-2500μm (I), 4500-6500μm (II). A) PPC migration in control conditions and B) 100ng/ml 
SDF-1α steady-state gradients. Measurements of migration parameters were performed between 18-
42hr cell incubation in the microchannels representing times of sustained steady state SDF gradients. C) 
RPC motility in the absence of SDF gradient (control) and D) RPC motility in 100ng/ml SDF-1α gradient. 
Both RPCs and PPCs show significant difference in their center of mass (COM) toward Y-axis source of 
the chemotactic factor (Figure 6: PPCs p=0.0033, RPCs p=0.0135). Red and black traces indicate cells 
with negative and positive COM respectively. Complete descriptive statistics of the trajectory data 
depicted here are reported in Table 4. The X- and Y-axis denote cell displacement in horizontal and 












Figure 5.10: Effects of 
AMD3100 inhibition on 
migration of PPCs and RPCs 
in uniform and steady state 
SDF-1α gradients. A) 
Antagonistic effects of 
AMD3100 (CXCR4 inhibitor) 
significantly reduced the 
number of RPCs migrating in 
uniform SDF1α gradients to 
levels observed in control 
conditions (** p=0.0364) using 
a transwell assay protocol. 
Each unit of normalization 
equals 1208 cells. Similarly, 
drug inhibition of the receptor 
on PPCs decreased their rate of 
migration but not to statistically 
significant levels (1 unit of 
normalization = 200 RPCs). 
Further investigation of the 
drug’s effects on cells in steady 
state SDF-1α gradients 
generated in bridged µ-lane 
microhannels revealed that 
AMD3100 had no effect on 
RPC accumulated distances (B) 
or Euclidean distances (C), and 
minimally reduced center of 
mass-Y-axis values (D), even 
though the ligand continues to 
stimulate directed chemotaxis 
as previously observed (* p= 
0.0108). Cell tracking data was 
obtained during 24hrs of SDF 
steady state gradient. All 
statistical analyses were 
performed using ANOVA and 
post-hoc Tukey HSD to resolve 
mean differences in pairwise 
comparisons. Error bars depict 
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CHAPTER 6: SYSTEMS PHARMACOLOGICAL APPROACH TO IDENTIFICATION OF NOVEL 
SMALL MOLECULES AND DRUGS TO MODULATE TRANSPLANTABLE RPC and PPC MIGRATION 
 
6.1: INTRODUCTION  
To advance a translational approach involving modulation of defined chemotactic signaling networks in 
transplantable PPCs, we performed computational drug analysis which generated a library of FDA 
approved drugs and small molecules predicted to modulate motility-deterministic networks in PPCs. In 
collaboration with the Ma’ayan Laboratory (Icahn School of Medicine at Mount Sinai (MSSM), NY), we 
employed the Expression2Kinases software to identify pharmacologic drug that modulate the 
transcriptional regulatory genes governing the expression of selected PPC chemotactic receptors. 
Following our drug analysis, we then validated the motogenic effects of the candidate drug 
aminophenazone, a pyrazolone determined to enhance CXCR4 receptor expression in RPCs using the 
Boyden Chamber motility assay. We then advanced our drug analysis using a more robust LINCS drug 
computational algorithm in which we entered our selected PPC migratory gene targets, which refined our 
library of pharmaceuticals to enhance transplantable RPC and PPC migration in response to ligands 
present in damaged retina.  
 
6.2: Systems Pharmacological Analysis of Novel Drugs and Small molecules Targeting RMS 
Neuroblast Migration  
 
We began our bioinformatics studies by modeling the characterization of radial and tangential motility 
guidance networks governing mouse neuroblast migration in the canonical rostral migratory stream 
(RMS) of the adult mouse brain previously conducted by Khodosevich et al [546] (Section 2.3.2, Chapter 
2). In the study, the authors compared gene expression patterns between two populations of neuroblasts. 
One population was obtained from the subventricular zone, so called the origin, and another subset of 
cells closer to the olfactory bulb, the migration destination (Figure 1.11, Chapter 1). Genes significantly 
expressed between both populations were predicted to govern neuroblast migration in the study. Using 
differentially expressed RMS neuronal motility-deterministic genes guiding neuroblast migration, we 
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sought to identify analogous or conserved chemotactic signaling pathways that may drive RPC and PPC 
migration (Table 2.2, Chapter 2).  We also sought to identify potential upstream regulatory cell signaling 
pathways responsible for the significant changes in the gene expression patterns exhibited by the 
neuroblast populations in the RMS. Having the advantage of a robust computational architecture and 
linked knowledgebase platforms, the Expression2Kinases (X2K) software program [547] developed by 
our collaborator Dr. Avi Ma’ayan was employed to identify transcription factors that are most likely 
involved in regulating the expression of the RMS motility genes. The program was also used to connect 
identified transcription factors using known protein-protein interactions to build a transcriptional regulatory 
subnetwork, and to identify protein kinases that have enriched substrates within the subnetwork. Figure 
6.1 displays the regulatory subnetwork governing differential up-regulation of genes facilitating migration 
of neuroblast in the RMS of the adult mouse brain. The top ten (10) transcription factors (TFs, cyan nodes 
on the left) identified were connected using known protein-protein interactions (gray nodes in the center) 
from literature reviews compiled in the X2K software knowledgebase, and the top ten (10) protein kinases 
(green nodes on the right) that are enriched in substrates within the transcriptional complex were also 
identified using the Kinase Enrichment Analysis tool. Rankings of transcription factors and protein kinases 
are based on a combination of a Fisher Exact test p‐value, that scores the degree to which a TF or a 
protein kinase selectively regulates or phosphorylates target motility genes or proteins in the 
transcriptional regulatory network above other TFs and protein kinases in the knowledgebase and a 
z‐score comparing ranked genes to background rank, if the TF or protein kinase enrichment was applied 
to random set of genes. The sizes of the nodes correspond to the degree of connectivity associated with 
each TF, interacting protein or protein kinase. The transcriptional regulatory network data was graphically 
represented using the yED graph editor.  
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Genes of the transcriptional regulatory network were used as input data for the X2K drug prediction tool 
to identify FDA approved drugs and other small molecules predicted to regulate the activity of genes in 
the transcriptional regulatory network. The drug analysis was performed using a Fisher exact test that 
ranked drugs based on their ability to selectively induce or decrease gene expression and on the number  
of genes affected based on drug testing experiments collated in the Broad Institute Connectivity Map 
database (Cambridge, MA, http://www.broadinstitute.org/cmap/) [548]. Table 6.1 displays lists of the top 
ten (10) unique drugs that can potentially be used to induce or reverse up-regulation of genes that 
increase in expression during migration of neuroblasts in the RMS of adult mouse brain. The overlapping 
Fig. 6.1: Resolving molecular regulators of motility-deterministic genes of neuronal rostral migratory stream 
(RMS) using Expression2Kinase (X2K) – X2K identified ten (10) transcription factors (cyan nodes on the left) that are 
likely upstream regulators of the differentially up-regulated genes governing migration of mouse cortical neuroblasts 
between the anterior and posterior subventricular zones [6]. These transcription factors are connected using known 
protein-protein interactions from the literature (gray nodes in the center). Finally, protein kinases (green nodes on the 
right) that are enriched in substrates within the transcriptional complex are identified using the Kinase Enrichment 
Analysis tool. All enrichment analyses implemented a Fisher test and a z‐score test which both assess the probability 
that elements of the transcriptional regulatory network affect neuronal motility genes of the RMS by random chance 
only. Node size is proportional to degree of connectivity. Resolved gene data is graphically represented using the yED 
graph editor. 
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genes columns show the number of genes that the drug induces or suppresses in the right direction 
whereas conflicting genes show the number of genes the drug induces or suppresses gene expression in 














Metanephrine 35 10 Irinotecan 46 5 
Ribostamycin 31 6 Phenoxybenzamine 36 11 
Vorinostat 32 8 Pargyline 32 7 
PF-00562151-00 31 8 Khellin 29 5 
Wortmannin 27 5 Josamycin 31 8 
Adiphenine 33 11 5230742 30 8 
Disopyramide 32 11 Phenoxybenzamine 34 12 
Trichostatin A 36 15 Androsterone 35 14 
Phenazone 32 11 Glimepiride 30 9 
Hydroflumethiazide 31 10 Acepromazine 30 9 
 
Table 6.1. Potential drug targets for RMS neuroblast migration - Top 10 unique drugs that can 
potentially be used to induce or reverse up-regulation of genes that increase in expression during 
migration of neuroblasts in the rostral migratory stream (RMS) of adult mouse brain. The overlapping 
genes columns show the number of genes that the drug induces or suppresses in the right direction 
whereas conflicting genes show the number of genes the drug induces or suppresses in the opposite 
unwanted direction. Drug analysis was performed using the drug prediction tool of the X2K gene 
expression analysis software (MSSM, NY). 	  
 
6.3: Systems Pharmacological Analysis of Novel Drugs and Small molecules Targeting Retinal 
Progenitor and Photoreceptor Precursor Cell Migration  
 
A unique focus of this study was to describe transcriptional networks regulating migratory gene 
expression and to identify drugs to modulate network expression to enhance migration of transplantable 
RPCs and PPCs. Following the resolution of candidate chemotactic molecules and signaling networks 
from our bioinformatics studies (Chapter 5), we reasoned that by modulating the expression of genes that 
regulate the expression of target chemotactic receptors, we could pharmacologically drive optimal 
receptor expression levels to improve migration of RPCs and PPCs in vitro and when transplanted into 
damaged host retina. In this light, we applied the X2K analysis, initially used to identify motogenic genes 
of migrating RMS neuroblasts, to define transcriptional regulatory networks and drug targets that can 
potentially affect expression of the candidate receptor protein C-X-C motif receptor 4 (CXCR4). CXCR4 
was identified in our previous bioinformatics analysis (Chapter 5) as a likely motogenic receptor affecting 
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RPC and PPC migration. Using CXCR4 as a singular input gene in X2K, we resolved the top ten (10) 
transcription factors (TFs, red nodes on left), their protein-protein interconnectivities (yellow nodes in the 
center, N=72), and top ten (10) protein kinases enriching the transcriptional regulatory network (green 
nodes on the right) using the Kinase Enrichment Analysis tool (Figure 6.2). Node sizes in the 
transcriptional regulatory network correspond to the degree of interconnectivity associated with each 
gene, a marker of their relative overall effect on the whole regulatory network.  
 
Notable upstream regulators of CXCR4 expression include the transcription factors avian 
myelocytomatosis viral oncogene (MYC), signal transducer and activator of transcription 3 (STAT3), 
interconnecting proteins signal transducer and activator of transcription 1 (STAT1), hypoxia inducible 
factor 1 alpha (HIF1A), and protein kinases PRKCD and mitogen activated protein kinase 3 (MAPK3). 
These transcription factors have been previously identified as key genes in intracellular signaling 
cascades transducing SDF-1 ligand binding effects on CXCR4 (Figure 5.5A, Chapter 5). However, the 
node sizes of the genes depicted in X2K regulatory network illustrate the relative strength of effect of 
these signaling molecules on CXCR4 expression. We then compiled these regulatory network genes as 
input data for the X2K drug prediction analysis tool and identified drugs that target these regulatory 




Drug analysis results depicted in Table 6.2 reveals the top ten (10) pharmacologic molecules specified for 
CXCR4 regulation, the number of genes in the regulatory network whose up-regulation they induce or 
repress, and the number of genes that conflict with the desired drug-induced regulatory activity. Given the 
native down-regulated expression state of CXCR4 in the resolved microarray data of cone and rod PPCs 
(Figure 5.5, Chapter 5), we were primarily interested in drugs predicted to upregulate the expression of 
the receptor as a potential strategy to activate migratory phenotypes in RPCs and PPCs. After a literature 
review of the specificity of the identified CXCR4-inducing drug targets, we selected the candidate drug 
Aminophenazone (AMP) to up-regulate CXCR4 expression on RPCs prior to cell motility assays that 
validate the efficacy of the drug to induce the desired cell migratory phenotype. 
 
Fig. 6.2: Identifying transcriptional modulators specific for CXCR4 expression using Expression2Kinase (X2K) – Given 
the motility-deterministic potential of CXCR4 for PPCs and RPCs determined in chapter 5, we sought to resolve transcriptional 
regulatory networks potentially controlling its expression and thus, its subsequent effect on cell motility. The top ten (10) 
transcription factors (red nodes on the left), their protein interconnectivities (yellow nodes, N=72) and protein kinases enriched 
within the transcriptional network (green nodes on the right, N=10) were resolved using X2K and graphically displayed with the 
yED graph editor. Protein kinases were identified using the Kinase Enrichment Analysis tool. Node size is proportional to the 
degree of connectivity associated with each gene. Further analysis was performed using X2K to identify drug targets that 




6.4: Validating the Efficacy of Aminophenazone (AMP) induction of CXCR4 Expression and 
Consequent RPC migration Potential. 
Aminophenazone (AMP) (4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one; M.W=231.2g/mol) is a 
small molecule phenylpyrazole that used to be widely used in clinical practice for its with analgesic, anti-
inflammatory, and antipyretic properties, but has since been largely replaced by safer alternatives. After 
oral administration, the drug is rapidly and almost completely absorbed from the gastrointestinal tract, and 
then evenly distributed throughout body water [549], explaining its current use in measuring body water 
volumes in clinical practice. AMP is also currently under assessment for use in non-invasive breath tests 
to measure cytochrome P-450 metabolic activity in liver function tests augmenting traditional liver 
biopsies [550], and to determine residual hydrogen peroxide activity in catalase activity assays via an 
oxidative coupling reaction with benzenesulfonic acids [551]. However, with the reported acute toxicity 












Streptomycin 14 2 propantheline bromide 16 1 
Cefotiam 15 3 trichostatin A-1971 16 2 
Dropropizine 16 5 trichostatin A-5209 14 1 
Ticarcillin 13 2 PHA-00767505E 15 2 
Sulfadiazine 14 3 trichostatin A-6916 16 3 
Flecainide 15 4 acetylsalicylic acid 14 1 
Aminophenazone 13 3 8-azaguanine 14 2 
demecarium bromide 11  1 trichostatin A-3428 13 1 
Carmustine 12 2 trichostatin A-6579 14 2 
(-)-atenolol 10 1 oxybutynin 16 4 
 
Table 6.2: Potential pharmacological drugs targeting CXCR4 expression – X2k was further used to identify top 10 unique drugs that 
can potentially induce or reverse up-regulation of CXCR4 by a concatenation of their effects on gene targets in the transcriptional 
regulatory network resolved in Figure 6.3. Drug ranking was performed using a Fisher Exact test for their effects on transcriptional genes 
from experimental results collated in the Broad Institute Connectivity Map [548]. The four-digit numbers differentiating identical drug 
selections references the specific connectivity Map experiment. The overlapping genes columns show the number of genes that each 
respective drug induces or suppresses in the right direction whereas conflicting genes show the number of genes the drug induces or 
suppresses in the opposite unwanted direction. Candidate drug Aminophenazone (AMP, bold in red), a pyrazolone, was selected to 
upregulate CXCR4 in PPCs and RPCs and validate its motogenic effects given its reported specificity for the receptor.	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LD50 of 2.88 mol/kg in rats, variations from optimal dosages has caused life-threatening agranulocytosis 
in mammals with increased risk of infections with up to 50% mortality rates [552, 553].  
 
In addition to up-regulating the expression of key regulatory proteins to increase CXCR4 expression, X2K 
analysis reveals that AMP also directly contributes to sustained receptor expression when compared to 
other top-ranked drugs in the category. Currently the FDA has withdrawn its approval for the anti-
inflammatory and anti-pyretic clinical use of AMP due to adverse toxicity reports. We reasoned that in 
vitro treatment of PPCs at safe dosage concentrations, followed by rinsing prior to migration assays or 
transplantation into retina, the drug may be re-purposed to serve a novel cytological role in upregulating 
the migratory CXCR4 receptor thereby enhancing migration. To initiate in vitro cell incubation trials with 
the drug, we firstly assessed the toxic effects of AMP at recommended dosage concentration of 
0.231ug/ml on the viability of RPCs using a trypan blue cell viability count. Approximately 1X105 cells/ml 
were plated in 6-well culture plates and exposed to the drug for 2 hours at either room temperature or 
37°C given that there was inconsistent information regarding standardized cell experimentation protocols 
using the drug. Live/dead cell counts were obtained before and after drug exposure to cells and results of 
the assay are displayed in Table 6.3. Results indicate that at the optimal incubation temperature of 37°C, 
AMP resulted in the death of about 20% more RPCs than control cell cultures not exposed to the drug. 
We then tested whether the drug specifically affected CXCR4 protein expression using western blot 
analysis with an anti-CXCR4 antibodiy to compare receptor protein levels in lysates isolated from control 
non-AMP exposed RPCs and experimental AMP-exposed RPCs. Results depicted in Figure 6.3B 
qualitatively demonstrate that one effect of AMP on RPCs is the slight observable increase of CXCR4 in 




We next ascertained the chemotactic effect of AMP-induced up-regulation of CXCR4 in RPCs cultured in 
both uniform and steady state gradients of the stimulatory SDF-1α ligand using Boyden Chambers and 
the bridged µ-lane microfluidic chamber respectively. In the Boyden assay, prior RPC exposure to AMP 
stimulated a slight increase in transmigration of cells to 100ng/ml of SDF-1α through the 8µm pore PET 
filters, although there was no significant difference in the number of migrating cells between control and 
drug-treated conditions (Figure 6.3A). Detailed examination of cyto-chemotactic parameters influenced 
by AMP drug-treatment was performed by live-cell imaging of RPCs over a 24hr period in steady state 
SDF-1α following the 2hr AMP-exposure compared to control RPC motility phenotype without prior 
exposure to the drug. Results depicted in Figure 6.4A reveal that RPCs exhibited higher accumulated 
distances but traveled shorter Euclidean distances in the drug-treated condition compared to movement 
in control conditions, although mean differences between both treatment groups were not statistically 
significant in a Student T-test. There was also no significant difference in overall chemotaxis towards the 























(cells/ml)/ % of total 
cell concentration 
25°C 
0 hrs. 120375 127687 120375 127687 48.53% 51.47% 48.53% 51.47% 
 
2 hrs. 32625 119250 35437 92250 21.48% 78.52% 27.75% 72.25% 
 
37°C 
0 hrs. 120375 127687 120375 127687 48.53% 51.47% 48.53% 51.47% 
 
2 hrs. 23625 83812.5 25875 37125 21.99% 78.01% 41.07% 58.93% 
 
Table 6.3: Trypan Blue Viability Assay to determine Aminophenazone (AMP) toxicity properties on mouse retinal 
progenitor cells (mRPCs) - Sequential identification of transcription factors, intermediate signaling proteins and protein kinases 
that significantly affect the expression of resolved receptors on mouse RPCs was performed using a Kinase Enrichment Analysis 
algorithm in the Expression2Kinase (X2K) software [547]. X2K was then further used to resolve FDA approved drugs and other 
small molecules that can regulate the activity of the predicted transcription factors in this protein connectivity sub-network [554]. 
AMP was identified as one of the target drugs that induces increased CXCR4 expression via transcriptional factor activation and 
was assessed for its effect on P23-RPC viability over the recommended 2 hour duration of incubation at either room temperature 
(25°C) or 37°C to optimize protocols for subsequent cell motility assays using the drug. Results indicate that AMP at 
recommended dosage concentrations of 0.231ug/ml caused approximately 20% more cell death at optimal culturing temperature 
of 37°C over the course of 2hrs. In control conditions at 37°C, only 7% increase in RPC death was recorded. Cell death rate at 
room temperature remained constant in both treatment conditions. 
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both treatment conditions (Figure 6.4B). Table 6.2 displays results of descriptive statistics including 
number of tracked cells, mean, standard error of mean (SEM) and p-values of independent samples t-
tests used for analysis. These preliminary results suggest that AMP exposure induced modest increases 
in RPC chemokinesis but not chemotaxis towards the chemotactic ligand, however, more replicate 
microfluidic runs are required before this AMP-induced migratory phenomena can be confirmed. 
Additionally, at the cell concentration of 106 cells/ml used in the microfluidic assays, RPCs readily formed 
clusters within microchannels that were then tracked for analysis. As such, the nature of chemotaxis of 	  
clusters versus single cells would also need to be taken into consideration.  
 
6.5: Method Improvement Study – Drug Analysis for PPC Chemotaxis Using LINCS (Library of 
Integrated Network-Based Cellular Signatures) Software. 
 
Several factors likely contribute to the tentative results obtained for preliminary drug effect tests of AMP 
on RPC chemotaxis and CXCR4 receptor expression. X2k drug prediction tools rank drug relevance to 
Drug 
Induction 
# of cell 
counting fields Mean ± SEM 
p-
Value 
-AMP 60 848.94 ± 91.7 0.8450 +AMP 64 878.48 ± 119.57 
Figure 6.3: Transwell Assay for Effects of drug-Induced activation of CXCR4 receptors on RPC chemotaxis - A) 
P17 mouse RPCs were pre-incubated in 0.231μg/ml of Aminophenazone (AMP) for 2hours at 37°C to stimulate 
upregulation of CXCR4 receptors prior to 24hr transmigration assays in Boyden Chambers containing 100ng/ml SDF-1α 
ligand. There was no significant difference in the number of migrated cells in a T-test (t0.05 = 1.960; p=0.8450) although 
more RPCs did migrate following drug induction (Table 6.4). Each error bar is constructed using 1 standard error from the 
mean. B) Western blots comparing CXCR4 receptor expression levels in RPCs before and after drug  exposure reveal 
slightly increased band intensity in the drug-treated lysates although a more quantitative assessment of protein levels will 
























Aminophenazone (AMP) Drug Test
A Table 6.4 




molecular regulatory signaling without stipulating cell-type specific drug dosage requirements, or 
temperature and cell incubation times that yield optimal cyto-physiological effects. In addition, there is the 
need to characterize drug-induced effects on individual molecules of the targeted transcriptional 
regulatory networks that facilitate the desired motility phenotypes in RPCs. To address some of these 
limitations, we tested a more robust drug computational analysis platform, the LINCS software program 
upon recommendation by our collaborator, Dr. Avi Maya’an. LINCS employs the L1000 technology to 
catalogue changes in gene expression that occur when cells are exposed to perturbing agents, into a set 





















Figure 6.4: Microfluidics analysis of retinal progenitor cell chemotaxis in steady state gradients of SDF-
1α  following drug induction of Aminophenazone (AMP) CXCR4 receptor upregulator  - P17 mouse 
RPCs were pre-incubated in 0.231μg/ml of AMP for 2hours at 37°C to stimulate upregulation of CXCR4 
receptors prior to migration assays in steady state gradients of 100ng/ml SDF-1α ligand generated in the 
bridged μ-lane microfluidic device. A) RPCs traveled higher accumulated distances but lower Euclidean 
distances when exposed to AMP although mean differences were not statistically significant in a Student’s T-
test. B) There was also no significant difference in overall cell movement towards the ligand source with 
mRPCs in both treatment conditions scoring very similar center of mass (COM) values in the Y-axis direction. 
Table 6.5 displays results of descriptive statistics including number of tracked cells, mean, standard error of 
mean (SEM) and p-values of independent samples t-tests used for analysis. These preliminary results seem to 
indicate that AMP induced an increased degree of chemokinesis in mRPCs but not chemotaxis towards the 
SDF-1α chemotactic ligand source. It is worthy of note that in this preliminary drug analysis, only single runs 
per experimental condition were performed and more replicate assays would be required before a definitive 
assertion can be made of the inductive ability of AMP and its consequent effect on RPC migration. Additionally, 
at the cell concentration of 106 cells/ml used in the microfluidic assays, RPCs readily formed clusters within 
microchannels that were then tracked for analysis. As such, nature of chemotaxis of clusters versus single cells 
would also need to be considered. Each blue/black error bar is constructed using 1 standard error from the 
mean. 	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perturbations can thus be characterized through the molecular regulatory mechanisms those 
perturbations induce, and linked to their cellular phenotypes. L1000 technology improves upon  
computational algorithms utilized in the CMAP program of X2K drug prediction tool by concatenating over 
1 million gene expression profiles into a LINCS canvas browser user interface composed of two separate 
analyses types: A) a measurement of about 1000 genes per experiment for over 22,000 unique 
perturbations applied to approximately 56 different cellular contexts of human origin, including only 
primary cell lines and cancers cells. These perturbations include small molecule and chemical drug tests, 
as well as genetic perturbations such as silencing and gene overexpression experiments, B) a gene set 
enrichment analysis that allows for perturbation-induced genetic signatures to be associated with curated 
biological functions ranked by statistical probability that they contain the specific gene list patterns queried 
by chance alone. Experimental conditions facilitating the production of each gene expression profile are 
also stipulated. An exemplary schematic of drug prediction analysis protocol using an input set of genes 
is displayed in Figure 6.5. 
 
We thus employed LINCS to query our resolved PPC motility-deterministic signaling network genes for 
applicable therapeutic molecules that may affect their expression and the signaling events of their 
upstream and downstream regulators with predictable accuracy, while specifying the experimental 
conditions associated with the perturbation. To exemplify the application of the LINCS program, we 
queried the motility-deterministic signaling network of the NSR/Rod (PPC) matched dataset (Table 5.5A, 
Chapter 5) to specify small molecules that can potentially upregulate receptor expression of rod PPCs 
with a special focus on our candidate CXCR4 receptor. We performed this task to support our postulate 









(Mean ± SEM) 
Max. Euclidean Distance (
μm) 
(Mean ± SEM) 
Center of Mass – Y axis (
μm) (Mean ± SEM) 




314.97 ± 37.02 
0.4848 
173.46 ± 19.55 
0.0622 




351.43 ± 35.57 120.32 ± 18.78 22.74 ± 11.54 
Table 6.5:  Descriptive statistics results of microfluidics analysis of retinal progenitor cell 
chemotaxis in steady state gradients of SDF-1α  following drug induction of Aminophenazone 
(AMP) CXCR4 receptor upregulator  	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PPC microarray data, may account for low migratory rates of PPCs frequently observed in current 
transplantation studies. Using CXCR4 singly and in combination with other downregulated migratory rod-
PPC receptor genes as input data in the LINCS canvas browser, we sourced drug targets that reverse the  
 
downregulated states of the receptors based on their correlation to differentially expressed gene lists 
curated in the LINCS gene signatures and obtained from perturbation experiments. Output results 
provided in Table 6.6 reveal the top matching experiments that upregulate the expression of CXCR4 
alone and in a group with all motility-deterministic downregulated receptors expressed on rod PPCs 
including ITGAV, TSHR, FYN, EGFR, RAC1, PTPRZ1, CDH2, LRP1, DDR1, SDC1, RET, GFRA1, AXL, 
TYRO3 (See Table 5.2, Chapter 5). Experiments were selected based on an overlap score quantifying 
correlation between our input gene list and the Z-score signatures of the 1000 genes measured per 
experiment using Pearson’s correlation. The Z -score signature is a vector of moderated Z -scores 
calculated by the CMAP group at the Broad Institute from the replicates of an experimental condition as it 
compares with the population background [3]. Drug targeting CXCR4 upregulation was used at a dosage 
Figure 6.5: Exemplary Schematic of Drug Prediction Analysis Protocol Using the LINCS Canvas 
Browser Search Interface. Differentially expressed genes are computed for each condition and stored in two 
large text files. The search engine takes as input the lists of genes and other selected options. After scoring 
overlap with the back-end dataset, the resultant list of matching experiments is returned for visualization. 
Figure adapted from ‘LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS 
L1000 gene expression signatures. (2014). Duan Q, Flynn C, Niepel M et al. Nucleic Acids Res.:42: W449-
460 [3].’ 
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of 10µM for either 6hrs or 24hrs on human prostate cancer cell lines VCaP and PC3 of experimental 
batch CPC003 and resolved an overlap score of 0.02. Drugs up-regulating the group list of receptor 
genes displayed overlap scores of 0.06-0.08. Overlap scores increase with increased correlation between 
our input genes and back-end gene signatures, and higher number of input query genes. Tolazamide, 
Flucloxacillin sodium and Enrofloxacin were identified as small molecules that commonly up-regulate 
CXCR4 (bold, in red) and target the gene list of rod PPC receptors. These newly identified small 
molecules serve as candidates for pharmacologic modulation of RPCs and PPCs migration. Additional 
LINCS queries using gene lists of whole rod and cone motility-deterministic network pathways sorted by 
up- or down-regulated gene expression states yielded lists of applicable experiments containing 
significant overlap in genes that change expression due to chemical perturbation, are presented as 
supplemental tables 6.1-6.5.  
 
THESIS CONCLUSION 
Given the intrinsic complexity of biological systems, which is further compounded in diseased states, 
many scientists have over the years forecasted the predominance of computational biologic approaches 
able to process the dynamic molecular interrelationships characterizing such systems, and thereby 
sourcing solutions for the most enduring human disorders, including retinal degeneration [23, 555]. 











CXCR4 Receptor Up-regulation  
(Overlap Score  = 0.02; Dosage = 10 μM; Cell Batch No. = 
CPC003) 
Motogenic Rod Receptors 
Group Gene Up-regulation (Overlap Score = 0.06) 
Chemical Perturbation Incubation Time (hrs.) Cell Type Chemical Perturbation Dosage (μM) 
Incubation 
Time (hrs.) Cell Type Batch No. 
Estradiol 24 VCAP Salbutamol (z = 0.08) 10 24 MCF7 CPC011 
Bufalin 6 VCAP Valsartan 10 24 VCAP CPC011 
Bongkrekic acid 24 PC3 Tolazamide 10 24 VCAP CPC020 
Vincristine Sulfate 6 VCAP nor-Binaltorphimine dihydrochloride 10 24 HT29 CPC005 
Vinblastine Sulfate 24 PC3 Nobiletin 10 6 VCAP CPC011 
Trap 101 24 VCAP Modafinil 10 24 MCF7 CPC011 
Tolazamide 6 VCAP Dolasetron 10 24 VCAP CPC010 
TCB2 24 PC3 Benactyzine 10 24 VCAP CPC011 
TC 2559 difumarate 6, 24 VCAP Zoxazolamine 10 24 PC3 CPD001 
Sulpiride 6 VCAP VU0418946-2 10 24 MCF7 CPC008 
SCH 442416 24 PC3 TPCA-1 0.4 6h MCF7 LJP002 
Remacemide hydrochloride 24 VCAP Phenoxazine 10 6 SKMEL1 CPC006 
RS 100329 hydrochloride 24 PC3 PX12 30 6 NOMO1 CPC006 
Rhizocarpic acid 6 VCAP Protryptyline Hydrochloride  10 6 MCF7 CPC004 
RG-14620 6 VCAP Penicillic Acid  10 6 A549 CPC005 
Quinidine hydrochloride monohydrate 24 PC3 PAC 1 10 24 PC3 CPC006 
Podofilox 6 VCAP Oxyphenbutazone 10 6 MCF7 CPD003 
Pinacidil 6 VCAP NCGC00184891-01 10 6 VCAP CPC008 
Nizatidine 6 VCAP NCGC00183242-01 10 24 MCF7 CPC007 
Nitrocaramiphen hydrochloride 6 VCAP NCGC00182833-01 10 6 A549 CPC007 
Nonoxynol-9 6 VCAP NCGC00167118-01 10 6 VCAP CPC008 
MRS 1220 24 VCAP Methoxy-6-harmalan 10 24 HCC515 CPC004 
MR 16728 hydrochloride 24 VCAP JZL-184,11 1 24 A549 CPC006 
Loreclezole hydrochloride 6 VCAP JWE-035, 2 6 MCF7 LJP002 
Leoidin Dimethyl Ether  6 VCAP JAS07_008 10 24 PC3 CPC007 
Kawain 6 VCAP Ingenol 3, 20-dibenzoate 10 6 SNUC5 CPC006 
Ivermectin 6 VCAP IKK Inhibitor X 6 6 CL34 CPC006 
Hippeastrine hydrobromide 6 VCAP Flucloxacillin sodium 10 24 VCAP CPC003 
Hexamethylquercetagetin 6 VCAP FPL 64176 10 6 NCIH596 CPC006 
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GW 405833 6 VCAP Enrofloxacin 10 24 HCC515 CPC003 
Glipizide 6, 24 VCAP EI-335, 10 24 MCF7 CPC014 
Fluvoxamine maleate 6 VCAP DPO-1 10 24 VCAP CPC005 
Flurofamide 24 VCAP Dihydro-obliquin 10 24 VCAP CPC005 
Flucloxacillin sodium 24 VCAP Clofilium tosylate 10 24 PC3 CPD001 
Fillalbin 6 VCAP CHR 2797 80 6 NOMO1 CPC006 
Flumethasone 6 VCAP BAPTA-AM 10 24 VCAP CPC001 
Enrofloxacin 24 VCAP AZD6244 2 6 MCF7 LJP001 
Doxorubicin hydrochloride 24 PC3 ABT-751 10 6 A673 CPC006 
Daunorubicin hydrochloride 24 PC3 2512-0754 10 6 HT29 CPC013 
Deguelin (-) 6 VCAP 1069-0075 10 6 A549 CPC013 
CPCCOEt 6 VCAP      
CGS 12066B 24 PC3      
Biperiden hydrochloride 24 VCAP      
Bucladesine 24 VCAP      
Bicalutamide 6 VCAP      
BAY 59-3074 24 VCAP      
Altanserin hydrochloride 6 VCAP      
AG 490 24 VCAP      
 
Table 6.6: L1000 Analysis for Drug Perturbations Reversing Down-regulated Receptor Expression state of Rod Photoreceptors – Analysis of rod 
photoreceptor microarray data using IPA bioinformatics tools revealed an overall downregulated expression state of receptor proteins, postulated to cause the low 
migration rates in current transplantation studies. Using the L100 LINCS search tool we queried input gene CXCR4 singly and in combination with other down-
regulated motility-deterministic receptor genes for drugs and small molecules that can reverse the expression states of our gene lists. Listed are top ranked 
experimental drugs and their testing conditions that potentially upregulate CXCR4 expression alone, or as part of the group of motogenic receptors as follows: 
ITGAV, TSHR, FYN, EGFR, RAC1, PTPRZ1, CXCR4, CDH2, LRP1, DDR1, SDC1, RET, GFRA1, AXL, TYRO3, culled from results of IPA bioinformatics analysis 
of NSR/Rod matched dataset depicted in Table 5.2 (Chapter 5). Rankings of chemical perturbation experiments was performed using an overlap score that 
quantifies the correlation between our input gene list and z-score gene expression signatures of the 1000 genes measured per experiment using Pearson’s 
correlation. Drug targeting CXCR4 upregulation were used at a dosage of 10μM for either 6hrs or 24hrs on human prostate cancer cell lines VCaP and PC3 of 
experimental batch CPC003 and resolved an overlap score of 0.02. Drugs up-regulating the group list of receptor genes displayed overlap scores of 0.06-0.08, 
and overlap scores increase with increased correlation between our input genes and back-end gene signatures, and higher number of input query genes. Ranked 
experiments were performed in a variety of cancer cell lines including lung carcinoma (NCIH596, HCC515, A549), intestinal (CL34) and gastric (SNUC5) 
carcinoma, breast (MCF7), muscle (A673), colon (HT29), melanoma (SKMEL1) and myeloid leukemia (NOMO1). Tolazamide, Flucloxacillin sodium and 
Enrofloxacin are highlighted in bold red color as they were identified as small molecules that commonly up-regulate CXCR4 (bold, in red) and the gene list of rod 
PPC receptors, and may serve as candidates for future drug effects tests on transplantable PPCs. Additional LINCS queries using gene lists of whole rod and 
cone motility-deterministic network pathways sorted by up- or down-regulated gene expression states yielded lists of applicable experiments containing significant 




scientific data to form hypotheses that can be tested with in silico applications, which in turn provide 
predictions verifiable by in vitro and in vivo studies [23]. We exemplify this systems biology approach 
through the course of our laboratory investigations, by configuring a step-wise bioinformatics paradigm for 
analyzing tissue- and disease-specific microarray data yielding streamlined, statistically determined 
chemotactic molecules inducing intracellular biochemical signaling that drives the movement of 
transplantable PPCs in light-damaged retina. We were also able to establish the accuracy of our in silico 
analytic method by validating the motogenic influence of resolved ligand SDF-1α on PPCs and 
multipotent RPCs, and providing evidence supporting our hypothesis of the gradated nature of the 
ligand’s influence on motility. In the fabricated microenvironments suitably generating these uniform and 
steady state chemical gradients, we were also able to distinguish the chemokinetic nature of EGF’s 
inductive effect on RPCs, the chemotactic effect of sdf1 on RPCs and PPCs and characterize 
downstream signaling supporting these cell motility phenomena. 
 
Kitano Hiroaki had earlier proposed a functional linkage between the computational biology approach and 
drug discovery, with the potential to provide individualized treatment regimes as depicted in Figure 7.1 
[23], a symbiosis currently hailed as the strategy for future personalized medicine [556, 557]. In this 
systemic relationship, bioinformatics-resolved and experimentally validated genetic and molecular 
markers associated with specific tissue physiological or disease conditions can be targeted to express a 
desired phenotype or reverse diseased conditions on a per-patient basis. Similarly we were able to target 
retinal precursor cell-specific chemotactic molecular markers resolved from our bioinformatics analysis for 
FDA-approved small molecular drugs that can influence their expression in a damaged retinal 
microenvironment, and potentially enhance migration of the cells post-transplantation, achieving our 
desired investigative goal. We have compiled libraries of RPC and PPC motility markers and defined 
protocols to identify potentially effective pharmacological drugs that may positively affect the motility 
















Figure 7.3: Linkage of a basic systems-biology research cycle with drug discovery and treatment cycles – Systems 
biology is an integrated process of computational modeling, system analysis, technology development for experiments, and 
quantitative experiments. With sufficient progress in basic systems biology, this cycle can be applied to drug discovery and the 
development of new treatments. In the future, in silico experiments and screening of lead candidates and multiple drug systems 
as well as introduced genetic circuits, will have a key role in the upstream processes of the pharmaceutical industry, 
significantly reducing costs and increasing the success of product and service development. Figure adapted from 

























































Supplemental Figure 4.1: Predicted EGF-induced Network of Direct and Indirect 
Molecular Interactions influencing RPC migration - The network was generated using 
Ingenuity Pathway Analysis (IPA) bioinformatics tool. Molecular components of the EGF 
signaling pathway are localized to extracellular space, plasma membrane, cytoplasm and 
nucleus. Solid and dashed arrows indicate direct and indirect interactions between upstream 
and downstream pathway molecules. Molecules significantly associated with the chemotaxis 
function as determined by a right-tailed Fisher test is identified by an overlay of green 
connected lines. The overlay of the indirect molecular connections highlights many relevant 
cascades including the EGF-induced phospholipase C-γ-1 (PLCG) mediated hydrolysis of 
Phosphatidylinositol-4,5-bisphosphate (PIP2) to yield Inositol tris-phosphate (IP3) that 























Supplemental Figure 4.2: Immunocytochemical localization of RPC total and phosphorylated EGFR expression 
upon exposure to a saturated EGF concentration of 10μg/ml - Analysis of phosphorylated EGFR (A-D) and total 
EGFR localization (E-H) were performed on RPCs isolated from P3-5 transgenic mice expressing green fluorescent 
protein (GFP) on the actin promoter (actin-GFP). A) Actin-GFP RPCs express GFP ubiquitously revealing the more 
primitive multipolar retinal neuron morphology with a cell body and hollow nuclear location (C) extending a long axonic 
process with whiplash synaptic ends B) Rhodamine bound anti-phospho (activated) EGFR antibody staining reveals 
receptor concentration around the periphery of the cell body and punctate receptor localization along the length of the 
axon C) DAPI labeling of nuclei, D) Overlay of A-C. Panels E and F show identical imaging parameters as A and D, 
with the exception that F) utilizes anti-total EGFR labeling. Scale: 20 microns.  
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Supplemental Figure 5.1: Summary Results of Bioinformatics Core Analysis of Matched PPC Receptor / ECM ligands from 
Damaged Retina – Using the Ingenuity Pathway Analysis (IPA) software platform, extracellular matrix genes of damaged retinal models 
matched to plasma membrane receptors of either rod or cone photoreceptor precursors were analyzed to resolve canonical pathways and 
molecular and physiological functions annotated to each respective matched dataset. Analysis parameters specified 140 molecules per 
network for the top 10 functional networks associated with each matched dataset by random chance using a right-tailed Fisher Exact test 
(p<0.05). A) Top ten functional clusters in the IPA knowledgebase associated with ECM molecules of retinal pigment epithelium (RPE) and 
rod receptors (RPE/Rods, N=1945 genes) reveal cellular movement function as the top functional category (outlined in red). C) Similar 
results were obtained using matched dataset of neurosensory retina ECM molecules and cone receptor genes (NSR/Cones, N=735 genes). 
B and D) Cytokine and Growth factor canonical signaling pathways that significantly overlapped with each matched dataset were selectively 
ranked based on their probability of containing our molecular datasets by chance alone using a right-talied Fisher’s Exact test with threshold 
p-value of 0.05. Ratios comparing the number of our matched dataset genes in each canonical pathway to the total number of genes 
originally designated to the pathway were also quantified and connected by a line graph. This ranking is also color-coded by assigned Z-
scores that predict activation (orange bars) or inhibition (blue bars) of the canonical signaling pathways based on the expression state of 
molecules in our datasets. Resolved canonical pathways common to both RPE/Rods (B) and NSR/Cones (D) matched datasets include 
interleukins IL-1 and IL-8 signaling, C-X-C motif receptor 4 (CXCR4) signaling, acute phase response signaling and transcriptional regulator 
























































Supplemental Figure 5.2: Modified volcano plots of cellular movement genes with 
statistically significant expression states resolved from transplantable photoreceptors 
and damaged recipient adult retina matched microarray dataset pairs – To mimic typical 
transplantation paradigms, normalized gene transcripts of donor P4 rod and E17.5 cone PPCs 
and light-damaged adult recipient retina were sorted by their tissue and subcellular localization, 
and filtered for their statistical difference (p=0.05, T-test) from negative-FAC-sorted replicates, 
and ligand-receptor pairs matched. Following bioinformatics analysis, genes annotated to the 
cellular movement function in the Ingenuity Pathways Analysis (IPA) knowledgebase were 
graphed. A) Cell motility genes resolved from matched pairs of rod receptors and extracellular 
matrix (ECM) ligands of damaged retinal pigment epithelia (RPE) (N=479 genes). The negative 
logarithm of their p-values was plotted against fold change. These genes were used to design 
signaling interaction networks predicting activating or inhibitory interactions between ligand and 
receptor pairs based on their expression states. B) A similar analysis was performed using 
resolved cellular movement molecules from matched ECM genes released from the 
neurosensory retina (NSR) after light-damage and receptors expressed on transplantable cone 
photoreceptors (N=223 genes). Tables listing these selected gene pairs are presented in 
supplemental tables 5.1C and 5.1D for RPE/Rods and NSR/Cones matched datasets 




















Supplemental Figure 5.3A: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-
Deterministic Interactions in the Matched NSR/Cones Dataset - Downstream signaling interactions between motogenic 
ECM ligands released from light-damaged neurosensory retina (NSR) and their cognate receptors expressed on cone 
PPCs were correlated to the expected causal interaction between each molecular pair at their given expression state (up-
regulation (red genes) or down-regulation (blue genes)) using the molecular activity prediction tool of the Ingenuity 
Pathway Analysis (IPA) protocol suite. Predictions of activating (orange connections) or inhibitory (blue connections) 
effects on downstream receptor genes were then computed based on similarities or differences between a causal effect 
model of known gene expression states and the expression profile of our resolved matched dataset genes. Yellow 
connecting lines denote interactions between genes whose expression states differ from the curated information in the IPA 
knowledgebase supporting such an interaction. Molecular interactions whose downstream effects are not predicted, as well 
as all upstream signaling relationships have been excluded from the network for clarity.  Asterisks denote genes whose 
expression profiles were computed after resolving duplicate gene identifiers in our matched dataset. Further analysis of the 
















Supplemental Figure 5.3B: Molecular Activity Prediction Identifies Downstream Ligand-Receptor Motility-
Deterministic Interactions in the Matched RPE/Rods Dataset – Downstream signaling interactions between cell 
motility ECM ligands released from light-damaged retinal pigment epithelium (RPE) and their cognate receptors 
expressed on rod PPCs are presented. Asterisks denote genes whose expression profiles were computed after 
resolving duplicate gene identifiers in our matched dataset. Further analysis of the causal effect of these network 






5.1A: Plasma Membrane Molecules from Rod Photoreceptor Precursors 
Gene 
Symbol Entrez Gene Name 
Fold 
Change 
RHO rhodopsin 3.54 
DMD dystrophin 2.42 
SLC11A1 solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 2.09 
PLA2R1 phospholipase A2 receptor 1, 180kDa 1.98 
WDPCP WD repeat containing planar cell polarity effector 1.91 
NFASC neurofascin 1.83 
ADRB2 adrenoceptor beta 2, surface 1.80 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 1.69 
SLC12A5 solute carrier family 12 (potassium/chloride transporter), member 5 1.67 
LIFR leukemia inhibitory factor receptor alpha 1.65 
MC1R melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) 1.63 
FGFR3 fibroblast growth factor receptor 3 1.63 
CDH13 cadherin 13 1.62 
STX3 syntaxin 3 1.62 
CLDN7 claudin 7 1.60 
ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26 1.53 
RAMP3 receptor (G protein-coupled) activity modifying protein 3 1.53 
SCUBE3 signal peptide, CUB domain, EGF-like 3 1.51 
INADL InaD-like (Drosophila) 1.50 
PTP4A3 protein tyrosine phosphatase type IVA, member 3 1.50 
SIRPA signal-regulatory protein alpha 1.46 
MAP2 microtubule-associated protein 2 1.45 
Col17a1 collagen, type XVII, alpha 1 1.44 
GNB1 guanine nucleotide binding protein (G protein), beta polypeptide 1 1.39 
NT5E 5'-nucleotidase, ecto (CD73) 1.39 
CADM1 cell adhesion molecule 1 1.38 
ADRA2A adrenoceptor alpha 2A 1.37 
CD8A CD8a molecule 1.36 
EPS8 epidermal growth factor receptor pathway substrate 8 1.35 
DNM2 dynamin 2 1.34 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit 1.32 
PARD6B par-6 family cell polarity regulator beta 1.30 
CXCR6 chemokine (C-X-C motif) receptor 6 1.30 
SCARB1 scavenger receptor class B, member 1 1.29 
Podxl podocalyxin-like 1.29 
LIMS1 LIM and senescent cell antigen-like domains 1 1.29 
MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2 1.28 
 208 
PGLYRP1 peptidoglycan recognition protein 1 1.28 
PKP2 plakophilin 2 1.27 
SLC12A6 solute carrier family 12 (potassium/chloride transporter), member 6 1.27 
VLDLR very low density lipoprotein receptor 1.27 
ACVRL1 activin A receptor type II-like 1 1.26 
GPR183 G protein-coupled receptor 183 1.25 
CD276 CD276 molecule 1.24 
STAB2 stabilin 2 1.24 
RAB28 RAB28, member RAS oncogene family 1.23 
USP9X ubiquitin specific peptidase 9, X-linked 1.22 
ANGPTL1 angiopoietin-like 1 1.22 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 1.22 
TREML2 triggering receptor expressed on myeloid cells-like 2 1.20 
PKD1 polycystic kidney disease 1 (autosomal dominant) 1.19 
EPB41L5 erythrocyte membrane protein band 4.1 like 5 1.19 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 1.19 
ADAM9 ADAM metallopeptidase domain 9 1.19 
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 1.18 
VCL vinculin 1.18 
F2RL3 coagulation factor II (thrombin) receptor-like 3 1.18 
IFNGR1 interferon gamma receptor 1 1.18 
PTAFR platelet-activating factor receptor 1.17 
GNAI1 guanine nucleotide binding protein (G protein),  alpha inhibiting activity polypeptide 1 1.17 
TRPM7 transient receptor potential cation channel, subfamily M, member 7 1.16 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 1.16 
SDC4 syndecan 4 1.16 
CSF2RB colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 1.16 
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein 1.15 
C1GALT1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 1.15 
STIM1 stromal interaction molecule 1 1.15 
LAT linker for activation of T cells 1.15 
CD4 CD4 molecule 1.15 
FLOT1 flotillin 1 1.15 
EDNRA endothelin receptor type A 1.14 
ROBO4 roundabout, axon guidance receptor, homolog 4 (Drosophila) 1.14 
GNAS GNAS complex locus 1.14 
TNFRSF10
A tumor necrosis factor receptor superfamily, member 10a 1.14 
CMKLR1 chemokine-like receptor 1 1.14 
SNPH syntaphilin 1.14 
CCR3 chemokine (C-C motif) receptor 3 1.13 
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HLA-A major histocompatibility complex, class I, A 1.13 
CCR10 chemokine (C-C motif) receptor 10 1.13 
CLEC1B C-type lectin domain family 1, member B 1.12 
TLR5 toll-like receptor 5 1.12 
FLT4 fms-related tyrosine kinase 4 1.12 
TRPM2 transient receptor potential cation channel, subfamily M, member 2 1.12 
CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) 1.12 
MARVELD3 MARVEL domain containing 3 1.12 
P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 1.12 
PLXNA2 plexin A2 1.11 
IL20RA interleukin 20 receptor, alpha 1.11 
TNFRSF11
B tumor necrosis factor receptor superfamily, member 11b 1.11 
PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C) 1.11 
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 1.10 
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 1.10 
OSBPL8 oxysterol binding protein-like 8 1.10 
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 1.10 
BDKRB2 bradykinin receptor B2 1.10 
TNFSF8 tumor necrosis factor (ligand) superfamily, member 8 1.10 
UNC5A unc-5 homolog A (C. elegans) 1.10 
C5AR1 complement component 5a receptor 1 1.10 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 1.09 
LTB4R2 leukotriene B4 receptor 2 1.09 
ITGB7 integrin, beta 7 1.08 
MBOAT7 membrane bound O-acyltransferase domain containing 7 1.08 
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit 1.07 
PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme 1.07 
FPR2 formyl peptide receptor 2 1.07 
SCN2B sodium channel, voltage-gated, type II, beta subunit 1.07 
JAM2 junctional adhesion molecule 2 1.07 
PRNP prion protein 1.07 
RGS1 regulator of G-protein signaling 1 1.06 
PLP1 proteolipid protein 1 1.06 
HRH2 histamine receptor H2 1.06 
TNFRSF4 tumor necrosis factor receptor superfamily, member 4 1.06 
FUZ fuzzy planar cell polarity protein 1.06 
CXADR coxsackie virus and adenovirus receptor 1.06 
GNB2 guanine nucleotide binding protein (G protein),  beta polypeptide 2 1.06 
GPR182 G protein-coupled receptor 182 1.06 
AQP4 aquaporin 4 1.05 
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MSR1 macrophage scavenger receptor 1 1.05 
LRPAP1 low density lipoprotein receptor-related protein associated protein 1 1.05 
INPP5B inositol polyphosphate-5-phosphatase, 75kDa 1.05 
CR1L complement component (3b/4b) receptor 1-like 1.05 
CLEC4M C-type lectin domain family 4, member M 1.05 
HRH4 histamine receptor H4 1.05 
HAS1 hyaluronan synthase 1 1.05 
DRD3 dopamine receptor D3 1.04 
TGFBR3 transforming growth factor, beta receptor III 1.04 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 1.04 
ORAI1 ORAI calcium release-activated calcium modulator 1 1.03 
CD247 CD247 molecule -1.02 
HAS2 hyaluronan synthase 2 -1.03 
SDC3 syndecan 3 -1.03 
GPER1 G protein-coupled estrogen receptor 1 -1.03 
GJB1 gap junction protein, beta 1, 32kDa -1.04 
BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) -1.05 
Cdc42 cell division cycle 42 -1.05 
RAP2A RAP2A, member of RAS oncogene family -1.06 
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) -1.06 
SH2B3 SH2B adaptor protein 3 -1.06 
IL17RA interleukin 17 receptor A -1.06 
NCKAP1 NCK-associated protein 1 -1.06 
IGHM immunoglobulin heavy constant mu -1.06 
TRPV2 transient receptor potential cation channel, subfamily V, member 2 -1.06 
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) -1.06 
PIP5K1C phosphatidylinositol-4-phosphate 5-kinase, type I, gamma -1.07 
SEMA6C sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C -1.07 
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 -1.07 
DIAPH1 diaphanous-related formin 1 -1.07 
WASF2 WAS protein family, member 2 -1.08 
IGF2R insulin-like growth factor 2 receptor -1.08 
ACTR2 ARP2 actin-related protein 2 homolog (yeast) -1.08 
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporter), member 2 -1.08 
AQP5 aquaporin 5 -1.08 
JAM3 junctional adhesion molecule 3 -1.08 
LTK leukocyte receptor tyrosine kinase -1.08 
ARRDC3 arrestin domain containing 3 -1.09 
RYK receptor-like tyrosine kinase -1.09 
ADAM10 ADAM metallopeptidase domain 10 -1.09 
BMPR1A bone morphogenetic protein receptor, type IA -1.10 
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CTTN cortactin -1.10 
GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) -1.11 
SFRP4 secreted frizzled-related protein 4 -1.11 
IGSF8 immunoglobulin superfamily, member 8 -1.11 
PARD3 par-3 family cell polarity regulator -1.11 
TGFBR1 transforming growth factor, beta receptor 1 -1.11 
ARF6 ADP-ribosylation factor 6 -1.11 
CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) -1.11 
AJAP1 adherens junctions associated protein 1 -1.12 
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 -1.12 
SELP selectin P (granule membrane protein 140kDa, antigen CD62) -1.12 
VASP vasodilator-stimulated phosphoprotein -1.13 
PTH1R parathyroid hormone 1 receptor -1.14 
Abcb1b ATP-binding cassette, sub-family B (MDR/TAP), member 1B -1.15 
EPHB4 EPH receptor B4 -1.15 
DSG2 desmoglein 2 -1.15 
EVL Enah/Vasp-like -1.15 
F3 coagulation factor III (thromboplastin, tissue factor) -1.15 
SDCBP syndecan binding protein (syntenin) -1.16 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 -1.17 
ANO6 anoctamin 6 -1.17 
PLXNA1 plexin A1 -1.17 
Cd99 CD99 antigen -1.17 
GPR173 G protein-coupled receptor 173 -1.17 
GNA13 guanine nucleotide binding protein (G protein), alpha 13 -1.18 
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) -1.18 
GNAQ guanine nucleotide binding protein (G protein),  q polypeptide -1.19 
NRP1 neuropilin 1 -1.19 
ACKR1 atypical chemokine receptor 1 (Duffy blood group) -1.19 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 -1.19 
GEM GTP binding protein overexpressed in skeletal muscle -1.19 
CD99L2 CD99 molecule-like 2 -1.19 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) -1.19 
Marcks myristoylated alanine rich protein kinase C substrate -1.19 
CD47 CD47 molecule -1.20 
ITGB5 integrin, beta 5 -1.20 
DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) -1.20 
EPHB6 EPH receptor B6 -1.20 
TNFRSF12
A tumor necrosis factor receptor superfamily, member 12A -1.20 
SPRY4 sprouty homolog 4 (Drosophila) -1.21 
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GNG12 guanine nucleotide binding protein (G protein), gamma 12 -1.21 
LGR4 leucine-rich repeat containing G protein-coupled receptor 4 -1.21 
EPHA5 EPH receptor A5 -1.21 
SEMA6D sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D -1.22 
EFNB3 ephrin-B3 -1.22 
FGFR4 fibroblast growth factor receptor 4 -1.22 
EPHB2 EPH receptor B2 -1.22 
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 -1.23 
JUP junction plakoglobin -1.23 
LDLR low density lipoprotein receptor -1.23 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog -1.24 
NOTCH1 notch 1 -1.24 
GPM6A glycoprotein M6A -1.25 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) -1.26 
GNA12 guanine nucleotide binding protein (G protein) alpha 12 -1.27 
PHACTR4 phosphatase and actin regulator 4 -1.27 
MRAS muscle RAS oncogene homolog -1.28 
SSTR2 somatostatin receptor 2 -1.28 
NOTCH3 notch 3 -1.28 
KCNK2 potassium channel, subfamily K, member 2 -1.29 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) -1.29 
SLC9A3R1 solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1 -1.30 
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 -1.31 
RECK reversion-inducing-cysteine-rich protein with kazal motifs -1.31 
RAP2B RAP2B, member of RAS oncogene family -1.32 
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 -1.32 
IL4R interleukin 4 receptor -1.33 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 -1.33 
SEMA4C 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and  
short cytoplasmic domain, (semaphorin) 4C 
-1.33 
LRP5 low density lipoprotein receptor-related protein 5 -1.34 
EPHB3 EPH receptor B3 -1.34 
SEMA4D 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and  
short cytoplasmic domain, (semaphorin) 4D 
-1.34 
CNTN1 contactin 1 -1.35 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) -1.35 
Cald1 caldesmon 1 -1.36 
GNAI2 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 -1.36 
CLIC4 chloride intracellular channel 4 -1.36 
CD151 CD151 molecule (Raph blood group) -1.36 
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SLC12A4 solute carrier family 12 (potassium/chloride transporter), member 4 -1.38 
PAG1 phosphoprotein membrane anchor with glycosphingolipid microdomains 1 -1.38 
NOTCH4 notch 4 -1.40 
RRAS2 related RAS viral (r-ras) oncogene homolog 2 -1.40 
FYN FYN proto-oncogene, Src family tyrosine kinase -1.40 
GPC1 glypican 1 -1.41 
MAGI1 membrane associated guanylate kinase,  WW and PDZ domain containing 1 -1.41 
PTPRM protein tyrosine phosphatase, receptor type, M -1.41 
EPHB1 EPH receptor B1 -1.42 
EPHA2 EPH receptor A2 -1.43 
PTPRF protein tyrosine phosphatase, receptor type, F -1.43 
PPAP2B phosphatidic acid phosphatase type 2B -1.44 
PTPRJ protein tyrosine phosphatase, receptor type, J -1.44 
MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 -1.44 
ST14 suppression of tumorigenicity 14 (colon carcinoma) -1.46 
APP amyloid beta (A4) precursor protein -1.46 
SEMA4A 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and  
short cytoplasmic domain, (semaphorin) 4A 
-1.46 
STX4 syntaxin 4 -1.46 
AMOT angiomotin -1.46 
FAT3 FAT atypical cadherin 3 -1.47 
FZD3 frizzled class receptor 3 -1.47 
DDR1 discoidin domain receptor tyrosine kinase 1 -1.47 
FAT1 FAT atypical cadherin 1 -1.47 
AMOTL1 angiomotin like 1 -1.47 
EFNA1 ephrin-A1 -1.48 
TNS3 tensin 3 -1.49 
DCC DCC netrin 1 receptor -1.50 
Cd59a CD59a antigen -1.52 
PEAK1 pseudopodium-enriched atypical kinase 1 -1.52 
ZYX zyxin -1.52 
ANXA5 annexin A5 -1.52 
RHOC ras homolog family member C -1.52 
EZR ezrin -1.53 
LRP1 low density lipoprotein receptor-related protein 1 -1.53 
SMO smoothened, frizzled class receptor -1.54 
PCDH10 protocadherin 10 -1.54 
SPATA13 spermatogenesis associated 13 -1.56 
GAP43 growth associated protein 43 -1.56 
TSHR thyroid stimulating hormone receptor -1.56 
GPR124 G protein-coupled receptor 124 -1.58 
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GFRA1 GDNF family receptor alpha 1 -1.59 
Cd24a CD24a antigen -1.59 
CADPS2 Ca++-dependent secretion activator 2 -1.60 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) -1.62 
ITGAV integrin, alpha V -1.62 
NRCAM neuronal cell adhesion molecule -1.62 
EFNB1 ephrin-B1 -1.62 
DLL1 delta-like 1 (Drosophila) -1.63 
PTPRK protein tyrosine phosphatase, receptor type, K -1.64 
CD9 CD9 molecule -1.65 
S1PR2 sphingosine-1-phosphate receptor 2 -1.65 
ADAM19 ADAM metallopeptidase domain 19 -1.66 
FGFR1 fibroblast growth factor receptor 1 -1.66 
MAPT microtubule-associated protein tau -1.67 
ROBO3 roundabout, axon guidance receptor, homolog 3 (Drosophila) -1.68 
MGLL monoglyceride lipase -1.68 
PTPRG protein tyrosine phosphatase, receptor type, G -1.68 
ROR1 receptor tyrosine kinase-like orphan receptor 1 -1.70 
CTNND2 catenin (cadherin-associated protein), delta 2 -1.70 
GAS1 growth arrest-specific 1 -1.70 
SFRP2 secreted frizzled-related protein 2 -1.73 
GRID2 glutamate receptor, ionotropic, delta 2 -1.73 
ACVR1 activin A receptor, type I -1.73 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -1.73 
EFNA5 ephrin-A5 -1.74 
PALLD palladin, cytoskeletal associated protein -1.74 
PDPN podoplanin -1.74 
ADAM12 ADAM metallopeptidase domain 12 -1.75 
NRP2 neuropilin 2 -1.76 
CNTNAP2 contactin associated protein-like 2 -1.76 
BMPR1B bone morphogenetic protein receptor, type IB -1.76 
S1PR3 sphingosine-1-phosphate receptor 3 -1.77 
CELSR1 cadherin, EGF LAG seven-pass G-type receptor 1 -1.77 
EFNB2 ephrin-B2 -1.77 
TYRO3 TYRO3 protein tyrosine kinase -1.78 
DOCK4 dedicator of cytokinesis 4 -1.79 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 -1.80 
GRIA3 glutamate receptor, ionotropic, AMPA 3 -1.83 
GPR56 G protein-coupled receptor 56 -1.84 
CTNNA2 catenin (cadherin-associated protein), alpha 2 -1.85 
AXL AXL receptor tyrosine kinase -1.86 
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NGFR nerve growth factor receptor -1.86 
NRXN1 neurexin 1 -1.87 
TPBG trophoblast glycoprotein -1.88 
PMP22 peripheral myelin protein 22 -1.88 
CD1D CD1d molecule -1.88 
MCAM melanoma cell adhesion molecule -1.89 
GPC3 glypican 3 -1.91 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 -1.91 
NOTCH2 notch 2 -1.92 
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 -1.92 
CD200 CD200 molecule -1.93 
TENM2 teneurin transmembrane protein 2 -1.94 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide -1.94 
DRD1 dopamine receptor D1 -1.94 
ITGB8 integrin, beta 8 -1.95 
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A -1.97 
F2R coagulation factor II (thrombin) receptor -1.99 
CNTN4 contactin 4 -2.00 
SEMA4F 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and  
short cytoplasmic domain, (semaphorin) 4F 
-2.01 
FZD7 frizzled class receptor 7 -2.03 
CD44 CD44 molecule (Indian blood group) -2.03 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog -2.04 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) -2.05 
PLXNC1 plexin C1 -2.06 
PON2 paraoxonase 2 -2.06 
CNR1 cannabinoid receptor 1 (brain) -2.07 
RET ret proto-oncogene -2.08 
MSN moesin -2.08 
FLRT3 fibronectin leucine rich transmembrane protein 3 -2.09 
GPR161 G protein-coupled receptor 161 -2.09 
GLRB glycine receptor, beta -2.10 
LRRC4C leucine rich repeat containing 4C -2.16 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 -2.17 
EDNRB endothelin receptor type B -2.19 
CXCR4 chemokine (C-X-C motif) receptor 4 -2.23 
EPHA4 EPH receptor A4 -2.25 
SEMA5A 
sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A 
-2.39 
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) -2.47 
EGFR epidermal growth factor receptor -2.76 
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PDGFRB platelet-derived growth factor receptor, beta polypeptide -2.78 
GRIA2 glutamate receptor, ionotropic, AMPA 2 -2.82 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 -2.97 






5.1B: Plasma Membrane Molecules from Cone Photoreceptor Precursors 
Gene 
Symbol Entrez Gene Name 
Fold 
Change 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 3.86 
PTPRO protein tyrosine phosphatase, receptor type, O 2.35 
STX3 syntaxin 3 2.27 
PLXNA2 plexin A2 2.23 
JAM2 junctional adhesion molecule 2 2.21 
KCNMA1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1 1.99 
MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 1.64 
L1CAM L1 cell adhesion molecule 1.41 
INSR insulin receptor 1.36 
APP amyloid beta (A4) precursor protein 1.35 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 1.33 
GNAI1 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 1.25 
SLC9A1 solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 1.24 
C1GALT1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 1.19 
CD200 CD200 molecule 1.16 
CD93 CD93 molecule 1.15 
MC1R melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) 1.15 
ADAM9 ADAM metallopeptidase domain 9 1.11 
TNFRSF4 tumor necrosis factor receptor superfamily, member 4 1.11 
CD38 CD38 molecule 1.10 
TACR1 tachykinin receptor 1 1.09 
MARVELD
3 MARVEL domain containing 3 1.08 
ENG endoglin 1.06 
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 1.05 
SH2B3 SH2B adaptor protein 3 1.05 
ADAM21 ADAM metallopeptidase domain 21 1.03 
Cdc42 cell division cycle 42 1.03 
IL20RA interleukin 20 receptor, alpha 1.02 
AMOTL1 angiomotin like 1 1.02 
SCN5A sodium channel, voltage-gated, type V, alpha subunit 1.02 
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SPN sialophorin -1.03 
CATSPER
1 cation channel, sperm associated 1 -1.03 
PLVAP plasmalemma vesicle associated protein -1.06 
WASF2 WAS protein family, member 2 -1.07 
CD97 CD97 molecule -1.07 
ALPL alkaline phosphatase, liver/bone/kidney -1.07 
SFRP5 secreted frizzled-related protein 5 -1.07 
TMEM102 transmembrane protein 102 -1.08 
F2RL3 coagulation factor II (thrombin) receptor-like 3 -1.08 
TM4SF4 transmembrane 4 L six family member 4 -1.09 
TLR2 toll-like receptor 2 -1.09 
ANXA1 annexin A1 -1.10 
LRP1 low density lipoprotein receptor-related protein 1 -1.10 
ICAM1 intercellular adhesion molecule 1 -1.11 
CTTN cortactin -1.12 
TRPC1 transient receptor potential cation channel, subfamily C, member 1 -1.12 
MGLL monoglyceride lipase -1.13 
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A -1.14 
Klra4  killer cell lectin-like receptor, subfamily A, member 4 -1.14 
RAB28 RAB28, member RAS oncogene family -1.16 
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) -1.18 




inducible T-cell co-stimulator ligand -1.23 
RECK reversion-inducing-cysteine-rich protein with kazal motifs -1.25 
MC4R melanocortin 4 receptor -1.26 
SLC4A2 solute carrier family 4 (anion exchanger), member 2 -1.32 
MRC2 mannose receptor, C type 2 -1.33 
ZYX zyxin -1.34 
LIMS1 LIM and senescent cell antigen-like domains 1 -1.36 
SLC12A4 solute carrier family 12 (potassium/chloride transporter), member 4 -1.40 




C15orf38-AP3S2 readthrough -1.42 
ERBB2 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 -1.48 
EPHB4 EPH receptor B4 -1.52 
FAT1 FAT atypical cadherin 1 -1.53 
GRID2 glutamate receptor, ionotropic, delta 2 -1.59 
EPHB1 EPH receptor B1 -1.73 
PMP22 peripheral myelin protein 22 -1.76 






5.1C: Extracellular Matrix (ECM) Molecules from Neurosensory Retina 
Gene 
Symbol Entrez Gene Name 
Fold 
Change 
Ccl2 chemokine (C-C motif) ligand 2 3.22 
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 2.13 
LIF leukemia inhibitory factor 2.11 
A2M alpha-2-macroglobulin 2.05 
SPP1 secreted phosphoprotein 1 1.99 
IL1A interleukin 1, alpha 1.90 
LCN2 lipocalin 2 1.86 
CCL3L3 chemokine (C-C motif) ligand 3-like 3 1.75 
CXCL3 chemokine (C-X-C motif) ligand 3 1.70 
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 1.67 
TIMP1 TIMP metallopeptidase inhibitor 1 1.64 
LGALS1 lectin, galactoside-binding, soluble, 1 1.63 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 1.59 
PROS1 protein S (alpha) 1.57 
CXCL10 chemokine (C-X-C motif) ligand 10 1.55 
FGF2 fibroblast growth factor 2 (basic) 1.55 
RBP1 retinol binding protein 1, cellular 1.53 
PENK proenkephalin 1.48 
BTC betacellulin 1.48 
LYZ lysozyme 1.43 
HBEGF heparin-binding EGF-like growth factor 1.43 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1.41 
IL1B interleukin 1, beta 1.40 
IL33 interleukin 33 1.40 
MGP matrix Gla protein 1.39 
CSF1 colony stimulating factor 1 (macrophage) 1.37 
MMP14 matrix metallopeptidase 14 (membrane-inserted) 1.36 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 1.34 
ERAP1 endoplasmic reticulum aminopeptidase 1 1.33 
CXCL16 chemokine (C-X-C motif) ligand 16 1.32 
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 -1.89 
CXCR4 chemokine (C-X-C motif) receptor 4 -1.97 
ARHGEF2
6 Rho guanine nucleotide exchange factor (GEF) 26 -2.06 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 -2.29 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 -2.29 
PON2 paraoxonase 2 -2.64 
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EDN2 endothelin 2 1.30 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 1.29 
C3 complement component 3 1.29 
CCL17 chemokine (C-C motif) ligand 17 1.28 
MATN2 matrilin 2 1.27 
PLAT plasminogen activator, tissue 1.26 
NDP Norrie disease (pseudoglioma) 1.26 
ANGPT1 angiopoietin 1 1.25 
CYR61 cysteine-rich, angiogenic inducer, 61 1.23 
Ccl7 chemokine (C-C motif) ligand 7 1.22 
NAMPT nicotinamide phosphoribosyltransferase 1.22 
LGALS3 lectin, galactoside-binding, soluble, 3 1.22 
TIMP3 TIMP metallopeptidase inhibitor 3 1.22 
EDN1 endothelin 1 1.22 
KITLG KIT ligand 1.22 
IGFBP5 insulin-like growth factor binding protein 5 1.21 
TGFB2 transforming growth factor, beta 2 1.21 
Saa3 serum amyloid A 3 1.20 
FN1 fibronectin 1 1.20 
VAV3 vav 3 guanine nucleotide exchange factor 1.19 
CXCL2 chemokine (C-X-C motif) ligand 2 1.18 
TIMP2 TIMP metallopeptidase inhibitor 2 1.17 
CCL5 chemokine (C-C motif) ligand 5 1.17 
CXCL12 chemokine (C-X-C motif) ligand 12 1.17 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.16 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 1.16 
TAC1 tachykinin, precursor 1 1.15 
IL1RN interleukin 1 receptor antagonist 1.14 
IL21 interleukin 21 1.14 
COCH cochlin 1.13 
GDNF glial cell derived neurotrophic factor 1.13 
FAM60A family with sequence similarity 60, member A 1.13 
CXCL6 chemokine (C-X-C motif) ligand 6 1.12 
IL34 interleukin 34 1.12 
Ceacam10 carcinoembryonic antigen-related cell adhesion molecule 10 1.12 
INHBB inhibin, beta B 1.12 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 1.11 
GRN granulin 1.10 
BDNF brain-derived neurotrophic factor 1.10 
THPO thrombopoietin 1.10 
CARTPT CART prepropeptide 1.10 
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PRSS3 protease, serine, 3 1.09 
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 1.09 
HDGF hepatoma-derived growth factor 1.08 
IL4 interleukin 4 1.08 
FGL2 fibrinogen-like 2 1.08 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 1.08 
TNF tumor necrosis factor 1.08 
NDNF neuron-derived neurotrophic factor 1.08 
CFB complement factor B 1.07 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 1.06 
HTRA1 HtrA serine peptidase 1 1.06 
C4A/C4B complement component 4B (Chido blood group) 1.05 
KDM6B lysine (K)-specific demethylase 6B 1.05 
IL12A interleukin 12A 1.05 
MBP myelin basic protein 1.05 
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 1.04 
Defb3 defensin beta 3 1.04 
LGALS8 lectin, galactoside-binding, soluble, 8 1.04 
SLIT2 slit homolog 2 (Drosophila) 1.03 
CATSPERD catsper channel auxiliary subunit delta 1.02 
CST3 cystatin C -1.02 
ZP3 zona pellucida glycoprotein 3 (sperm receptor) -1.03 
WNT11 wingless-type MMTV integration site family, member 11 -1.03 
FBN1 fibrillin 1 -1.03 
COL1A1 collagen, type I, alpha 1 -1.04 
VASH1 vasohibin 1 -1.04 
CCL4 chemokine (C-C motif) ligand 4 -1.04 
PNOC prepronociceptin -1.05 
COL7A1 collagen, type VII, alpha 1 -1.05 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b -1.05 
TFF1 trefoil factor 1 -1.05 
SFTPC surfactant protein C -1.05 
ANGPT4 angiopoietin 4 -1.05 
DEF6 differentially expressed in FDCP 6 homolog (mouse) -1.05 
SEMA3D sema domain, immunoglobulin domain (Ig) short basic domain, secreted, (semaphorin) 3D -1.05 
FGF8 fibroblast growth factor 8 (androgen-induced) -1.06 
IGFBP1 insulin-like growth factor binding protein 1 -1.06 
KIRREL3 kin of IRRE like 3 (Drosophila) -1.06 
LTBP2 latent transforming growth factor beta binding protein 2 -1.06 
BBS1 Bardet-Biedl syndrome 1 -1.06 
PRTN3 proteinase 3 -1.06 
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IL17C interleukin 17C -1.07 
BMP7 bone morphogenetic protein 7 -1.07 
PRSS27 protease, serine 27 -1.07 
SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F -1.07 
MDK midkine (neurite growth-promoting factor 2) -1.07 
ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 -1.07 
IFNB1 interferon, beta 1, fibroblast -1.07 
REN renin -1.07 
IL25 interleukin 25 -1.07 
NPPC natriuretic peptide C -1.07 
KLK3 kallikrein-related peptidase 3 -1.08 
MST1 macrophage stimulating 1 (hepatocyte growth factor-like) -1.08 
TGFB3 transforming growth factor, beta 3 -1.08 
GAS6 growth arrest-specific 6 -1.08 
WNT4 wingless-type MMTV integration site family, member 4 -1.09 
COL3A1 collagen, type III, alpha 1 -1.10 
KLK6 kallikrein-related peptidase 6 -1.10 
MFGE8 milk fat globule-EGF factor 8 protein -1.10 
PLTP phospholipid transfer protein -1.11 
AZGP1 alpha-2-glycoprotein 1, zinc-binding -1.11 
BMP4 bone morphogenetic protein 4 -1.12 
SAA1 serum amyloid A1 -1.13 
DKK3 dickkopf WNT signaling pathway inhibitor 3 -1.13 
VTN vitronectin -1.13 
JAG1 jagged 1 -1.14 
NGF nerve growth factor (beta polypeptide) -1.15 
APOE apolipoprotein E -1.15 
Ifnz  interferon zeta -1.15 
IGF2 insulin-like growth factor 2 -1.16 
WISP3 WNT1 inducible signaling pathway protein 3 -1.16 
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) -1.18 
PLA2G5 phospholipase A2, group V -1.19 
PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) -1.22 
PTN pleiotrophin -1.28 










5.1D: Extracellular Matrix (ECM) Molecules from Retinal Pigment Epithelium (RPE) 
Gene 
Symbol Entrez Gene Name 
Fold 
Change 
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 4.15 
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 3.71 
LCN2 lipocalin 2 3.22 
MMP12 matrix metallopeptidase 12 (macrophage elastase) 3.11 
TIMP1 TIMP metallopeptidase inhibitor 1 2.51 
IL6 interleukin 6 2.43 
NMU neuromedin U 2.18 
TNC tenascin C 1.92 
PTX3 pentraxin 3, long 1.66 
Ccl2 chemokine (C-C motif) ligand 2 1.62 
SPP1 secreted phosphoprotein 1 1.58 
CXCL10 chemokine (C-X-C motif) ligand 10 1.58 
PROS1 protein S (alpha) 1.58 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 1.46 
Ccl9 chemokine (C-C motif) ligand 9 1.42 
C3 complement component 3 1.42 
C4A/C4B complement component 4B (Chido blood group) 1.42 
ANGPTL4 angiopoietin-like 4 1.40 
PLAU plasminogen activator, urokinase 1.38 
ALB albumin 1.36 
Saa3 serum amyloid A 3 1.34 
LOX lysyl oxidase 1.33 
FBLN5 fibulin 5 1.32 
TGFBI transforming growth factor, beta-induced, 68kDa 1.31 
MMP19 matrix metallopeptidase 19 1.31 
CSF1 colony stimulating factor 1 (macrophage) 1.31 
ERAP1 endoplasmic reticulum aminopeptidase 1 1.24 
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 1.24 
A2M alpha-2-macroglobulin 1.23 
VCAN versican 1.22 
HTRA1 HtrA serine peptidase 1 1.21 
LIF leukemia inhibitory factor 1.20 
CXCL2 chemokine (C-X-C motif) ligand 2 1.18 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.18 
MATN2 matrilin 2 1.17 
FN1 fibronectin 1 1.16 
CXCL14 chemokine (C-X-C motif) ligand 14 1.16 
Ccl6 chemokine (C-C motif) ligand 6 1.15 
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CCL25 chemokine (C-C motif) ligand 25 1.15 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 1.15 
TGFB2 transforming growth factor, beta 2 1.14 
CCL20 chemokine (C-C motif) ligand 20 1.14 
EMILIN2 elastin microfibril interfacer 2 1.13 
AIMP1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 1.12 
PMCH pro-melanin-concentrating hormone 1.12 
INHBB inhibin, beta B 1.11 
LGALS1 lectin, galactoside-binding, soluble, 1 1.11 
TRIP6 thyroid hormone receptor interactor 6 1.11 
DKK3 dickkopf WNT signaling pathway inhibitor 3 1.11 
Defb3 defensin beta 3 1.10 
NAMPT nicotinamide phosphoribosyltransferase 1.09 
THBS4 thrombospondin 4 1.08 
PRSS3 protease, serine, 3 1.07 
CFB complement factor B 1.07 
MFGE8 milk fat globule-EGF factor 8 protein 1.07 
PROK2 prokineticin 2 1.05 
HDGF hepatoma-derived growth factor 1.05 
LAMA5 laminin, alpha 5 1.05 
CLEC11A C-type lectin domain family 11, member A 1.04 
KLK6 kallikrein-related peptidase 6 1.04 
MMP10 matrix metallopeptidase 10 (stromelysin 2) 1.02 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) -1.01 
RBP1 retinol binding protein 1, cellular -1.03 
VEGFC vascular endothelial growth factor C -1.04 
VEGFB vascular endothelial growth factor B -1.04 
MOG myelin oligodendrocyte glycoprotein -1.06 
BBS1 Bardet-Biedl syndrome 1 -1.06 
DLL4 delta-like 4 (Drosophila) -1.06 
THBS1 thrombospondin 1 -1.06 
TFF2 trefoil factor 2 -1.06 
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) -1.07 
NPY neuropeptide Y -1.07 
BMP4 bone morphogenetic protein 4 -1.07 
IL16 interleukin 16 -1.07 
IFNL3 interferon, lambda 3 -1.07 
GPI glucose-6-phosphate isomerase -1.08 
APOE apolipoprotein E -1.08 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -1.08 
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NPTX1 neuronal pentraxin I -1.09 
RETN resistin -1.09 
PLTP phospholipid transfer protein -1.09 
CFH complement factor H -1.09 
MMP11 matrix metallopeptidase 11 (stromelysin 3) -1.10 
JAG1 jagged 1 -1.11 
APOA1 apolipoprotein A-I -1.11 
GDF5 growth differentiation factor 5 -1.11 
TIMP3 TIMP metallopeptidase inhibitor 3 -1.11 
FAM60A family with sequence similarity 60, member A -1.11 
BDNF brain-derived neurotrophic factor -1.11 
PDGFA platelet-derived growth factor alpha polypeptide -1.12 
SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) -1.13 
FSTL1 follistatin-like 1 -1.13 
FGF13 fibroblast growth factor 13 -1.13 
LAMB1 laminin, beta 1 -1.14 
PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) -1.14 
COL18A1 collagen, type XVIII, alpha 1 -1.14 
TIMP2 TIMP metallopeptidase inhibitor 2 -1.16 
FGF1 fibroblast growth factor 1 (acidic) -1.16 
PLA2G5 phospholipase A2, group V -1.17 
PGF placental growth factor -1.17 
CCBE1 collagen and calcium binding EGF domains 1 -1.18 
DCDC2 doublecortin domain containing 2 -1.19 
BMP7 bone morphogenetic protein 7 -1.19 
FGF7 fibroblast growth factor 7 -1.19 
FBN1 fibrillin 1 -1.19 
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) -1.19 
MIA melanoma inhibitory activity -1.21 
VEGFA vascular endothelial growth factor A -1.21 
IL18 interleukin 18 -1.21 
CYR61 cysteine-rich, angiogenic inducer, 61 -1.23 
IGF2 insulin-like growth factor 2 -1.24 
NTN4 netrin 4 -1.24 
BMP2 bone morphogenetic protein 2 -1.24 
IL25 interleukin 25 -1.24 
GIP gastric inhibitory polypeptide -1.25 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa -1.26 
MMP16 matrix metallopeptidase 16 (membrane-inserted) -1.27 
BMP6 bone morphogenetic protein 6 -1.29 
PDGFD platelet derived growth factor D -1.57 
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Supplemental Table 5.1: Listing of Resolved Cellular Movement Genes – An 
Ingenuity Pathway (IPA) core analysis of significantly expressed genes (right-tailed 
Fisher Exact Test; p<0.05) culled from our ligand-receptor matched dataset pairs 
revealed cellular movement as the top functional annotation ascribed to our gene 
datasets. The genes correlating to this cellular movement function cluster in IPA are 
tabulated according to their subcellular localization and presented as plasma membrane 
molecules expressed on rods (5.1A; N=360 genes) and Cones (5.1B; N=75 genes), and 
extracellular matrix ligands released from the neurosensory retina (NSR) (5.1C; N=147 
genes) and retinal pigment epithelia (RPE) (5.1D; N=119 genes). These genes are 
ranked by their fold change values and after the appropriate ligand-receptor matches, 
will be analyzed to resolve ligands that exhibit downstream effects on their cognate 









































1.19 ACTIVATION ACTIVATION 
BTC betacellulin 1.48 EGFR epidermal growth factor receptor -2.76 ACTIVATION INCONSISTENT 
C3 complement component 3 1.29 ITGAM 
integrin, alpha M 
(complement 
component 3 
receptor 3 subunit) 
1.18 ACTIVATION ACTIVATION 
CCL5 chemokine (C-C motif) ligand 5 1.17 CCR3 
chemokine (C-C 
motif) receptor 3 1.13 ACTIVATION ACTIVATION 
CXCL12 chemokine (C-X-C motif) ligand 12 1.17 CXCR4 
chemokine (C-X-C 









substrate 1 (rho 
family, small GTP 
binding protein 
Rac1) 







EDNRA endothelin receptor type A 1.14 ACTIVATION ACTIVATION 













TSHR thyroid stimulating hormone receptor -1.56 ACTIVATION INCONSISTENT 




substrate 1 (rho 





oncogene, Src family 
tyrosine kinase 
-1.40 ACTIVATION INCONSISTENT 
EGFR epidermal growth factor receptor -2.76 ACTIVATION INCONSISTENT 








AXL AXL receptor tyrosine kinase -1.86 ACTIVATION INHIBITION 
TYRO3 TYRO3 protein tyrosine kinase -1.78 ACTIVATION INHIBITION 
GDNF 
 
glial cell derived 
neurotrophic factor 
 
1.13 GFRA1 GDNF family receptor alpha 1 -1.59 ACTIVATION INCONSISTENT 
1.13 RET ret proto-oncogene -2.08 ACTIVATION INCONSISTENT 
HTRA1 HtrA serine peptidase 1 1.06 EGFR 
epidermal growth 
factor receptor -2.76 INHIBITION INHIBITION 
IL1B interleukin 1, beta 1.40 APP amyloid beta (A4) precursor protein -1.46 ACTIVATION INCONSISTENT 
IL4 interleukin 4 1.08 IL4R interleukin 4 receptor -1.33 ACTIVATION INCONSISTENT 
JAG1 jagged 1 -1.14 NOTCH3 notch 3 -1.28 ACTIVATION INHIBITION 
LIF leukemia inhibitory factor 2.11 LIFR 
leukemia inhibitory 





like domains 1 


















cadherin 2, type 1, 
N-cadherin 
(neuronal) 





-1.47 INHIBITION INHIBITION 




related protein 1 




















1.19 ACTIVATION INCONSISTENT 
PROS1 protein S (alpha) 1.57 TYRO3 TYRO3 protein tyrosine kinase -1.78 ACTIVATION INCONSISTENT 
PRTN3 proteinase 3 -1.06 F2R coagulation factor II (thrombin) receptor -1.99 INHIBITION INCONSISTENT 





-2.97 INHIBITION INCONSISTENT 
SPP1 secreted phosphoprotein 1 1.99 ITGAV integrin, alpha V -1.62 ACTIVATION INCONSISTENT 
TGFB3 
transforming 




factor, beta receptor 
III 
1.04 ACTIVATION INCONSISTENT 
VAV3 






substrate 1 (rho 
family, small GTP 
binding protein 
Rac1) 
























1.35 INHIBITION INCONSISTENT 












C motif) receptor 
4 











































































IGF2 insulin-like growth factor 2 -1.16 INSR insulin receptor 1.36 ACTIVATION INCONSISTENT 









-1.10 INHIBITION INHIBITION 
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inserted) protein 1 





-2.29 INHIBITION INCONSISTENT 
TAC1 tachykinin, precursor 1 1.15 TACR1 
tachykinin 




















ALB albumin 1.36 APP amyloid beta (A4) precursor protein -1.46 INHIBITION INHIBITION 
APOA1 apolipoprotein A-I -1.11 ABCA1 
ATP-binding 
cassette, sub-
family A (ABC1), 
member 1 













receptor, type 2 




receptor, type 3 
1.19 ACTIVATION INCONSISTENT 
NGFR nerve growth factor receptor -1.86 ACTIVATION INHIBITION 
C3 complement component 3 1.42 ITGAM 





1.18 ACTIVATION ACTIVATION 
FGF1 
fibroblast 
growth factor 1 
(acidic) 





















ITGAV integrin, alpha V -1.62 
EGFR epidermal growth factor receptor -2.76 
HTRA1 HtrA serine peptidase 1 1.21 EGFR 
epidermal growth 
factor receptor -2.76 INHIBITION INHIBITION 
JAG1 jagged 1 -1.11 NOTCH3 notch 3 -1.28 ACTIVATION INHIBITION 









-like domains 1 









C motif) receptor 
4 






















-1.07 ACTIVATION INCONSISTENT 
PROS1 protein S (alpha) 1.58 TYRO3 
TYRO3 protein 





1.58 ITGAV integrin, alpha V -1.62 ACTIVATION INCONSISTENT 
THBS1 thrombospondin 1 -1.06 ITGB1 







-1.38 ACTIVATION INHIBITION 
THBS1 thrombospondin 1 -1.06 CD47 CD47 molecule -1.20 ACTIVATION INHIBITION 
 
 232 








(a type III 
receptor tyrosine 
kinase) 





















(a type III 
receptor tyrosine 
kinase) 
-1.62 ACTIVATION INHIBITION 
FLT4 fms-related tyrosine kinase 4 1.12 ACTIVATION INCONSISTENT 
 
Supplemental Table 5.2: Matching ECM Ligands Predicted to Exhibit Downstream Signaling Effects to their Cognate 
PPC Receptors - Following IPA resolution of cellular movement genes from our matched datasets, released motogenic 
ligands from light-damaged retinal tissues that are predicted to directly interact with their downstream receptors on cone and 
rod PPCs were selectively used to create custom signaling networks (Figure 5.3 and Supplemental Figure 5.3). These 
network genes are compiled and presented as matched interacting ligand-receptor molecular pairs in A-D resolved from the 
NSR/Rods, RPE/Cones, NSR/Cones, and RPE/Rods cellular movement gene networks respectively. The native interaction 
between the ligands and receptors described with reference to curated interactions of each model gene pair in the IPA 
knowledgebase are presented along with the predicted interactions between gene pairs based on their expression states. 
Predictions of gene interactions described to be ‘INCONSISTENT’ represent downstream ligand effects on receptors whose 
expression states differ from expected receptor gene expression in an IPA causal effect model of the interacting molecular pair 














Receptor Overlap Score (Up-regulation) 




(Perturbation, Dose, Time, Cell, 
Batch) 
ITGAV 
0.0132 TNFA,100ng/ul,6h,MCF7,LJP004 0.0122 bNGF,1ng/ul,24h,SKBR3,LJP004 
0.012 EPG,100ng/ul,1h,MCF10A,LJP004 0.0122 HBEGF,1ng/ul,3h,MCF10A,LJP004 
0.0118 SCF,3ng/ul,1h,MDAMB231,LJP004 0.012 EGF,0.1ng/ul,24h,MCF10A,LJP004 
0.0118 IL6,1ng/ul,24h,HS578T,LJP004 0.0116 bNGF,1ng/ul,24h,BT20,LJP004 
0.0115 IL1,1ng/ul,3h,MCF10A,LJP004 0.0116 INS,1ng/ul,6h,SKBR3,LJP004 
0.0115 HRG,1ng/ul,6h,SKBR3,LJP004 0.0112 PDGFBB,1ng/ul,3h,BT20,LJP004 
0.011 HRG,100ng/ul,24h,SKBR3,LJP004 0.0112 MCSF,100ng/ul,24h,MDAMB231,LJP004 
0.0108 bNGF,1ng/ul,6h,HS578T,LJP004 0.0112 EGF,1ng/ul,3h,MCF10A,LJP004 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0.0111 IL6,1ng/ul,6h,SKBR3,LJP004 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0.0111 AR,100ng/ul,3h,HS578T,LJP004 
0 Ethisterone,10um,24h,VCAP,CPC003   
TSHR 
0 Estrone,10um,24h,VCAP,CPC003 0.0127 EPR,1ng/ul,3h,HS578T,LJP004 
0 Equilin,10um,24h,VCAP,CPC003 0.0123 IGF2,100ng/ul,3h,MDAMB231,LJP004 
0 Eplerenone,10um,24h,VCAP,CPC003 0.012 IL6,100ng/ul,1h,MCF10A,LJP004 






0 ESTRADIOL ACETATE,10um,24h,VCAP,CPC003 0 
FARNESYLTHIOACETIC 
ACID,10um,24h,VCAP,CPC003 
0 ERYTHROMYCIN,10um,24h,VCAP,CPC003 0 Ethisterone,10um,24h,VCAP,CPC003 
0 ERGOCORNINE,10um,24h,VCAP,CPC003 0 Estrone,10um,24h,VCAP,CPC003 







0.02 vorinostat,10um,24h,VCAP,CPC003 0.02 deoxyrhapontin,10um,6h,PC3,CPC003 










0.02 XYLAZINE,10um,24h,VCAP,CPC003 0.02 XYLAZINE,10um,6h,PC3,CPC003 
0.02 WEB 2086,10um,24h,VCAP,CPC003 0.02 Vincamine,10um,24h,HA1E,CPC003 




0.02 Vincamine,10um,24h,VCAP,CPC003 0.02 Timolol maleate salt,10um,24h,PC3,CPC003 
0.02 VINCRISTINE SULFATE,10um,24h,VCAP,CPC003 0.02 
TYRPHOSTIN B44 (-
),10um,24h,VCAP,CPC003 









0.02 deoxyrhapontin,10um,24h,VCAP,CPC003 0.02 deoxyrhapontin,10um,6h,PC3,CPC003 
0.02 ZOLMITRIPTAN,10um,24h,VCAP,CPC003 0.02 
deoxyrhapontin,10um,24h,HCC515,CP
C003 












0.02 SCH 442416,10um,6h,VCAP,CPC003 0.02 TELMISARTAN,10um,24h,PC3,CPC003 
0.02 SC-514,10um,24h,VCAP,CPC003 0.02 SCH 442416,10um,6h,HCC515,CPC003 
0.02 SC 560,10um,24h,VCAP,CPC003 0.02 SB 366791,10um,6h,HCC515,CPC003 
0.02 S-(+)-ibuprofen,10um,24h,VCAP,CPC003 0.02 SB 366791,10um,6h,HA1E,CPC003 
0.02 Racecadotril,10um,24h,VCAP,CPC003 0.02 SB 221284,10um,6h,HCC515,CPC003 
RAC1 
0.012 IL6,1ng/ul,24h,MCF10A,LJP004 0.0143 IL1,100ng/ul,1h,MDAMB231,LJP004 
0.012 IL4,100ng/ul,3h,MDAMB231,LJP004 0.0132 IL6,1ng/ul,3h,MCF7,LJP004 
0.0115 IL4,1ng/ul,24h,MCF10A,LJP004 0.0127 PDGFBB,100ng/ul,1h,BT20,LJP004 
0.0111 IL4,100ng/ul,3h,SKBR3,LJP004 0.0122 MCSF,1ng/ul,3h,MDAMB231,LJP004 
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0.0111 IFNA,1ng/ul,3h,MDAMB231,LJP004 0.0122 EGF,0.1ng/ul,24h,MCF7,LJP004 
0.0111 EGF,0.1ng/ul,3h,MCF7,LJP004 0.012 INS,1ng/ul,3h,MCF10A,LJP004 
0.0109 INS,100ng/ul,3h,HS578T,LJP004 0.0118 IFNA,1ng/ul,6h,MCF10A,LJP004 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0.0114 HGF,1ng/ul,24h,BT20,LJP004 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0.0112 PDGFBB,100ng/ul,24h,BT20,LJP004 
0 Ethisterone,10um,24h,VCAP,CPC003 0.0104 MCSF,1ng/ul,6h,HS578T,LJP004 
PTPRZ1 
0.0122 IL17,100ng/ul,24h,MCF10A,LJP004 0.0123 MSP,1ng/ul,24h,MCF7,LJP004 
0.0119 PDGFBB,100ng/ul,3h,MDAMB231,LJP004 0.0123 FGF1,100ng/ul,3h,BT20,LJP004 
0.0119 HGF,100ng/ul,3h,MDAMB231,LJP004 0.012 EGF,0.1ng/ul,6h,HS578T,LJP004 
0.0118 TNFA,100ng/ul,1h,MCF10A,LJP004 0 FINASTERIDE,10um,24h,VCAP,CPC003 
0.0118 IFNG,100ng/ul,1h,MCF7,LJP004 0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 
0.0115 HGF,1ng/ul,1h,MCF7,LJP004 0 Ethisterone,10um,24h,VCAP,CPC003 
0.0112 TGFa,100ng/ul,24h,MDAMB231,LJP004 0 Estrone,10um,24h,VCAP,CPC003 
0.0111 IL17,1ng/ul,6h,MCF10A,LJP004 0 Equilin,10um,24h,VCAP,CPC003 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0 Eplerenone,10um,24h,VCAP,CPC003 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0 EUGENITOL,10um,24h,VCAP,CPC003 
CXCR4 
0.02 estradiol,10um,24h,VCAP,CPC003 0.02 ZM 323881 hydrochloride,10um,24h,VCAP,CPC003 




0.02 bongkrekic acid,10um,24h,PC3,CPC003 0.02 
TRIAMTERENE,10um,24h,VCAP,CPC
003 
0.02 VINCRISTINE SULFATE,10um,6h,VCAP,CPC003 0.02 
THIABENDAZOLE,10um,24h,HCC515,
CPC003 
0.02 VINBLASTINE SULFATE,10um,24h,PC3,CPC003 0.02 
TAMOXIFEN 
CITRATE,10um,24h,VCAP,CPC003 
0.02 Trap 101,10um,24h,VCAP,CPC003 0.02 Seneciphylline,10um,24h,VCAP,CPC003 
0.02 TOLAZAMIDE,10um,6h,VCAP,CPC003 0.02 SR-95639A,10um,6h,VCAP,CPC003 




0.02 TC 2559 difumarate,10um,6h,VCAP,CPC003 0.02 SC 560,10um,6h,PC3,CPC003 
0.02 TC 2559 difumarate,10um,24h,VCAP,CPC003 0.02 SC 560,10um,24h,PC3,CPC003 
CDH2 
0.012 IL4,100ng/ul,1h,MCF10A,LJP004 0.0116 IGF2,100ng/ul,3h,BT20,LJP004 
0.0119 IL1,1ng/ul,24h,MCF10A,LJP004 0.0115 TNFA,1ng/ul,6h,MCF7,LJP004 
0.0116 IL4,100ng/ul,1h,BT20,LJP004 0.0114 BTC,1ng/ul,6h,MCF7,LJP004 
0.0115 EPR,100ng/ul,24h,MCF7,LJP004 0.0112 bNGF,100ng/ul,24h,SKBR3,LJP004 
0.0112 KGF,100ng/ul,24h,MDAMB231,LJP004 0.0112 EGF,100ng/ul,1h,MCF7,LJP004 
0.011 EPR,100ng/ul,3h,MCF7,LJP004 0.011 SCF,3ng/ul,6h,HS578T,LJP004 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0.0109 IFNG,100ng/ul,1h,MDAMB231,LJP004 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0.0108 HGF,100ng/ul,6h,MCF7,LJP004 
0 Ethisterone,10um,24h,VCAP,CPC003 0.0106 IFNG,100ng/ul,1h,MCF10A,LJP004 
0 Estrone,10um,24h,VCAP,CPC003 0 FINASTERIDE,10um,24h,VCAP,CPC003 
LRP1 
0.0122 TNFA,100ng/ul,1h,BT20,LJP004 0.012 EPR,1ng/ul,24h,SKBR3,LJP004 
0.012 IL17,1ng/ul,24h,MCF7,LJP004 0.0119 IGF2,1ng/ul,3h,SKBR3,LJP004 
0.0118 bFGF,100ng/ul,24h,BT20,LJP004 0.0116 TGFa,1ng/ul,6h,BT20,LJP004 
0.0115 SCF,300ng/ul,6h,SKBR3,LJP004 0.0116 FGF1,1ng/ul,24h,MDAMB231,LJP004 
0.0115 MSP,1ng/ul,24h,BT20,LJP004 0.0116 BTC,100ng/ul,1h,MCF10A,LJP004 
0.0114 GAS6,100ng/ul,1h,SKBR3,LJP004 0.0115 IL4,1ng/ul,1h,MDAMB231,LJP004 
0.0112 GDNF,100ng/ul,6h,SKBR3,LJP004 0.0111 EGF,1ng/ul,24h,MDAMB231,LJP004 
0.0108 MCSF,100ng/ul,1h,BT20,LJP004 0.011 INS,1ng/ul,24h,MDAMB231,LJP004 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0.011 EPR,100ng/ul,6h,MDAMB231,LJP004 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0.0109 IL4,100ng/ul,6h,HS578T,LJP004 
DDR1 
0.02 wortmannin,10um,24h,VCAP,CPC003 0.02 ZOLMITRIPTAN,10um,6h,PC3,CPC003 
0.02 geldanamycin,10um,24h,VCAP,CPC003 0.02 
ZOLMITRIPTAN,10um,24h,HCC515,C
PC003 
0.02 estradiol,10um,24h,VCAP,CPC003 0.02 YM 976,10um,6h,VCAP,CPC003 








0.02 Trap 101,10um,24h,VCAP,CPC003 0.02 Timolol maleate salt,10um,6h,VCAP,CPC003 
0.02 TER14687,10um,24h,VCAP,CPC003 0.02 TRIOXSALEN,10um,24h,PC3,CPC003 
0.02 TC 2559 difumarate,10um,24h,VCAP,CPC003 0.02 
TRIOXSALEN,10um,24h,HCC515,CPC
003 
0.02 SULPIRIDE,10um,24h,VCAP,CPC003 0.02 TOLBUTAMIDE,10um,24h,VCAP,CPC003 
0.02 SU1498,10um,24h,VCAP,CPC003 0.02 TEMEFOS,10um,24h,HA1E,CPC003 
SDC1 
0.012 IL6,1ng/ul,3h,MDAMB231,LJP004 0.0132 GDNF,100ng/ul,24h,BT20,LJP004 
0.0116 PDGFBB,1ng/ul,6h,HS578T,LJP004 0.013 IL1,1ng/ul,1h,SKBR3,LJP004 
0.0116 EGF,0.1ng/ul,3h,MCF10A,LJP004 0.013 IGF1,1ng/ul,24h,SKBR3,LJP004 
0 FINASTERIDE,10um,24h,VCAP,CPC003 0.013 HRG,100ng/ul,1h,MCF10A,LJP004 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0.0128 IFNA,1ng/ul,24h,SKBR3,LJP004 
0 Ethisterone,10um,24h,VCAP,CPC003 0.0127 INS,100ng/ul,3h,SKBR3,LJP004 
0 Estrone,10um,24h,VCAP,CPC003 0.0125 IGF1,1ng/ul,24h,BT20,LJP004 
0 Equilin,10um,24h,VCAP,CPC003 0.0125 FGF1,100ng/ul,24h,MCF10A,LJP004 
0 Eplerenone,10um,24h,VCAP,CPC003 0.0123 SCF,3ng/ul,6h,BT20,LJP004 
0 EUGENITOL,10um,24h,VCAP,CPC003 0.0123 IL6,1ng/ul,24h,BT20,LJP004 
RET 
0.0125 TGFa,100ng/ul,1h,HS578T,LJP004 0.0133 IFNA,100ng/ul,6h,MDAMB231,LJP004 
0.0123 KGF,1ng/ul,3h,MCF7,LJP004 0.0123 FGF1,100ng/ul,6h,MCF10A,LJP004 
0.0123 IL17,100ng/ul,6h,BT20,LJP004 0.0122 GAS6,1ng/ul,1h,MDAMB231,LJP004 
0.0119 HGF,1ng/ul,6h,HS578T,LJP004 0.012 HRG,100ng/ul,24h,MCF7,LJP004 
0.0118 KGF,1ng/ul,1h,BT20,LJP004 0.012 EGF,100ng/ul,1h,MDAMB231,LJP004 
0.0116 bNGF,1ng/ul,24h,SKBR3,LJP004 0.0119 EGF,100ng/ul,3h,BT20,LJP004 
0.0116 IL17,100ng/ul,6h,SKBR3,LJP004 0.0118 IL1,1ng/ul,6h,MCF10A,LJP004 
0.0114 IGF2,1ng/ul,1h,MCF7,LJP004 0.0116 bFGF,1ng/ul,1h,MDAMB231,LJP004 
0.011 SCF,3ng/ul,6h,HS578T,LJP004 0.0116 bFGF,100ng/ul,24h,MCF10A,LJP004 
0.0109 IL4,1ng/ul,6h,BT20,LJP004 0.0116 HBEGF,1ng/ul,24h,HS578T,LJP004 
GFRA1 
0.0127 bFGF,100ng/ul,6h,MCF10A,LJP004 0.0118 EGF,100ng/ul,1h,BT20,LJP004 
0.0123 PDGFBB,100ng/ul,6h,MCF7,LJP004 0.0111 PDGFBB,1ng/ul,3h,HS578T,LJP004 
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0 FINASTERIDE,10um,24h,VCAP,CPC003 0 
FINASTERIDE,10um,24h,VCAP,CPC0
03 
0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 0 
FARNESYLTHIOACETIC 
ACID,10um,24h,VCAP,CPC003 
0 Ethisterone,10um,24h,VCAP,CPC003 0 Ethisterone,10um,24h,VCAP,CPC003 
0 Estrone,10um,24h,VCAP,CPC003 0 Estrone,10um,24h,VCAP,CPC003 
0 Equilin,10um,24h,VCAP,CPC003 0 Equilin,10um,24h,VCAP,CPC003 
0 Eplerenone,10um,24h,VCAP,CPC003 0 Eplerenone,10um,24h,VCAP,CPC003 










0.013 HGF,100ng/ul,3h,MCF10A,LJP004 0.0122 HBEGF,1ng/ul,3h,MCF10A,LJP004 
0.013 EPR,100ng/ul,6h,MCF10A,LJP004 0.0116 FGF1,1ng/ul,24h,MDAMB231,LJP004 
0.0125 GDNF,100ng/ul,3h,MCF7,LJP004 0.0115 bNGF,100ng/ul,6h,BT20,LJP004 
0.0123 EPG,100ng/ul,1h,BT20,LJP004 0.0112 MCSF,1ng/ul,24h,MCF7,LJP004 
0.0122 TGFa,100ng/ul,24h,SKBR3,LJP004 0.0109 GAS6,100ng/ul,6h,MCF10A,LJP004 
0.0122 SCF,300ng/ul,6h,MCF7,LJP004 0.0106 IFNG,100ng/ul,3h,BT20,LJP004 
0.0119 BTC,100ng/ul,24h,BT20,LJP004 0 FINASTERIDE,10um,24h,VCAP,CPC003 
0.0118 BTC,100ng/ul,3h,MCF7,LJP004 0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 
0.0116 bNGF,1ng/ul,24h,SKBR3,LJP004 0 Ethisterone,10um,24h,VCAP,CPC003 
0.0115 IL17,1ng/ul,1h,MCF10A,LJP004 0 Estrone,10um,24h,VCAP,CPC003 
TYRO3 
0.0128 bFGF,100ng/ul,6h,SKBR3,LJP004 0.0132 MSP,100ng/ul,1h,SKBR3,LJP004 
0.0127 INS,1ng/ul,6h,MDAMB231,LJP004 0.0122 PDGFBB,100ng/ul,24h,HS578T,LJP004 
0.0119 HBEGF,100ng/ul,24h,BT20,LJP004 0.0119 FGF1,100ng/ul,1h,SKBR3,LJP004 
0.0115 IGF1,1ng/ul,3h,BT20,LJP004 0.0118 IL1,1ng/ul,1h,MCF10A,LJP004 
0.0114 MCSF,1ng/ul,24h,SKBR3,LJP004 0.0118 IL1,100ng/ul,6h,MCF10A,LJP004 
0.0114 IL17,1ng/ul,3h,BT20,LJP004 0.0116 EGF,10ng/ul,6h,BT20,LJP004 
0.0112 IFNG,100ng/ul,1h,HS578T,LJP004 0.0115 GDNF,1ng/ul,6h,MCF10A,LJP004 
0.0111 IGF2,100ng/ul,24h,BT20,LJP004 0.0114 MSP,1ng/ul,1h,MCF10A,LJP004 
0.0111 EPR,1ng/ul,24h,SKBR3,LJP004 0.0111 IL1,100ng/ul,24h,SKBR3,LJP004 




Supplemental Table 6.1: L1000 Analysis for drug perturbations potentially influencing down-regulated receptor expression states of 
rod photoreceptors – Listed are top 10 ranked experiments that potentially reverse (up-regulate) or aggravate (down-regulate) the expression 
of each resolved down-regulated motility-deterministic rod receptor culled from results of IPA bioinformatics analysis of NSR/Rod matched 
dataset depicted in Table 5.2 (Chapter 5). Rankings of chemical perturbation experiments was performed using an overlap score that 
quantifies the correlation between our input gene list and z-score gene expression signatures of the 1000 genes measured per experiment 
using Pearson’s correlation. Experimental conditions associated with selected drugs and small molecule effectors are presented as clickable 










(Down-regulation) (Perturbation, Dose, Time, Cell, Batch) 
Overlap Score 
(Up-regulation)  (Perturbation, Dose, Time, Cell, Batch) 
0.16 (+)-Isoproterenol (+)-bitartrate salt,10um,24h,MCF7,CPD003 0.18 Sertindole,10um,24h,PC3,CPD002 
0.16 KUC104236N,10um,24h,HT29,CPC007 0.18 PLX4032,0.4um,6h,MCF10A,LJP001 
0.16 Roxithromycin,10um,24h,MCF7,CPD003 0.16 PAC 1,10um,24h,PC3,CPC006 
0.14 3-methyladenine,10um,6h,SNUC5,CPC006 0.16 OSI-027,0.4um,6h,MDAMB231,LJP001 
0.14 Anabasine,10um,6h,PC3,CPC002 0.16 O-2050,10um,24h,PC3,CPC001 
0.14 ARRY-704,0.4um,24h,MCF7,LJP002 0.16 NCGC00183223-01,10um,6h,A549,CPC007 
0.14 atenolol,10um,6h,HCC515,CPC020 0.16 Methoxy-6-harmalan,10um,24h,HCC515,CPC004 
0.14 corticosterone,10um,24h,VCAP,CPC010 0.16 GSK429286A,10um,6h,MCF10A,LJP001 
0.14 Cortisone,10um,24h,MCF7,CPC005 0.16 DIETHYLCARBAMAZINE CITRATE,10um,6h,HA1E,CPC004 
0.14 D-64131,10um,24h,HCC515,CPC002 0.16 CARBAMAZEPINE,10um,24h,HCC515,CPC004 
0.14 Dorzolamide hydrochloride,10um,24h,MCF7,CPD003 0.14 sulfisoxazole,10um,6h,A375,CPC020 
0.14 Ethotoin,10um,24h,MCF7,CPD002 0.14 probenecid,10um,24h,PC3,CPC020 
0.14 flumazenil,10um,24h,PC3,CPC011 0.14 manumycin A,9.08um,6h,HT115,CPC006 
0.14 GDC-0879,10um,6h,SKBR3,LJP002 0.14 erastin,4.8um,6h,CL34,CPC006 
0.14 Gliquidone,10um,6h,HCC515,CPC002 0.14 duremesin,10um,6h,MCF7,CPC020 
0.14 GW 583340 dihydrochloride,10um,24h,HCC515,CPC001 0.14 
Tubocurarine chloride pentahydrate 
(+),10um,24h,HCC515,CPC001 
0.14 H-8,10um,24h,VCAP,CPC003 0.14 TOLAZAMIDE,10um,6h,SKMEL1,CPC006 
0.14 Isradipine,10um,24h,HA1E,CPC005 0.14 TBB,10um,24h,HCC515,CPC002 
0.14 JWE-035,10um,6h,SKBR3,LJP002 0.14 STAT3 Inhibitor VI, S31-201,160um,6h,SNUC4,CPC006 
0.14 LIQUIRITIGENIN DIMETHYL ETHER,10um,6h,MCF7,CPC005 0.14 SID 26681509,88.8um,6h,NOMO1,CPC006 







0.14 Norcyclobenzaprine,10um,6h,HCC515,CPC003 0.14 
NF-kB Activation Inhibitor II, JSH-
23,6um,6h,OV7,CPC006 
0.14 Parthenolide,10um,24h,HCC515,CPC006 0.14 NCGC00242557-01,10um,24h,VCAP,CPC008 
0.14 PCI-32765,2um,24h,MCF7,LJP002 0.14 NCGC00188488-01,10um,6h,A375,CPC008 





0.14 PD0325901,2um,24h,MDAMB231,LJP002 0.14 MDL-28170,10um,6h,PC3,CPC002 
0.14 SAFROLGLYCOL,10um,6h,HT29,CPC005 0.14 JAS07_006,10um,24h,HA1E,CPC007 
0.14 SB 202190,10um,24h,VCAP,CPC002 0.14 Iodipamide,10um,24h,PC3,CPC001 
0.14 SB525334,0.08um,24h,MCF7,LJP002 0.14 HTS 12526,10um,24h,PC3,CPC014 
0.14 SC-9,10um,6h,PC3,CPC003 0.14 H5902,10um,6h,HT29,CPC012 
0.14 SID 26681509,88.8um,6h,PL21,CPC006 0.14 FELAMIDIN,10um,6h,PC3,CPC002 
0.14 sirolimus,10um,6h,SKM1,CPC006 0.14 ENROFLOXACIN,10um,24h,HCC515,CPC003 
0.14 SPIPERONE,10um,24h,HCC515,CPC004 0.14 Closantel,10um,24h,PC3,CPD002 
0.14 SR 57227 hydrochloride,10um,24h,VCAP,CPC002 0.14 
Canrenoic acid potassium 
salt,10um,24h,PC3,CPC003 
0.14 THIOTEPA,10um,6h,MCF7,CPC004 0.14 CDC,10um,24h,VCAP,CPC001 
0.14 Tpl2,40um,6h,HCC515,CPC006 0.14 C247,10um,24h,PC3,CPC014 
0.14 triamterene,10um,6h,HA1E,CPC020 0.14 Adamantamine fumarate,10um,24h,PC3,CPD002 








0.14 trichostatin A,10um,6h,HA1E,CPC011 0.14 3027-0077,10um,6h,MCF7,CPC014 




0.14 Tyrphostin AG 1478,56.78um,6h,SNUC5,CPC006 0.14 2541665-P2,80um,6h,RMGI,CPC006 
0.14 Tyrphostin AG 1478,56.78um,6h,VCAP,CPC006 0.14 2541665-P1,11.1um,6h,U937,CPC006 




0.14 VU0415011,10um,24h,MCF7,CPC008 0.14 17757146,0.35um,6h,RMGI,CPC006 




0.14 Y27632,4um,6h,PC3,CPC006   
0.14 Z2777,10um,6h,VCAP,CPC014   
 
Supplemental Table 6.2: L1000 Analysis for drug perturbations potentially influencing the expression state of all motility-
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deterministic down-regulated genes of rod photoreceptors – Listed are top-ranked experimental drugs and their testing conditions that 
potentially reverse (up-regulate) or aggravate (down-regulate) the expression of all resolved down-regulated motility-deterministic gene culled 
from results of IPA bioinformatics analysis of NSR/Rod matched dataset depicted in Figure 5.4A (Chapter 5). Resolved down-regulated motility 
genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors. Rankings of chemical perturbation 
experiments was performed using an overlap score that quantifies the correlation between our input gene list and z-score gene expression 












(Up-regulation) (Perturbation, Dose, Time, Cell, Batch) 
Overlap Score 
(Down-regulation) (Perturbation, Dose, Time, Cell, Batch) 
0.12 moban,10um,6h,HA1E,CPC020 0.12 BMY 14802 hydrochloride,10um,24h,VCAP,CPC001 
0.12 VINBLASTINE SULFATE,10um,6h,HCC515,CPC003 0.1 venlafaxine hcl,10um,6h,VCAP,CPC011 
0.12 Erlotinib,0.08um,24h,HS578T,LJP002 0.1 minoxidil,10um,6h,SW948,CPC006 
0.1 wortmannin,10um,6h,SKM1,CPC006 0.1 betulinic acid,10um,24h,HCC515,CPC002 
0.1 Sulfamethoxypyridazine,10um,24h,PC3,CPD002 0.1 
YM 298198 
hydrochloride,10um,24h,VCAP,CPC001 
0.1 S1475,10um,6h,A549,CPC014 0.1 RIZATRIPTAN BENZOATE,10um,6h,HA1E,CPC004 
0.1 Merbromin,10um,24h,PC3,CPD002 0.1 PZ0005,10um,24h,PC3,CPC014 
0.1 IMD 0354,10um,6h,U937,CPC006 0.1 O-2050,10um,24h,VCAP,CPC001 
0.1 71820,10um,24h,PC3,CPC014 0.1 MLS-0390945.0001,10um,6h,HT29,CPC013 
0.08 zacopride,10um,6h,VCAP,CPC011 0.1 MLS-0390837.0001,10um,6h,A549,CPC012 
0.08 wortmannin,10um,6h,VCAP,CPC003 0.1 IKK Inhibitor X,6um,24h,PC3,CPC006 
0.08 wortmannin,10um,24h,MCF7,CPD002 0.1 DY131,10um,6h,HCC515,CPC001 
0.08 wortmannin,10um,24h,MCF7,CPC010 0.1 AZD-6482,0.08um,24h,HS578T,LJP001 
0.08 wortmannin,10um,24h,MCF7,CPC008 0.1 AG-370,10um,6h,HCC515,CPC002 
0.08 tropicamide,10um,6h,PC3,CPC020 0.1 5540735,10um,24h,MCF7,CPC013 
0.08 tripelennamine,10um,6h,A375,CPC011 0.08 spironolactone,10um,6h,HT29,CPC020 
0.08 tolazamide,10um,24h,PC3,CPC020 0.08 nadolol,10um,6h,HA1E,CPC020 
0.08 tofranil,10um,6h,MCF7,CPC020 0.08 m-Chlorophenylbiguanide hydrochloride,10um,24h,VCAP,CPC002 
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0.08 theophylline,10um,6h,MCF7,CPC020 0.08 ginsenoside-Rc,10um,24h,HCC515,CPC001 
0.08 oxyphenonium,10um,6h,PC3,CPC010 0.08 doxycycline,10um,24h,MCF7,CPC020 
0.08 minoxidil,10um,24h,PC3,CPC020 0.08 chloramphenicol,10um,6h,HA1E,CPC020 
0.08 linezolid,10um,6h,PC3,CPC011 0.08 S2005,10um,24h,VCAP,CPC013 
0.08 fluticasone,10um,24h,VCAP,CPC011 0.08 S1472,10um,6h,A375,CPC014 
0.08 fluocinolone acetonide,10um,6h,HCC515,CPC020 0.08 Ro 08-2750,10um,24h,HCC515,CPC001 
0.08 fluocinolone acetonide,10um,6h,A549,CPC020 0.08 RWJ 21757,10um,24h,PC3,CPC003 
0.08 fluocinolone acetonide 21-acetate,10um,6h,MCF7,CPC020 0.08 
ROTENONIC 
ACID,10um,6h,HCC515,CPC002 
0.08 docetaxel,10um,6h,VCAP,CPC011 0.08 Piperacetazine,10um,24h,VCAP,CPC001 
0.08 depo-medrol,10um,6h,MCF7,CPC020 0.08 Norethindrone,10um,24h,HCC515,CPC001 






0.08 TL_HRAS24 BRD-K93060291,10um,6h,A375,CPC008 0.08 LFM-A13,10um,24h,PC3,CPC002 
0.08 ROTENONIC ACID,10um,24h,PC3,CPC002 0.08 L-692,585,10um,6h,HA1E,CPC003 
0.08 Naltriben mesylate,10um,6h,HA1E,CPC001 0.08 HY-11000,10um,6h,A549,CPC013 
0.08 Medrysone,10um,6h,PC3,CPC002 0.08 HY-10228,10um,6h,A549,CPC014 
0.08 MLS-0013618.0001,10um,24h,MCF7,CPC008 0.08 
Gabexate 
mesylate,10um,24h,VCAP,CPC002 
0.08 JTC 801,10um,24h,PC3,CPC003 0.08 G-220,10um,24h,MCF7,CPC014 
0.08 Docetaxel,10um,24h,MCF7,CPD003 0.08 Flavoxate hydrochloride,10um,6h,HA1E,CPC002 
0.08 DICYCLOHEXYLUREA,10um,6h,HCC515,CPC003 0.08 F3103-0039,10um,24h,VCAP,CPC014 
0.08 Clorgyline hydrochloride,10um,6h,PC3,CPD001 0.08 Dibucaine,10um,6h,MCF7,CPD001 
0.08 CARPROFEN,10um,24h,HA1E,CPC003 0.08 Caffeic acid phenethyl ester,10um,6h,PC3,CPC001 
0.08 C1386,10um,6h,A375,CPC013 0.08 CIGLITAZONE,10um,6h,HCC515,CPC002 
0.08 Bisacodyl,10um,24h,MCF7,CPD002 0.08 Benoxinate hydrochloride,10um,24h,VCAP,CPC001 
0.08 Bicalutamide,10um,24h,MCF7,CPD003 0.08 BL-080,10um,6h,HA1E,CPC014 











0.08 2-(trifluoromethyl)-10H-phenothiazine,10um,6h,A375,CPC008 0.08 
BD 1047 
dihydrobromide,10um,24h,VCAP,CPC002 
0.08 (-)-MK 801 hydrogen maleate,10um,6h,PC3,CPD003 0.08 7910663,10um,6h,HEPG2,CPC013 
  0.08 7706-0139,10um,6h,MCF7,CPC014 
  0.08 5-azacytidine,10um,6h,HA1E,CPC020 
  0.08 19-norethindrone,10um,6h,A375,CPC020 
Supplemental Table 6.3: L1000 Analysis for drug perturbations potentially Influencing the expression state of all motility-
deterministic up-regulated genes of rod photoreceptors – Listed are top-ranked experimental drugs and their testing conditions that 
potentially reverse (down-regulate) or aggravate (up-regulate) the expression of all resolved up-regulated motility-deterministic gene 
culled from results of IPA bioinformatics analysis of NSR/Rod matched dataset depicted in Figure 5.4A (Chapter 5). Resolved up-
regulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors. Rankings of 
chemical perturbation experiments was performed using an overlap score that quantifies the correlation between our input gene list and 




(Down-regulation) (Perturbation, Dose, Time, Cell, Batch) 
Overlap Score 
(Up-regulation) (Perturbation, Dose, Time, Cell, Batch) 
0.02 ZM 323881 hydrochloride,10um,24h,VCAP,CPC003 0.02 estradiol,10um,24h,VCAP,CPC003 
0.02 VARDENAFIL HYDROCHLORIDE,10um,24h,PC3,CPC003 0.02 bufalin,10um,6h,VCAP,CPC003 
0.02 TRIAMTERENE,10um,24h,VCAP,CPC003 0.02 bongkrekic acid,10um,24h,PC3,CPC003 
0.02 THIABENDAZOLE,10um,24h,HCC515,CPC003 0.02 
VINCRISTINE 
SULFATE,10um,6h,VCAP,CPC003 
0.02 TAMOXIFEN CITRATE,10um,24h,VCAP,CPC003 0.02 
VINBLASTINE 
SULFATE,10um,24h,PC3,CPC003 
0.02 Seneciphylline,10um,24h,VCAP,CPC003 0.02 Trap 101,10um,24h,VCAP,CPC003 
0.02 SR-95639A,10um,6h,VCAP,CPC003 0.02 TOLAZAMIDE,10um,6h,VCAP,CPC003 
0.02 SCOPOLAMINE HYDROBROMIDE,10um,6h,PC3,CPC003 0.02 TCB2,10um,24h,PC3,CPC003 
0.02 SC 560,10um,6h,PC3,CPC003 0.02 TC 2559 difumarate,10um,6h,VCAP,CPC003 
0.02 SC 560,10um,24h,PC3,CPC003 0.02 TC 2559 difumarate,10um,24h,VCAP,CPC003 
0.02 Rimexolone,10um,24h,VCAP,CPC003 0.02 SULPIRIDE,10um,6h,VCAP,CPC003 




0.02 Ranitidine hydrochloride,10um,6h,PC3,CPC003 0.02 
Remacemide 
hydrochloride,10um,24h,VCAP,CPC003 
0.02 Ranitidine hydrochloride,10um,24h,HCC515,CPC003 0.02 
RS 100329 
hydrochloride,10um,24h,PC3,CPC003 
0.02 RS 45041-190 hydrochloride,10um,24h,PC3,CPC003 0.02 
RHIZOCARPIC 
ACID,10um,6h,VCAP,CPC003 
0.02 RESERPINE,10um,24h,VCAP,CPC003 0.02 RG-14620,10um,6h,VCAP,CPC003 
0.02 Proxyfan maleate,10um,6h,PC3,CPC003 0.02 Quinidine hydrochloride monohydrate,10um,24h,PC3,CPC003 
0.02 PSOROMIC ACID,10um,6h,PC3,CPC003 0.02 PODOFILOX,10um,6h,VCAP,CPC003 
0.02 PSOROMIC ACID,10um,6h,HCC515,CPC003 0.02 PINACIDIL,10um,6h,VCAP,CPC003 
0.02 PROTHIONAMIDE,10um,24h,HCC515,CPC003 0.02 Nizatidine,10um,6h,VCAP,CPC003 
0.02 PNU 282987,10um,6h,PC3,CPC003 0.02 Nitrocaramiphen hydrochloride,10um,6h,VCAP,CPC003 
0.02 PINACIDIL,10um,24h,VCAP,CPC003 0.02 NONOXYNOL-9,10um,6h,VCAP,CPC003 
0.02 Nitrocaramiphen hydrochloride,10um,24h,HCC515,CPC003 0.02 MRS 1220,10um,24h,VCAP,CPC003 
0.02 METHYL EVERNINATE,10um,6h,PC3,CPC003 0.02 
MR 16728 
hydrochloride,10um,24h,VCAP,CPC003 
0.02 Levocabastine hydrochloride,10um,6h,PC3,CPC003 0.02 
Loreclezole 
hydrochloride,10um,6h,VCAP,CPC003 
0.02 LIDOCAINE HYDROCHLORIDE,10um,6h,PC3,CPC003 0.02 
LEOIDIN DIMETHYL 
ETHER,10um,6h,VCAP,CPC003 
0.02 INDOLE-3-CARBINOL,10um,6h,PC3,CPC003 0.02 KAWAIN,10um,6h,VCAP,CPC003 
0.02 HYDRASTINE (1R, 9S),10um,24h,VCAP,CPC003 0.02 IVERMECTIN,10um,6h,VCAP,CPC003 
0.02 HOMOSALATE,10um,6h,PC3,CPC003 0.02 Hippeastrine hydrobromide,10um,6h,VCAP,CPC003 





0.02 GW 405833,10um,6h,VCAP,CPC003 
0.02 GBR 13069,10um,6h,HCC515,CPC003 0.02 GLIPIZIDE,10um,6h,VCAP,CPC003 
0.02 GBR 13069,10um,24h,VCAP,CPC003 0.02 GLIPIZIDE,10um,24h,VCAP,CPC003 
0.02 GAMMA-LINOLENIC ACID (18:3 n-6),10um,6h,HCC515,CPC003 0.02 
Fluvoxamine 
maleate,10um,6h,VCAP,CPC003 
0.02 Fillalbin,10um,6h,PC3,CPC003 0.02 Flurofamide,10um,24h,VCAP,CPC003 
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0.02 Felodipine,10um,24h,VCAP,CPC003 0.02 Flucloxacillin sodium,10um,24h,VCAP,CPC003 
0.02 Fananserin,10um,24h,PC3,CPC003 0.02 Fillalbin,10um,6h,VCAP,CPC003 
0.02 Ethisterone,10um,6h,PC3,CPC003 0.02 FLUMETHASONE,10um,6h,VCAP,CPC003 
0.02 Eplerenone,10um,24h,VCAP,CPC003 0.02 ENROFLOXACIN,10um,24h,VCAP,CPC003 
0.02 EUGENITOL,10um,24h,PC3,CPC003 0.02 Doxorubicin hydrochloride,10um,24h,PC3,CPC003 
0.02 Co 102862,10um,24h,PC3,CPC003 0.02 Daunorubicin hydrochloride,10um,24h,PC3,CPC003 






0.02 CCMQ,10um,24h,VCAP,CPC003 0.02 CGS 12066B,10um,24h,PC3,CPC003 
0.02 CCMQ,10um,24h,HA1E,CPC003 0.02 Biperiden hydrochloride,10um,24h,VCAP,CPC003 
0.02 Bemegride,10um,24h,HCC515,CPC003 0.02 BUCLADESINE,10um,24h,VCAP,CPC003 
0.02 BEZAFIBRATE,10um,24h,HCC515,CPC003 0.02 BICALUTAMIDE,10um,6h,VCAP,CPC003 
0.02 Altanserin hydrochloride,10um,24h,HCC515,CPC003 0.02 BAY 59-3074,10um,24h,VCAP,CPC003 
0.02 AG 9,10um,6h,HCC515,CPC003 0.02 Altanserin hydrochloride,10um,6h,VCAP,CPC003 
0.02 AG 555,10um,24h,VCAP,CPC003 0.02 AG 490,10um,24h,VCAP,CPC003 
Supplemental Table 6.4: L1000 Analysis for drug perturbations potentially influencing the expression state of all motility-
deterministic down-regulated genes of cone photoreceptors – Listed are top-ranked 50 experimental drugs and their testing conditions 
that potentially reverse (up-regulate) or aggravate (down-regulate) the expression of all resolved down-regulated motility-deterministic genes 
culled from results of IPA bioinformatics analysis of RPE/Rod matched dataset depicted in Figure 5.4B (Chapter 5). Resolved down-
regulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus of rod photoreceptors and include: 
CTNNB1, PRDX1, KDR, CXCR4. Rankings of chemical perturbation experiments was performed using an overlap score that quantifies the 
















(Perturbation, Dose, Time, Cell, 
Batch) 
Overlap Score 
(Down-regulation) (Perturbation, Dose, Time, Cell, Batch) 
0.0225 EGF,100ng/ul,3h,MCF10A,LJP004 0.0247 IL6,1ng/ul,24h,MDAMB231,LJP004 
0.0135 IFNA,100ng/ul,3h,SKBR3,LJP004 0.0222 IL1,100ng/ul,1h,BT20,LJP004 
0.0135 AR,100ng/ul,1h,SKBR3,LJP004 0.0133 bNGF,1ng/ul,24h,HS578T,LJP004 
0.0132 TNFA,100ng/ul,6h,MCF7,LJP004 0.0125 bNGF,100ng/ul,3h,BT20,LJP004 
0.0132 IL1,100ng/ul,3h,BT20,LJP004 0.0125 GAS6,100ng/ul,6h,BT20,LJP004 
0.013 IL1,100ng/ul,1h,BT20,LJP004 0.0125 EPR,100ng/ul,24h,MCF10A,LJP004 
0.0128 IL6,100ng/ul,6h,SKBR3,LJP004 0.0123 HRG,100ng/ul,24h,MCF10A,LJP004 
0.0128 IFNA,100ng/ul,24h,HS578T,LJP004 0.0122 EPG,100ng/ul,24h,MCF10A,LJP004 
0.0127 IFNG,1ng/ul,6h,BT20,LJP004 0.012 KGF,1ng/ul,24h,MDAMB231,LJP004 
0.0127 IFNG,100ng/ul,6h,MCF10A,LJP004 0.0119 INS,1ng/ul,3h,SKBR3,LJP004 
0.0125 TGFa,100ng/ul,1h,HS578T,LJP004 0.0119 EGF,0.1ng/ul,6h,SKBR3,LJP004 
0.0125 IL1,100ng/ul,1h,MDAMB231,LJP004 0.0116 INS,1ng/ul,6h,SKBR3,LJP004 
0.0125 EPR,1ng/ul,24h,MCF7,LJP004 0.0116 IGF2,100ng/ul,3h,BT20,LJP004 
0.0123 TGFa,100ng/ul,1h,BT20,LJP004 0.0116 HBEGF,100ng/ul,24h,MCF7,LJP004 
0.0123 IL6,100ng/ul,1h,MCF10A,LJP004 0.0116 FGF1,1ng/ul,1h,SKBR3,LJP004 
0.0123 EGF,100ng/ul,1h,HS578T,LJP004 0.0116 EGF,10ng/ul,24h,HS578T,LJP004 
0.0123 EGF,0.1ng/ul,1h,MCF10A,LJP004 0.0116 EGF,0.1ng/ul,3h,SKBR3,LJP004 
0.0122 TNFA,100ng/ul,6h,BT20,LJP004 0.0115 IL17,1ng/ul,6h,SKBR3,LJP004 
0.0122 SCF,300ng/ul,24h,BT20,LJP004 0.0115 HGF,100ng/ul,1h,BT20,LJP004 
0.0122 HGF,1ng/ul,1h,MCF10A,LJP004 0.0114 MSP,1ng/ul,1h,MCF7,LJP004 
0.0122 EGF,100ng/ul,1h,SKBR3,LJP004 0.0114 MSP,1ng/ul,1h,HS578T,LJP004 
0.012 bFGF,100ng/ul,1h,HS578T,LJP004 0.0114 IFNG,100ng/ul,6h,MCF7,LJP004 
0.012 TGFa,100ng/ul,1h,MDAMB231,LJP004 0.0114 HBEGF,100ng/ul,6h,MCF7,LJP004 
0.012 MSP,1ng/ul,6h,SKBR3,LJP004 0.0114 BTC,1ng/ul,6h,MDAMB231,LJP004 
0.012 MCSF,100ng/ul,24h,HS578T,LJP004 0.0112 GAS6,100ng/ul,24h,BT20,LJP004 
0.012 IL4,100ng/ul,1h,MCF10A,LJP004 0.0111 bFGF,1ng/ul,3h,MCF10A,LJP004 
0.012 IL1,1ng/ul,1h,BT20,LJP004 0.0111 KGF,1ng/ul,24h,BT20,LJP004 
0.012 BTC,100ng/ul,1h,BT20,LJP004 0.0111 IL4,100ng/ul,3h,SKBR3,LJP004 
0.0119 IL6,100ng/ul,1h,SKBR3,LJP004 0.0111 HGF,1ng/ul,1h,MDAMB231,LJP004 
0.0118 KGF,1ng/ul,6h,BT20,LJP004 0.011 TGFa,100ng/ul,1h,BT20,LJP004 
0.0118 IFNA,1ng/ul,24h,MDAMB231,LJP004 0.011 FGF1,100ng/ul,3h,SKBR3,LJP004 
0.0118 EPG,1ng/ul,1h,MCF10A,LJP004 0.0109 HGF,1ng/ul,24h,MCF10A,LJP004 
0.0116 GAS6,100ng/ul,3h,SKBR3,LJP004 0.0108 IL1,100ng/ul,1h,HS578T,LJP004 
0.0116 GAS6,100ng/ul,24h,MCF7,LJP004 0.0108 EPR,100ng/ul,6h,MCF10A,LJP004 
0.0116 FGF1,100ng/ul,6h,BT20,LJP004 0.0106 IGF1,100ng/ul,24h,MCF10A,LJP004 
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0.0116 EPR,1ng/ul,24h,MDAMB231,LJP004 0.0106 EPG,100ng/ul,1h,MCF10A,LJP004 
0.0115 bNGF,100ng/ul,1h,SKBR3,LJP004 0 FINASTERIDE,10um,24h,VCAP,CPC003 
0.0115 bFGF,1ng/ul,1h,SKBR3,LJP004 0 FARNESYLTHIOACETIC ACID,10um,24h,VCAP,CPC003 
0.0115 MCSF,100ng/ul,1h,MCF7,LJP004 0 Ethisterone,10um,24h,VCAP,CPC003 
0.0115 KGF,1ng/ul,6h,MDAMB231,LJP004 0 Estrone,10um,24h,VCAP,CPC003 
0.0115 IGF1,1ng/ul,24h,MCF7,LJP004 0 Equilin,10um,24h,VCAP,CPC003 
0.0115 GAS6,1ng/ul,24h,BT20,LJP004 0 Eplerenone,10um,24h,VCAP,CPC003 
0.0114 TNFA,100ng/ul,6h,SKBR3,LJP004 0 EUGENITOL,10um,24h,VCAP,CPC003 




0.0114 IL4,1ng/ul,3h,MDAMB231,LJP004 0 ESTRADIOL ACETATE,10um,24h,VCAP,CPC003 
0.0114 HGF,100ng/ul,6h,HS578T,LJP004 0 ERYTHROMYCIN,10um,24h,VCAP,CPC003 
0.0114 EGF,100ng/ul,6h,HS578T,LJP004 0 ERGOCORNINE,10um,24h,VCAP,CPC003 
0.0112 TNFA,1ng/ul,24h,MCF7,LJP004 0 EPITESTOSTERONE,10um,24h,VCAP,CPC003 
0.0112 KGF,100ng/ul,1h,SKBR3,LJP004 0 ENROFLOXACIN,10um,24h,VCAP,CPC003 
0.0112 IL1,100ng/ul,1h,SKBR3,LJP004 0 ANANDAMIDE (20:3,n-6),10um,24h,VCAP,CPC003 
 
Supplemental Table 6.5: L1000 Analysis for Drug Perturbations Potentially Influencing the expression state of all 
motility-deterministic up-regulated genes of Cone Photoreceptors – Listed are top-ranked 50 experimental drugs and their 
testing conditions that potentially reverse (down-regulate) or aggravate (up-regulate) the expression of all resolved up-regulated 
motility-deterministic genes culled from results of IPA bioinformatics analysis of RPE/Rod matched dataset depicted in Figure 
5.4B (Chapter 5). Resolved up-regulated motility genes analyzed are localized to the plasma membrane, cytoplasm and nucleus 
of rod photoreceptors and include: GRIN1, SOCS3, STAT2, ITCH, JAK2. Rankings of chemical perturbation experiments was 
performed using an overlap score that quantifies the correlation between our input gene list and z-score gene expression 
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